- entity: node
  type: pdq_cancer_information_summary
  title: 'Breast Cancer Prevention (PDQ®)–Health Professional Version'
  status: 1
  langcode: en
  field_hhs_syndication:
    - syndicate: 1
      keywords: breast cancer, cancer prevention
  moderation_state:
    value: published
  field_pdq_url:
    value: /types/breast/hp/breast-prevention-pdq
  field_pdq_cdr_id:
    value: 62779
  field_pdq_audience:
    value: Health Professionals
  field_pdq_summary_type:
    value: Prevention
  field_date_posted:
    value: '2019-03-11'
  field_date_updated:
    value: '2018-09-14'
  field_browser_title:
    value: 'Breast Cancer Prevention'
  field_page_description:
    value: 'Risk factors for breast cancer are female sex and advancing age, inherited risk, breast density, obesity, alcohol consumption, and exposure to ionizing radiation. Interventions to prevent breast cancer include chemoprevention (e.g. SERMs, AIs), risk-reducing surgery (e.g. mastectomy, oophorectomy). Review the evidenc'
  field_public_use:
    value: 1
  field_summary_sections:
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _558
      field_pdq_section_title:
        - format: plain_text
          value: 'Who Is at Risk?'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_558" class="pdq-sections"><div class="pdq-hp-patient-toggle"><a href="/types/breast/patient/breast-prevention-pdq">Go to Patient Version</a></div><p id="_559" tabindex="-1">Besides female sex, advancing age is the biggest risk factor for breast cancer.  Reproductive factors that increase exposure to endogenous estrogen, such as early menarche and late menopause, increase risk, as does the use of combination estrogen-progesterone hormones after menopause. Nulliparity and alcohol consumption also are associated with increased risk.</p><p id="_680" tabindex="-1">Women with a family history or personal history of invasive breast cancer, ductal carcinoma <em>in situ</em> or lobular carcinoma <em>in situ</em>, or a history of breast biopsies that show benign proliferative disease have an increased risk of breast cancer.[<a href="#cit/section_1.1">1</a>-<a href="#cit/section_1.4">4</a>]</p><p id="_560" tabindex="-1">Increased breast density is associated with increased risk.  It is often a heritable trait but is also seen more frequently in nulliparous women, women whose first pregnancy occurs late in life, and women who use postmenopausal hormones and alcohol.</p><p id="_561" tabindex="-1">Exposure to ionizing radiation, especially during puberty or young adulthood, and the inheritance of detrimental genetic mutations increase breast cancer risk.</p><h6 do-not-show="toc">References</h6><ol><li id="section_1.1">Kotsopoulos J, Chen WY, Gates MA, et al.: Risk factors for ductal and lobular breast cancer: results from the nurses' health study. Breast Cancer Res 12 (6): R106, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21143857&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21143857&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.2">Goldacre MJ, Abisgold JD, Yeates DG, et al.: Benign breast disease and subsequent breast cancer: English record linkage studies. J Public Health (Oxf) 32 (4): 565-71, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20154063&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20154063&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.3">Kabat GC, Jones JG, Olson N, et al.: A multi-center prospective cohort study of benign breast disease and risk of subsequent breast cancer. Cancer Causes Control 21 (6): 821-8, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20084540&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20084540&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.4">Worsham MJ, Raju U, Lu M, et al.: Risk factors for breast cancer from benign breast disease in a diverse population. Breast Cancer Res Treat 118 (1): 1-7, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18836828&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18836828&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _1
      field_pdq_section_title:
        - format: plain_text
          value: 'Overview'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_1" class="pdq-sections"><p id="_2" tabindex="-1">Note: Separate PDQ summaries on <a href="/types/breast/hp/breast-screening-pdq">Breast Cancer Screening</a>; <a href="/types/breast/hp/breast-treatment-pdq">Breast Cancer
            Treatment</a>; <a href="/types/breast/hp/male-breast-treatment-pdq">Male Breast Cancer Treatment</a>;  <a href="/types/breast/hp/pregnancy-breast-treatment-pdq">Breast Cancer Treatment During Pregnancy</a>; and <a href="/publications/pdq/levels-evidence/screening-prevention">Levels of Evidence for Cancer Screening and Prevention Studies</a> are
            also available.
            </p><section id="_175"><h3 id="_175_toc">Factors With Adequate Evidence of Increased Risk of Breast Cancer</h3><section id="_562"><h4 id="_562_toc">Sex and age</h4><p id="_563" tabindex="-1">Based on solid evidence, female sex and increasing age are the major risk factors for the development of breast cancer.</p><p id="_564" tabindex="-1"><strong>Magnitude of Effect</strong>: Women have a lifetime risk of developing breast cancer that is approximately 100 times the risk for men.  The short-term risk of breast cancer in a 70-year-old woman is about ten times that of a 30-year-old woman.</p><div class="pdq-content-list"><ul id="_565" class="pdq-address-block"><li><strong>Study Design</strong>: Many epidemiologic trials.</li><li><strong>Internal Validity</strong>: Good.</li><li><strong>Consistency</strong>: Good.</li><li><strong>External Validity</strong>: Good.</li></ul></div></section><section id="_697"><h4 id="_697_toc">Inherited risk</h4><p id="_698" tabindex="-1">Based on solid evidence, women who have a family history of breast cancer, especially in a first-degree relative, have an increased risk of breast cancer.</p><p id="_699" tabindex="-1"><strong>Magnitude of Effect</strong>: Risk is doubled if a single first-degree relative is affected; risk is increased fivefold if two first-degree relatives are diagnosed.</p><div class="pdq-content-list"><ul id="_700" class="pdq-address-block"><li><strong>Study Design</strong>: Population studies, cohort studies, and case-control studies.</li><li><strong>Internal Validity</strong>: Good.</li><li><strong>Consistency</strong>: Good.</li><li><strong>External Validity</strong>: Good.</li></ul></div><p id="_567" tabindex="-1">Based on solid evidence, women who inherit gene mutations associated with breast cancer have an increased risk.</p><p id="_568" tabindex="-1"><strong>Magnitude of Effect</strong>: Variable, depending on gene mutation, family history, and other risk factors affecting gene expression.</p><div class="pdq-content-list"><ul id="_569" class="pdq-address-block"><li><strong>Study Design</strong>: Cohort or case-control studies.</li><li><strong>Internal Validity</strong>: Good.</li><li><strong>Consistency</strong>: Good.</li><li><strong>External Validity</strong>: Good.</li></ul></div></section><section id="_570"><h4 id="_570_toc">Breast density</h4><p id="_571" tabindex="-1">Based on solid evidence, women with dense breasts have an increased risk of breast cancer. This is most often an inherent characteristic, to some extent modifiable by reproductive behavior, medications, and alcohol.[<a href="#cit/section_2.1">1</a>]</p><p id="_572" tabindex="-1"><strong>Magnitude of Effect</strong>: Women with dense breasts have increased risk, proportionate to the degree of density. This increased relative risk (RR) ranges from 1.79 for women with slightly increased density to 4.64 for women with very dense breasts, compared with women who have the lowest breast density.[<a href="#cit/section_2.2">2</a>]</p><div class="pdq-content-list"><ul id="_573" class="pdq-address-block"><li><strong>Study Design</strong>: Cohort, case-control studies.</li><li><strong>Internal Validity</strong>: Good.</li><li><strong>Consistency</strong>: Good.</li><li><strong>External Validity</strong>: Good.</li></ul></div></section></section><section id="_574"><h3 id="_574_toc">Modifiable Factors With Adequate Evidence of Increased Risk of Breast Cancer</h3><section id="_575"><h4 id="_575_toc">Combination hormone therapy</h4><p id="_576" tabindex="-1">Based on  solid evidence,  combination hormone  therapy  (HT) (estrogen-progestin)  is associated with an increased risk of developing breast cancer.</p><p id="_577" tabindex="-1"><strong>Magnitude of Effect</strong>: Approximately a 26% increase in incidence of invasive breast cancer; the number needed to produce one excess breast cancer is 237.</p><div class="pdq-content-list"><ul id="_578" class="pdq-address-block"><li><strong>Study Design</strong>: Randomized controlled trials (RCTs).  Furthermore, cohort and ecological studies show that cessation of combination HT is associated with a decrease in rates of breast cancer. </li><li><strong>Internal Validity</strong>: Good.</li><li><strong>Consistency</strong>: Good.</li><li><strong>External Validity</strong>: Good.</li></ul></div></section><section id="_579"><h4 id="_579_toc">Ionizing radiation</h4><p id="_580" tabindex="-1">Based on solid evidence, exposure of the breast to ionizing radiation is associated with an increased risk of developing breast cancer, starting 10 years after exposure and persisting lifelong. Risk depends on radiation dose and age at exposure, and is especially high if exposure occurs during puberty, when the breast develops.</p><p id="_581" tabindex="-1"><strong>Magnitude of Effect</strong>: Variable but approximately a sixfold increase overall. </p><div class="pdq-content-list"><ul id="_582" class="pdq-address-block"><li><strong>Study Design</strong>: Cohort or case-control studies.</li><li><strong>Internal Validity</strong>: Good.</li><li><strong>Consistency</strong>: Good.</li><li><strong>External Validity</strong>: Good.</li></ul></div></section><section id="_583"><h4 id="_583_toc">Obesity</h4><p id="_584" tabindex="-1">Based on solid evidence, obesity is associated with an increased breast cancer risk in postmenopausal women who have not used HT. It is uncertain whether weight reduction decreases the risk of breast cancer in obese women.</p><p id="_585" tabindex="-1"><strong>Magnitude of Effect</strong>: The Women's Health Initiative observational study of 85,917 postmenopausal women found body weight to be associated with breast cancer. Comparing women weighing more than 82.2 kg with those weighing less than 58.7 kg, the RR was 2.85 (95% confidence interval [CI], 1.81&#x2013;4.49).</p><div class="pdq-content-list"><ul id="_586" class="pdq-address-block"><li><strong>Study Design</strong>: Case-control and cohort studies.</li><li><strong>Internal Validity</strong>: Good.</li><li><strong>Consistency</strong>: Good.</li><li><strong>External Validity</strong>: Good.</li></ul></div></section><section id="_587"><h4 id="_587_toc">Alcohol</h4><p id="_588" tabindex="-1">Based on solid evidence, alcohol consumption is associated with increased breast cancer risk in a dose-dependent fashion. It is uncertain whether decreasing alcohol intake by heavy drinkers reduces the risk.</p><p id="_589" tabindex="-1"><strong>Magnitude of Effect</strong>: The RR for women consuming approximately four alcoholic drinks per day compared with nondrinkers is 1.32 (95% CI, 1.19&#x2013;1.45). The RR increases by 7% (95% CI, 5.5%&#x2013;8.7%) for each drink per day.</p><div class="pdq-content-list"><ul id="_590" class="pdq-address-block"><li><strong>Study Design</strong>: Case-control and cohort studies.</li><li><strong>Internal Validity</strong>: Good.</li><li><strong>Consistency</strong>: Good.</li><li><strong>External Validity</strong>: Good.</li></ul></div></section></section><section id="_366"><h3 id="_366_toc">Factors With Adequate Evidence of Decreased Risk of Breast Cancer</h3><section id="_591"><h4 id="_591_toc">Early pregnancy</h4><p id="_592" tabindex="-1">Based on solid evidence, women who have a full-term pregnancy before age 20 years have decreased breast cancer risk. </p><p id="_593" tabindex="-1"><strong>Magnitude of Effect</strong>: 50% decrease in breast cancer, compared with nulliparous women or women who give birth after age 35 years.</p><div class="pdq-content-list"><ul id="_594" class="pdq-address-block"><li><strong>Study Design</strong>: Case-control and cohort studies.</li><li><strong>Internal Validity</strong>: Good.</li><li><strong>Consistency</strong>: Good.</li><li><strong>External Validity</strong>: Good.</li></ul></div></section><section id="_595"><h4 id="_595_toc">Breast-feeding</h4><p id="_596" tabindex="-1">Based on solid evidence, women who breast-feed have a decreased risk of breast cancer.</p><p id="_597" tabindex="-1"><strong>Magnitude of Effect</strong>: The RR of breast cancer is decreased 4.3% for every 12 months of breast-feeding, in addition to 7% for each birth.[<a href="#cit/section_2.3">3</a>]</p><div class="pdq-content-list"><ul id="_598" class="pdq-address-block"><li><strong>Study Design</strong>: Case-control and cohort studies.</li><li><strong>Internal Validity</strong>: Good.</li><li><strong>Consistency</strong>: Good.</li><li><strong>External Validity</strong>: Good.</li></ul></div></section><section id="_599"><h4 id="_599_toc">Exercise</h4><p id="_600" tabindex="-1">Based on solid evidence, exercising strenuously for more than 4 hours per week is associated with reduced breast cancer risk.</p><p id="_601" tabindex="-1"><strong>Magnitude of Effect</strong>: Average RR reduction is 30% to 40%. The effect may be greatest for premenopausal women of normal or low body weight.</p><div class="pdq-content-list"><ul id="_602" class="pdq-address-block"><li><strong>Study Design</strong>: Prospective observational and case-control studies.</li><li><strong>Internal Validity</strong>: Good.</li><li><strong>Consistency</strong>: Good.</li><li><strong>External Validity</strong>: Good.</li></ul></div></section><section id="_523"><h4 id="_523_toc">Estrogen use by women with prior hysterectomy: benefits</h4><p id="_524" tabindex="-1">Based on fair evidence, women who have undergone a prior hysterectomy and who are treated with conjugated equine estrogen have a lower incidence of breast cancer. However, epidemiological studies yield conflicting results. </p><p id="_525" tabindex="-1"><strong>Magnitude of Effect</strong>: After 6.8 years, incidence was 23% lower in women treated with estrogen in an RCT (0.27% per year, with a median of 5.9 years of use, compared with 0.35% per year among those taking a placebo), but was 30% higher in women treated with estrogen in an observational study. The difference in these results may be explained by different screening behavior by the women in both studies.</p><div class="pdq-content-list"><ul id="_526" class="pdq-address-block"><li><strong>Study Design</strong>: One RCT, observational studies.</li><li><strong>Internal Validity</strong>:   Fair.</li><li><strong>Consistency</strong>:  Poor.</li><li><strong>External Validity</strong>: Poor.</li></ul></div></section><section id="_765"><h4 id="_765_toc">Estrogen use by women with prior hysterectomy: harms</h4><p id="_604" tabindex="-1">Based on solid evidence, women who have undergone hysterectomy and who are taking postmenopausal estrogen have an increased risk of stroke and total cardiovascular disease.</p><p id="_605" tabindex="-1"><strong>Magnitude of Effect</strong>: There is a 39% increase in the incidence of stroke (RR, 1.39; 95% CI, 1.1&#x2013;1.77) and a 12% increase in cardiovascular disease (RR, 1.12; 95% CI, 1.01&#x2013;1.24).</p><div class="pdq-content-list"><ul id="_606" class="pdq-address-block"><li><strong>Study Design</strong>: RCTs, observational studies.</li><li><strong>Internal Validity</strong>: Good.</li><li><strong>Consistency</strong>: Good.</li><li><strong>External Validity</strong>: Poor.</li></ul></div></section></section><section id="_115"><h3 id="_115_toc">Interventions With Adequate Evidence of Decreased Risk of Breast Cancer</h3><section id="_184"><h4 id="_184_toc"> Selective estrogen receptor modulators (SERMs): benefits</h4><p id="_250" tabindex="-1">Based on solid evidence, tamoxifen and raloxifene reduce the incidence of breast cancer in postmenopausal women, and tamoxifen reduces the risk of breast cancer in high-risk premenopausal women. The effects observed for tamoxifen and raloxifene show persistence several years after active treatment is discontinued, with longer duration of effect noted for tamoxifen than for raloxifene.[<a href="#cit/section_2.4">4</a>]</p><p id="_547" tabindex="-1">All fractures were reduced by SERMs, primarily noted with raloxifene but not with tamoxifen. Reductions in vertebral fractures (34% reduction) and small reductions in nonvertebral fractures (7%) were noted.[<a href="#cit/section_2.4">4</a>]</p><p id="_386" tabindex="-1"><strong>Magnitude of Effect</strong>: Tamoxifen reduced breast cancer incidence in high-risk women from about 30% to about 50% over 5 years of treatment but only for estrogen receptor&#x2013;positive (ER&#x2013;positive) cancer and ductal carcinoma <em>in situ</em> (DCIS).  The reduction in ER&#x2013;positive invasive breast cancer was maintained at about this level for at least 16 years after starting treatment, 11 years after cessation of tamoxifen.  There was no loss of effect between years 10 and 16 after starting tamoxifen (for 5 years) compared with years 0 to 10.  There was no effect on breast cancer mortality.[<a href="#cit/section_2.5">5</a>]</p><div class="pdq-content-list"><ul id="_251" class="pdq-address-block"><li><strong>Study Design</strong>: RCTs.</li><li><strong>Internal Validity</strong>: Good.</li><li><strong>Consistency</strong>: Good.</li><li><strong>External Validity</strong>: Good.</li></ul></div></section><section id="_766"><h4 id="_766_toc">Selective estrogen receptor modulators: harms</h4><p id="_609" tabindex="-1">Based on solid evidence, tamoxifen treatment increases the risk of endometrial cancer, which was apparent in the first 5 years of follow-up but not beyond; thrombotic vascular events (i.e., pulmonary embolism, stroke, and deep venous thrombosis); and cataracts. Many of these risks are reduced after active treatment with tamoxifen is discontinued. Based on solid evidence, raloxifene also increases venous pulmonary embolism and deep venous thrombosis but not endometrial cancer.</p><p id="_610" tabindex="-1"><strong>Magnitude of Effect</strong>:  Meta-analysis showed RR of 2.4 (95% CI, 1.5&#x2013;4.0) for endometrial cancer and 1.9 (95% CI, 1.4&#x2013;2.6) for venous thromboembolic events. Meta-analysis showed the hazard ratio (HR) for endometrial cancer was 2.18 (95% CI, 1.39&#x2013;3.42) for tamoxifen and 1.09 (95% CI, 0.74&#x2013;1.62) for raloxifene. Overall, HR for venous thromboembolic events was 1.73 (95% CI, 1.47&#x2013;2.05). Harms were significantly higher in women over 50 years than in younger women.</p><div class="pdq-content-list"><ul id="_611" class="pdq-address-block"><li><strong>Study Design</strong>: RCTs.</li><li><strong>Internal Validity</strong>: Good.</li><li><strong>Consistency</strong>: Good.</li><li><strong>External Validity</strong>: Good.</li></ul></div></section><section id="_260"><h4 id="_260_toc">Aromatase inhibitors or inactivators: benefits</h4><p id="_261" tabindex="-1">Based on solid evidence, aromatase inhibitors or inactivators (AIs) reduce the incidence of new breast cancers in postmenopausal women who have an increased risk.</p><p id="_388" tabindex="-1"><strong>Magnitude of Effect</strong>: After a median follow-up of 35 months, women aged 35 years and older who had at least one risk factor (age  &gt;60 years, a Gail 5-year risk      &gt;1.66%, or DCIS with mastectomy) and who took 25 mg of exemestane daily had a decreased risk of invasive breast cancer (HR,  0.35; 95% CI, 0.18&#x2013;0.70).  The absolute risk reduction was 21 cancers avoided out of 2,280 participants over 35 months. The number needed to treat was about 100.[<a href="#cit/section_2.6">6</a>]</p><div class="pdq-content-list"><ul id="_291" class="pdq-address-block"><li><strong>Study Design</strong>:  One RCT.</li><li><strong> Internal Validity</strong>: Good.</li><li><strong>Consistency</strong>: One study in women with no history of breast cancer but consistent with RCTs in women with history of breast cancer.</li><li><strong>External Validity</strong>: Good for women who meet inclusion criteria.</li></ul></div></section><section id="_767"><h4 id="_767_toc">Aromatase inhibitors or inactivators: harms</h4><p id="_263" tabindex="-1">Based on fair evidence  from a single RCT of 4,560 women over 35 months, exemestane is associated with  hot flashes  and fatigue  but not with fractures, osteoporosis, or cardiovascular events, compared with placebo.[<a href="#cit/section_2.6">6</a>,<a href="#cit/section_2.7">7</a>]</p><p id="_389" tabindex="-1"><strong>Magnitude of Effect</strong>: The absolute increase in hot flashes was 8% and the absolute increase in fatigue was 2%.</p><div class="pdq-content-list"><ul id="_292" class="pdq-address-block"><li><strong>Study Design</strong>: One RCT.</li><li><strong> Internal Validity</strong>: Good.</li><li><strong>Consistency</strong>: Good.</li><li><strong>External Validity</strong>: Good for women who meet inclusion criteria.</li></ul></div></section><section id="_186"><h4 id="_186_toc">Prophylactic mastectomy: benefits</h4><p id="_187" tabindex="-1">Based on solid evidence, bilateral prophylactic mastectomy reduces the risk of breast cancer in women with a strong family history, and most women experience relief from anxiety about breast cancer risk.  There are no studies examining breast cancer outcomes in women who undergo contralateral prophylactic mastectomy after surgery for ipsilateral breast cancer.</p><p id="_390" tabindex="-1"><strong>Magnitude of Effect</strong>: Breast cancer risk after bilateral prophylactic mastectomy in women at high risk is reduced as much as 90%, but published study designs may have produced an overestimate.</p><div class="pdq-content-list"><ul id="_293" class="pdq-address-block"><li><strong>Study Design</strong>: Evidence obtained from case-control and  cohort studies.</li><li><strong> Internal Validity</strong>: Good.</li><li><strong>Consistency</strong>: Good.</li><li><strong>External Validity</strong>: Good.</li></ul></div></section><section id="_266"><h4 id="_266_toc">Prophylactic oophorectomy or ovarian ablation: benefits</h4><p id="_267" tabindex="-1">Based on solid evidence, premenopausal women with <em>BRCA</em> gene mutations who undergo prophylactic oophorectomy have lower breast cancer incidence.   Similarly, oophorectomy or ovarian ablation is associated with decreased breast cancer incidence in normal premenopausal women and in women with increased breast cancer risk resulting from thoracic irradiation. </p><p id="_392" tabindex="-1"><strong>Magnitude of Effect</strong>: Breast cancer incidence is decreased by 50%, but published study designs may have produced an overestimate.</p><div class="pdq-content-list"><ul id="_295" class="pdq-address-block"><li><strong>Study Design</strong>: Observational, case-control, and cohort studies.</li><li> <strong>Internal Validity</strong>: Good.</li><li><strong>Consistency</strong>: Good.</li><li><strong>External Validity</strong>: Good.</li></ul></div></section><section id="_768"><h4 id="_768_toc">Prophylactic oophorectomy or ovarian ablation: harms</h4><p id="_617" tabindex="-1">Based on solid evidence, castration may cause the abrupt onset of menopausal symptoms such as hot flashes, insomnia, anxiety, and depression. Long-term effects include decreased libido, vaginal dryness, and decreased bone mineral density.</p><p id="_618" tabindex="-1"><strong>Magnitude of Effect</strong>: Nearly all women experience some sleep disturbances, mood changes, hot flashes, and bone demineralization, but the severity of these symptoms varies greatly. </p><div class="pdq-content-list"><ul id="_619" class="pdq-address-block"><li><strong>Study Design</strong>: Observational, case-control, and cohort studies.</li><li><strong> Internal Validity</strong>: Good.</li><li><strong>Consistency</strong>: Good.</li><li><strong>External Validity</strong>: Good.</li></ul></div></section></section><h6 do-not-show="toc">References</h6><ol><li id="section_2.1">Boyd NF, Martin LJ, Rommens JM, et al.: Mammographic density: a heritable risk factor for breast cancer. Methods Mol Biol 472: 343-60, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19107441&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19107441&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.2">McCormack VA, dos Santos Silva I: Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15 (6): 1159-69, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16775176&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16775176&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.3">Col: Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 360 (9328): 187-95, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12133652&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12133652&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.4">Cuzick J, Sestak I, Bonanni B, et al.: Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 381 (9880): 1827-34, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23639488&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23639488&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.5">Cuzick J, Sestak I, Cawthorn S, et al.: Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 16 (1): 67-75, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25497694&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25497694&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.6">Goss PE, Ingle JN, Al&#xE9;s-Mart&#xED;nez JE, et al.: Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364 (25): 2381-91, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21639806&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21639806&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.7">Maunsell E, Goss PE, Chlebowski RT, et al.: Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. J Clin Oncol 32 (14): 1427-36, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24711552&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24711552&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _29
      field_pdq_section_title:
        - format: plain_text
          value: 'Description of the Evidence'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_29" class="pdq-sections"><section id="_30"><h3 id="_30_toc">Incidence and Mortality</h3><p id="_31" tabindex="-1">With an estimated  266,120 cases expected, breast
            cancer will be the most frequently diagnosed nonskin malignancy in U.S. women
            in 2018.[<a href="#cit/section_3.1">1</a>]  Also in 2018, breast cancer will kill an estimated 40,920
            women, second only to lung cancer as a cause of cancer mortality in women.
            Breast cancer also occurs in men, and it is estimated that   2,550 new cases will be diagnosed in
            2018.[<a href="#cit/section_3.1">1</a>]    Despite a prior long-term trend of gradually increasing breast cancer
            incidence in women, data from the Surveillance, Epidemiology, and End Results
            Program show a decrease in breast cancer mortality of 1.8% per year from 2005 to 2014.[<a href="#cit/section_3.2">2</a>,<a href="#cit/section_3.3">3</a>]</p><p id="_624" tabindex="-1">The major risk factor for breast cancer is advancing age.  A 30-year-old woman has a 1 in 250 chance of being diagnosed with breast cancer in the next 10 years, whereas a 70-year-old woman has a 1 in 27 chance.[<a href="#cit/section_3.4">4</a>]</p><p id="_679" tabindex="-1">Breast cancer incidence and mortality risk also vary on the basis of geography, culture, race, ethnicity, and socioeconomic status. Compared with other races, white women have a higher incidence of breast cancer that may be attributable, in part, to screening behavior. However, breast cancer incidence rates increased slightly in black women  by 0.3% per year between 2005 and 2014, resulting in the convergence of rates in blacks
            with those in whites.[<a href="#cit/section_3.1">1</a>,<a href="#cit/section_3.5">5</a>]</p><p id="_625" tabindex="-1">Screening by mammography decreases breast cancer mortality by identifying cases for treatment at an earlier stage. However, screening also identifies more cases than would become symptomatic in a woman&#x2019;s lifetime, so screening increases breast cancer incidence. (Refer to the Overdiagnosis section in the PDQ summary on <a href="/types/breast/hp/breast-screening-pdq">Breast Cancer Screening</a> for more information.)</p></section><section id="_34"><h3 id="_34_toc">Etiology and Pathogenesis of Breast Cancer</h3><p id="_35" tabindex="-1">Breast cancer develops when a series of genetic mutations occurs.[<a href="#cit/section_3.6">6</a>]  Initially, mutations do not change the histologic appearance of the tissue, but accumulated mutations will result in hyperplasia, dysplasia, carcinoma <em>in situ</em>, and eventually, invasive cancer.[<a href="#cit/section_3.7">7</a>] The longer a woman lives, the more somatic mutations occur, and the more likely it is that these mutations will produce populations of cells that will evolve into malignancies. Estrogen and progestin cause growth and proliferation of breast cells that may work through growth factors such as transforming growth factor (TGF)-alpha.[<a href="#cit/section_3.8">8</a>] These hormones, whether endogenous or exogenous, may promote the development and proliferation of breast cancer cells.
            </p><p id="_36" tabindex="-1">International variation in breast cancer rates may be explained by differences in genetics, reproductive factors, diet, exercise and screening behavior.  Some of these factors are modifiable, as evidenced by the observation that Japanese immigrants to the United States increase their breast cancer risk from lower Japanese levels to higher American levels within two generations.[<a href="#cit/section_3.9">9</a>-<a href="#cit/section_3.11">11</a>]
            </p></section><section id="_37"><h3 id="_37_toc">Endogenous Estrogen</h3><p id="_276" tabindex="-1">Many of the risk factors for breast cancer suggest that longer exposure to endogenous estrogen plays a role in the development of the disease. Women who experienced menarche at age 11 years or younger have about a 20% greater chance of developing breast cancer than do those who experienced menarche at age 14 years or older.[<a href="#cit/section_3.12">12</a>-<a href="#cit/section_3.14">14</a>] Women who experience late menopause also have an increased risk. Women who develop breast cancer tend to have higher endogenous estrogen and androgen levels.[<a href="#cit/section_3.14">14</a>-<a href="#cit/section_3.18">18</a>]</p><p id="_38" tabindex="-1">Conversely, women who experience premature menopause have a lower risk of breast cancer.   Following ovarian ablation,
            breast cancer risk may be reduced as much as 75% depending on age, weight, and parity, with the greatest reduction for young,
            thin, nulliparous women.[<a href="#cit/section_3.19">19</a>-<a href="#cit/section_3.22">22</a>] The removal of one ovary
            also reduces the risk of breast cancer but to a lesser degree than does the removal
            of both ovaries.[<a href="#cit/section_3.23">23</a>]
            </p><p id="_39" tabindex="-1">Other hormonal changes also
            influence breast cancer risk.  (Refer to the <a href="/types/breast/hp/breast-prevention-pdq#link/_428">Early pregnancy</a> and <a href="/types/breast/hp/breast-prevention-pdq#link/_430">Breast-feeding</a> sections in the <a href="/types/breast/hp/breast-prevention-pdq#link/_423">Factors With Adequate Evidence of Decreased Risk of Breast Cancer</a> section of this summary for more information.)</p><p id="_626" tabindex="-1">The interaction of endogenous estrogen levels, insulin levels, and obesity&#x2014;all of which affect breast cancer risk&#x2014;are poorly understood but suggest strategies for interventions to decrease that risk.  It is likely that reproductive risk factors interact with predisposing genotypes. For example, in the Nurses&#x2019; Health Study,[<a href="#cit/section_3.24">24</a>] the associations between age at first birth, menarche, and menopause and the development of breast cancer were observed only among women without a family history of breast cancer in a mother or sister.</p></section><section id="_701"><h3 id="_701_toc">Inherited Risk</h3><p id="_702" tabindex="-1">Breast cancer risk increases in women with a positive family history, particularly if first-degree relatives are affected.[<a href="#cit/section_3.24">24</a>]  The following risk assessment models, derived from databases, cohort, and case-control studies, quantitate this risk:</p><div class="pdq-content-list"><ul id="_741"><li><a href="https://bcrisktool.cancer.gov" title="https://bcrisktool.cancer.gov">Breast Cancer Risk Assessment Tool [Gail Model]</a>.</li><li><a href="https://tools.bcsc-scc.org/BC5yearRisk/intro.htm" title="https://tools.bcsc-scc.org/BC5yearRisk/intro.htm">Breast Cancer Surveillance Consortium [BCSC] Risk Calculator</a>.</li><li><a href="https://www.breastcancergenescreen.org/" title="https://www.breastcancergenescreen.org/">Breast Cancer Referral Screening Tool [B-RST]</a>.</li><li><a href="http://halls.md/breast/risk.htm" title="http://halls.md/breast/risk.htm">Hall Detailed Breast Risk Calculator</a>.</li><li><a href="http://www.ems-trials.org/riskevaluator/" title="http://www.ems-trials.org/riskevaluator/">IBIS Breast Cancer Risk Calculator Tool</a>.</li></ul></div><p id="_742" tabindex="-1">Specific abnormal alleles are associated with approximately 5% of breast cancers. (Refer to the  PDQ summary on <a href="/types/breast/hp/breast-ovarian-genetics-pdq">Genetics of Breast and Gynecologic Cancers</a> for more information.)  Mutations in <em>BRCA</em> genes are inherited in an autosomal dominant fashion and are highly penetrant in causing cancer, often at a younger age.[<a href="#cit/section_3.25">25</a>-<a href="#cit/section_3.27">27</a>] Family history and mutation location within the <em>BRCA1</em> or <em>BRCA2</em> gene may contribute to the risk of cancer development among those with an inherited predisposition to breast cancer.[<a href="#cit/section_3.28">28</a>] The lifetime risk of breast cancer is 55% to 65% for <em>BRCA1</em> mutation carriers and 45% to 47% for <em>BRCA2</em> mutation carriers.[<a href="#cit/section_3.29">29</a>,<a href="#cit/section_3.30">30</a>] In comparison, the lifetime risk of breast cancer is 12.4% in the general population.[<a href="#cit/section_3.31">31</a>]</p><p id="_743" tabindex="-1">Some women inherit a susceptibility to mutagens or growth factors, which increase breast cancer risk.[<a href="#cit/section_3.32">32</a>,<a href="#cit/section_3.33">33</a>] (Refer to the <a href="/types/breast/hp/breast-prevention-pdq#link/_149">Ionizing radiation exposure</a> section in the <a href="/types/breast/hp/breast-prevention-pdq#link/_410">Factors With Adequate Evidence of Increased Risk of Breast Cancer</a> section of this summary for more information.)</p></section><section id="_703"><h3 id="_703_toc">Increased Breast Density</h3><p id="_704" tabindex="-1">Widespread use of screening mammograms has revealed varying amounts of mammographically dense tissue and that women with a greater proportion of dense tissue have a higher incidence of breast cancer. Mammographic density also confounds the identification of cancers by that technology.  The extent of increased risk was described in a report of three nested case-control studies in screened populations with 1,112 matched case-control pairs.  Compared with women with density comprising less than 10% of breast tissue, women with density in 75% or more of their breast had an increased risk of breast cancer (odds ratio [OR], 4.7; 95% confidence interval [CI], 3.0&#x2013;7.4), whether the cancer was detected by screening (OR, 3.5; 95% CI, 2.0&#x2013;6.2) or detected less than 12 months after a negative screening examination (OR, 17.8; 95% CI, 4.8&#x2013;65.9). Increased risk of breast cancer, whether detected by screening or other means, persisted for at least 8 years after study entry and was greater in younger women than in older women. For women younger than the median age of 56 years, 26% of all breast cancers and 50% of cancers detected less than 12 months after a negative screening test were identified in women with mammographic breast density of 50% or more.[<a href="#cit/section_3.34">34</a>,<a href="#cit/section_3.35">35</a>]</p><p id="_705" tabindex="-1">Women with dense breasts have increased risk, proportionate to the degree of density. This increased relative risk (RR) ranges from 1.79 for women with slightly increased breast density to 4.64 for women with very dense breasts, compared with women who have the lowest breast density.[<a href="#cit/section_3.36">36</a>] There is no increased risk of breast cancer mortality among women with dense breast tissue.[<a href="#cit/section_3.37">37</a>]</p></section><section id="_410"><h3 id="_410_toc">Factors With Adequate Evidence of Increased Risk of Breast Cancer</h3><section id="_416"><h4 id="_416_toc">Hormone therapy</h4><p id="_480" tabindex="-1">Based on a 1997 reanalysis of 51 epidemiological studies encompassing more than 150,000 women,  hormone therapy (HT) after menopause was shown to be associated with increased  breast cancer risk.[<a href="#cit/section_3.38">38</a>]</p><p id="_481" tabindex="-1">The Heart and Estrogen/Progestin Replacement Study supported this finding  in 2002.[<a href="#cit/section_3.39">39</a>] In this study, 2,763 women with coronary heart disease at a mean age of 67 years were randomly assigned to receive either estrogen and progestin therapy or placebo. After a mean follow-up of 6.8 years, the RR for breast cancer was 1.27 (95% CI, 0.84&#x2013;1.94). Although not statistically significant, the RR estimate is consistent with the much larger  Women&#x2019;s Health Initiative (WHI), also published in 2002.</p><p id="_482" tabindex="-1">The WHI investigated the effect of hormones and dietary interventions on heart disease and breast cancer risk.[<a href="#cit/section_3.40">40</a>] Women aged 50 to 79 years with intact uteri were randomly assigned to receive combined conjugated estrogen with continuous progestin (n = 8,506) or placebo (n = 8,102). The trial was terminated early because combined HT did not decrease coronary heart disease risk but did increase the risk of stroke and breast cancer. An increased rate of invasive breast cancer risk  (hazard ratio [HR], 1.24; 95% CI, 1.02&#x2013;1.50), but not for <em>in situ</em> breast cancer,  was observed in all subgroups of women. The combined HT-related cancers had similar grade, histology, and expression of estrogen receptor (ER), progesterone receptor, and <em>HER2</em>/neu, with a trend toward larger size and higher incidence of lymph node metastases in the combined HT group.[<a href="#cit/section_3.41">41</a>] Extended follow-up  of a mean of 11 years showed higher breast cancer&#x2013;specific mortality for the HT group (25 vs. 12 deaths, 0.03% vs. 0.01% per year; HR, 1.95; 95% CI, 1.0&#x2013;4.04; <em>P</em> = .049). Combined HT was also associated with a higher percentage of abnormal mammograms.[<a href="#cit/section_3.42">42</a>]</p><p id="_544" tabindex="-1">The WHI observational study was conducted in parallel with the WHI randomized controlled trial (RCT), recruiting postmenopausal women aged 50 to 79 years.  An analysis was conducted in the observational study of the WHI to further examine the  prognosis of women taking combination HT who were diagnosed with breast cancer and the risks based on time between menopause and initiation of HT. After a mean follow-up of 11.3 years,  the annualized incidence of breast cancer among women using estrogen plus progestin  was 0.60%, compared with 0.42% among nonusers (HR, 1.55; 95% CI, 1.41&#x2013;1.70). Survival after the diagnosis of breast cancer was similar for combined HT users and nonusers.  Death from breast cancer was higher among combined HT users than among nonusers, but the difference was not statistically significant (HR, 1.3; 94% CI, 0.90&#x2013;1.93).  Risks were highest among women initiating HT at the time of menopause, and risks diminished but persisted  with increasing time between menopause and starting combination HT.     All-cause mortality after the diagnosis of breast cancer was statistically significantly higher among combined HT users than among nonusers (HR, 1.87; 95% CI, 1.37&#x2013;2.54.)  Overall, these findings were consistent with results from the RCT.[<a href="#cit/section_3.43">43</a>]</p><p id="_511" tabindex="-1">The WHI also studied women who had previously undergone a hysterectomy and thus were not at risk for endometrial cancer, which is associated with unopposed estrogen therapy. Women aged 50 to 79 years (N = 10,739) were randomly assigned to receive conjugated equine estrogen (CEE) or placebo. This trial was also stopped early because of an increased risk of stroke and no improvement in a global risk-benefit index.[<a href="#cit/section_3.44">44</a>,<a href="#cit/section_3.45">45</a>] After an average 6.8 years of follow-up, breast cancer incidence was lower in the group receiving CEE (0.26% per year vs. 0.33%; HR, 0.77; 95% CI, 0.59&#x2013;1.01). The global risk-benefit index was slightly worse for CEE.[<a href="#cit/section_3.44">44</a>] An extended follow-up for a median of 11.8 years included 78% of the trial participants.[<a href="#cit/section_3.45">45</a>,<a href="#cit/section_3.46">46</a>] Results seen in the initial study persisted, with a similar risk reduction for breast cancer in CEE recipients  (HR, 0.77; 95% CI, 0.62&#x2013;0.95) [<a href="#cit/section_3.45">45</a>,<a href="#cit/section_3.46">46</a>] and a decrease in breast cancer mortality (6 vs. 16 deaths; HR, 0.37; 95% CI, 0.13&#x2013;0.91). All-cause mortality was also lower in the CEE group (0.046% vs. 0.076% per year; HR, 0.62; 95% CI, 0.39&#x2013;0.97). After CEE was discontinued, the risk of stroke decreased in the postintervention period. Over the entire follow-up period, there was no difference in the incidence of coronary heart disease, deep vein thrombosis, stroke, hip fracture, or colorectal cancer.[<a href="#cit/section_3.45">45</a>] Breast cancer incidence was similar for women who initiated CEE or placebo within the first 5 years after onset of menopause (HR, 1.06; 95% CI, 0.74&#x2013;1.51).</p><p id="_535" tabindex="-1">A Danish trial of HT for 1,006 women entering menopause was designed to evaluate cardiovascular outcomes.  Combined HT (triphasic estradiol and norethisterone) was given to 407 women with intact uteri, and estradiol was given to 95 women who had undergone hysterectomy.  Controls (407 with intact uteri and 97 with hysterectomy) were not treated.  At 10 years, there was considerable contamination. Only one-half of the women assigned to the HT group were still taking the prescribed HT, and 22% of the control women had begun HT.  Cardiovascular outcomes favored HT-treated women, and there was no difference in breast cancer incidence.[<a href="#cit/section_3.47">47</a>]</p><p id="_627" tabindex="-1">Observational studies augment the information obtained in RCTs.</p><p id="_512" tabindex="-1">The Million Women Study [<a href="#cit/section_3.48">48</a>] recruited 1,084,110 women aged 50 to 64 years in the United Kingdom between 1996 and 2001 and obtained information about HT use and other personal details.  The women were followed for breast cancer incidence and death.  One-half of the women had used HT.  At 2.6 years of follow up, there were 9,364 invasive breast cancers; at 4.1 years, there were 637 breast cancer deaths.  Current users of HT at recruitment were more likely than never-users to develop breast cancer (adjusted RR = 1.66; 95% CI, 1.58&#x2013;1.75; <em>P</em> &lt; .0001) and to die from the disease (adjusted RR, 1.22; 95% CI, 1.00&#x2013;1.48; <em>P</em> = .05). Past users of HT were, however, not at an increased risk of incident or fatal breast cancer (1.01 [95% CI, 0.94&#x2013;1.09] and 1.05 [95% CI, 0.82&#x2013;1.34], respectively). Incidence was significantly increased for current users of estrogen only (RR, 1.30; 95% CI, 1.21&#x2013;1.40; <em>P</em> &lt; .0001), combined HT (RR, 2.00; 95% CI, 1.88&#x2013;2.12; <em>P</em> &lt; .0001), and tibolone (RR, 1.45; 95% CI, 1.25&#x2013;1.68; <em>P</em> &lt; .0001).  The magnitude of the associated risk was substantially greater for combined HT than for other types of HT (<em>P</em> &lt; .0001).</p><p id="_628" tabindex="-1">A population-based survey of 965 women with breast cancer and 1,007 controls was conducted by the Cancer Surveillance System of Puget Sound. It showed that combined HT users had a 1.7-fold increased risk of invasive breast cancer, whereas estrogen-only users did not.[<a href="#cit/section_3.49">49</a>]</p><p id="_629" tabindex="-1">The association between the use of combined HT and increased breast cancer risk is consistent throughout all the trials. In contrast, the association between estrogen-only HT and breast cancer incidence is confusing because some studies show increased risk and some show protection.  It is possible that the timing of estrogen-only HT in relation to the onset of menopause is critical.  Furthermore, observational studies may not account for different screening behavior between HT users and nonusers, whereas RCTs, by design, will control that variable.[<a href="#cit/section_3.50">50</a>,<a href="#cit/section_3.51">51</a>]</p><p id="_494" tabindex="-1">Following publication of the WHI results, HT use dropped dramatically in the United States and elsewhere.  Follow-up of WHI participants on the combined HT arm demonstrated a rapid decrease in the elevated breast cancer risk of therapy within 2 years, despite similar rates of mammography screening.[<a href="#cit/section_3.52">52</a>]   Analysis of changes in breast cancer rates in the United States  observed a sharp decline in breast cancer incidence rates from 2002 to 2003 among women aged 50 years and older, especially for estrogen receptor (ER)&#x2013;positive cancers.[<a href="#cit/section_3.53">53</a>,<a href="#cit/section_3.54">54</a>] Similarly, in multiple  countries where  HT use was high, breast cancer rates decreased  in a similar time frame, coincident with decreases in prescribing patterns and/or reported prevalence of use.[<a href="#cit/section_3.55">55</a>-<a href="#cit/section_3.57">57</a>]         A study among women receiving regular mammography screening supports that the observed sharp decline from 2002 to 2003 in breast cancer incidence was primarily caused by withdrawal of HT rather than declines in mammography rates.[<a href="#cit/section_3.58">58</a>]    After  the decline in breast cancer incidence  from 2002 to 2003, rates in the United States stabilized.[<a href="#cit/section_3.58">58</a>,<a href="#cit/section_3.59">59</a>]   </p></section><section id="_149"><h4 id="_149_toc">Ionizing radiation exposure</h4><p id="_150" tabindex="-1">A well-established relationship exists between exposure to ionizing radiation
            and subsequent breast cancer.[<a href="#cit/section_3.60">60</a>]  Excess breast cancer risk has been  observed in association with atomic bomb exposure, frequent
            fluoroscopy for tuberculosis, and radiation therapy  for acne, tinea, thymic
            enlargement, postpartum mastitis, and lymphoma.  Risk is higher for the young, especially around puberty.  An
            estimate of the risk of breast cancer associated with medical radiology puts
            the figure at less than 1% of the total.[<a href="#cit/section_3.61">61</a>] However, it has been theorized that
            certain populations, such as <em>AT</em>  heterozygotes, are at
            an increased risk of breast cancer from  radiation exposure.[<a href="#cit/section_3.32">32</a>] A large cohort study of women who carry mutations of <em>BRCA1</em> or <em>BRCA2</em> concluded that chest x-rays increase the risk of breast cancer even more (RR, 1.54; 95% CI, 1.1&#x2013;2.1), especially for women who had x-rays before age  20 years.[<a href="#cit/section_3.62">62</a>]</p><p id="_151" tabindex="-1">Women treated for Hodgkin lymphoma by  age  16 years have a subsequent risk up to 35% of
            developing breast cancer by  age 40 years.[<a href="#cit/section_3.63">63</a>-<a href="#cit/section_3.65">65</a>]  Higher radiation doses  (median dose, 40 Gy in breast cancer cases) and
            treatment  between the ages of 10 and 16 years are associated with   higher risk.[<a href="#cit/section_3.63">63</a>]    Unlike the risk for secondary leukemia, the risk of
            treatment-related breast cancer does not abate with duration of follow-up, persisting more than 25 years after treatment.[<a href="#cit/section_3.63">63</a>,<a href="#cit/section_3.65">65</a>,<a href="#cit/section_3.66">66</a>]
            In these studies, most  patients  (85%&#x2013;100%) who developed
            breast cancer did so either within the field of radiation or at the
            margin.[<a href="#cit/section_3.63">63</a>,<a href="#cit/section_3.64">64</a>,<a href="#cit/section_3.66">66</a>] A Dutch study examined 48 women who developed breast cancer at least 5 years after treatment for Hodgkin disease and  compared them with 175 matched female Hodgkin disease patients who did not develop breast cancer. Patients treated with chemotherapy and mantle radiation were less likely to develop breast cancer than were those treated with mantle radiation alone, possibly because of chemotherapy-induced ovarian suppression (RR, 0.06; 95% CI, 0.01&#x2013;0.45).[<a href="#cit/section_3.67">67</a>] Another study of 105 radiation-associated breast cancer patients and 266  age-matched and radiation-matched controls showed a similar protective effect for ovarian radiation.[<a href="#cit/section_3.65">65</a>]  These studies suggest that ovarian hormones promote the proliferation of breast tissue with radiation-induced mutations.[<a href="#cit/section_3.65">65</a>]  </p><p id="_152" tabindex="-1">The question arises whether breast cancer patients treated with lumpectomy and radiation therapy
            (L-RT) are at higher risk for second breast malignancies or other malignancies
            than are  those treated by mastectomy.  Outcomes of 1,029 L-RT patients
            were compared with  outcomes of 1,387 patients who underwent mastectomies.
            After a median follow-up of 15 years, there was no difference in the risk of
            second malignancies.[<a href="#cit/section_3.68">68</a>]   Further evidence from three RCTs is also reassuring. One report of 1,851 women randomly assigned to undergo total mastectomy, lumpectomy alone, or L-RT showed rates of contralateral breast cancer to be 8.5%, 8.8%, and 9.4%, respectively.[<a href="#cit/section_3.69">69</a>]  Another study of 701 women randomly assigned to undergo radical mastectomy or breast-conserving surgery followed by radiation therapy demonstrated the rate of contralateral breast carcinomas per 100 woman-years to be 10.2 versus 8.7, respectively.[<a href="#cit/section_3.70">70</a>]  The third study compared 25-year outcomes of 1,665 women randomly assigned to undergo radical mastectomy, total mastectomy, or total mastectomy with radiation. There was no significant difference in the rate of contralateral breast cancer according to treatment group, and the  overall rate was 6%.[<a href="#cit/section_3.71">71</a>]</p></section><section id="_153"><h4 id="_153_toc">Obesity</h4><p id="_154" tabindex="-1">Obesity is associated with increased breast cancer risk, especially among postmenopausal women who do not use HT. The WHI observed 85,917 women aged 50 to 79 years and collected information on weight history and known risk factors for breast cancer.[<a href="#cit/section_3.72">72</a>,<a href="#cit/section_3.73">73</a>] Height, weight, and  waist and hip circumferences were measured.  With a median follow-up of 34.8 months, 1,030 of the women developed invasive breast cancer.  Among the women who never used HT, increased breast cancer risk was associated with weight at entry, body mass index (BMI) at entry, BMI at age 50 years,  maximum BMI, adult and postmenopausal weight change, and waist and hip circumferences.  Weight was the strongest predictor, with a RR of 2.85 (95% CI, 1.81&#x2013;4.49) for women weighing more than 82.2 kg, compared with  those weighing less than 58.7 kg.</p><p id="_630" tabindex="-1">The association between obesity, diabetes, and insulin levels with breast cancer risk have been studied but not clearly defined.  The British Women&#x2019;s Heart and Health Study of women aged 60 to 79 years compared 151 women who had a diagnosis of breast cancer with 3,690 women who did not.  The age-adjusted OR was 1.34 (95% CI, 1.02&#x2013;1.77) for each unit increase in log(e) insulin level among nondiabetic women.  The association was observed, after adjustment for confounders and for potential mediating factors, for both pre- and postmenopausal breast cancers.  In addition, fasting glucose level, homeostatic model assessment score (the product of fasting glucose and insulin levels divided by 22.5), diabetes, and a history of gestational glycosuria or diabetes were also associated with breast cancer.[<a href="#cit/section_3.74">74</a>]</p></section><section id="_155"><h4 id="_155_toc">Alcohol</h4><p id="_156" tabindex="-1">Alcohol consumption increases the risk of breast cancer.  A British meta-analysis included individual data from 53 case-control and cohort studies.[<a href="#cit/section_3.75">75</a>] Compared with the RR of breast cancer for women who reported no alcohol consumption, the RR of breast cancer was 1.32 (95% CI, 1.19&#x2013;1.45; <em>P</em> &lt; .001) for women consuming 35 g to 44 g of alcohol per day and 1.46 (95% CI, 1.33&#x2013;1.61; <em>P</em> &lt; .001) for those consuming at least 45 g of alcohol per day. The RR of breast cancer increases by about 7% (95% CI, 5.5%&#x2013;8.7%; <em>P</em> &lt; .001) for each 10 g of alcohol (i.e., one drink) consumed per day. These findings persist after stratification for race, education, family history, age at menarche, height, weight, BMI, breast-feeding, oral contraceptive use, menopausal hormone use and type, and age at menopause.</p></section></section><section id="_423"><h3 id="_423_toc">Factors With Adequate Evidence of Decreased Risk of Breast Cancer</h3><section id="_428"><h4 id="_428_toc">Early pregnancy</h4><p id="_429" tabindex="-1">Childbirth is followed by an increase in risk of breast cancer for several years, and then a long-term reduction in risk, which is greater for younger women.[<a href="#cit/section_3.22">22</a>,<a href="#cit/section_3.76">76</a>,<a href="#cit/section_3.77">77</a>] In one study, women who experienced a first full-term pregnancy before age 20 years were half as likely to develop breast cancer as nulliparous women or women whose first full-term pregnancy occurred at age 35 years or older.[<a href="#cit/section_3.78">78</a>,<a href="#cit/section_3.79">79</a>] </p></section><section id="_430"><h4 id="_430_toc">Breast-feeding</h4><p id="_431" tabindex="-1">Breast-feeding is associated with a decreased risk of breast cancer.[<a href="#cit/section_3.80">80</a>]  A reanalysis of individual data from 47 epidemiological studies in 30 countries of 50,302 women with breast cancer and 96,973 controls revealed that breast cancer incidence was lower in parous women who had ever breast-fed than in parous women who had not.  It was also proportionate to duration of breast-feeding.[<a href="#cit/section_3.81">81</a>] The RR of breast cancer decreased by 4.3% (95%, CI, 2.9%&#x2013;5.8%; <em>P</em> &lt; .0001) for every 12 months of breast-feeding in addition to a decrease of 7.0% (95% CI, 5.0%&#x2013;9.0%; <em>P</em> &lt; .0001) for each birth.</p></section><section id="_426"><h4 id="_426_toc">Exercise</h4><p id="_427" tabindex="-1">Active exercise may reduce
            breast cancer risk, particularly in young parous women.[<a href="#cit/section_3.82">82</a>] Numerous observational studies on  the relationship between the level of
            physical activity and breast cancer risk have shown an inverse relationship.[<a href="#cit/section_3.83">83</a>]    The average RR reduction is  30% to 40%, but confounding variables&#x2014;such as diet or a genetic predisposition to breast
            cancer&#x2014;have not been addressed.  A prospective study of more than 25,000 Norwegian women found that
            heavy manual labor or at least 4 hours of exercise  per week is associated with
            decreased  breast cancer risk, especially in
            premenopausal women and those  of normal or lower-than-normal body weight.[<a href="#cit/section_3.84">84</a>]
            In a case-control study of African American women, strenuous recreational
            physical activity more than 7 hours per week was associated with
            decreased breast cancer incidence.[<a href="#cit/section_3.85">85</a>]</p></section></section><section id="_432"><h3 id="_432_toc">Interventions With Adequate Evidence of Benefit </h3><section id="_158"><h4 id="_158_toc">Selective estrogen receptor modulators (SERMs)</h4><p id="_159" tabindex="-1">Data from adjuvant breast cancer trials using tamoxifen have shown that
            tamoxifen not only suppresses the recurrence of breast cancer but also prevents
            new primary contralateral breast cancers.[<a href="#cit/section_3.86">86</a>]  Tamoxifen also maintains bone density among postmenopausal women with breast cancer.[<a href="#cit/section_3.87">87</a>-<a href="#cit/section_3.91">91</a>]  Adverse effects include hot flashes, venous thromboembolic events, and endometrial cancer.[<a href="#cit/section_3.92">92</a>-<a href="#cit/section_3.94">94</a>]  </p><p id="_160" tabindex="-1">These adjuvant trial results were the basis for the Breast Cancer Prevention Trial (BCPT) that randomly assigned 13,388 patients at elevated risk of breast cancer  to receive  tamoxifen or placebo.[<a href="#cit/section_3.95">95</a>,<a href="#cit/section_3.96">96</a>]
            The  study was closed early because of a 49% reduction in the
            incidence of breast cancer for the tamoxifen group (85 vs. 154 invasive breast cancer cases and 31 vs. 59 <em>in situ</em> cases at 4 years). Tamoxifen-treated women also had fewer fractures (47 vs. 71) but more endometrial cancer (33 vs. 14 cases) and thrombotic events (99 vs. 70), including pulmonary emboli (17 vs. 6).[<a href="#cit/section_3.96">96</a>]  </p><p id="_299" tabindex="-1">An update of the BCPT  results after 7 years of follow-up demonstrated results similar to those in the initial report.[<a href="#cit/section_3.97">97</a>] There were some dropouts among women in the placebo arm; some of them enrolled in a subsequent trial, so new women were added to the placebo group.      Benefits and risks of tamoxifen were not significantly different from those in the original report, with persistent benefit of fewer fractures and persistent increased risk of endometrial cancer, thrombosis, and cataract surgery.                      No overall mortality benefit was observed after 7 years of follow-up (RR, 1.10; 95% CI, 0.85&#x2013;1.43).</p><p id="_631" tabindex="-1">Three other trials of tamoxifen for primary prevention of breast cancer have been completed.[<a href="#cit/section_3.98">98</a>-<a href="#cit/section_3.100">100</a>]</p><div class="pdq-content-list"><ul id="_671"><li>A study in the United Kingdom [<a href="#cit/section_3.98">98</a>]
            focused on 2,471 women at increased breast cancer risk because of their family
            history of breast and/or ovarian cancer.  After a median follow-up of nearly 6 years, no protective
            effect of tamoxifen was detected (RR, 1.06), but there was a slight  reduction in breast cancer risk in the tamoxifen arm  (HR,  0.78; 95% CI, 0.58&#x2013;1.04) at a median  of 13 years. However, risk of ER-positive breast cancer was significantly reduced in the treatment arm (HR, 0.61; 95% CI, 0.43&#x2013;0.86), an effect noted predominantly in the posttreatment period.[<a href="#cit/section_3.101">101</a>]</li><li>An Italian study [<a href="#cit/section_3.99">99</a>] focused on 5,408
            women who had undergone hysterectomy and who were described as low to normal
            risk. After a median follow-up of nearly 4 years, no protective effect of tamoxifen was observed.  Longer follow-up and subgroup analysis in this trial found a protective effect of tamoxifen among women at high risk for hormone receptor&#x2013;positive breast cancer (RR, 0.24; 95% CI, 0.10&#x2013;0.59) and among women who were taking HT during the trial (RR, 0.43; 95% CI, 0.20&#x2013;0.95).[<a href="#cit/section_3.102">102</a>,<a href="#cit/section_3.103">103</a>]</li><li>The   International Breast Cancer Intervention Study (IBIS-I) randomly assigned 7,152 women aged 35 to 70  years who were at an increased risk of breast cancer to receive tamoxifen (20 mg/day ) or placebo for 5 years.[<a href="#cit/section_3.100">100</a>]   After a median follow-up of 50 months, fewer tamoxifen-treated women  had developed invasive or <em>in situ</em> breast cancer (absolute rate, 4.6 vs. 6.75  per 1,000 woman-years;  risk reduction, 32%; 95% CI, 8%&#x2013;50%). The RR   reduction in ER-positive invasive breast cancer was 31%; there was no reduction in  ER-negative cancers. There was an excess of all-cause mortality in the tamoxifen group (25 vs. 11; <em>P</em> = .028), which the authors attributed to chance. The beneficial effect of tamoxifen on breast cancer persisted after active treatment, with a median posttherapy follow-up of 46 months; 27% fewer women in the tamoxifen arm developed breast cancer (142 vs. 195 cases, respectively; RR, 0.73, 95% CI, 0.58&#x2013;0.91).[<a href="#cit/section_3.104">104</a>] </li></ul></div><p id="_231" tabindex="-1">A meta-analysis  of these primary prevention tamoxifen trials showed  a 38% reduction in the incidence of breast cancer without statistically significant heterogeneity.[<a href="#cit/section_3.94">94</a>]  ER-positive    tumors were reduced by 48%.  Rates of endometrial cancer were increased (consensus RR, 2.4; 95% CI, 1.5&#x2013;4.0), as were venous thromboembolic events (RR, 1.9; 95% CI, 1.4&#x2013;2.6).  None of these primary prevention trials was designed to detect differences in breast cancer mortality. </p><p id="_163" tabindex="-1">Women with a history of ductal carcinoma <em>in situ</em> (DCIS) are at increased risk
            for contralateral breast cancer. The National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-24 addressed their management. Women were randomly assigned to receive lumpectomy and radiation therapy (L-RT) either with or without adjuvant tamoxifen.  At 6 years, the tamoxifen-treated women had fewer invasive and <em>in situ</em> breast cancers (8.2% vs. 13.4%; RR, 0.63; 95% CI, 0.47&#x2013;0.83).   The risk of contralateral breast cancer was also lower in women treated with tamoxifen (RR, 0.49; 95% CI, 0.26 &#x2013; 0.87).[<a href="#cit/section_3.105">105</a>]</p><p id="_165" tabindex="-1">Raloxifene hydrochloride (Evista) is a SERM that has antiestrogenic effects on breast
            and estrogenic effects on bone, lipid metabolism, and
            blood clotting. Unlike tamoxifen, it has antiestrogenic effects on the endometrium.[<a href="#cit/section_3.106">106</a>]  The Multiple Outcomes of Raloxifene Evaluation (MORE) trial was a
            randomized, double-blind trial that evaluated 7,705 postmenopausal women with
            osteoporosis from 1994 to 1998 at 180 clinical centers in the United States.  Vertebral fractures were reduced.  The
            effect on breast cancer incidence was a secondary endpoint.    After a median follow-up of 47 months, the risk of invasive breast cancer
            decreased in the raloxifene-treated women (RR, 0.25; 95% CI, 0.17&#x2013;0.45).[<a href="#cit/section_3.107">107</a>]  As with tamoxifen, raloxifene
            reduced the risk of ER-positive breast cancer but not
            ER-negative breast cancer and was associated with an excess risk of hot flashes and thromboembolic events.    No excess risk of endometrial cancer or hyperplasia was
            observed after 47 months of follow-up.[<a href="#cit/section_3.108">108</a>]</p><p id="_253" tabindex="-1">An extension of the MORE trial was the Continuing Outcomes Relevant to Evista (CORE) trial, which studied  about 80% of MORE participants in their randomly assigned groups for an additional 4 years.      Although there was a median 10-month gap between the two studies, and only about 55% of women were adherent to their assigned medications, the raloxifene group continued to experience a lower incidence of invasive ER-positive breast cancer.    The overall reduction in invasive breast cancer during the 8 years of MORE and CORE was 66% (HR, 0.34; 95% CI, 0.22&#x2013;0.50); the reduction for ER-positive invasive breast cancer was 76% (HR, 0.24; 95% CI, 0.15&#x2013;0.40).[<a href="#cit/section_3.109">109</a>]</p><p id="_466" tabindex="-1">The Raloxifene Use for the Heart trial was a randomized, placebo-controlled trial to evaluate the effects of raloxifene on incidence of coronary events and invasive breast cancer.  As in the MORE and CORE studies, raloxifene reduced the risk of invasive breast cancer (HR, 0.56; 95% CI, 0.38&#x2013;0.83).[<a href="#cit/section_3.110">110</a>]</p><p id="_328" tabindex="-1">The Study of Tamoxifen and Raloxifene (STAR) (NSABP P-2) compared tamoxifen and raloxifene in 19,747 high-risk women who were monitored for  a mean of 3.9 years.  Invasive breast cancer incidence was approximately the same for both drugs, but there were fewer noninvasive cancers  in the tamoxifen group. Adverse events of uterine cancer, venous thrombolic events, and cataracts were more common in tamoxifen-treated women, and there was no difference in ischemic heart disease events, strokes, or fractures.[<a href="#cit/section_3.111">111</a>] Treatment-associated symptoms of dyspareunia, musculoskeletal problems, and weight gain occurred less frequently in  tamoxifen-treated women, whereas vasomotor flushing, bladder control symptoms, gynecologic symptoms, and leg cramps occurred less frequently in those receiving raloxifene.[<a href="#cit/section_3.112">112</a>]</p><table id="_332" class="table-default expandable-container"><caption>Incidence of Outcomes Per 1,000 Women</caption><colgroup><col width="25.00%"><col width="25.00%"><col width="25.00%"><col width="25.00%"></colgroup><THead><tr><th>&#xA0;</th><th>Tamoxifen</th><th>Raloxifene</th><th>RR, 95% CI</th></tr></THead><TFoot class="pdq-footer"><tr><td colspan="4">CI = confidence interval;      RR = relative risk; VTE = venous thromboembolism.</td></tr></TFoot><tbody><tr><td>Invasive breast cancer</td><td>4.3</td><td>4.41</td><td>1.02, 0.82&#x2013;1.28</td></tr><tr><td>Noninvasive breast cancer</td><td>1.51</td><td>2.11</td><td>1.4, 0.98&#x2013;2.00</td></tr><tr><td>Uterine cancer </td><td>2.0</td><td>1.25</td><td>0.62, 0.35&#x2013;1.08</td></tr><tr><td>VTE</td><td>3.8</td><td>2.6</td><td>0.7, 0.68&#x2013;0.99</td></tr><tr><td>Cataracts</td><td>12.3</td><td>9.72</td><td>0.79, 0.68&#x2013;0.92</td></tr><tr><td colspan="4"><strong>Incidence of Symptoms (0&#x2013;4 scale)</strong></td></tr><tr><td colspan="4">Favor Tamoxifen</td></tr><tr><td>Dyspareunia</td><td>0.68</td><td>0.78</td><td><em>P </em>&lt; .001</td></tr><tr><td>Musculoskeletal problems</td><td>1.10</td><td>1.15</td><td><em>P</em> = .002</td></tr><tr><td>Weight gain</td><td>0.76</td><td>0.82</td><td><em>P</em> &lt; .001</td></tr><tr><td colspan="4">Favor Raloxifene</td></tr><tr><td>Vasomotor symptoms</td><td>0.96</td><td>0.85</td><td><em>P </em>&lt; .001</td></tr><tr><td>Bladder control symptoms</td><td>0.88</td><td>0.73</td><td><em>P </em>&lt; .001</td></tr><tr><td>Leg cramps</td><td>1.10</td><td>0.91</td><td><em>P </em>&lt; .001</td></tr><tr><td>Gynecologic problems</td><td>0.29</td><td>0.19</td><td><em>P </em>&lt; .001</td></tr></tbody></table></section><section id="_199"><h4 id="_199_toc">Aromatase inhibitors or inactivators (Als)</h4><p id="_200" tabindex="-1">Another class of agents that is commercially available for the treatment of women with hormone-sensitive breast cancer may also prevent breast cancer.  These  drugs interfere with  aromatase, the adrenal enzyme that allows   estrogen production in postmenopausal women.  Anastrozole  and letrozole  inhibit aromatase activity, whereas exemestane  inactivates the enzyme.  Side effects for all three drugs include  fatigue, arthralgia, myalgia, decreased bone mineral density, and increased fracture rate.  </p><p id="_716" tabindex="-1">Women with a previous diagnosis of breast cancer have a lower risk of recurrence and of new breast cancers when treated with AIs, as shown in the following studies:</p><div class="pdq-content-list"><ol id="_717"><li>In the Arimidex, Tamoxifen, Alone or in  Combination trial, which compared anastrozole with tamoxifen as adjuvant therapy for primary breast cancer, the rate of locoregional and distant recurrence was lower for anastrozole (7.1% vs. 8.5%) but higher for the combination (9.1%).[<a href="#cit/section_3.113">113</a>] Anastrozole was also more effective in reducing the incidence of new contralateral breast cancer (0.4% vs. 1.1% vs. 0.9%).</li><li>In another trial, 5,187 women who received 5 years of adjuvant tamoxifen were randomly assigned to receive either letrozole or placebo.[<a href="#cit/section_3.114">114</a>] After only 2.5 years of median follow-up, the study was terminated because previously defined efficacy endpoints had been reached. Not only did patients treated with letrozole have a lower incidence of locoregional and distant cancer recurrence, they also had a lower incidence of new contralateral breast cancer (14 vs. 26).</li><li>Another placebo-controlled trial of 1,918 women with breast cancer examined the effect of extending letrozole treatment for an additional 5 years in women who had received adjuvant tamoxifen followed by 5 years of letrozole.[<a href="#cit/section_3.115">115</a>]  At a median of 6.3 years from study entry, the extended letrozole group had an improved 5-year disease-free survival of 95% (95% CI, 93%&#x2013;96%) compared with 91% (95% CI, 89%&#x2013;93%) for the control group (HR, 0.66) but no difference in overall survival.  The difference in new contralateral breast cancer diagnoses was statistically significant: 21% (95% CI, 10%&#x2013;32%) for the extended letrozole group compared with  49% (32%&#x2013;67%) for the control group (HR, 0.42). Women treated with letrozole had an increased risk of bone pain (18% vs. 14%), bone fracture (14% vs. 9%), and new-onset osteoporosis (11% vs. 6%).</li><li>A trial randomly assigned 4,742 women who had received 2 years of adjuvant tamoxifen to either continue the tamoxifen or switch to exemestane.[<a href="#cit/section_3.116">116</a>] After 2.4 years of median follow-up, the exemestane group had a decreased risk of local or metastatic recurrence and a decreased incidence of new contralateral breast cancer (9 vs. 20).</li></ol></div><p id="_718" tabindex="-1">Aromatase inhibitors or inactivators also have been shown to prevent breast cancer in women at increased risk, as shown in the following studies:</p><div class="pdq-content-list"><ol id="_719"><li>An RCT of primary prevention of breast cancer compared exemestane with placebo in 4,560 women with at least one risk factor (age &gt;60 years, a Gail 5-year risk &gt;1.66%, or a history of DCIS with mastectomy).  After 35 months of median follow-up, invasive breast cancer was diagnosed less frequently in the exemestane group (11 vs. 32; HR, 0.35; 95% CI, 0.18&#x2013;0.70; number needed-to-treat, about 100 for 35 months). Compared with the placebo group, the exemestane-treated women had more hot flashes (increase, 8%) and fatigue (increase, 2%) but no difference in fractures or cardiovascular events.[<a href="#cit/section_3.117">117</a>]</li><li>The International Breast Cancer Intervention Study II (IBIS-II) randomly assigned 3,864 postmenopausal women who were at increased risk of developing breast cancer to receive either daily anastrazole (1 mg) or placebo for 5 years.[<a href="#cit/section_3.118">118</a>] The definition of high risk varied by age and was defined by the RR compared with the general population:  women aged 40 to 44 years  had to have an RR of at least 4; women aged 45 to 60 years  had to have an RR of at least 2; and women aged 60 to 70 years  had to have an RR of at least 1.5.   Alternatively, women with an estimated 10-year risk of developing breast cancer of at least 5%  (per the Tyer-Cuzick model) were eligible for inclusion.  Women with DCIS diagnosed within 6 months and treated with unilateral mastectomy were eligible for the trial, and 326 were assigned randomly.    After a median follow-up of 5 years, fewer breast cancers (invasive and DCIS) occurred in the anastrazole-treated group than in the placebo group (HR, 0.47; 95% CI, 0.32&#x2013;0.68).  The risk of hormone receptor&#x2013;positive, but not hormone receptor&#x2013;negative, breast cancer was reduced.   Based on predicted cumulative incidence over 7 years, the number of high-risk women (per the IBIS-II eligibility criteria) needed-to-treat for 5 years to prevent one breast cancer in 7 years of follow-up was estimated to be 36 (95% CI, 33&#x2013;44).  Women treated with anastrazole were more likely than those taking placebo to have musculoskeletal symptoms, including arthralgias (51% vs. 46%), joint stiffness (7% vs. 5%), pain in hand or foot (9% vs. 8%) , and carpal tunnel syndrome (3% vs. 2%);  hypertension (5% vs. 3%);  vasomotor symptoms (57% vs. 49%);  and dry eyes (4% vs. 2%).  The association between hand or foot pain with anastrazole treatment was of borderline statistical significance; all other side effects noted above were statistically significantly associated with anastrazole treatment.</li></ol></div></section><section id="_166"><h4 id="_166_toc">Prophylactic mastectomy</h4><p id="_167" tabindex="-1">A retrospective cohort study evaluated the impact of bilateral prophylactic mastectomy on breast cancer incidence among women at high and moderate risk on the basis of family history.[<a href="#cit/section_3.119">119</a>] <em>BRCA</em> mutation status was not known. Subcutaneous, rather than total, mastectomy was performed in 90% of these women.  After a median follow-up of 14 years postsurgery, the risk reduction for the 425 moderate-risk women was 89%; for the 214 high-risk women, it was 90% to 94%, depending on the method used to calculate expected rates of breast cancer. The risk reduction for breast cancer mortality was 100% for moderate-risk women and 81% for high-risk women. Because the study used family history as a risk indicator rather than genetic testing, breast cancer risk may be overestimated.</p><p id="_689" tabindex="-1">The rate of bilateral mastectomy among women with unilateral disease (DCIS and early-stage invasive breast cancer) was reported to have increased from 1.9% in 1998 to 11.2% in 2011 based on data from the U.S. National Cancer Data Base.[<a href="#cit/section_3.120">120</a>]</p><p id="_636" tabindex="-1">No studies have been done on the benefits of prophylactic mastectomy in the average-risk population to prevent contralateral breast cancer in women with an ipsilateral breast cancer.</p></section><section id="_193"><h4 id="_193_toc">Prophylactic oophorectomy</h4><p id="_194" tabindex="-1">Ovarian ablation and oophorectomy are associated with decreased breast cancer risk in normal women and in women with increased risk resulting from thoracic irradiation.  (Refer to the <a href="/types/breast/hp/breast-prevention-pdq#link/_37">Endogenous estrogen</a> section in the  <a href="/types/breast/hp/breast-prevention-pdq#link/_29">Description of the Evidence</a> section of this summary for more information.) Observational studies of women with high breast cancer risk resulting from <em>BRCA1</em> or <em>BRCA2</em> gene mutations showed that prophylactic oophorectomy to prevent ovarian cancer was also associated with a 50% decrease in breast cancer incidence.[<a href="#cit/section_3.121">121</a>-<a href="#cit/section_3.123">123</a>] These studies are confounded by selection bias, family relationships between patients and controls, indications for oophorectomy, and inadequate information about hormone use.  A prospective cohort study had similar findings, with a greater breast cancer risk reduction in <em>BRCA2</em> mutation carriers than in <em>BRCA1</em> carriers.[<a href="#cit/section_3.124">124</a>]</p></section></section><section id="_433"><h3 id="_433_toc">Factors and Interventions With Inadequate Evidence of an Association</h3><section id="_434"><h4 id="_434_toc">Hormonal contraceptives</h4><p id="_435" tabindex="-1">Oral contraceptives have been associated with a small  increased risk of breast cancer in current users  that  diminishes over time.[<a href="#cit/section_3.125">125</a>]  A well-conducted case-control study did not observe an association between breast cancer risk and oral contraceptive use for every use, duration of use, or recency of use.[<a href="#cit/section_3.126">126</a>]</p><p id="_436" tabindex="-1">Another case-control study found no increased risk of breast cancer associated with the use of injectable or implantable progestin-only contraceptives in women aged 35 to 64 years.[<a href="#cit/section_3.127">127</a>]</p><p id="_762" tabindex="-1">A nationwide prospective cohort study in Denmark found that women who currently or recently used contemporary hormonal contraceptives had a higher risk of breast cancer than did women who had never used hormonal contraceptives.  Moreover, the risk of breast cancer increased with longer duration of hormonal contraceptive use.  However, in absolute terms, the effect of oral contraceptives on breast  cancer risk was very small.  Thus, approximately one extra case of breast cancer would be expected for every 7,690 women using hormonal contraception for 1 year.[<a href="#cit/section_3.128">128</a>]</p></section><section id="_283"><h4 id="_283_toc">Environmental factors</h4><p id="_284" tabindex="-1">Occupational, environmental, or chemical exposures have been proposed as causes of  breast cancer. Although some findings suggest
            that organochlorine exposures, such as those associated with insecticides,
            might be associated with an increase in breast cancer risk,[<a href="#cit/section_3.129">129</a>,<a href="#cit/section_3.130">130</a>] other
            case-control and nested case-control studies do not.[<a href="#cit/section_3.131">131</a>-<a href="#cit/section_3.136">136</a>]  Studies reporting positive associations have been inconsistent in the identification of responsible organochlorines. Some of these substances have weak estrogenic effects, but their effect on breast cancer risk remains unproven. The use of dichloro-diphenyl-trichloroethane  was banned in the United States in 1972, and the production of  polychlorinated biphenyls  was stopped in 1977.</p></section></section><section id="_642"><h3 id="_642_toc">Factors and Interventions With Adequate Evidence of Little or No Association</h3><section id="_643"><h4 id="_643_toc">Abortion</h4><p id="_644" tabindex="-1">Abortion has been proposed as a risk factor for breast cancer. Findings from observational studies have varied; some studies showed an association, while other studies did not. Observational studies that support this association were less rigorous and  potentially biased because of differential recall by women on a socially sensitive issue.[<a href="#cit/section_3.137">137</a>-<a href="#cit/section_3.140">140</a>] For example, the impact of recall or reporting bias was demonstrated in a study that compared regions with different social attitudes on abortion.[<a href="#cit/section_3.141">141</a>] The Committee on Gynecologic Practice of the American College of Obstetricians and Gynecologists has concluded that &#x201C;more rigorous recent studies demonstrate no causal relationship between induced abortion and a subsequent increase in breast cancer risk.&#x201D;[<a href="#cit/section_3.142">142</a>] Studies that used prospectively recorded data regarding abortion, thereby avoiding recall bias, largely showed no association with the subsequent development of breast cancer.[<a href="#cit/section_3.143">143</a>-<a href="#cit/section_3.148">148</a>]</p></section><section id="_645"><h4 id="_645_toc">Diet</h4><p id="_647" tabindex="-1">Any effect of dietary modifications on breast cancer would likely depend on the type of modification. However, there is little evidence that dietary modifications of any kind have an impact on the incidence of breast cancer.</p><p id="_710" tabindex="-1">There are very few randomized trials in humans comparing cancer incidence for different diets. Most studies are observational&#x2014;including post hoc analyses of randomized trials&#x2014;and are subject to biases that may be so large as to render the observation difficult to interpret. In particular, <em>p</em>-values and CIs do not have the same interpretation as when calculated for the primary endpoint in a randomized trial.</p><p id="_648" tabindex="-1">A summary of ecological studies published before 1975 showed a positive correlation between international age-adjusted breast cancer mortality rates and the estimated per capita consumption of dietary fat.[<a href="#cit/section_3.149">149</a>] Results of case-control studies have been mixed.  Twenty years later, a pooled analysis of results from seven cohort studies found no association between total dietary fat intake and breast cancer risk.[<a href="#cit/section_3.150">150</a>]</p><p id="_649" tabindex="-1">A randomized, controlled, dietary modification study was undertaken among 48,835 postmenopausal women aged 50 to 79 years who were also enrolled in the WHI. The intervention promoted a goal of reducing total fat intake by 20% by increasing vegetable, fruit, and grain consumption. The intervention group reduced fat intake by approximately 10% for more than 8.1 years of follow-up, resulting in lower estradiol and gamma-tocopherol levels, but no persistent weight loss. The incidence of invasive breast cancer was numerically, but not statistically lower in the intervention group, with an HR of 0.91 (95% CI, 0.83&#x2013;1.01).[<a href="#cit/section_3.151">151</a>] There was no difference in all-cause mortality, overall mortality, or the incidence of  cardiovascular events.[<a href="#cit/section_3.152">152</a>]</p><p id="_715" tabindex="-1">With regard to fruit and vegetable intake, a pooled analysis of eight cohort studies including more than 350,000 women with 7,377 incident breast cancers showed little or no association for various assumed statistical models.[<a href="#cit/section_3.153">153</a>]</p><p id="_651" tabindex="-1">The Women's Healthy Eating and Living Randomized Trial [<a href="#cit/section_3.154">154</a>] examined the effect of diet on the incidence of new primary breast cancers in women previously diagnosed with breast cancer. More than 3,000 women were enrolled and randomly assigned to an intense regimen of increased fruit and vegetable intake, increased fiber intake, and decreased fat intake, or a comparison group receiving printed materials on the &#x201C;5-A-Day&#x201D; dietary guidelines. After a mean of 7.3 years of follow-up, there was no reduction in new primary cancers, no difference in disease-free survival, and no difference in overall survival.</p><p id="_711" tabindex="-1">A randomized trial in Spain [<a href="#cit/section_3.155">155</a>]  assigned participants who were at high cardiovascular risk to one of three diets: a Mediterranean diet supplemented with extra-virgin olive oil, a Mediterranean diet supplemented with mixed nuts, or a control Mediterranean diet (counseling to reduce dietary fat). The investigators reported a statistically significant reduction in major cardiovascular events, which was the trial&#x2019;s primary endpoint.[<a href="#cit/section_3.156">156</a>] The investigators also addressed other endpoints, including the incidence of breast cancer, although it is not specified how many were examined. Based on only 35 cases of invasive breast cancer (as compared with 288 major cardiovascular events), the respective rates of breast cancer were 8 of 1,476 (0.54%); 10 of 1,285 (0.78%); and 17 of 1,391 (1.22%) with respective average follow-up durations of 4.8, 4.3, and 4.2 years. The circumstances of the study make it difficult to determine the statistical significance of these differences.</p></section><section id="_712"><h4 id="_712_toc">Vitamins</h4><p id="_713" tabindex="-1">The potential role of specific micronutrients for breast cancer risk reduction has been examined in clinical trials, with cardiovascular disease and cancer as outcomes. The Women&#x2019;s Health Study, a randomized trial with 39,876 women, found no difference in breast cancer incidence at 2 years between women assigned to take either beta carotene or placebo.[<a href="#cit/section_3.157">157</a>] In this same study, no overall effect on cancer was seen in women taking 600 IU of vitamin E every other day.[<a href="#cit/section_3.158">158</a>] The Women&#x2019;s Antioxidant Cardiovascular Study examined 8,171 women for incidence of total cancer and invasive breast cancer and found no effect for vitamin C, vitamin E, or beta carotene.[<a href="#cit/section_3.159">159</a>] Two years later, a subset of 5,442 women were randomly assigned to take 1.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12, or placebo. After 7.3 years, there was no difference in the incidence of total invasive cancer or invasive breast cancer.[<a href="#cit/section_3.160">160</a>]</p><p id="_714" tabindex="-1">Fenretinide [<a href="#cit/section_3.161">161</a>] is a vitamin A analog that has been shown to reduce breast carcinogenesis in preclinical studies. A phase III Italian trial compared the efficacy of a 5-year intervention with fenretinide versus no treatment in 2,972 women, aged 30 to 70 years, with surgically removed stage I breast cancer or DCIS. At a median observation time of 97 months, there were no statistically significant differences in the occurrence of contralateral breast cancer (<em>P</em> = .642), ipsilateral breast cancer (<em>P </em>= .177), incidence of distant metastases, nonbreast malignancies, and all-cause mortality.[<a href="#cit/section_3.162">162</a>]</p></section><section id="_672"><h4 id="_672_toc">Active and passive cigarette smoking</h4><p id="_673" tabindex="-1">The potential role of active cigarette smoking in the etiology of breast cancer has been studied for more than three decades, with no clear-cut evidence of an association.[<a href="#cit/section_3.163">163</a>]  Since the mid-1990s, studies of cigarette smoking and breast cancer have more carefully accounted for secondhand smoke exposure.[<a href="#cit/section_3.163">163</a>,<a href="#cit/section_3.164">164</a>] A recent meta-analysis suggests that there is no overall association between passive smoking and breast cancer and that study methodology (ascertainment of exposure after breast cancer diagnosis) may be responsible for the apparent risk associations seen in some studies.[<a href="#cit/section_3.165">165</a>]</p></section><section id="_674"><h4 id="_674_toc">Underarm deodorants/antiperspirants</h4><p id="_675" tabindex="-1">Despite warnings to women in lay publications that underarm deodorants and antiperspirants cause breast cancer, there is no evidence to support these concerns. A study based on interviews with 813 women who had breast cancer and 793 controls found no association between the risk of breast cancer  and the use of antiperspirants, the use of deodorants,  or the use of blade razors before these products were applied.[<a href="#cit/section_3.166">166</a>]  In contrast, a study of 437 breast cancer survivors found that women who used antiperspirants/deodorants and shaved their underarms more frequently had cancer diagnosed at a significantly younger age. A possible explanation for this finding is that these women had an earlier menarche or higher levels of endogenous hormones, both known to be risk factors for breast cancer and to increase body hair.[<a href="#cit/section_3.167">167</a>]</p></section><section id="_676"><h4 id="_676_toc">Statins</h4><p id="_677" tabindex="-1">Two well-conducted meta-analyses of RCTs [<a href="#cit/section_3.168">168</a>] and RCTs plus observational studies [<a href="#cit/section_3.169">169</a>] found no evidence that statin use either increases or decreases the risk of breast cancer.</p></section><section id="_685"><h4 id="_685_toc">Bisphosphonates</h4><p id="_686" tabindex="-1">Oral and intravenous bisphosphonates for the treatment of hypercalcemia and osteoporosis have been studied for a possible beneficial effect on breast cancer prevention.  Initial observational studies suggested that women who used these drugs for durations of approximately 1 to 4 years had a lower incidence of breast cancer.[<a href="#cit/section_3.170">170</a>-<a href="#cit/section_3.173">173</a>]  These findings are confounded by the fact that women with osteoporosis have lower breast cancer risk than those with normal bone density.  Additional evidence came from studies of women with a breast cancer diagnosis; the use of these drugs was associated with fewer new contralateral cancers.[<a href="#cit/section_3.174">174</a>]  With this background, two large randomized placebo-controlled trials were done.   The Fracture Intervention Trial (FIT) treated 6,194 postmenopausal osteopenic women with either alendronate or placebo and found no difference at 3.8 years in breast cancer incidence, with incidence of 1.8% and 1.5%, respectively (HR, 1.24; CI, 0.84&#x2013;1.83).  The Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly-Pivotal Fracture Trial (HORIZON-PRT) examined 7,580 postmenopausal osteoporotic women with either intravenous zoledronate or placebo and found no difference at 2.8 years in breast cancer incidence, with incidence of 0.8% and 0.9%, respectively (HR, 1.15; CI, 0.7&#x2013;1.89).[<a href="#cit/section_3.175">175</a>]</p></section><section id="_752"><h4 id="_752_toc">Working night shifts</h4><p id="_753" tabindex="-1">In 2007, the World Health Organization&#x2019;s International Agency for Research on Cancer (IARC) classified shift work that involves circadian disruption as a probable breast carcinogen. The principal evidence was from animal studies. There was limited evidence from human studies at the time.[<a href="#cit/section_3.176">176</a>] In 2013, a meta-analysis of 15 epidemiologic studies concluded that there was weak evidence of an increased incidence of breast cancer among women who had ever worked night shifts.[<a href="#cit/section_3.177">177</a>] In 2016, the results from three recent prospective studies from the United Kingdom, involving nearly 800,000 women, were combined with results from seven other prospective studies and showed no evidence of any association between breast cancer incidence and night shift work. In particular, the confidence intervals for the incidence rate ratios were narrow, even for 20 years or more of night shift work (rate ratio, 1.01; 95% CI, 0.93&#x2013;1.10). These results exclude a moderate association of breast cancer incidence with long duration of night shift work.[<a href="#cit/section_3.178">178</a>]</p></section></section><h6 do-not-show="toc">References</h6><ol><li id="section_3.1">American Cancer Society: Cancer Facts and Figures 2018. Atlanta, Ga: American Cancer Society, 2018. <a href="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf" title="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf">Available online</a>. Last accessed August 3, 2018.</li><li id="section_3.2">Howlader N, Noone AM, Krapcho M, et al., eds.: SEER Cancer Statistics Review, 1975-2012. Bethesda, Md: National Cancer Institute, 2015. <a href="http://seer.cancer.gov/csr/1975_2012/" title="http://seer.cancer.gov/csr/1975_2012/">Also available online</a>. Last accessed August 13, 2018.</li><li id="section_3.3">American Cancer Society: Cancer Facts and Figures 2017. Atlanta, Ga: American Cancer Society, 2017. <a href="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf" title="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf">Available online</a>. Last accessed August 13, 2018.</li><li id="section_3.4">Altekruse SF, Kosary CL, Krapcho M, et al.: SEER Cancer Statistics Review, 1975-2007. Bethesda, Md: National Cancer Institute, 2010. <a href="http://seer.cancer.gov/archive/csr/1975_2007/" title="http://seer.cancer.gov/archive/csr/1975_2007/">Also available online</a>.    Last accessed August 13, 2018.</li><li id="section_3.5">Pfeiffer RM, Mitani A, Matsuno RK, et al.: Racial differences in breast cancer trends in the United States (2000-2004). J Natl Cancer Inst 100 (10): 751-2, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18477805&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18477805&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.6">Boone CW, Kelloff GJ, Freedman LS: Intraepithelial and postinvasive neoplasia as a stochastic continuum of clonal evolution, and its relationship to mechanisms of chemopreventive drug action. J Cell Biochem Suppl 17G: 14-25, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8007692&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8007692&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.7">Kelloff GJ, Boone CW, Steele VE, et al.: Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials. Cancer Res 54 (7 Suppl): 2015s-2024s, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8137331&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8137331&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.8">Knabbe C, Lippman ME, Wakefield LM, et al.: Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48 (3): 417-28, 1987.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2879636&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2879636&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.9">Parkin DM: Cancers of the breast, endometrium and ovary: geographic correlations. Eur J Cancer Clin Oncol 25 (12): 1917-25, 1989.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2698807&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2698807&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.10">Dunn JE Jr: Breast cancer among American Japanese in the San Francisco Bay area. Natl Cancer Inst Monogr 47: 157-60, 1977.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=613235&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=613235&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.11">Kliewer EV, Smith KR: Breast cancer mortality among immigrants in Australia and Canada. J Natl Cancer Inst 87 (15): 1154-61, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7674320&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7674320&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.12">Brinton LA, Schairer C, Hoover RN, et al.: Menstrual factors and risk of breast cancer. Cancer Invest 6 (3): 245-54, 1988.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3167610&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3167610&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.13">Collaborative Group on Hormonal Factors in Breast Cancer: Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol 13 (11): 1141-51, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23084519&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23084519&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.14">Ritte R, Lukanova A, Tj&#xF8;nneland A, et al.: Height, age at menarche and risk of hormone receptor-positive and -negative breast cancer: a cohort study. Int J Cancer 132 (11): 2619-29, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23090881&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23090881&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.15">Endogenous Hormones and Breast Cancer Collaborative Group: Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94 (8): 606-16, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11959894&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11959894&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.16">Key TJ, Appleby PN, Reeves GK, et al.: Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer 105 (5): 709-22, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21772329&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21772329&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.17">Kaaks R, Rinaldi S, Key TJ, et al.: Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer 12 (4): 1071-82, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16322344&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16322344&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.18">Kaaks R, Berrino F, Key T, et al.: Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 97 (10): 755-65, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15900045&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15900045&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.19">Smith PG, Doll R: Late effects of x irradiation in patients treated for metropathia haemorrhagica. Br J Radiol 49 (579): 224-32, 1976.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1276589&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1276589&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.20">Trichopoulos D, MacMahon B, Cole P: Menopause and breast cancer risk. J Natl Cancer Inst 48 (3): 605-13, 1972.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5058966&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5058966&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.21">Feinleib M: Breast cancer and artificial menopause: a cohort study. J Natl Cancer Inst 41 (2): 315-29, 1968.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5671283&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5671283&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.22">Kampert JB, Whittemore AS, Paffenbarger RS Jr: Combined effect of childbearing, menstrual events, and body size on age-specific breast cancer risk. Am J Epidemiol 128 (5): 962-79, 1988.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3189296&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3189296&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.23">Hirayama T, Wynder EL: A study of the epidemiology of cancer of the breast. II. The influence of hysterectomy. Cancer 15: 28-38, 1962 Jan-Feb.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=13907646&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=13907646&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.24">Colditz GA, Kaphingst KA, Hankinson SE, et al.: Family history and risk of breast cancer: nurses' health study. Breast Cancer Res Treat 133 (3): 1097-104, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22350789&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22350789&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.25">Miki Y, Swensen J, Shattuck-Eidens D, et al.: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266 (5182): 66-71, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7545954&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7545954&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.26">Futreal PA, Liu Q, Shattuck-Eidens D, et al.: BRCA1 mutations in primary breast and ovarian carcinomas. Science 266 (5182): 120-2, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7939630&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7939630&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.27">Wooster R, Neuhausen SL, Mangion J, et al.: Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265 (5181): 2088-90, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8091231&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8091231&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.28">Kuchenbaecker KB, Hopper JL, Barnes DR, et al.: Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA 317 (23): 2402-2416, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28632866&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28632866&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.29">Antoniou A, Pharoah PD, Narod S, et al.: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72 (5): 1117-30, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12677558&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12677558&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.30">Chen S, Parmigiani G: Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25 (11): 1329-33, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17416853&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17416853&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.31">National Cancer Institute: SEER Stat Fact Sheets: Female Breast Cancer. Bethesda, MD: National Cancer Institute. <a href="https://seer.cancer.gov/statfacts/html/breast.html" title="https://seer.cancer.gov/statfacts/html/breast.html">Available online</a>. Last accessed August 13, 2018.</li><li id="section_3.32">Swift M, Morrell D, Massey RB, et al.: Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 325 (26): 1831-6, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1961222&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1961222&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.33">Cybulski C, Woko&#x142;orczyk D, Jakubowska A, et al.: Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol 29 (28): 3747-52, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21876083&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21876083&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.34">Boyd NF, Guo H, Martin LJ, et al.: Mammographic density and the risk and detection of breast cancer. N Engl J Med 356 (3): 227-36, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17229950&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17229950&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.35">Razzaghi H, Troester MA, Gierach GL, et al.: Mammographic density and breast cancer risk in White and African American Women. Breast Cancer Res Treat 135 (2): 571-80, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22864770&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22864770&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.36">McCormack VA, dos Santos Silva I: Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15 (6): 1159-69, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16775176&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16775176&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.37">Gierach GL, Ichikawa L, Kerlikowske K, et al.: Relationship between mammographic density and breast cancer death in the Breast Cancer Surveillance Consortium. J Natl Cancer Inst 104 (16): 1218-27, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22911616&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22911616&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.38">Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 350 (9084): 1047-59, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10213546&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10213546&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.39">Hulley S, Furberg C, Barrett-Connor E, et al.: Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288 (1): 58-66, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12090863&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12090863&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.40">Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288 (3): 321-33, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12117397&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12117397&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.41">Chlebowski RT, Anderson GL, Gass M, et al.: Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304 (15): 1684-92, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20959578&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20959578&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.42">Chlebowski RT, Hendrix SL, Langer RD, et al.: Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289 (24): 3243-53, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12824205&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12824205&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.43">Chlebowski RT, Manson JE, Anderson GL, et al.: Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. J Natl Cancer Inst 105 (8): 526-35, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23543779&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23543779&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.44">Anderson GL, Limacher M, Assaf AR, et al.: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291 (14): 1701-12, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15082697&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15082697&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.45">LaCroix AZ, Chlebowski RT, Manson JE, et al.: Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 305 (13): 1305-14, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21467283&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21467283&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.46">Anderson GL, Chlebowski RT, Aragaki AK, et al.: Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol 13 (5): 476-86, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22401913&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22401913&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.47">Schierbeck LL, Rejnmark L, Tofteng CL, et al.: Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 345: e6409, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23048011&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23048011&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.48">Beral V, Reeves G, Bull D, et al.: Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst 103 (4): 296-305, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21278356&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21278356&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.49">Li CI, Malone KE, Porter PL, et al.: Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289 (24): 3254-63, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12824206&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12824206&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.50">Chlebowski RT, Anderson GL: The influence of time from menopause and mammography on hormone therapy-related breast cancer risk assessment. J Natl Cancer Inst 103 (4): 284-5, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21278357&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21278357&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.51">Prentice RL, Chlebowski RT, Stefanick ML, et al.: Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol 167 (12): 1407-15, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18448442&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18448442&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.52">Chlebowski RT, Kuller LH, Prentice RL, et al.: Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 360 (6): 573-87, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19196674&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19196674&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.53">Cronin KA, Ravdin PM, Edwards BK: Sustained lower rates of breast cancer in the United States. Breast Cancer Res Treat 117 (1): 223-4, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18979196&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18979196&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.54">Ravdin PM, Cronin KA, Howlader N, et al.: The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356 (16): 1670-4, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17442911&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17442911&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.55">Parkin DM: Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy? Eur J Cancer 45 (9): 1649-53, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19217279&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19217279&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.56">Lambe M, Wigertz A, Holmqvist M, et al.: Reductions in use of hormone replacement therapy: effects on Swedish breast cancer incidence trends only seen after several years. Breast Cancer Res Treat 121 (3): 679-83, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19894110&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19894110&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.57">Renard F, Vankrunkelsven P, Van Eycken L, et al.: Decline in breast cancer incidence in the Flemish region of Belgium after a decline in hormonal replacement therapy. Ann Oncol 21 (12): 2356-60, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20439342&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20439342&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.58">Farhat GN, Walker R, Buist DS, et al.: Changes in invasive breast cancer and ductal carcinoma in situ rates in relation to the decline in hormone therapy use. J Clin Oncol 28 (35): 5140-6, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21060026&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21060026&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.59">DeSantis C, Howlader N, Cronin KA, et al.: Breast cancer incidence rates in U.S. women are no longer declining. Cancer Epidemiol Biomarkers Prev 20 (5): 733-9, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21357727&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21357727&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.60">John EM, Kelsey JL: Radiation and other environmental exposures and breast cancer. Epidemiol Rev 15 (1): 157-62, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8405198&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8405198&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.61">Evans JS, Wennberg JE, McNeil BJ: The influence of diagnostic radiography on the incidence of breast cancer and leukemia. N Engl J Med 315 (13): 810-5, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3748092&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3748092&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.62">Andrieu N, Easton DF, Chang-Claude J, et al.: Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group. J Clin Oncol 24 (21): 3361-6, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16801631&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16801631&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.63">Bhatia S, Robison LL, Oberlin O, et al.: Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 334 (12): 745-51, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8592547&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8592547&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.64">Hancock SL, Tucker MA, Hoppe RT: Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 85 (1): 25-31, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8416252&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8416252&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.65">Travis LB, Hill DA, Dores GM, et al.: Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 290 (4): 465-75, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12876089&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12876089&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.66">Sankila R, Garwicz S, Olsen JH, et al.: Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. Association of the Nordic Cancer Registries and the Nordic Society of Pediatric Hematology and Oncology. J Clin Oncol 14 (5): 1442-6, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8622057&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8622057&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.67">van Leeuwen FE, Klokman WJ, Stovall M, et al.: Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 95 (13): 971-80, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12837833&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12837833&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.68">Obedian E, Fischer DB, Haffty BG: Second malignancies after treatment of early-stage breast cancer: lumpectomy and radiation therapy versus mastectomy. J Clin Oncol 18 (12): 2406-12, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10856100&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10856100&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.69">Fisher B, Anderson S, Bryant J, et al.: Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347 (16): 1233-41, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12393820&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12393820&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.70">Veronesi U, Cascinelli N, Mariani L, et al.: Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347 (16): 1227-32, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12393819&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12393819&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.71">Fisher B, Jeong JH, Anderson S, et al.: Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 347 (8): 567-75, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12192016&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12192016&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.72">Morimoto LM, White E, Chen Z, et al.: Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control 13 (8): 741-51, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12420953&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12420953&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.73">Wolin KY, Carson K, Colditz GA: Obesity and cancer. Oncologist 15 (6): 556-65, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20507889&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20507889&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.74">Lawlor DA, Smith GD, Ebrahim S: Hyperinsulinaemia and increased risk of breast cancer: findings from the British Women's Heart and Health Study. Cancer Causes Control 15 (3): 267-75, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15090721&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15090721&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.75">Hamajima N, Hirose K, Tajima K, et al.: Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer 87 (11): 1234-45, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12439712&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12439712&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.76">Pike MC, Krailo MD, Henderson BE, et al.: 'Hormonal' risk factors, 'breast tissue age' and the age-incidence of breast cancer. Nature 303 (5920): 767-70, 1983.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6866078&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6866078&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.77">Lambe M, Hsieh C, Trichopoulos D, et al.: Transient increase in the risk of breast cancer after giving birth. N Engl J Med 331 (1): 5-9, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8202106&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8202106&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.78">Henderson BE, Pike MC, Ross RK, et al.: Epidemiology and risk factors. In: Bonadonna G, ed.: Breast Cancer: Diagnosis and Management. Chichester, NY: John Wiley &amp; Sons, 1984, pp 15-33.</li><li id="section_3.79">Gail MH, Brinton LA, Byar DP, et al.: Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81 (24): 1879-86, 1989.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2593165&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2593165&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.80">Col: Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 360 (9328): 187-95, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12133652&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12133652&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.81">Furberg H, Newman B, Moorman P, et al.: Lactation and breast cancer risk. Int J Epidemiol 28 (3): 396-402, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10405840&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10405840&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.82">Bernstein L, Henderson BE, Hanisch R, et al.: Physical exercise and reduced risk of breast cancer in young women. J Natl Cancer Inst 86 (18): 1403-8, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8072034&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8072034&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.83">Friedenreich CM: Physical activity and cancer prevention: from observational to intervention research. Cancer Epidemiol Biomarkers Prev 10 (4): 287-301, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11319168&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11319168&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.84">Thune I, Brenn T, Lund E, et al.: Physical activity and the risk of breast cancer. N Engl J Med 336 (18): 1269-75, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9113929&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9113929&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.85">Adams-Campbell LL, Rosenberg L, Rao RS, et al.: Strenuous physical activity and breast cancer risk in African-American women. J Natl Med Assoc 93 (7-8): 267-75, 2001 Jul-Aug.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11491277&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11491277&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.86">Nayfield SG, Karp JE, Ford LG, et al.: Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 83 (20): 1450-9, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1920492&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1920492&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.87">Love RR, Barden HS, Mazess RB, et al.: Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 154 (22): 2585-8, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7979855&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7979855&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.88">Powles TJ, Hickish T, Kanis JA, et al.: Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14 (1): 78-84, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8558225&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8558225&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.89">Costantino JP, Kuller LH, Ives DG, et al.: Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst 89 (11): 776-82, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9182975&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9182975&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.90">McDonald CC, Stewart HJ: Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ 303 (6800): 435-7, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1912833&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1912833&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.91">Rutqvist LE, Mattsson A: Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 85 (17): 1398-406, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8350363&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8350363&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.92">Fisher B, Costantino JP, Redmond CK, et al.: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86 (7): 527-37, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8133536&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8133536&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.93">Bergman L, Beelen ML, Gallee MP, et al.: Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet 356 (9233): 881-7, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11036892&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11036892&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.94">Cuzick J, Powles T, Veronesi U, et al.: Overview of the main outcomes in breast-cancer prevention trials. Lancet 361 (9354): 296-300, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12559863&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12559863&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.95">Redmond CK, Wickerham DL, Cronin W, et al.: The NSABP breast cancer prevention trial (BCPT): a progress report. [Abstract] Proceedings of the American Society of Clinical Oncology  12: A-78, 69, 1993.</li><li id="section_3.96">Fisher B, Costantino JP, Wickerham DL, et al.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 (18): 1371-88, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9747868&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9747868&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.97">Fisher B, Costantino JP, Wickerham DL, et al.: Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97 (22): 1652-62, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16288118&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16288118&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.98">Powles T, Eeles R, Ashley S, et al.: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352 (9122): 98-101, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9672274&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9672274&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.99">Veronesi U, Maisonneuve P, Costa A, et al.: Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 352 (9122): 93-7, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9672273&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9672273&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.100">Cuzick J, Forbes J, Edwards R, et al.: First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360 (9336): 817-24, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12243915&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12243915&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.101">Powles TJ, Ashley S, Tidy A, et al.: Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99 (4): 283-90, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17312305&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17312305&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.102">Veronesi U, Maisonneuve P, Rotmensz N, et al.: Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 99 (9): 727-37, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17470740&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17470740&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.103">Martino S, Costantino J, McNabb M, et al.: The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials. Oncologist 9 (2): 116-25, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15047916&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15047916&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.104">Cuzick J, Forbes JF, Sestak I, et al.: Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99 (4): 272-82, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17312304&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17312304&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.105">Fisher B, Dignam J, Wolmark N, et al.: Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353 (9169): 1993-2000, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10376613&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10376613&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.106">Khovidhunkit W, Shoback DM: Clinical effects of raloxifene hydrochloride in women. Ann Intern Med 130 (5): 431-9, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10068418&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10068418&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.107">Cauley JA, Norton L, Lippman ME, et al.: Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65 (2): 125-34, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11261828&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11261828&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.108">Cummings SR, Eckert S, Krueger KA, et al.: The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281 (23): 2189-97, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10376571&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10376571&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.109">Martino S, Cauley JA, Barrett-Connor E, et al.: Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96 (23): 1751-61, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15572757&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15572757&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.110">Grady D, Cauley JA, Geiger MJ, et al.: Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk. J Natl Cancer Inst 100 (12): 854-61, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18544744&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18544744&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.111">Vogel VG, Costantino JP, Wickerham DL, et al.: Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295 (23): 2727-41, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16754727&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16754727&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.112">Land SR, Wickerham DL, Costantino JP, et al.: Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295 (23): 2742-51, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16754728&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16754728&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.113">The ATAC Trialists' Group. Arimidex, tamoxifen alone or in combination: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 (9324): 2131-9, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12090977&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12090977&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.114">Goss PE, Ingle JN, Martino S, et al.: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349 (19): 1793-802, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14551341&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14551341&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.115">Goss PE, Ingle JN, Pritchard KI, et al.: Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. N Engl J Med 375 (3): 209-19, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27264120&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27264120&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.116">Coombes RC, Hall E, Gibson LJ, et al.: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 (11): 1081-92, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15014181&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15014181&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.117">Goss PE, Ingle JN, Al&#xE9;s-Mart&#xED;nez JE, et al.: Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364 (25): 2381-91, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21639806&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21639806&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.118">Cuzick J, Sestak I, Forbes JF, et al.: Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 383 (9922): 1041-8, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24333009&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24333009&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.119">Hartmann LC, Schaid DJ, Woods JE, et al.: Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340 (2): 77-84, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9887158&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9887158&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.120">Kummerow KL, Du L, Penson DF, et al.: Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg 150 (1): 9-16, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25408966&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25408966&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.121">Rebbeck TR, Levin AM, Eisen A, et al.: Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91 (17): 1475-9, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10469748&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10469748&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.122">Kauff ND, Satagopan JM, Robson ME, et al.: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346 (21): 1609-15, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12023992&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12023992&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.123">Rebbeck TR, Lynch HT, Neuhausen SL, et al.: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346 (21): 1616-22, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12023993&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12023993&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.124">Kauff ND, Domchek SM, Friebel TM, et al.: Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 26 (8): 1331-7, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18268356&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18268356&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.125">Breast cancer and hormonal contraceptives: further results. Collaborative Group on Hormonal Factors in Breast Cancer. Contraception 54 (3 Suppl): 1S-106S, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8899264&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8899264&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.126">Marchbanks PA, McDonald JA, Wilson HG, et al.: Oral contraceptives and the risk of breast cancer. N Engl J Med 346 (26): 2025-32, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12087137&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12087137&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.127">Strom BL, Berlin JA, Weber AL, et al.: Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer. Contraception 69 (5): 353-60, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15105056&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15105056&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.128">M&#xF8;rch LS, Skovlund CW, Hannaford PC, et al.: Contemporary Hormonal Contraception and the Risk of Breast Cancer. N Engl J Med 377 (23): 2228-2239, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=29211679&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=29211679&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.129">Wolff MS, Toniolo PG, Lee EW, et al.: Blood levels of organochlorine residues and risk of breast cancer. J Natl Cancer Inst 85 (8): 648-52, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8468722&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8468722&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.130">H&#xF8;yer AP, Grandjean P, J&#xF8;rgensen T, et al.: Organochlorine exposure and risk of breast cancer. Lancet 352 (9143): 1816-20, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9851382&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9851382&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.131">Shames LS, Munekata MT, Pike MC: Re: Blood levels of organochlorine residues and risk of breast cancer. J Natl Cancer Inst 86 (21): 1642-3, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7802816&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7802816&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.132">Krieger N, Wolff MS, Hiatt RA, et al.: Breast cancer and serum organochlorines: a prospective study among white, black, and Asian women. J Natl Cancer Inst 86 (8): 589-99, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8145274&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8145274&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.133">Hunter DJ, Hankinson SE, Laden F, et al.: Plasma organochlorine levels and the risk of breast cancer. N Engl J Med 337 (18): 1253-8, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9345073&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9345073&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.134">Laden F, Collman G, Iwamoto K, et al.: 1,1-Dichloro-2,2-bis(p-chlorophenyl)ethylene and polychlorinated biphenyls and breast cancer: combined analysis of five U.S. studies. J Natl Cancer Inst 93 (10): 768-76, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11353787&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11353787&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.135">Ward EM, Schulte P, Grajewski B, et al.: Serum organochlorine levels and breast cancer: a nested case-control study of Norwegian women. Cancer Epidemiol Biomarkers Prev 9 (12): 1357-67, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11142422&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11142422&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.136">Laden F, Hankinson SE, Wolff MS, et al.: Plasma organochlorine levels and the risk of breast cancer: an extended follow-up in the Nurses' Health Study. Int J Cancer 91 (4): 568-74, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11251983&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11251983&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.137">Huang Y, Zhang X, Li W, et al.: A meta-analysis of the association between induced abortion and breast cancer risk among Chinese females. Cancer Causes Control 25 (2): 227-36, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24272196&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24272196&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.138">Sanderson M, Shu XO, Jin F, et al.: Abortion history and breast cancer risk: results from the Shanghai Breast Cancer Study. Int J Cancer 92 (6): 899-905, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11351314&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11351314&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.139">Beral V, Bull D, Doll R, et al.: Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83,000 women with breast cancer from 16 countries. Lancet 363 (9414): 1007-16, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15051280&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15051280&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.140">Melbye M, Wohlfahrt J, Olsen JH, et al.: Induced abortion and the risk of breast cancer. N Engl J Med 336 (2): 81-5, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8988884&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8988884&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.141">Rookus MA, van Leeuwen FE: Induced abortion and risk for breast cancer: reporting (recall) bias in a Dutch case-control study. J Natl Cancer Inst 88 (23): 1759-64, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8944006&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8944006&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.142">Committee on Gynecologic Practice: ACOG Committee Opinion No. 434: induced abortion and breast cancer risk. Obstet Gynecol 113 (6): 1417-8, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19461458&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19461458&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.143">Henderson KD, Sullivan-Halley J, Reynolds P, et al.: Incomplete pregnancy is not associated with breast cancer risk: the California Teachers Study. Contraception 77 (6): 391-6, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18477486&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18477486&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.144">Lash TL, Fink AK: Null association between pregnancy termination and breast cancer in a registry-based study of parous women. Int J Cancer 110 (3): 443-8, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15095312&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15095312&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.145">Michels KB, Xue F, Colditz GA, et al.: Induced and spontaneous abortion and incidence of breast cancer among young women: a prospective cohort study. Arch Intern Med 167 (8): 814-20, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17452545&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17452545&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.146">Wu JQ, Li YY, Ren JC, et al.: Induced abortion and breast cancer: results from a population-based case control study in China. Asian Pac J Cancer Prev 15 (8): 3635-40, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24870770&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24870770&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.147">Bra&#xFC;ner CM, Overvad K, Tj&#xF8;nneland A, et al.: Induced abortion and breast cancer among parous women: a Danish cohort study. Acta Obstet Gynecol Scand 92 (6): 700-5, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23402419&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23402419&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.148">Guo J, Huang Y, Yang L, et al.: Association between abortion and breast cancer: an updated systematic review and meta-analysis based on prospective studies. Cancer Causes Control 26 (6): 811-9, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25779378&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25779378&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.149">Carroll KK, Khor HT: Dietary fat in relation to tumorigenesis. Prog Biochem Pharmacol 10: 308-53, 1975.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=165553&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=165553&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.150">Hunter DJ, Spiegelman D, Adami HO, et al.: Cohort studies of fat intake and the risk of breast cancer--a pooled analysis. N Engl J Med 334 (6): 356-61, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8538706&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8538706&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.151">Prentice RL, Caan B, Chlebowski RT, et al.: Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 295 (6): 629-42, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16467232&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16467232&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.152">Howard BV, Van Horn L, Hsia J, et al.: Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 295 (6): 655-66, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16467234&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16467234&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.153">Smith-Warner SA, Spiegelman D, Yaun SS, et al.: Intake of fruits and vegetables and risk of breast cancer: a pooled analysis of cohort studies. JAMA 285 (6): 769-76, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11176915&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11176915&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.154">Pierce JP, Natarajan L, Caan BJ, et al.: Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. JAMA 298 (3): 289-98, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17635889&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17635889&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.155">Toledo E, Salas-Salvad&#xF3; J, Donat-Vargas C, et al.: Mediterranean Diet and Invasive Breast Cancer Risk Among Women at High Cardiovascular Risk in the PREDIMED Trial: A Randomized Clinical Trial. JAMA Intern Med 175 (11): 1752-60, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26365989&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26365989&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.156">Estruch R, Ros E, Salas-Salvad&#xF3; J, et al.: Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 368 (14): 1279-90, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23432189&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23432189&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.157">Lee IM, Cook NR, Manson JE, et al.: Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study. J Natl Cancer Inst 91 (24): 2102-6, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10601381&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10601381&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.158">Lee IM, Cook NR, Gaziano JM, et al.: Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA 294 (1): 56-65, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15998891&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15998891&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.159">Lin J, Cook NR, Albert C, et al.: Vitamins C and E and beta carotene supplementation and cancer risk: a randomized controlled trial. J Natl Cancer Inst 101 (1): 14-23, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19116389&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19116389&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.160">Zhang SM, Cook NR, Albert CM, et al.: Effect of combined folic acid, vitamin B6, and vitamin B12 on cancer risk in women: a randomized trial. JAMA 300 (17): 2012-21, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18984888&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18984888&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.161">Costa A, Formelli F, Chiesa F, et al.: Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res 54 (7 Suppl): 2032s-2037s, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8137334&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8137334&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.162">Veronesi U, De Palo G, Marubini E, et al.: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 91 (21): 1847-56, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10547391&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10547391&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.163">The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, Ga: U.S. Department of Health and Human Services, CDC, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2004. <a href="https://www.cdc.gov/tobacco/data_statistics/sgr/2004/index.htm" title="https://www.cdc.gov/tobacco/data_statistics/sgr/2004/index.htm">Also available online</a>.                Last accessed August 13, 2018.</li><li id="section_3.164">U.S. Department of Health and Human Services: The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. Atlanta, Ga: U.S. Department of Health and Human Services, Centers for Disease Control and
            Prevention, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2006. <a href="https://www.ncbi.nlm.nih.gov/books/NBK44324/" title="https://www.ncbi.nlm.nih.gov/books/NBK44324/">Also available online</a>.                       Last accessed   August 13, 2018.</li><li id="section_3.165">Pirie K, Beral V, Peto R, et al.: Passive smoking and breast cancer in never smokers: prospective study and meta-analysis. Int J Epidemiol 37 (5): 1069-79, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18544575&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18544575&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.166">Mirick DK, Davis S, Thomas DB: Antiperspirant use and the risk of breast cancer. J Natl Cancer Inst 94 (20): 1578-80, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12381712&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12381712&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.167">McGrath KG: An earlier age of breast cancer diagnosis related to more frequent use of antiperspirants/deodorants and underarm shaving. Eur J Cancer Prev 12 (6): 479-85, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14639125&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14639125&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.168">Dale KM, Coleman CI, Henyan NN, et al.: Statins and cancer risk: a meta-analysis. JAMA 295 (1): 74-80, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16391219&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16391219&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.169">Bonovas S, Filioussi K, Tsavaris N, et al.: Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 23 (34): 8606-12, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16260694&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16260694&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.170">Newcomb PA, Trentham-Dietz A, Hampton JM: Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer 102 (5): 799-802, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20160722&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20160722&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.171">Rennert G, Pinchev M, Rennert HS: Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 28 (22): 3577-81, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20567021&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20567021&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.172">Chlebowski RT, Chen Z, Cauley JA, et al.: Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 28 (22): 3582-90, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20567009&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20567009&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.173">Cardwell CR, Abnet CC, Veal P, et al.: Exposure to oral bisphosphonates and risk of cancer. Int J Cancer 131 (5): E717-25, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22161552&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22161552&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.174">Monsees GM, Malone KE, Tang MT, et al.: Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancer. J Natl Cancer Inst 103 (23): 1752-60, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22021667&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22021667&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.175">Hue TF, Cummings SR, Cauley JA, et al.: Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid. JAMA Intern Med 174 (10): 1550-7, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25111880&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25111880&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.176">Straif K, Baan R, Grosse Y, et al.: Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol 8 (12): 1065-1066, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28581429&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28581429&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.177">Kamdar BB, Tergas AI, Mateen FJ, et al.: Night-shift work and risk of breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 138 (1): 291-301, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23400581&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23400581&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.178">Travis RC, Balkwill A, Fensom GK, et al.: Night Shift Work and Breast Cancer Incidence: Three Prospective Studies and Meta-analysis of Published Studies. J Natl Cancer Inst 108 (12): , 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27758828&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27758828&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _85
      field_pdq_section_title:
        - format: plain_text
          value: 'Changes to This Summary (09/14/2018)'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_85" class="pdq-sections"><p id="_89" tabindex="-1">The PDQ cancer information summaries are reviewed regularly and updated as
            new information becomes available.  This section describes the latest
            changes made to this summary as of the date above.</p><p id="_769" tabindex="-1">Editorial changes were made to this summary.</p><p id="_disclaimerHP_3" tabindex="-1">This summary is written and maintained by the <a href="https://www.cancer.gov/publications/pdq/editorial-boards/screening-prevention" title="https://www.cancer.gov/publications/pdq/editorial-boards/screening-prevention">PDQ Screening and Prevention Editorial Board</a>, which is
            editorially independent of NCI.  The summary reflects an independent review of
            the literature and does not represent a policy statement of NCI or NIH.  More
            information about summary policies and the role of the PDQ Editorial Boards  in
            maintaining the PDQ summaries can be found on the <a href="/types/breast/hp/breast-prevention-pdq#link/_AboutThis_1">About This PDQ Summary</a> and <a href="https://www.cancer.gov/publications/pdq" title="https://www.cancer.gov/publications/pdq">PDQ&#xAE; - NCI's Comprehensive Cancer Database</a> pages.
            </p></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _AboutThis_1
      field_pdq_section_title:
        - format: plain_text
          value: 'About This PDQ Summary'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_AboutThis_1" class="pdq-sections"><section id="_AboutThis_2"><h3 id="_AboutThis_2_toc">Purpose of This Summary</h3><p id="_AboutThis_3" tabindex="-1">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about breast cancer prevention. It is intended as a resource to inform and assist clinicians who care for cancer patients.  It does not provide formal guidelines or recommendations for making health care decisions.</p></section><section id="_AboutThis_4"><h3 id="_AboutThis_4_toc">Reviewers and Updates</h3><p id="_AboutThis_5" tabindex="-1">This summary is reviewed regularly and updated as necessary by the <a href="https://www.cancer.gov/publications/pdq/editorial-boards/screening-prevention" title="https://www.cancer.gov/publications/pdq/editorial-boards/screening-prevention">PDQ Screening and Prevention Editorial Board</a>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</p><p id="_AboutThis_22" tabindex="-1"> Board members review recently published articles each month to determine whether an article should:</p><div class="pdq-content-list"><ul id="_AboutThis_6"><li>be discussed at a meeting,</li><li>be cited with text, or</li><li>replace or update an existing article that is already cited.</li></ul></div><p id="_AboutThis_7" tabindex="-1">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</p><p id="_AboutThis_9" tabindex="-1">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <a href="https://www.cancer.gov/contact/email-us" title="https://www.cancer.gov/contact/email-us">Email Us</a>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</p></section><section id="_AboutThis_10"><h3 id="_AboutThis_10_toc">Levels of Evidence</h3><p id="_AboutThis_11" tabindex="-1">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Screening and Prevention Editorial Board uses a <a href="/publications/pdq/levels-evidence/screening-prevention">formal evidence ranking system</a> in developing its level-of-evidence designations.</p></section><section id="_AboutThis_12"><h3 id="_AboutThis_12_toc">Permission to Use This Summary</h3><p id="_AboutThis_13" tabindex="-1">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as &#x201C;NCI&#x2019;s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].&#x201D;</p><p id="_AboutThis_14" tabindex="-1">The preferred citation for this PDQ summary is:</p><p id="_AboutThis_15" tabindex="-1">PDQ&#xAE; Screening and Prevention Editorial Board. PDQ Breast Cancer Prevention. Bethesda, MD: National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <a href="https://www.cancer.gov/types/breast/hp/breast-prevention-pdq" title="https://www.cancer.gov/types/breast/hp/breast-prevention-pdq">https://www.cancer.gov/types/breast/hp/breast-prevention-pdq</a>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 26389323]</p><p id="_AboutThis_16" tabindex="-1">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <a href="https://visualsonline.cancer.gov/" title="https://visualsonline.cancer.gov/">Visuals Online</a>, a collection of over 2,000 scientific images.
            </p></section><section id="_AboutThis_17"><h3 id="_AboutThis_17_toc">Disclaimer</h3><p id="_AboutThis_19" tabindex="-1">The information in these summaries should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <a href="https://www.cancer.gov/about-cancer/managing-care" title="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</a> page.</p></section><section id="_AboutThis_20"><h3 id="_AboutThis_20_toc">Contact Us</h3><p id="_AboutThis_21" tabindex="-1">More information about contacting us or receiving help with the Cancer.gov website can be found on our <a href="https://www.cancer.gov/contact" title="https://www.cancer.gov/contact">Contact Us for Help</a> page. Questions can also be submitted to Cancer.gov through the website&#x2019;s <a href="https://www.cancer.gov/contact/email-us" title="https://www.cancer.gov/contact/email-us">Email Us</a>.</p></section></div>
  title__ES:
    value: 'Prevención del cáncer de seno (mama) (PDQ®)–Versión para profesionales de salud'
  status__ES:
    value: 1
  langcode__ES:
    value: es
  moderation_state__ES:
    value: published
  field_pdq_url__ES:
    value: /tipos/seno/pro/prevencion-seno-pdq
  field_pdq_cdr_id__ES:
    value: 744468
  field_pdq_audience__ES:
    value: Health Professionals
  field_pdq_summary_type__ES:
    value: Prevention
  field_date_posted__ES:
    value: '2013-01-04'
  field_date_updated__ES:
    value: '2018-08-24'
  field_browser_title__ES:
    value: 'Prevención del cáncer de seno (mama)'
  field_page_description__ES:
    value: 'Sumario de información revisada por expertos sobre factores que influyen en el riesgo de presentar cáncer de mama y sobre las investigaciones dirigidas a la prevención de esta enfermedad.'
  field_public_use__ES:
    value: 1
  field_summary_sections__ES:
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _552
      field_pdq_section_title:
        - format: plain_text
          value: '¿Quién está en riesgo?'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_552" class="pdq-sections"><div class="pdq-hp-patient-toggle"><a href="/espanol/tipos/seno/paciente/prevencion-seno-pdq">Vaya a la versi&#xF3;n para pacientes</a></div><p id="_553" tabindex="-1">Adem&#xE1;s de pertenecer al sexo femenino, el envejecimiento es el principal factor de riesgo del c&#xE1;ncer de mama. Los factores reproductivos que aumentan la exposici&#xF3;n a los estr&#xF3;genos end&#xF3;genos, como la menarquia prematura y la menopausia tard&#xED;a, aumentan el riesgo, al igual que lo hace el uso de una combinaci&#xF3;n de las hormonas estr&#xF3;geno y progesterona despu&#xE9;s de la menopausia. La nuliparidad y el consumo de alcohol tambi&#xE9;n se relacionan con un mayor riesgo.</p><p id="_698" tabindex="-1">Las mujeres con antecedentes familiares o personales de c&#xE1;ncer de mama invasivo, carcinoma ductal <em>in situ</em> o carcinoma lobulillar <em>in situ</em>, o con antecedentes de biopsia de mama que muestra enfermedad proliferativa benigna, tienen un aumento de riesgo de c&#xE1;ncer de mama.[<a href="#cit/section_1.1">1</a>-<a href="#cit/section_1.4">4</a>]</p><p id="_554" tabindex="-1">La densidad mamaria elevada se relaciona con un riesgo m&#xE1;s alto. A menudo, esta es una caracter&#xED;stica hereditaria, pero tambi&#xE9;n se observa con m&#xE1;s frecuencia en las mujeres nul&#xED;paras, las mujeres cuyo primer embarazo se presenta tarde en la vida,  las mujeres posmenop&#xE1;usicas que usan  hormonas y las que consumen alcohol.</p><p id="_555" tabindex="-1">La exposici&#xF3;n a la radiaci&#xF3;n ionizante, particularmente durante la pubertad o a principios de la adultez, y las mutaciones gen&#xE9;ticas hereditarias nocivas, aumentan el riesgo de c&#xE1;ncer de mama.</p><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_1.1">Kotsopoulos J, Chen WY, Gates MA, et al.: Risk factors for ductal and lobular breast cancer: results from the nurses' health study. Breast Cancer Res 12 (6): R106, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21143857&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21143857&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.2">Goldacre MJ, Abisgold JD, Yeates DG, et al.: Benign breast disease and subsequent breast cancer: English record linkage studies. J Public Health (Oxf) 32 (4): 565-71, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20154063&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20154063&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.3">Kabat GC, Jones JG, Olson N, et al.: A multi-center prospective cohort study of benign breast disease and risk of subsequent breast cancer. Cancer Causes Control 21 (6): 821-8, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20084540&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20084540&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.4">Worsham MJ, Raju U, Lu M, et al.: Risk factors for breast cancer from benign breast disease in a diverse population. Breast Cancer Res Treat 118 (1): 1-7, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18836828&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18836828&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _1
      field_pdq_section_title:
        - format: plain_text
          value: 'Información general'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_1" class="pdq-sections"><p id="_2" tabindex="-1">Nota: Tambi&#xE9;n est&#xE1;n disponibles otros sumarios del PDQ sobre <a href="/espanol/tipos/seno/pro/deteccion-seno-pdq">Ex&#xE1;menes de detecci&#xF3;n del c&#xE1;ncer de seno (mama)</a>; <a href="/espanol/tipos/seno/pro/tratamiento-seno-pdq">Tratamiento del c&#xE1;ncer de seno (mama)</a>; <a href="/espanol/tipos/seno/pro/tratamiento-seno-masculino-pdq">Tratamiento del c&#xE1;ncer de seno (mama) masculino</a>; <a href="/espanol/tipos/seno/pro/tratamiento-seno-embarazo-pdq">Tratamiento del c&#xE1;ncer de seno (mama) durante el embarazo</a> y <a href="/espanol/publicaciones/pdq/grados-comprobacion/deteccion-prevencion">Grados de comprobaci&#xF3;n cient&#xED;fica de los estudios de investigaci&#xF3;n sobre detecci&#xF3;n y prevenci&#xF3;n del c&#xE1;ncer</a>.</p><section id="_175"><h3 id="_175_toc">Factores con pruebas suficientes de un riesgo mayor de c&#xE1;ncer de mama</h3><section id="_556"><h4 id="_556_toc">Edad y sexo</h4><p id="_557" tabindex="-1">Sobre la base pruebas s&#xF3;lidas, el sexo femenino y el envejecimiento son los principales factores de riesgo de c&#xE1;ncer de mama.</p><p id="_558" tabindex="-1"><strong>Magnitud del efecto</strong>: las mujeres tienen un riesgo de por vida de c&#xE1;ncer de mama cerca de 100 veces m&#xE1;s alto que los hombres. El riesgo a corto plazo de c&#xE1;ncer de mama en una mujer de 70 a&#xF1;os es casi 10 veces mayor que el de una mujer de 30 a&#xF1;os.</p><div class="pdq-content-list"><ul id="_559" class="pdq-address-block"><li><strong>Dise&#xF1;o del estudio</strong>: varios ensayos epidemiol&#xF3;gicos.</li><li><strong>Validez interna</strong>: buena.</li><li><strong>Congruencia</strong>: buena.</li><li><strong>Validez externa</strong>: buena.</li></ul></div></section><section id="_734"><h4 id="_734_toc">Riesgo heredado</h4><p id="_721" tabindex="-1">Sobre la base de pruebas s&#xF3;lidas, las mujeres que tienen antecedentes familiares de c&#xE1;ncer de mama, sobre todo en un familiar de primer grado, tienen un aumento de riesgo de c&#xE1;ncer de mama.</p><p id="_722" tabindex="-1"><strong>Magnitud del efecto</strong>: el riesgo se duplica si afecta a un solo familiar de primer grado; el riesgo aumenta cinco veces si se diagnostica a dos familiares de primer grado.</p><div class="pdq-content-list"><ul id="_723" class="pdq-address-block"><li><strong>Dise&#xF1;o del estudio:</strong> estudios de poblaci&#xF3;n, estudios de cohorte y estudios de casos y controles.</li><li><strong>Validez interna</strong>: buena.</li><li><strong>Congruencia</strong>: buena.</li><li><strong>Validez externa</strong>: buena.</li></ul></div><p id="_767" tabindex="-1">Sobre la base de pruebas s&#xF3;lidas, las mujeres que heredan mutaciones g&#xE9;nicas relacionadas con el c&#xE1;ncer de mama tienen un aumento de riesgo.</p><p id="_768" tabindex="-1"><strong>Magnitud del efecto</strong>: variable; depende del gen mutado, los antecedentes familiares y otros factores de riesgo que afectan la expresi&#xF3;n g&#xE9;nica.</p><div class="pdq-content-list"><ul id="_769" class="pdq-address-block"><li><strong>Dise&#xF1;o del estudio</strong>: estudios de cohorte o estudios de casos y controles.</li><li><strong>Validez interna</strong>: buena.</li><li><strong>Congruencia</strong>: buena.</li><li><strong>Validez externa</strong>: buena.</li></ul></div></section><section id="_564"><h4 id="_564_toc">Densidad mamaria</h4><p id="_565" tabindex="-1">Sobre la base de pruebas s&#xF3;lidas, las mujeres con mamas densas tienen un riesgo mayor de c&#xE1;ncer. A menudo, esta es una caracter&#xED;stica inherente, hasta cierto punto modificable por la conducta reproductiva, los f&#xE1;rmacos y el alcohol.[<a href="#cit/section_2.1">1</a>]</p><p id="_566" tabindex="-1"><strong>Magnitud del efecto</strong>: las mujeres con mamas densas tienen un riesgo mayor, proporcional al grado de densidad. Este riesgo relativo (RR) elevado oscila entre 1,79 en las mujeres con densidad levemente mayor y 4,64 en las mujeres con mamas muy densas, en comparaci&#xF3;n con las mujeres con la menor densidad mamaria.[<a href="#cit/section_2.2">2</a>]</p><div class="pdq-content-list"><ul id="_567" class="pdq-address-block"><li><strong>Dise&#xF1;o del estudio</strong>: estudios de cohortes y de casos y controles.</li><li><strong>Validez interna</strong>: buena.</li><li><strong>Congruencia</strong>: buena.</li><li><strong>Validez externa</strong>: buena.</li></ul></div></section></section><section id="_568"><h3 id="_568_toc">Factores modificables con pruebas suficientes aumento de riesgo de c&#xE1;ncer de mama</h3><section id="_569"><h4 id="_569_toc">Terapia con hormonas combinada</h4><p id="_570" tabindex="-1">Sobre la base de pruebas s&#xF3;lidas, la terapia con hormonas (TH) combinada  (estr&#xF3;geno-progestina) se relaciona con un riesgo mayor de c&#xE1;ncer de mama.</p><p id="_571" tabindex="-1"><strong>Magnitud del efecto</strong>: un aumento de  casi 26&#xA0;%  en la incidencia de c&#xE1;ncer de mama invasivo; el n&#xFA;mero necesario para producir un  caso adicional de c&#xE1;ncer de mama  es 237.</p><div class="pdq-content-list"><ul id="_572" class="pdq-address-block"><li><strong>Dise&#xF1;o del estudio</strong>: ensayos controlados aleatorizados (ECA). Adem&#xE1;s, en los estudios de cohortes y ecol&#xF3;gicos, se muestra que el cese de dicha combinaci&#xF3;n de TH se relaciona con una disminuci&#xF3;n de las tasas de c&#xE1;ncer de mama.</li><li><strong>Validez interna</strong>: buena.</li><li><strong>Congruencia</strong>: buena.</li><li><strong>Validez externa</strong>: buena.</li></ul></div></section><section id="_573"><h4 id="_573_toc">Radiaci&#xF3;n ionizante</h4><p id="_574" tabindex="-1">Sobre la base de pruebas s&#xF3;lidas, la exposici&#xF3;n de la mama a la radiaci&#xF3;n ionizante se relaciona con un riesgo mayor de c&#xE1;ncer de este sitio, a partir de los 10 a&#xF1;os de la exposici&#xF3;n y durante toda la vida. El riesgo depende de la dosis de radiaci&#xF3;n y de la edad en el momento de la exposici&#xF3;n y es particularmente alto si ocurre en la pubertad, cuando se desarrollan las mamas.</p><p id="_575" tabindex="-1"><strong>Magnitud del efecto</strong>: variable, pero con un aumento general de casi seis veces.</p><div class="pdq-content-list"><ul id="_576" class="pdq-address-block"><li><strong>Dise&#xF1;o del estudio</strong>: estudios de cohortes o de casos y controles.</li><li><strong>Validez interna</strong>: buena.</li><li><strong>Congruencia</strong>: buena.</li><li><strong>Validez externa</strong>: buena.</li></ul></div></section><section id="_577"><h4 id="_577_toc">Obesidad</h4><p id="_578" tabindex="-1">Sobre la base de pruebas s&#xF3;lidas, la obesidad se relaciona con un riesgo mayor de c&#xE1;ncer de mama en las mujeres posmenop&#xE1;usicas que no recibieron TH. No est&#xE1; claro si bajar de peso disminuye el riesgo de c&#xE1;ncer de mama en las mujeres obesas.</p><p id="_579" tabindex="-1"><strong>Magnitud del efecto</strong>: en el estudio de observaci&#xF3;n de la Women's Health Initiative con 85&#xA0;917 mujeres  posmenop&#xE1;usicas, se observ&#xF3; que el peso corporal se relaciona con el c&#xE1;ncer de mama.  Al comparar a mujeres que pesaban m&#xE1;s de 82,2 kg con aquellas que pesaban menos de 58,7 kg, el RR fue de 2,85 (intervalo de confianza [IC] 95&#xA0;%, 1,81&#x2013;4,49).</p><div class="pdq-content-list"><ul id="_580" class="pdq-address-block"><li><strong>Dise&#xF1;o del estudio</strong>: estudios de cohortes, y de casos y controles.</li><li><strong>Validez interna</strong>: buena.</li><li><strong>Congruencia</strong>: buena.</li><li><strong>Validez externa</strong>: buena.</li></ul></div></section><section id="_581"><h4 id="_581_toc">Alcohol</h4><p id="_582" tabindex="-1">Sobre la base de pruebas s&#xF3;lidas, el consumo de alcohol se relaciona con un riesgo mayor de c&#xE1;ncer de mama proporcional a la dosis. No est&#xE1; claro si las personas con alto consumo de alcohol reducen el riesgo al disminuir su consumo.</p><p id="_585" tabindex="-1"><strong>Magnitud del efecto</strong>: el RR de las mujeres que consumen cerca de cuatro bebidas alcoh&#xF3;licas al d&#xED;a en comparaci&#xF3;n con las que no beben es de 1,32 (IC 95&#xA0;%, 1,19&#x2013;1,45). El RR aumenta 7&#xA0;% (IC 95&#xA0;%, 5,5&#x2013;8,7&#xA0;%) por cada bebida al d&#xED;a.</p><div class="pdq-content-list"><ul id="_586" class="pdq-address-block"><li><strong>Dise&#xF1;o del estudio:</strong> estudios de cohortes, y de  casos y controles.</li><li><strong>Validez interna</strong>: buena.</li><li><strong>Congruencia</strong>: buena.</li><li><strong>Validez externa</strong>: buena.</li></ul></div></section></section><section id="_366"><h3 id="_366_toc">Factores con pruebas suficientes de un  riesgo menor de c&#xE1;ncer de mama</h3><section id="_587"><h4 id="_587_toc">Embarazo temprano</h4><p id="_588" tabindex="-1">Sobre la base de pruebas s&#xF3;lidas, las mujeres con un embarazo a t&#xE9;rmino antes de los 20 a&#xF1;os de edad tienen menos riesgo de c&#xE1;ncer de mama.</p><p id="_589" tabindex="-1"><strong>Magnitud del efecto</strong>: una disminuci&#xF3;n de 50&#xA0;% del c&#xE1;ncer de mama, comparadas con mujeres nul&#xED;paras o mujeres que dieron a luz despu&#xE9;s de los 35 a&#xF1;os.</p><div class="pdq-content-list"><ul id="_590" class="pdq-address-block"><li><strong>Dise&#xF1;o del estudio</strong>: estudios de cohortes, y de casos y controles.</li><li><strong>Validez interna</strong>: buena.</li><li><strong>Congruencia</strong>: buena.</li><li><strong>Validez externa</strong>: buena.</li></ul></div></section><section id="_591"><h4 id="_591_toc">Lactancia materna</h4><p id="_592" tabindex="-1">Sobre la base de pruebas s&#xF3;lidas, las mujeres que lactan tienen menos riesgo de c&#xE1;ncer de mama.</p><p id="_593" tabindex="-1"><strong>Magnitud del efecto</strong>: el RR de c&#xE1;ncer de mama disminuye en 4,3&#xA0;% por cada 12 meses  de   lactancia, adem&#xE1;s de 7&#xA0;% por cada parto.[<a href="#cit/section_2.3">3</a>]</p><div class="pdq-content-list"><ul id="_594" class="pdq-address-block"><li><strong>Dise&#xF1;o del estudio</strong>: estudios de cohortes, y de casos y controles.</li><li><strong>Validez interna</strong>: buena.</li><li><strong>Congruencia</strong>: buena.</li><li><strong>Validez externa</strong>: buena.</li></ul></div></section><section id="_595"><h4 id="_595_toc">Ejercicio</h4><p id="_596" tabindex="-1">Sobre la base de pruebas s&#xF3;lidas, el ejercicio extenuante por m&#xE1;s de 4 horas semanales se relaciona con un riesgo menor de c&#xE1;ncer de mama.</p><p id="_597" tabindex="-1"><strong>Magnitud del efecto</strong>: la reducci&#xF3;n promedio del RR es de 30 a 40&#xA0;%. Es posible que el efecto sea m&#xE1;s pronunciado en las mujeres premenop&#xE1;usicas con peso corporal normal o bajo.</p><div class="pdq-content-list"><ul id="_598" class="pdq-address-block"><li><strong>Dise&#xF1;o del estudio</strong>: estudios prospectivos de observaci&#xF3;n, y de casos y controles.</li><li> <strong>Validez interna</strong>: buena.</li><li><strong>Congruencia</strong>: buena.</li><li><strong>Validez externa</strong>: buena.</li></ul></div></section><section id="_522"><h4 id="_522_toc">Uso de estr&#xF3;geno en las mujeres con histerectom&#xED;a previa: beneficios</h4><p id="_813" tabindex="-1">Sobre la base de pruebas razonables, las mujeres que se sometieron a una histerectom&#xED;a y que reciben tratamiento con estr&#xF3;genos equinos conjugados tienen una menor incidencia de c&#xE1;ncer de mama. Sin embargo, los estudios epidemiol&#xF3;gicos arrojan resultados contradictorios.</p><p id="_814" tabindex="-1"><strong> Magnitud del efecto</strong>: luego de 6,8 a&#xF1;os, la incidencia fue  23&#xA0;% menor en las mujeres tratadas con estr&#xF3;geno en un ECA (0,27&#xA0;% por a&#xF1;o, con una mediana de 5,9 a&#xF1;os de uso, en comparaci&#xF3;n con 0,35&#xA0;% por a&#xF1;o en aquellas que tomaron un placebo), pero fue 30&#xA0;% mayor en las mujeres tratadas con estr&#xF3;geno en un estudio de observaci&#xF3;n.  La diferencia en estos resultados se puede explicar por las diferentes conductas de detecci&#xF3;n en las mujeres de ambos estudios.</p><div class="pdq-content-list"><ul id="_815"><li><strong>Dise&#xF1;o del estudio</strong>: un ECA y estudios de observaci&#xF3;n.</li><li><strong>Validez interna</strong>: razonable.</li><li><strong>Congruencia</strong>: deficiente.</li><li><strong>Validez externa</strong>: deficiente.</li></ul></div></section><section id="_816"><h4 id="_816_toc">Uso de estr&#xF3;geno en las mujeres con histerectom&#xED;a previa: perjuicios</h4><p id="_817" tabindex="-1">Sobre la base de pruebas s&#xF3;lidas, las mujeres que se someten a una histerectom&#xED;a y que toman estr&#xF3;geno posmenop&#xE1;usico tienen un riesgo mayor de accidente cerebrovascular y de enfermedad cardiovascular total.</p><p id="_818" tabindex="-1"><strong>Magnitud del efecto</strong>: hay un aumento de 39&#xA0;% en la incidencia de accidentes cerebrovasculares  (RR, 1,39; IC 95&#xA0;%, 1,1&#x2013;1,77) y un aumento de 12&#xA0;% en la enfermedad  cardiovascular (RR, 1,12; IC 95&#xA0;%, 1,01&#x2013;1,24). </p><div class="pdq-content-list"><ul id="_819"><li><strong>Dise&#xF1;o del estudio</strong>: ECA y estudios de observaci&#xF3;n.</li><li><strong>Validez interna:</strong> buena.</li><li><strong>Congruencia</strong>: buena.</li><li><strong>Validez externa</strong>: deficiente.</li></ul></div></section></section><section id="_614"><h3 id="_614_toc">Intervenciones con pruebas suficientes de riesgo menor de c&#xE1;ncer de mama</h3><section id="_615"><h4 id="_615_toc">Moduladores selectivos del receptor de estr&#xF3;geno: beneficios</h4><p id="_820" tabindex="-1">Sobre la base de pruebas s&#xF3;lidas, el tamoxifeno y el raloxifeno reducen la incidencia de c&#xE1;ncer de mama en las mujeres posmenop&#xE1;usicas; el tamoxifeno reduce el riesgo de c&#xE1;ncer de mama en las mujeres premenop&#xE1;usicas de riesgo alto. Los efectos que se observan con el tamoxifeno y el raloxifeno permanecen por varios a&#xF1;os despu&#xE9;s de la descontinuaci&#xF3;n del tratamiento activo; se observa una mayor duraci&#xF3;n del efecto con el tamoxifeno que con el raloxifeno.[<a href="#cit/section_2.4">4</a>]</p><p id="_821" tabindex="-1">Los moduladores selectivos del receptor de estr&#xF3;geno (MSRE) redujeron todas las fracturas, lo que se observ&#xF3;, principalmente, con el raloxifeno, pero no con el tamoxifeno. Se observ&#xF3; una reducci&#xF3;n de las fracturas vertebrales (34&#xA0;%) y una peque&#xF1;a reducci&#xF3;n de las fracturas extravertebrales (7&#xA0;%).[<a href="#cit/section_2.4">4</a>]</p><p id="_822" tabindex="-1"><strong>Magnitud del efecto</strong>: el tamoxifeno redujo la incidencia de c&#xE1;ncer de mama en mujeres de riesgo alto de cerca de 30 a  50&#xA0;% al cabo de 5 a&#xF1;os de tratamiento, pero solo para el c&#xE1;ncer positivo al receptor de estr&#xF3;geno  (RE-positivo) y el carcinoma ductal <em>in situ</em> (CDIS). La reducci&#xF3;n en el c&#xE1;ncer de mama invasivo RE-positivo se mantuvo aproximadamente en este nivel durante por lo menos 16 a&#xF1;os despu&#xE9;s de comenzar el tratamiento y 11 a&#xF1;os despu&#xE9;s del cese del tamoxifeno. No hubo p&#xE9;rdida del efecto entre los a&#xF1;os 10 y 16 despu&#xE9;s de comenzar el tamoxifeno (por 5 a&#xF1;os) en comparaci&#xF3;n con los a&#xF1;os 0 a 10. No hubo ning&#xFA;n efecto en la mortalidad por  c&#xE1;ncer de mama.[<a href="#cit/section_2.5">5</a>]</p><div class="pdq-content-list"><ul id="_823"><li><strong>Dise&#xF1;o del estudio</strong>: ECA.</li><li><strong>Validez interna</strong>: buena.</li><li><strong>Congruencia</strong>: buena.</li><li><strong>Validez externa</strong>: buena.</li></ul></div></section><section id="_824"><h4 id="_824_toc">Moduladores selectivos del receptor de estr&#xF3;geno: perjuicios</h4><p id="_825" tabindex="-1">Sobre la base de pruebas s&#xF3;lidas, el tratamiento con tamoxifeno aumenta el riesgo de c&#xE1;ncer de endometrio, el cual fue obvio en los primeros 5 a&#xF1;os de seguimiento, pero no m&#xE1;s all&#xE1;; de episodios vasculares tromb&#xF3;ticos (es decir, embolia pulmonar, accidente cerebrovascular y trombosis venosa profunda) y de cataratas. Muchos de estos riesgos se reducen luego de descontinuar el tratamiento activo con tamoxifeno. Sobre la base de pruebas s&#xF3;lidas, el raloxifeno tambi&#xE9;n aumenta el riesgo de embolia pulmonar venosa y de  trombosis venosa profunda, pero no de c&#xE1;ncer de endometrio.</p><p id="_826" tabindex="-1"><strong>Magnitud del efecto</strong>: en un metan&#xE1;lisis, se mostr&#xF3; un RR de 2,4 (IC 95&#xA0;%, 1,5&#x2013;4,0) para el c&#xE1;ncer de endometrio y 1,9 (IC 95&#xA0;%, 1,4&#x2013;2,6) para episodios tromboemb&#xF3;licos venosos. En el metan&#xE1;lisis, se mostr&#xF3; que el cociente de riesgos instant&#xE1;neos (CRI) del c&#xE1;ncer de endometrio fue de 2,18 (IC 95&#xA0;%, 1,39&#x2013;3,42) para el tamoxifeno y  de 1,09 (IC 95&#xA0;%, 0,74&#x2013;1,62) para el raloxifeno.  En general, el CRI de episodios tromboemb&#xF3;licos venosos fue de 1,73 (IC 95&#xA0;%, 1,47&#x2013;2,05). Los perjuicios fueron mucho m&#xE1;s altos para las mujeres mayores de 50 a&#xF1;os que para las mujeres m&#xE1;s j&#xF3;venes.</p><div class="pdq-content-list"><ul id="_827"><li><strong>Dise&#xF1;o del estudio</strong>: ECA.</li><li><strong>Validez interna: </strong>buena</li><li><strong>Congruencia</strong>: buena.</li><li><strong>Validez externa: </strong>buena.</li></ul></div></section><section id="_682"><h4 id="_682_toc">Inhibidores o inactivadores de la aromatasa: beneficios</h4><p id="_828" tabindex="-1">Sobre la base de pruebas s&#xF3;lidas, los inhibidores o inactivadores de la aromatasa (IA) reducen la incidencia de c&#xE1;nceres de mama nuevos en las mujeres posmenop&#xE1;usicas con un riesgo mayor.</p><p id="_829" tabindex="-1"><strong>Magnitud del efecto</strong>: luego de una mediana de seguimiento de 35 meses, las mujeres de 35 a&#xF1;os o m&#xE1;s con al menos un factor de riesgo (&gt; 60 a&#xF1;os, riesgo de Gail a 5 a&#xF1;os &gt;1,66&#xA0;% o CDIS con mastectom&#xED;a) y que tomaron 25 mg de exemestano diario tuvieron menor riesgo de c&#xE1;ncer de mama invasivo (CRI,  0,35; IC 95&#xA0;%, 0,18&#x2013;0,70).  La reducci&#xF3;n del riesgo absoluto en 35 meses consisti&#xF3; en evitar 21 c&#xE1;nceres en  un total de 2280 participantes. El n&#xFA;mero que es necesario tratar fue de alrededor de 100.[<a href="#cit/section_2.6">6</a>]</p><div class="pdq-content-list"><ul id="_830"><li><strong>Dise&#xF1;o del estudio</strong>: un ECA.</li><li><strong>Validez interna</strong>: buena.</li><li><strong>Congruencia</strong>: un estudio de mujeres sin antecedentes de c&#xE1;ncer de mama, pero congruentes con los ECA de mujeres con antecedentes de este c&#xE1;ncer.</li><li><strong>Validez externa</strong>: buena en las mujeres que satisficieron los criterios de inclusi&#xF3;n.</li></ul></div></section><section id="_831"><h4 id="_831_toc">Inhibidores o inactivadores de la aromatasa: perjuicios</h4><p id="_832" tabindex="-1">Sobre la base de pruebas razonables de un solo ECA con 4560 mujeres por m&#xE1;s de 35 meses, el exemestano se relaciona con sofocos  y fatiga, pero no con fracturas, osteoporosis o episodios cardiovasculares, en comparaci&#xF3;n con el placebo.[<a href="#cit/section_2.6">6</a>,<a href="#cit/section_2.7">7</a>]</p><p id="_833" tabindex="-1"><strong>Magnitud del efecto</strong>: el aumento absoluto de los sofocos fue de 8&#xA0;% y el aumento absoluto de la fatiga fue de 2&#xA0;%.</p><div class="pdq-content-list"><p class="pdq-list-title"></p><ul id="_834"><li><strong>Dise&#xF1;o del estudio</strong>: un ECA.</li><li><strong>Validez interna</strong>: buena.</li><li><strong>Congruencia</strong>: buena.</li><li><strong>Validez externa</strong>: buena en las mujeres que satisfacen los criterios de inclusi&#xF3;n.</li></ul></div></section><section id="_624"><h4 id="_624_toc">Mastectom&#xED;a profil&#xE1;ctica: beneficios</h4><p id="_835" tabindex="-1">Sobre la base de pruebas s&#xF3;lidas, la mastectom&#xED;a profil&#xE1;ctica bilateral reduce el riesgo de c&#xE1;ncer de mama en mujeres con antecedentes familiares marcados y la mayor&#xED;a disminuye su ansiedad por el riesgo de c&#xE1;ncer de mama. No hay estudios que examinen los resultados de los  c&#xE1;nceres de mama en mujeres que se someten a mastectom&#xED;a profil&#xE1;ctica contralateral luego de una cirug&#xED;a por c&#xE1;ncer de mama ipsilateral.</p><p id="_836" tabindex="-1">Magnitud del efecto: el riesgo de c&#xE1;ncer de mama luego de una mastectom&#xED;a profil&#xE1;ctica bilateral en mujeres con riesgo alto se reduce hasta en 90&#xA0;%, pero es posible que los dise&#xF1;os de estudios publicados sobreestimaran el resultado.</p><div class="pdq-content-list"><ul id="_837"><li><strong>Dise&#xF1;o del estudio</strong>: pruebas obtenidas de estudios de cohortes, y de casos y controles.</li><li><strong>Validez interna</strong>: buena.</li><li><strong>Congruencia</strong>: buena.</li><li><strong>Validez externa</strong>: buena.</li></ul></div></section><section id="_629"><h4 id="_629_toc">Ooforectom&#xED;a profil&#xE1;ctica o ablaci&#xF3;n ov&#xE1;rica: beneficios</h4><p id="_838" tabindex="-1">Sobre la base de pruebas s&#xF3;lidas, las mujeres premenop&#xE1;usicas  con mutaciones en el gen <em>BRCA</em> que se someten a ooforectom&#xED;a profil&#xE1;ctica tienen una incidencia m&#xE1;s baja de c&#xE1;ncer de mama. De modo similar,  la ooforectom&#xED;a o ablaci&#xF3;n ov&#xE1;rica se relaciona con una disminuci&#xF3;n de la incidencia del c&#xE1;ncer de mama en las mujeres premenop&#xE1;usicas normales y en aquellas con mayor riesgo de c&#xE1;ncer de mama como consecuencia de la irradiaci&#xF3;n tor&#xE1;cica.</p><p id="_839" tabindex="-1"><strong>Magnitud del efecto</strong>: la incidencia del c&#xE1;ncer de mama disminuye  en 50&#xA0;%, pero es posible que los dise&#xF1;os de estudios publicados sobreestimaran el resultado.</p><div class="pdq-content-list"><ul id="_840"><li><strong>Dise&#xF1;o del estudio</strong>: estudios de observaci&#xF3;n, de cohortes o de casos y controles.</li><li><strong>Validez interna</strong>: buena.</li><li><strong>Congruencia</strong>: buena.</li><li><strong>Validez externa</strong>: buena.</li></ul></div></section><section id="_841"><h4 id="_841_toc">Ooforectom&#xED;a profil&#xE1;ctica o ablaci&#xF3;n ov&#xE1;rica: perjuicios</h4><p id="_842" tabindex="-1">Sobre la base de pruebas s&#xF3;lidas, la castraci&#xF3;n puede causar un inicio abrupto de los s&#xED;ntomas menop&#xE1;usicos, como sofocos, insomnio, ansiedad y depresi&#xF3;n. Los efectos a largo plazo incluyen disminuci&#xF3;n de la libido, sequedad vaginal y reducci&#xF3;n  de la densidad mineral &#xF3;sea.</p><p id="_843" tabindex="-1"><strong>Magnitud del efecto</strong>: casi todas las mujeres presentan algunas perturbaciones del sue&#xF1;o, cambios de humor, sofocos y desmineralizaci&#xF3;n &#xF3;sea, pero la gravedad de estos s&#xED;ntomas var&#xED;a mucho.</p><div class="pdq-content-list"><ul id="_844"><li><strong>Dise&#xF1;o del estudio</strong>: estudios de observaci&#xF3;n, de cohortes o de casos y controles.</li><li><strong>Validez interna</strong>: buena.</li><li><strong>Congruencia</strong>: buena.</li><li><strong>Validez externa</strong>: buena.</li></ul></div></section></section><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_2.1">Boyd NF, Martin LJ, Rommens JM, et al.: Mammographic density: a heritable risk factor for breast cancer. Methods Mol Biol 472: 343-60, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19107441&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19107441&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.2">McCormack VA, dos Santos Silva I: Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15 (6): 1159-69, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16775176&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16775176&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.3">Col: Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 360 (9328): 187-95, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12133652&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12133652&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.4">Cuzick J, Sestak I, Bonanni B, et al.: Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 381 (9880): 1827-34, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23639488&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23639488&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.5">Cuzick J, Sestak I, Cawthorn S, et al.: Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 16 (1): 67-75, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25497694&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25497694&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.6">Goss PE, Ingle JN, Al&#xE9;s-Mart&#xED;nez JE, et al.: Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364 (25): 2381-91, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21639806&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21639806&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.7">Maunsell E, Goss PE, Chlebowski RT, et al.: Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. J Clin Oncol 32 (14): 1427-36, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24711552&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24711552&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _29
      field_pdq_section_title:
        - format: plain_text
          value: 'Descripción de las pruebas'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_29" class="pdq-sections"><section id="_786"><h3 id="_786_toc">Incidencia y mortalidad</h3><p id="_787" tabindex="-1"> Con un c&#xE1;lculo de 266&#xA0;120 casos previstos, el c&#xE1;ncer de mama ser&#xE1; la neoplasia maligna extracut&#xE1;nea diagnosticada con mayor frecuencia en las mujeres de los Estados Unidos en 2018.[<a href="#cit/section_3.1">1</a>] Tambi&#xE9;n en 2018, el c&#xE1;ncer de mama causar&#xE1; la muerte de casi 40&#xA0;920 mujeres, por lo que ocupar&#xE1; el segundo lugar tras el c&#xE1;ncer de pulm&#xF3;n como causa de mortalidad por c&#xE1;ncer en las mujeres. El c&#xE1;ncer de mama tambi&#xE9;n se presenta en los hombres y se calcula que, en 2018, se diagnosticar&#xE1;n 2550 casos nuevos.[<a href="#cit/section_3.1">1</a>] A pesar de una tendencia previa a largo plazo de un aumento gradual en la incidencia del c&#xE1;ncer de mama en las mujeres, los datos del Surveillance, Epidemiology, and End Results Program revelan una disminuci&#xF3;n de la mortalidad por c&#xE1;ncer de mama de 1,8&#xA0;% por a&#xF1;o de 2005 a 2014.[<a href="#cit/section_3.2">2</a>,<a href="#cit/section_3.3">3</a>]</p><p id="_788" tabindex="-1">El principal factor de riesgo del c&#xE1;ncer de mama es la edad avanzada. La probabilidad de que una mujer de 30 a&#xF1;os reciba un diagn&#xF3;stico de c&#xE1;ncer en los siguientes 10 a&#xF1;os es de 1 en 250, mientras que la probabilidad de una mujer de 70 a&#xF1;os es de 1 en 27.[<a href="#cit/section_3.4">4</a>]</p><p id="_789" tabindex="-1">La incidencia de c&#xE1;ncer de mama y el riesgo de mortalidad  tambi&#xE9;n var&#xED;an seg&#xFA;n la  ubicaci&#xF3;n geogr&#xE1;fica, la cultura, la raza y la posici&#xF3;n socioecon&#xF3;mica. En comparaci&#xF3;n con otras etnias, las mujeres blancas tienen una incidencia m&#xE1;s alta de c&#xE1;ncer de mama que se puede atribuir, en parte, a la conducta de someterse a ex&#xE1;menes de detecci&#xF3;n. No obstante, las tasas de incidencia de c&#xE1;ncer de mama aumentaron un poco en las mujeres negras: 0,3&#xA0;% por a&#xF1;o entre 2005 y 2014, lo que  deriv&#xF3; en una  convergencia de las tasas de las personas de raza negra  con las de  raza blanca.[<a href="#cit/section_3.1">1</a>,<a href="#cit/section_3.5">5</a>]</p><p id="_790" tabindex="-1">El examen de detecci&#xF3;n por mamograf&#xED;a disminuye la mortalidad por c&#xE1;ncer de mama al identificar los casos para su tratamiento en estadio temprano. Sin embargo, los ex&#xE1;menes de detecci&#xF3;n tambi&#xE9;n identifican m&#xE1;s casos que se volver&#xED;an sintom&#xE1;ticos en la vida de una mujer, por lo tanto, los ex&#xE1;menes de detecci&#xF3;n aumentan la incidencia de los c&#xE1;nceres de mama. (Para obtener m&#xE1;s informaci&#xF3;n, consultar la secci&#xF3;n sobre <a href="/espanol/tipos/seno/pro/deteccion-seno-pdq#link/_666">Sobrediagn&#xF3;stico</a> en el sumario del PDQ <a href="/espanol/tipos/seno/pro/deteccion-seno-pdq">Ex&#xE1;menes de detecci&#xF3;n del c&#xE1;ncer de mama</a>).</p></section><section id="_791"><h3 id="_791_toc">Caracter&#xED;sticas etiol&#xF3;gicas y patog&#xE9;nicas del c&#xE1;ncer de mama</h3><p id="_792" tabindex="-1">El c&#xE1;ncer de mama se forma cuando se presenta una serie de mutaciones gen&#xE9;ticas.[<a href="#cit/section_3.6">6</a>] Inicialmente, las mutaciones no cambian el aspecto histol&#xF3;gico del tejido, pero las mutaciones acumuladas producir&#xE1;n hiperplasia, displasia, carcinoma <em>in situ</em> y,  a la larga, c&#xE1;ncer invasivo.[<a href="#cit/section_3.7">7</a>] Mientras m&#xE1;s tiempo vive una mujer, se presentan m&#xE1;s mutaciones som&#xE1;ticas y mayores son las probabilidades  de que estas produzcan poblaciones celulares que se convertir&#xE1;n en neoplasias malignas. El estr&#xF3;geno y la progestina causan crecimiento y proliferaci&#xF3;n  de c&#xE9;lulas mamarias al parecer  mediante factores de crecimiento, como el factor de crecimiento transformante (FCT)-&#x3B1;.[<a href="#cit/section_3.8">8</a>] Es posible que estas hormonas, sean end&#xF3;genas o ex&#xF3;genas, promuevan promover la formaci&#xF3;n y la proliferaci&#xF3;n de c&#xE9;lulas de c&#xE1;ncer de mama.</p><p id="_793" tabindex="-1">Las variaciones internacionales en las tasas de c&#xE1;ncer de mama se pueden explicar por las diferencias de las caracter&#xED;sticas gen&#xE9;ticas, los factores reproductivos, la alimentaci&#xF3;n, el ejercicio y el patr&#xF3;n de sometimiento a los ex&#xE1;menes de detecci&#xF3;n. Algunos de estos factores son modificables, como lo prueba la observaci&#xF3;n de que los inmigrantes japoneses en los Estados Unidos aumentan el riesgo de c&#xE1;ncer de mama de los &#xED;ndices bajos de Jap&#xF3;n a los &#xED;ndices altos de los Estados Unidos en dos generaciones.[<a href="#cit/section_3.9">9</a>-<a href="#cit/section_3.11">11</a>]</p></section><section id="_794"><h3 id="_794_toc">Estr&#xF3;geno end&#xF3;geno</h3><p id="_795" tabindex="-1">Muchos de los factores de riesgo de c&#xE1;ncer de mama indican que una exposici&#xF3;n m&#xE1;s prolongada a los estr&#xF3;genos end&#xF3;genos cumple una funci&#xF3;n en la formaci&#xF3;n de la enfermedad. Las mujeres  que presentaron la menarquia a los 11 a&#xF1;os o m&#xE1;s  tienen alrededor de 20&#xA0;% m&#xE1;s de probabilidades  de c&#xE1;ncer de mama que las que lo hicieron a los 14 a&#xF1;os o m&#xE1;s.[<a href="#cit/section_3.12">12</a>-<a href="#cit/section_3.14">14</a>] Las mujeres que presentan menopausia tard&#xED;a tambi&#xE9;n presentan un aumento de riesgo. Las mujeres con c&#xE1;ncer de mama tienden a  tener concentraciones m&#xE1;s altas de estr&#xF3;geno y andr&#xF3;geno end&#xF3;genos.[<a href="#cit/section_3.14">14</a>-<a href="#cit/section_3.18">18</a>]</p><p id="_796" tabindex="-1">Por el contrario, las mujeres que presentan menopausia prematura tienen un riesgo menor de c&#xE1;ncer de mama. Tras la ablaci&#xF3;n ov&#xE1;rica, el riesgo de c&#xE1;ncer de mama se puede reducir hasta en 75&#xA0;% seg&#xFA;n la edad, el peso y la cantidad de partos; la reducci&#xF3;n m&#xE1;s marcada se presenta en las mujeres j&#xF3;venes, delgadas y nul&#xED;paras.[<a href="#cit/section_3.19">19</a>-<a href="#cit/section_3.22">22</a>] La extirpaci&#xF3;n de un ovario reduce tambi&#xE9;n el riesgo de c&#xE1;ncer de mama, pero en un menor grado que la extirpaci&#xF3;n de ambos ovarios.[<a href="#cit/section_3.23">23</a>]</p><p id="_797" tabindex="-1">Otros cambios hormonales tambi&#xE9;n influyen en el riesgo de c&#xE1;ncer de mama. (Para obtener m&#xE1;s informaci&#xF3;n, consultar las subsecciones sobre  <a href="/espanol/tipos/seno/pro/prevencion-seno-pdq#link/_587">Embarazo temprano</a> y <a href="/espanol/tipos/seno/pro/prevencion-seno-pdq#link/_656">Lactancia</a> en la secci&#xF3;n de este sumario sobre <a href="/espanol/tipos/seno/pro/prevencion-seno-pdq#link/_175">Factores con pruebas suficientes de menor riesgo de c&#xE1;ncer de mama</a>).</p><p id="_798" tabindex="-1">La interacci&#xF3;n de las concentraciones de estr&#xF3;geno end&#xF3;geno, las concentraciones de insulina y la obesidad, que inciden en el riesgo de c&#xE1;ncer, no se comprende del todo, pero indica estrategias de intervenci&#xF3;n para disminuir el riesgo. Es probable que los factores de  riesgo reproductivos  interaccionen con genotipos predisponentes. Por ejemplo, en el Nurses&#x2019; Health Study,[<a href="#cit/section_3.24">24</a>] se observaron relaciones entre la edad del primer parto, la menarquia y la menopausia, y la formaci&#xF3;n del c&#xE1;ncer de mama solo en mujeres sin antecedentes familiares de este c&#xE1;ncer en la madre o una hermana.</p></section><section id="_799"><h3 id="_799_toc">Riesgo heredado</h3><p id="_800" tabindex="-1">El riesgo de c&#xE1;ncer de mama aumenta en las mujeres con antecedentes familiares, sobre todo si afecta a familiares de primer grado.[<a href="#cit/section_3.24">24</a>] A fin de cuantificarlo, se presentaron los siguientes modelos de evaluaci&#xF3;n del riesgo derivados de bases de datos, estudios de cohortes y de casos y controles:</p><div class="pdq-content-list"><ul id="_801"><li><a href="https://bcrisktool.cancer.gov/" title="https://bcrisktool.cancer.gov/">Breast Cancer Risk Assessment Tool</a>.</li><li><a href="https://tools.bcsc-scc.org/BC5yearRisk/intro.htm" title="https://tools.bcsc-scc.org/BC5yearRisk/intro.htm">Breast Cancer Surveillance Consortium [BCSC] Risk Calculator</a>.</li><li><a href="https://www.breastcancergenescreen.org/" title="https://www.breastcancergenescreen.org/">Breast Cancer Referral Screening Tool [B-RST]</a>.</li><li><a href="http://halls.md/breast/risk.htm" title="http://halls.md/breast/risk.htm">Hall Detailed Breast Risk Calculator</a>.</li><li><a href="http://www.ems-trials.org/riskevaluator/" title="http://www.ems-trials.org/riskevaluator/">IBIS Breast Cancer Risk Calculator Tool</a>.</li></ul></div><p id="_802" tabindex="-1">Hay alelos anormales espec&#xED;ficos que se relacionan con alrededor de 5&#xA0;% de los c&#xE1;nceres de mama. (Para obtener m&#xE1;s informaci&#xF3;n, consultar el sumario del PDQ <a href="/types/breast/hp/breast-ovarian-genetics-pdq">Genetics of Breast and Gynecologic Cancers</a>). Las mutaciones en los genes <em>BRCA</em> se heredan de forma autos&#xF3;mica dominante y tienen penetrancia muy alta como causa del c&#xE1;ncer, a menudo a una edad m&#xE1;s temprana.[<a href="#cit/section_3.25">25</a>-<a href="#cit/section_3.27">27</a>] Los antecedentes familiares y la localizaci&#xF3;n de la mutaci&#xF3;n en el gen <em>BRCA1</em> o <em>BRCA2</em> quiz&#xE1;s contribuyan al riesgo de presentaci&#xF3;n del c&#xE1;ncer entre quienes tienen una predisposici&#xF3;n heredada al c&#xE1;ncer de mama.[<a href="#cit/section_3.28">28</a>] El riesgo de por vida de c&#xE1;ncer de mama es de 55 a 65&#xA0;% para las portadoras de la mutaci&#xF3;n en <em>BRCA1</em> y de 45 a 47&#xA0;% para las portadoras de la mutaci&#xF3;n en <em>BRCA2</em>.[<a href="#cit/section_3.29">29</a>,<a href="#cit/section_3.30">30</a>] En comparaci&#xF3;n, el riesgo de por vida de c&#xE1;ncer de mama para la poblaci&#xF3;n general es de 12,4&#xA0;%.[<a href="#cit/section_3.31">31</a>]</p><p id="_803" tabindex="-1">Algunas mujeres heredan una susceptibilidad a mut&#xE1;genos o factores de crecimiento, que aumenta el riesgo de c&#xE1;ncer de mama.[<a href="#cit/section_3.32">32</a>,<a href="#cit/section_3.33">33</a>] (Para obtener m&#xE1;s informaci&#xF3;n, consultar la subsecci&#xF3;n <a href="/espanol/tipos/seno/pro/prevencion-seno-pdq#link/_149">Exposici&#xF3;n a la radiaci&#xF3;n ionizante</a> en la secci&#xF3;n de este sumario sobre <a href="/espanol/tipos/seno/pro/prevencion-seno-pdq#link/_175">Factores con pruebas suficientes de un riesgo mayor de c&#xE1;ncer de mama</a>).</p></section><section id="_804"><h3 id="_804_toc">Aumento de la densidad de la mama</h3><p id="_805" tabindex="-1">El  uso generalizado de ex&#xE1;menes de detecci&#xF3;n con mamograf&#xED;a ha revelado cantidades variables de tejido denso detectado mediante mamograf&#xED;as y que las mujeres con una proporci&#xF3;n mayor de tejido denso tienen una incidencia m&#xE1;s alta de c&#xE1;ncer de mama. La densidad mamogr&#xE1;fica   tambi&#xE9;n introduce una variable de confusi&#xF3;n para la identificaci&#xF3;n de c&#xE1;nceres mediante esa tecnolog&#xED;a. El grado del aumento del riesgo se describi&#xF3; en un informe de 3 estudios de casos y controles anidados de poblaciones sometidas a ex&#xE1;menes de detecci&#xF3;n con 1112 pares de casos y controles emparejados. En comparaci&#xF3;n con las mujeres con una densidad menor de 10&#xA0;% del tejido mamario, las mujeres con densidad de 75&#xA0;% o m&#xE1;s en su mama presentaron un aumento en el riesgo de c&#xE1;ncer de mama (oportunidad relativa [OR], 4,7; intervalo de confianza  [IC] 95&#xA0;%, 3,0&#x2013;7,4), ya sea que el c&#xE1;ncer se hubiera identificado en un examen de detecci&#xF3;n (OR, 3,5; IC 95&#xA0;%, 2,0&#x2013;6,2) o menos de 12 meses despu&#xE9;s de un examen de detecci&#xF3;n con resultado negativo (OR, 17,8;  IC 95&#xA0;%, 4,8&#x2013;65,9).  El aumento de riesgo de c&#xE1;ncer de mama, ya sea identificado mediante un examen de detecci&#xF3;n u otro medio, persisti&#xF3; durante un m&#xED;nimo de 8 a&#xF1;os luego de entrar al estudio; el riesgo fue mayor en las mujeres m&#xE1;s j&#xF3;venes que en las de mayor edad. En el caso de las mujeres m&#xE1;s j&#xF3;venes que la mediana de edad de 56 a&#xF1;os, 26&#xA0;% de todos los c&#xE1;nceres de mama y  50&#xA0;% de todos los c&#xE1;nceres detectados menos de 12 meses despu&#xE9;s de un examen negativo se identificaron en mujeres con una densidad de 50&#xA0;% o m&#xE1;s en las mamograf&#xED;as.[<a href="#cit/section_3.34">34</a>,<a href="#cit/section_3.35">35</a>]</p><p id="_806" tabindex="-1">Las mujeres con mamas densas tienen un aumento del riesgo que es proporcional al grado de densidad. Este aumento del riesgo relativo (RR) oscila entre 1,79 en las mujeres con una densidad ligeramente mayor y 4,64 en las mujeres con mamas muy densas, en comparaci&#xF3;n con mujeres que presentan la densidad m&#xE1;s baja.[<a href="#cit/section_3.36">36</a>] No hay aumento del riesgo de mortalidad por c&#xE1;ncer de mama en mujeres con tejido de mama denso.[<a href="#cit/section_3.37">37</a>]</p></section><section id="_410"><h3 id="_410_toc">Factores  con pruebas suficientes de mayor riesgo de c&#xE1;ncer de mama</h3><section id="_416"><h4 id="_416_toc">Terapia con hormonas</h4><p id="_480" tabindex="-1">A partir de una revaluaci&#xF3;n de 1997 de 51 estudios epidemiol&#xF3;gicos en los que participaron m&#xE1;s de 150&#xA0;000 mujeres, la terapia con hormonas (TH) ex&#xF3;genas despu&#xE9;s de la menopausia mostr&#xF3; estar relacionada con un mayor riesgo de c&#xE1;ncer de mama.[<a href="#cit/section_3.38">38</a>]</p><p id="_481" tabindex="-1">El Heart and Estrogen/Progestin Replacement Study, respald&#xF3; esta conclusi&#xF3;n en 2002.[<a href="#cit/section_3.39">39</a>] En este estudio, se asign&#xF3; al azar a 2763 mujeres con cardiopat&#xED;a coronaria  y una media de edad de 67 a&#xF1;os a recibir terapia con estr&#xF3;geno y progestina o placebo. Tras una media de  seguimiento de 6,8 a&#xF1;os, el RR de c&#xE1;ncer de mama fue de 1,27 (IC 95&#xA0;%, 0,84&#x2013;1,94). Si bien no reviste significaci&#xF3;n estad&#xED;stica, el c&#xE1;lculo del RR es congruente con el estudio mucho m&#xE1;s grande Women&#x2019;s Health Initiative (WHI), que tambi&#xE9;n se public&#xF3; en 2002.</p><p id="_646" tabindex="-1">En el WHI se investig&#xF3; el efecto de las hormonas y las intervenciones alimentarias en las cardiopat&#xED;as y el riesgo de c&#xE1;ncer de mama.[<a href="#cit/section_3.40">40</a>] Se asign&#xF3; al azar a mujeres entre 50 y 79 a&#xF1;os con el &#xFA;tero intacto a recibir estr&#xF3;geno conjugado combinado con progestina continua (n = 8506) o placebo (n = 8102). El ensayo se cerr&#xF3; antes de tiempo debido a que la combinaci&#xF3;n de TH no disminuy&#xF3; el riesgo de cardiopat&#xED;a coronaria, pero aument&#xF3; el riesgo de accidente cerebrovascular y c&#xE1;ncer de mama. Se observ&#xF3; un aumento de la tasa de c&#xE1;ncer de mama invasivo (cociente de riesgos instant&#xE1;neos [CRI], 1,24; IC 95&#xA0;%, 1,02&#x2013;1,50), pero no de c&#xE1;ncer de mama <em>in situ</em> en todos los subgrupos de mujeres. La combinaci&#xF3;n de c&#xE1;nceres relacionados con TH present&#xF3; grados, caracter&#xED;sticas histol&#xF3;gicas, y expresi&#xF3;n del receptor de estr&#xF3;geno  (RE), receptor de progesterona, y <em>HER2</em>/neu similares, con una tendencia hacia un tama&#xF1;o m&#xE1;s grande y una mayor incidencia  de met&#xE1;stasis a los ganglios linf&#xE1;ticos en el grupo de TH combinada.[<a href="#cit/section_3.41">41</a>] Un seguimiento prolongado con una media de 11 a&#xF1;os mostr&#xF3; una mayor mortalidad espec&#xED;fica por c&#xE1;ncer de mama en el grupo de TH (25 vs. 12 muertes, 0,03 vs. 0,01&#xA0;% por a&#xF1;o; CRI, 1,95; IC 95&#xA0;%, 1,0&#x2013;4,04; <em>P</em> = 0,049). La TH combinada tambi&#xE9;n se relacion&#xF3; con un porcentaje m&#xE1;s alto de mamograf&#xED;as anormales.[<a href="#cit/section_3.42">42</a>]</p><p id="_531" tabindex="-1">El estudio de observaci&#xF3;n WHI se realiz&#xF3; de forma paralela con el  ensayo controlado aleatorizado (ECA) de la WHI, en el que se inscribi&#xF3; a mujeres posmenop&#xE1;usicas entre 50 y 79 a&#xF1;os. Se llev&#xF3; a cabo un an&#xE1;lisis en el estudio de observaci&#xF3;n del WHI para examinar m&#xE1;s a fondo el pron&#xF3;stico de las mujeres con diagn&#xF3;stico de c&#xE1;ncer de mama que tomaban TH combinada,  y los riesgos seg&#xFA;n el tiempo entre la menopausia y el inicio de la TH. Luego de una mediana de seguimiento de 11,3 a&#xF1;os, la incidencia anualizada de c&#xE1;ncer de mama en las mujeres que usaron estr&#xF3;geno m&#xE1;s progestina fue de 0,60&#xA0;%, en comparaci&#xF3;n con 0,42&#xA0;% para aquellas que no las usaron  (CRI, 1,55; IC 95&#xA0;%, 1,41&#x2013;1,70).  La supervivencia despu&#xE9;s del diagn&#xF3;stico de c&#xE1;ncer de mama fue similar para las usuarias de TH combinada como para las que no la usaron. El n&#xFA;mero de muertes por c&#xE1;ncer de mama fue m&#xE1;s alto entre las usuarias de TH combinada que entre las que no la usaron, pero la diferencia no tuvo significaci&#xF3;n estad&#xED;stica (CRI, 1,3; IC 94&#xA0;%, 0,90&#x2013;1,93). Los riesgos fueron mayores en las mujeres que iniciaron la TH durante la menopausia; los riesgos disminuyeron, pero continuaron, con la prolongaci&#xF3;n del tiempo entre la menopausia y el inicio de la TH combinada. La mortalidad por todas las causas luego del diagn&#xF3;stico de c&#xE1;ncer de mama tuvo mayor significaci&#xF3;n estad&#xED;stica en las usuarias de TH combinada que en las que no las usaron (CRI, 1,87; IC 95&#xA0;%, 1,37&#x2013;2,54). En general, estos hallazgos fueron congruentes con los resultados del ECA.[<a href="#cit/section_3.43">43</a>]</p><p id="_647" tabindex="-1">En el WHI, tambi&#xE9;n se estudi&#xF3; a mujeres que se sometieron a una histerectom&#xED;a y, por lo tanto, no ten&#xED;an riesgo de c&#xE1;ncer de endometrio, el cual se relaciona con la terapia de estr&#xF3;geno sin oposici&#xF3;n. Se asign&#xF3; al azar a mujeres entre 50 y 79 a&#xF1;os (N = 10&#xA0;739) a recibir estr&#xF3;genos equinos conjugados (EEC) o placebo. Este ensayo tambi&#xE9;n se termin&#xF3; antes de tiempo debido al riesgo elevado de accidente cerebrovascular y a la ausencia de mejora  del &#xED;ndice global de beneficio en funci&#xF3;n del riesgo.[<a href="#cit/section_3.44">44</a>,<a href="#cit/section_3.45">45</a>] Luego de un promedio de 6,8 a&#xF1;os de seguimiento,  la incidencia de c&#xE1;ncer de mama fue menor en el grupo que recibi&#xF3; EEC (0,26&#xA0;% por a&#xF1;o vs. 0,33&#xA0;%; CRI, 0,77; IC 95&#xA0;%, 0,59&#x2013;1,01).  El &#xED;ndice global de beneficio en funci&#xF3;n del riesgo fue ligeramente peor para los EEC.[<a href="#cit/section_3.44">44</a>] Se incluy&#xF3; a 78&#xA0;% de las participantes del ensayo en un seguimiento prolongado con una mediana de 11,8 a&#xF1;os.[<a href="#cit/section_3.45">45</a>,<a href="#cit/section_3.46">46</a>] Los resultados del estudio inicial persistieron, con una reducci&#xF3;n similar de c&#xE1;ncer de mama en las mujeres que recib&#xED;an EEC (CRI, 0,77; IC 95&#xA0;%, 0,62&#x2013;0,95) [<a href="#cit/section_3.45">45</a>,<a href="#cit/section_3.46">46</a>] y una disminuci&#xF3;n de la mortalidad por c&#xE1;ncer de mama (6   vs. 16 muertes; CRI, 0,37; IC 95&#xA0;%, 0,13&#x2013;0,91). La mortalidad por todas las causas fue tambi&#xE9;n menor en el grupo de EEC  (0,046 vs. 0,076&#xA0;% por a&#xF1;o; CRI, 0,62; IC 95&#xA0;%,  0,39&#x2013;0,97). Tras la descontinuaci&#xF3;n de los EEC, disminuy&#xF3; el riesgo de accidente cerebrovascular en el per&#xED;odo posterior a la intervenci&#xF3;n. Durante todo el per&#xED;odo completo de seguimiento, no hubo ninguna diferencia en la incidencia de cardiopat&#xED;a coronaria, trombosis venosa profunda, accidente cerebrovascular, fractura de cadera o c&#xE1;ncer colorrectal.[<a href="#cit/section_3.45">45</a>] La incidencia de c&#xE1;ncer de mama fue similar en las mujeres que iniciaron los EEC o el placebo en los primeros 5 a&#xF1;os posteriores al inicio de  la menopausia (CRI, 1,06; IC 95&#xA0;%, 0,74&#x2013;1,51).</p><p id="_648" tabindex="-1">Se dise&#xF1;&#xF3; un ensayo dan&#xE9;s de TH con 1006 mujeres que comenzaban la menopausia para evaluar los resultados cardiovasculares. Se administr&#xF3; una combinaci&#xF3;n de TH (estradiol trif&#xE1;sico sin noretisterona) a 407 mujeres con &#xFA;tero intacto y estradiol a 95 que se hab&#xED;an sometido a histerectom&#xED;a. No se trat&#xF3; a los controles (407 con &#xFA;tero intacto y 97 con histerectom&#xED;a). A los 10 a&#xF1;os hubo contaminaci&#xF3;n considerable. Solo la mitad de las mujeres asignadas al grupo de  TH todav&#xED;a segu&#xED;an usando la TH prescrita y 22&#xA0;% de los controles hab&#xED;a comenzado  TH.  Los resultados cardiovasculares favorecieron a las mujeres que usaron TH y no hubo diferencia en la incidencia de c&#xE1;ncer de mama.[<a href="#cit/section_3.47">47</a>]</p><p id="_649" tabindex="-1">Los estudios de observaci&#xF3;n aumentaron la informaci&#xF3;n obtenida en los ECA.</p><p id="_650" tabindex="-1">En el Million Women Study,[<a href="#cit/section_3.48">48</a>] se inscribi&#xF3; a  1&#xA0;084&#xA0;110 mujeres entre 50 y 64 a&#xF1;os en el Reino Unido de 1996 a 2001 y se obtuvo informaci&#xF3;n sobre el uso de TH y otros detalles personales. A estas mujeres se les dio seguimiento en relaci&#xF3;n con la incidencia y la mortalidad. La mitad de ellas hab&#xED;an usado TH. A los 2,6 a&#xF1;os de seguimiento, hubo 9364 casos de c&#xE1;ncer de mama invasivo; a los 4,1 a&#xF1;os hubo 637 muertes por c&#xE1;ncer de mama. Las usuarias de TH en el momento de inscribirse tuvieron mayores probabilidades de c&#xE1;ncer de mama que las que nunca la usaron (RR ajustado = 1,66; IC 95&#xA0;%, 1,58&#x2013;1,75; <em>P</em> &lt; 0,0001) y de morir por la enfermedad (RR ajustado, 1,22; IC 95&#xA0;%, 1,00&#x2013;1,48; <em>P</em> = 0,05). Sin embargo, las usuarias anteriores de TH no tuvieron un  riesgo mayor de casos de c&#xE1;ncer de mama mortales   (1,01 [IC 95&#xA0;%, 0,94&#x2013;1,09] y 1,05 [IC 95&#xA0;%, 0,82&#x2013;1,34], respectivamente). La incidencia aument&#xF3; de manera significativa en las usuarias de estr&#xF3;geno solo  en el momento (RR, 1,30; IC 95&#xA0;%,  1,21&#x2013;1,40; <em>P</em> &lt; 0,0001), TH combinada (RR, 2,00; IC 95&#xA0;%, 1,88&#x2013;2,12; <em>P</em> &lt; 0,0001) y tibolona (RR, 1,45; IC 95&#xA0;%, 1,25&#x2013;1,68; <em>P</em> &lt; 0,0001).  La magnitud del riesgo relacionado fue mucho m&#xE1;s alto para la TH combinada que para otros tipos de TH (<em>P</em> &lt; 0,0001).</p><p id="_651" tabindex="-1">En un estudio de poblaci&#xF3;n con 965 mujeres con c&#xE1;ncer de mama y 1007 controles realizado por el Cancer Surveillance System of Puget Sound, se mostr&#xF3; que las usuarias de la TH combinada tuvieron un riesgo 1,7 veces m&#xE1;s alto de c&#xE1;ncer de mama invasivo que las usuarias de estr&#xF3;geno.[<a href="#cit/section_3.49">49</a>]</p><p id="_652" tabindex="-1">La relaci&#xF3;n entre el uso de TH combinada y el riesgo mayor de c&#xE1;ncer de mama es constante en todos los ensayos. Por el contrario, la relaci&#xF3;n entre la TH con estr&#xF3;geno solo y la incidencia de c&#xE1;ncer de mama es confusa debido a que, en algunos estudios,  se muestra un riesgo mayor y en otros, se muestra protecci&#xF3;n. Es posible que el tiempo oportuno entre la administraci&#xF3;n de TH con estr&#xF3;geno solo en relaci&#xF3;n con el inicio de la menopausia sea de suma importancia. Adem&#xE1;s, es posible que los estudios de observaci&#xF3;n no tomen en cuenta las conductas sobre los  ex&#xE1;menes de  detecci&#xF3;n en las usuarias de TH y las que no la usaron, mientras que los ECA, por dise&#xF1;o, controlar&#xE1;n esa variable.[<a href="#cit/section_3.50">50</a>,<a href="#cit/section_3.51">51</a>]</p><p id="_494" tabindex="-1">Tras la publicaci&#xF3;n de los resultados de WHI, el uso de la TH disminuy&#xF3; de forma dr&#xE1;stica en los Estados Unidos y otros lugares. El seguimiento de las participantes en el grupo WHI tratado con TH combinada mostr&#xF3; una disminuci&#xF3;n r&#xE1;pida del riesgo elevado de c&#xE1;ncer de mama debido al tratamiento en un lapso de 2 a&#xF1;os, a pesar de tasas similares de ex&#xE1;menes de detecci&#xF3;n mediante mamograf&#xED;a.[<a href="#cit/section_3.52">52</a>] En el an&#xE1;lisis de los cambios en las tasas de c&#xE1;ncer de mama en los Estados Unidos, se observ&#xF3; una disminuci&#xF3;n marcada en las tasas de incidencia de c&#xE1;ncer de mama entre 2002 y 2003 en mujeres de 50 a&#xF1;os o m&#xE1;s, en particular, para los c&#xE1;nceres positivos al receptor de estr&#xF3;geno  (RE).[<a href="#cit/section_3.53">53</a>,<a href="#cit/section_3.54">54</a>] De igual modo, en m&#xFA;ltiples pa&#xED;ses donde el uso de TH era alto, las tasas de c&#xE1;ncer de mama disminuyeron en un per&#xED;odo similar, lo que coincidi&#xF3; con las disminuciones de los patrones de prescripci&#xF3;n o la prevalencia notificada de uso.[<a href="#cit/section_3.55">55</a>-<a href="#cit/section_3.57">57</a>] Un estudio sobre mujeres que se sometieron a un examen de detecci&#xF3;n mediante mamograf&#xED;a sustenta que la disminuci&#xF3;n marcada que se observ&#xF3; entre 2002 y 2003 en la incidencia del c&#xE1;ncer de mama, principalmente debido a la suspensi&#xF3;n de la TH en lugar de disminuciones en las tasas de mamograf&#xED;as.[<a href="#cit/section_3.58">58</a>] Luego de la disminuci&#xF3;n de la incidencia del c&#xE1;ncer de mama entre 2002 y 2003, se estabilizaron las tasas en los Estados Unidos.[<a href="#cit/section_3.58">58</a>,<a href="#cit/section_3.59">59</a>] </p></section><section id="_149"><h4 id="_149_toc">Exposici&#xF3;n a la radiaci&#xF3;n ionizante</h4><p id="_150" tabindex="-1">Hay una relaci&#xF3;n bien establecida entre la exposici&#xF3;n a la radiaci&#xF3;n ionizante y el c&#xE1;ncer de mama posterior.[<a href="#cit/section_3.60">60</a>] El riesgo excesivo de c&#xE1;ncer de mama se observa  en relaci&#xF3;n con la exposici&#xF3;n a una bomba at&#xF3;mica, las frecuentes fluoroscopias para tuberculosis y la radioterapia para el acn&#xE9;, la ti&#xF1;a, el agrandamiento del timo, la mastitis posparto o el linfoma. El riesgo es mayor en los j&#xF3;venes, en especial alrededor de la pubertad. El c&#xE1;lculo del riesgo de c&#xE1;ncer de mama relacionado con la radiolog&#xED;a m&#xE9;dica resulta en una cifra inferior a 1&#xA0;% del total.[<a href="#cit/section_3.61">61</a>] Sin embargo, se especul&#xF3; que ciertas poblaciones, como las de heterocigotos <em>AT</em> presentan un riesgo m&#xE1;s alto de c&#xE1;ncer de mama a ra&#xED;z de la exposici&#xF3;n a la radiaci&#xF3;n.[<a href="#cit/section_3.32">32</a>] En un estudio de cohortes numeroso con mujeres portadoras de mutaciones en <em>BRCA1</em> o <em>BRCA2</em>, se concluy&#xF3; que las radiograf&#xED;as de t&#xF3;rax aumentan todav&#xED;a m&#xE1;s el riesgo de c&#xE1;ncer de mama (RR, 1,54; IC 95&#xA0;%, 1,1&#x2013;2,1), en especial en mujeres sometidas a radiograf&#xED;as antes de los 20 a&#xF1;os.[<a href="#cit/section_3.62">62</a>]</p><p id="_151" tabindex="-1">Las mujeres tratadas por linfoma de Hodgkin en los primeros 16 a&#xF1;os de vida tienen un riesgo posterior de hasta 35&#xA0;%  de presentar c&#xE1;ncer de mama alrededor de los 40 a&#xF1;os.[<a href="#cit/section_3.63">63</a>-<a href="#cit/section_3.65">65</a>] Las dosis m&#xE1;s altas de radiaci&#xF3;n (mediana de dosis, 40 Gy en casos de c&#xE1;ncer de mama) y el tratamiento entre  los 10 y 16 a&#xF1;os de edad se relacionan con un riesgo m&#xE1;s alto.[<a href="#cit/section_3.63">63</a>] A diferencia del riesgo de una leucemia secundaria, el riesgo de c&#xE1;ncer de mama relacionado con el tratamiento no se reduce con la duraci&#xF3;n del seguimiento, al persistir por m&#xE1;s de 25 a&#xF1;os despu&#xE9;s del tratamiento.[<a href="#cit/section_3.63">63</a>,<a href="#cit/section_3.65">65</a>,<a href="#cit/section_3.66">66</a>] En estos estudios, la mayor&#xED;a de las pacientes (85&#x2013;100&#xA0;%) que presentaron c&#xE1;ncer de mama lo hicieron dentro del campo de radiaci&#xF3;n o en el margen.[<a href="#cit/section_3.63">63</a>,<a href="#cit/section_3.64">64</a>,<a href="#cit/section_3.66">66</a>] En un estudio holand&#xE9;s se examin&#xF3; a 48 mujeres que presentaron c&#xE1;ncer de mama por lo menos 5 a&#xF1;os despu&#xE9;s del tratamiento por enfermedad de Hodgkin y se las compar&#xF3; con 175 pacientes mujeres similares con enfermedad de Hodgkin que no presentaron c&#xE1;ncer de mama. Las pacientes tratadas con quimioterapia y radiaci&#xF3;n dirigida al manto tuvieron menos probabilidades de c&#xE1;ncer de mama que aquellas que se trataron  con radiaci&#xF3;n dirigida solo al manto, quiz&#xE1;s como resultado de la supresi&#xF3;n ov&#xE1;rica inducida por la quimioterapia (RR, 0,06; IC 95&#xA0;%, 0,01&#x2013;0,45).[<a href="#cit/section_3.67">67</a>] Otro estudio con 105 pacientes de c&#xE1;ncer de mama relacionado con la radiaci&#xF3;n y 266 controles ajustados por edad y radiaci&#xF3;n mostr&#xF3; un efecto protector similar de la radiaci&#xF3;n dirigida a los ovarios.[<a href="#cit/section_3.65">65</a>] En estos estudios, se indica que las hormonas de los ovarios propician la proliferaci&#xF3;n del tejido mamario con mutaciones inducidas por la radiaci&#xF3;n.[<a href="#cit/section_3.65">65</a>]  </p><p id="_152" tabindex="-1">Surge la interrogante de si las pacientes con c&#xE1;ncer de mama tratadas con lumpectom&#xED;a y radioterapia (L-RT) presentan un riesgo mayor de segundas neoplasias malignas de mama o de otro tipo, en comparaci&#xF3;n con aquellas sometidas a mastectom&#xED;a. Los resultados de las 1029 pacientes sometidas a L-RT se compararon con aquellos de 1387 pacientes sometidas a mastectom&#xED;a. Tras una mediana de seguimiento de 15 a&#xF1;os, no hubo diferencia en el riesgo de segundas neoplasias malignas.[<a href="#cit/section_3.68">68</a>] Las pruebas adicionales de tres ECA tambi&#xE9;n lo confirman. Un informe de 1851 mujeres asignadas al azar para someterse a mastectom&#xED;a total, tumorectom&#xED;a sola o L-RT mostraron tasas de c&#xE1;ncer de mama contralateral de 8,5, 8,8, y 9,4&#xA0;%, respectivamente.[<a href="#cit/section_3.69">69</a>] Otro estudio con 701 mujeres asignadas al azar a una mastectom&#xED;a radical u operaci&#xF3;n para preservar la mama, seguida de radioterapia mostr&#xF3; que la tasa de carcinomas de mama contralaterales por 100 a&#xF1;os-mujer fue de 10,2 versus 8,7, respectivamente.[<a href="#cit/section_3.70">70</a>] En el tercer estudio se compararon resultados a 25 a&#xF1;os de 1665 mujeres asignadas al azar a mastectom&#xED;a radical, mastectom&#xED;a total o mastectom&#xED;a total con radiaci&#xF3;n. No hubo una diferencia significativa en la tasa de c&#xE1;ncer de mama contralateral seg&#xFA;n el grupo de tratamiento, y la tasa general fue de  6&#xA0;%.[<a href="#cit/section_3.71">71</a>]</p></section><section id="_153"><h4 id="_153_toc">Obesidad</h4><p id="_154" tabindex="-1">La obesidad se relaciona con riesgo de c&#xE1;ncer de mama, en especial en mujeres posmenop&#xE1;usicas que no usan TH. En el WHI, se observ&#xF3; a 85&#xA0;917 mujeres de 50 a 79 a&#xF1;os y se recopil&#xF3; informaci&#xF3;n sobre los antecedentes de peso y los factores de riesgo conocidos para el c&#xE1;ncer de mama.[<a href="#cit/section_3.72">72</a>,<a href="#cit/section_3.73">73</a>] Se midi&#xF3; la altura, el peso y las circunferencias de cintura y cadera. Con una mediana de seguimiento de 34,8 meses, 1030 mujeres presentaron c&#xE1;ncer de mama invasivo. Entre las mujeres que nunca se sometieron a TH, el aumento del riesgo de c&#xE1;ncer de mama se relacion&#xF3; con el peso en el momento de ingreso al estudio, el &#xED;ndice de masa corporal (IMC) en ese momento, el IMC a los 50 a&#xF1;os, el IMC m&#xE1;ximo, el cambio de peso en la edad adulta y posterior a la menopausia, y las circunferencias de cintura y cadera. El peso fue el factor pron&#xF3;stico m&#xE1;s firme, con un RR de 2,85 (IC 95&#xA0;%, 1,81&#x2013;4,49) para mujeres que pesaban m&#xE1;s de 82,2 kg, en comparaci&#xF3;n con las que pesaban menos de 58,7 kg.</p><p id="_653" tabindex="-1">Se ha estudiado la relaci&#xF3;n entre la obesidad, la diabetes y las concentraciones de insulina,  y el riesgo de c&#xE1;ncer de mama, pero no se ha definido claramente. En el British Women&#x2019;s Heart and Health Study  de mujeres entre los 60 y 79 a&#xF1;os, se compar&#xF3; a 151 mujeres con diagn&#xF3;stico de c&#xE1;ncer de mama con 3690 mujeres sin este diagn&#xF3;stico. La OR ajustada por edad fue de 1,34 (IC 95&#xA0;%, 1,02&#x2013;1,77) por cada aumento de  unidad en log(e) de las concentraciones de insulina en mujeres que no eran diab&#xE9;ticas. La relaci&#xF3;n se observ&#xF3;, luego del ajuste por los factores de confusi&#xF3;n y por los posibles factores de mediaci&#xF3;n, tanto en los casos de c&#xE1;ncer de mama premenop&#xE1;usicos como posmenop&#xE1;usicos. Adem&#xE1;s, las concentraciones de glucosa en ayunas, la evaluaci&#xF3;n del puntaje del modelo homeost&#xE1;tico (el producto de la glucosa en ayunas m&#xE1;s la concentraci&#xF3;n de insulina dividida por 22,5), la diabetes, y los antecedentes de glucosuria gestacional o diabetes tambi&#xE9;n se relacionaron con   c&#xE1;ncer de mama.[<a href="#cit/section_3.74">74</a>]</p></section><section id="_155"><h4 id="_155_toc">Alcohol</h4><p id="_156" tabindex="-1">El consumo de alcohol aumenta el riesgo de c&#xE1;ncer de mama.   En un metan&#xE1;lisis brit&#xE1;nico, se incluyeron datos individuales de 53 estudios de cohortes, y de casos y controles.[<a href="#cit/section_3.75">75</a>] En comparaci&#xF3;n con el RR de las mujeres con c&#xE1;ncer de mama que no notificaron consumo de alcohol, el RR de c&#xE1;ncer de mama fue de 1,32 (IC 95&#xA0;%, 1,19&#x2013;1,45; <em>P</em> &lt; 0,001) en mujeres que consum&#xED;an de 35 a 44 g de alcohol por d&#xED;a y de 1,46 (IC 95&#xA0;%, 1,33&#x2013;1,61; <em>P</em> &lt; 0,001) en las que consum&#xED;an al menos 45 g de alcohol por d&#xED;a. El RR de c&#xE1;ncer de mama aumenta alrededor de 7&#xA0;% (IC 95&#xA0;%, 5,5&#x2013;8,7&#xA0;%; <em>P</em> &lt; 0,001) por cada 10 g de alcohol (es decir, un trago) consumido por d&#xED;a. Estas conclusiones se mantienen despu&#xE9;s de la estratificaci&#xF3;n por raza, grado de escolaridad, antecedentes familiares, edad de la menarquia, estatura, peso, IMC, lactancia materna, uso de anticonceptivos orales, uso y tipo de hormonas menop&#xE1;usicas, y edad de la menopausia.</p></section></section><section id="_423"><h3 id="_423_toc">Factores con pruebas suficientes de menor riesgo de c&#xE1;ncer de mama</h3><section id="_654"><h4 id="_654_toc">Embarazo temprano</h4><p id="_655" tabindex="-1">El parto va  seguido de un riesgo mayor de c&#xE1;ncer de mama por varios a&#xF1;os y, luego, por una reducci&#xF3;n del riesgo a largo plazo, que es mayor en mujeres j&#xF3;venes.[<a href="#cit/section_3.22">22</a>,<a href="#cit/section_3.76">76</a>,<a href="#cit/section_3.77">77</a>] En un estudio, las mujeres con un primer embarazo a t&#xE9;rmino  antes de los 20 a&#xF1;os tuvieron la mitad de probabilidades de c&#xE1;ncer de mama que las mujeres nul&#xED;paras o aquellas cuyo primer embarazo a t&#xE9;rmino  se present&#xF3; a los 35 a&#xF1;os o m&#xE1;s.[<a href="#cit/section_3.78">78</a>,<a href="#cit/section_3.79">79</a>]</p></section><section id="_656"><h4 id="_656_toc">Lactancia</h4><p id="_657" tabindex="-1">La lactancia se relaciona con un riesgo menor de c&#xE1;ncer de mama.[<a href="#cit/section_3.80">80</a>] En un rean&#xE1;lisis de datos individuales de 47 estudios epidemiol&#xF3;gicos de 30 pa&#xED;ses  con 50&#xA0;302 mujeres con c&#xE1;ncer de mama y 96&#xA0;973 controles, se revel&#xF3; que la incidencia del c&#xE1;ncer de mama fue menor en las mujeres que tuvieron hijos y que lactaron que en quienes  tuvieron hijos y no lactaron. Tambi&#xE9;n fue proporcional a la duraci&#xF3;n de la lactancia.[<a href="#cit/section_3.81">81</a>] El RR de c&#xE1;ncer de mama disminuy&#xF3; en 4,3&#xA0;% (IC 95&#xA0;%, 2,9&#x2013;5,8&#xA0;%; <em>P</em> &lt; 0,0001) por cada 12 meses de lactancia y en 7,0&#xA0;% (IC 95&#xA0;%, 5,0&#x2013;9,0&#xA0;%; <em>P</em> &lt; 0,0001) por cada parto.</p></section><section id="_426"><h4 id="_426_toc">Ejercicio</h4><p id="_427" tabindex="-1">El ejercicio activo puede reducir el riesgo de c&#xE1;ncer de mama, en especial, en mujeres j&#xF3;venes que han tenido hijos.[<a href="#cit/section_3.82">82</a>] En numerosos estudios de observaci&#xF3;n sobre la relaci&#xF3;n entre el &#xED;ndice de  actividad f&#xED;sica y el riesgo de c&#xE1;ncer de mama, se  ha mostrado una relaci&#xF3;n inversa.[<a href="#cit/section_3.83">83</a>] La reducci&#xF3;n promedio del RR es de 30 a 40&#xA0;%, pero no se han abordado variables de confusi&#xF3;n, como la alimentaci&#xF3;n o una predisposici&#xF3;n gen&#xE9;tica al c&#xE1;ncer de mama. En un estudio prospectivo con m&#xE1;s de 25&#xA0;000 mujeres noruegas, se indic&#xF3; que el trabajo manual pesado o, al menos, cuatro  horas de ejercicio semanales se relacionan con un riesgo menor de c&#xE1;ncer de mama, en particular, en las mujeres premenop&#xE1;usicas y en aquellas de peso corporal normal o m&#xE1;s bajo que el normal.[<a href="#cit/section_3.84">84</a>] En un estudio de casos y controles de mujeres afroamericanas, la actividad f&#xED;sica extenuante con fines recreativos por m&#xE1;s de 7 horas semanales se relacion&#xF3; con una disminuci&#xF3;n en la incidencia de c&#xE1;ncer de mama.[<a href="#cit/section_3.85">85</a>]</p></section></section><section id="_432"><h3 id="_432_toc">Intervenciones con pruebas suficientes de beneficio</h3><section id="_158"><h4 id="_158_toc">Moduladores selectivos de los receptores de estr&#xF3;geno</h4><p id="_159" tabindex="-1">Los datos de ensayos complementarios de c&#xE1;ncer de mama con tamoxifeno revelaron que este no solo suprime la recidiva del c&#xE1;ncer de mama, sino que tambi&#xE9;n evita nuevos c&#xE1;nceres de mama primarios contralaterales.[<a href="#cit/section_3.86">86</a>] El tamoxifeno tambi&#xE9;n mantiene la densidad &#xF3;sea en las mujeres posmenop&#xE1;usicas con c&#xE1;ncer de mama.[<a href="#cit/section_3.87">87</a>-<a href="#cit/section_3.91">91</a>] Los efectos adversos incluyen sofocos, episodios tromboemb&#xF3;licos venosos y c&#xE1;ncer de endometrio.[<a href="#cit/section_3.92">92</a>-<a href="#cit/section_3.94">94</a>]</p><p id="_160" tabindex="-1">Los resultados de estos ensayos complementarios fueron la base del Breast Cancer Prevention Trial (BCPT) en el que se asign&#xF3; al azar a 13&#xA0;388 pacientes con riesgo elevado de c&#xE1;ncer de mama a recibir tratamiento con tamoxifeno o placebo.[<a href="#cit/section_3.95">95</a>,<a href="#cit/section_3.96">96</a>] El estudio se cerr&#xF3; antes de lo previsto debido a una reducci&#xF3;n de 49&#xA0;% de la incidencia del c&#xE1;ncer de mama en el grupo de tamoxifeno (85 vs. 154 casos de c&#xE1;ncer de mama invasivo y 31 vs. 59 casos <em>in situ</em> a los 4 a&#xF1;os).  Tambi&#xE9;n, las mujeres tratadas con tamoxifeno presentaron menos fracturas (47 vs. 71),  pero m&#xE1;s c&#xE1;nceres del endometrio (33 vs. 14 casos) y episodios tromb&#xF3;ticos (99 vs. 70), incluida embolia pulmonar (17 vs. 6).[<a href="#cit/section_3.96">96</a>]  </p><p id="_299" tabindex="-1">Una actualizaci&#xF3;n de los resultados del BCPT despu&#xE9;s de 7 a&#xF1;os de seguimiento reflej&#xF3; resultados similares a los del informe inicial.[<a href="#cit/section_3.97">97</a>] Hubo algunos abandonos en las mujeres del grupo de placebo; algunas de ellas se inscribieron en un ensayo posterior, de forma que se a&#xF1;adieron nuevas mujeres al grupo de placebo.   Los beneficios y riesgos del tamoxifeno no fueron significativamente diferentes de los del informe original, con un beneficio persistente de menos fracturas y mayor riesgo constante  de c&#xE1;ncer de endometrio, trombosis  y operaci&#xF3;n de cataratas. No se observ&#xF3; un beneficio general en la mortalidad despu&#xE9;s de 7 a&#xF1;os de seguimiento (RR, 1,10; IC 95&#xA0;%, 0,85&#x2013;1,43).</p><p id="_658" tabindex="-1">Se completaron otros tres ensayos de tamoxifeno para la prevenci&#xF3;n primaria del c&#xE1;ncer de mama.[<a href="#cit/section_3.98">98</a>-<a href="#cit/section_3.100">100</a>]</p><div class="pdq-content-list"><ul id="_659"><li> Un estudio en el Reino Unido [<a href="#cit/section_3.98">98</a>] se enfoc&#xF3; en 2471 mujeres con aumento de riesgo de c&#xE1;ncer de mama debido a sus antecedentes familiares de c&#xE1;ncer de mama u ovario. Luego de una mediana de seguimiento de casi 6 a&#xF1;os, no se observ&#xF3; ning&#xFA;n efecto protector  con el uso de tamoxifeno (RR, 1,06), pero hubo una reducci&#xF3;n ligera del riesgo de c&#xE1;ncer de mama en el grupo de tamoxifeno (CRI,  0,78; IC 95&#xA0;%, 0,58&#x2013;1,04) con una mediana de 13 a&#xF1;os. Sin embargo, el riesgo de c&#xE1;ncer de mama positivo para RE se redujo significativamente en el grupo de tratamiento (CRI, 0,61; IC 95&#xA0;%, 0,43&#x2013;0,86), un efecto que se observ&#xF3;, de forma predominante, en el per&#xED;odo postratamiento.[<a href="#cit/section_3.101">101</a>]</li><li>Un estudio italiano [<a href="#cit/section_3.99">99</a>] se enfoc&#xF3; en 5408 mujeres sometidas a histerectom&#xED;a y que se describieron como de riesgo bajo a normal. Luego de una mediana de seguimiento de casi 4 a&#xF1;os, no se observ&#xF3; ning&#xFA;n efecto protector con el tamoxifeno. Con un seguimiento m&#xE1;s prolongado y un an&#xE1;lisis de subgrupo en este ensayo, se encontr&#xF3; un efecto protector del tamoxifeno en mujeres de riesgo alto de c&#xE1;ncer de mama positivo para receptores hormonales. (RR, 0,24; IC 95&#xA0;%, 0,10&#x2013;0,59) y en mujeres que tomaban TH durante el ensayo (RR, 0,43; IC 95&#xA0;%, 0,20&#x2013;0,95).[<a href="#cit/section_3.102">102</a>,<a href="#cit/section_3.103">103</a>]</li><li>En el  International Breast Cancer Intervention Study (IBIS-I), se asign&#xF3; al azar a 7152 mujeres de 35 a 70 a&#xF1;os con aumento de riesgo de c&#xE1;ncer de mama a recibir tamoxifeno (20 mg/d&#xED;a) o placebo por 5 a&#xF1;os.[<a href="#cit/section_3.100">100</a>] Tras una mediana de seguimiento de 50 meses,  menos mujeres tratadas con tamoxifeno presentaron c&#xE1;ncer de mama invasivo o <em>in situ</em> (tasa absoluta, 4,6 vs. 6,75 por cada 1000 a&#xF1;os-mujer; reducci&#xF3;n del riesgo, 32&#xA0;%; IC 95&#xA0;%, 8&#x2013;50&#xA0;%). La reducci&#xF3;n del  RR   del c&#xE1;ncer de mama invasivo positivo para RE fue de 31&#xA0;%; no hubo reducci&#xF3;n de los c&#xE1;nceres negativos para RE. Hubo un exceso de mortalidad por todas las causas en el grupo de tamoxifeno (25 vs. 11; <em>P</em> = 0,028), que los autores atribuyeron a la casualidad. El efecto   beneficioso  del tamoxifeno en el c&#xE1;ncer de mama persisti&#xF3; despu&#xE9;s del tratamiento activo, con una mediana de seguimiento de 46 meses; 27&#xA0;% menos de mujeres del grupo de tamoxifeno present&#xF3; c&#xE1;ncer de mama   (142 vs. 195 casos, respectivamente; RR, 0,73, IC 95&#xA0;%, 0,58&#x2013;0,91).[<a href="#cit/section_3.104">104</a>]</li></ul></div><p id="_231" tabindex="-1">Se realiz&#xF3; un metan&#xE1;lisis de estos ensayos de prevenci&#xF3;n primaria con tamoxifeno, en el que se mostr&#xF3;  una reducci&#xF3;n de 38&#xA0;% en la incidencia del c&#xE1;ncer de mama sin heterogeneidad estad&#xED;sticamente significativa.[<a href="#cit/section_3.94">94</a>] Los tumores positivos para RE se redujeron en 48&#xA0;%. Las tasas de c&#xE1;ncer de endometrio aumentaron (RR consensuado, 2,4; IC 95&#xA0;%, 1,5&#x2013;4,0), al igual que los episodios tromboemb&#xF3;licos venosos (RR, 1,9; IC 95&#xA0;%, 1,4&#x2013;2,6). Ninguno de estos ensayos de prevenci&#xF3;n primaria se dise&#xF1;&#xF3; para detectar diferencias en la mortalidad por el c&#xE1;ncer de mama.</p><p id="_163" tabindex="-1">Las mujeres con antecedentes de carcinoma ductal <em>in situ</em> (CDIS) tienen mayor riesgo de c&#xE1;ncer de mama contralateral. El ensayo  National Surgical Adjuvant Breast and Bowel Project (NSABP) B-24 se concentr&#xF3; en su tratamiento. Se asign&#xF3; al azar a las mujeres a someterse a lumpectom&#xED;a y radioterapia (L-RT), con tamoxifeno adyuvante o sin este. A los 6 a&#xF1;os, las mujeres tratadas con tamoxifeno presentaron menos c&#xE1;nceres invasivos e <em>in situ</em>  (8,2 vs. 13,4&#xA0;%; RR, 0,63; IC 95&#xA0;%, 0,47&#x2013;0,83). El riesgo de c&#xE1;ncer de mama contralateral tambi&#xE9;n fue m&#xE1;s bajo en las mujeres tratadas con tamoxifeno (RR, 0,49; IC 95&#xA0;%, 0,26&#x2013;0,87).[<a href="#cit/section_3.105">105</a>]</p><p id="_165" tabindex="-1">El clorhidrato de raloxifeno (Evista) es un MSRE con efectos antiestrog&#xE9;nicos en las mamas y efectos estrog&#xE9;nicos en los huesos, el metabolismo de l&#xED;pidos y la coagulaci&#xF3;n sangu&#xED;nea. A diferencia del tamoxifeno, tiene efectos antiestrog&#xE9;nicos en el endometrio.[<a href="#cit/section_3.106">106</a>] En el ensayo aleatorizado con enmascaramiento doble Multiple Outcomes of Raloxifene Evaluation (MORE), se evalu&#xF3; a 7705 mujeres posmenop&#xE1;usicas con osteoporosis entre 1994 y 1998 en 180 centros cl&#xED;nicos estadounidenses. Se redujeron las fracturas vertebrales. El efecto en la incidencia del c&#xE1;ncer de mama fue un criterio de valoraci&#xF3;n secundario. Tras una mediana de seguimiento de 47 meses, el riesgo de c&#xE1;ncer de mama invasivo disminuy&#xF3; en las mujeres tratadas con raloxifeno (RR, 0,25; IC 95&#xA0;%, 0,17&#x2013;0,45).[<a href="#cit/section_3.107">107</a>]  De manera similar al tamoxifeno, el raloxifeno redujo el riesgo c&#xE1;ncer de mama positivo para RE, pero no el c&#xE1;ncer de mama negativo para RE y  se relacion&#xF3; con un exceso de  riesgo de sofocos y episodios tromboemb&#xF3;licos. No se observ&#xF3; un exceso de riesgo de c&#xE1;ncer de endometrio o hiperplasia tras 47 meses de seguimiento.[<a href="#cit/section_3.108">108</a>].</p><p id="_253" tabindex="-1">El ensayo Continuing Outcomes Relevant to Evista (CORE) fue una extensi&#xF3;n del ensayo MORE, en el que se estudi&#xF3; a casi 80&#xA0;% de las participantes del MORE en sus grupos asignados al azar por 4 a&#xF1;os m&#xE1;s. Si bien hubo una mediana de intervalo de 10 meses entre los dos estudios y solo cerca de 55&#xA0;% de las mujeres cumplieron con las indicaciones de los medicamentos asignados, el grupo tratado con raloxifeno continu&#xF3; presentando una incidencia m&#xE1;s baja de c&#xE1;ncer de mama invasivo positivo para RE.  La reducci&#xF3;n general en el c&#xE1;ncer de mama invasivo durante los 8 a&#xF1;os de MORE y CORE fue de 66&#xA0;% (CRI, 0,34; IC 95&#xA0;%, 0,22&#x2013;0,50); la reducci&#xF3;n para el c&#xE1;ncer de mama positivo para RE fue de 76&#xA0;% (CRI, 0,24; IC 95&#xA0;%, 0,15&#x2013;0,40).[<a href="#cit/section_3.109">109</a>]</p><p id="_466" tabindex="-1">El Raloxifene Use for the Heart fue un ensayo aleatorizado controlado con placebo para evaluar los efectos del raloxifeno en la incidencia de episodios coronarios y c&#xE1;ncer de mama invasivo. El raloxifeno, de manera similar a lo observado en los estudios MORE y CORE, redujo el riesgo de c&#xE1;ncer de mama invasivo (CRI, 0,56; IC 95&#xA0;%, 0,38&#x2013;0,83).[<a href="#cit/section_3.110">110</a>]</p><p id="_328" tabindex="-1">En el Study of Tamoxifen and Raloxifene (STAR) (NSABP P-2), se compararon el tamoxifeno y el raloxifeno en 19&#xA0;747 mujeres de riesgo alto que se sometieron a observaci&#xF3;n durante una mediana de seguimiento de 3,9 a&#xF1;os. La incidencia de c&#xE1;ncer de mama invasivo fue casi la misma con ambos f&#xE1;rmacos, pero hubo menos c&#xE1;nceres no invasivos en el grupo de tamoxifeno. Los episodios adversos de c&#xE1;ncer de cuello uterino, episodios tromb&#xF3;ticos venosos y las cataratas fueron m&#xE1;s comunes en las mujeres tratadas con tamoxifeno, y no hubo diferencia en los episodios de cardiopat&#xED;as isqu&#xE9;micas, accidente cerebrovascular o fracturas.[<a href="#cit/section_3.111">111</a>] Se presentaron, con menos frecuencia, s&#xED;ntomas relacionados con el tratamiento de dispareunia, problemas osteomusculares y aumento de peso en las mujeres tratadas con tamoxifeno; mientras que las crisis vasomotoras, los s&#xED;ntomas de control de la vejiga, los s&#xED;ntomas ginecol&#xF3;gicos y los calambres en las piernas ocurrieron con menos frecuencia en las que recibieron raloxifeno.[<a href="#cit/section_3.112">112</a>]</p><table id="_332" class="table-default expandable-container"><caption>Incidencia de resultados por 1000 mujeres</caption><colgroup><col width="25.00%"><col width="25.00%"><col width="25.00%"><col width="25.00%"></colgroup>
            <THead>
            <tr>
            <th>&#xA0;</th>
            <th>Tamoxifeno</th>
            <th>Raloxifeno</th>
            <th>RR, IC 95&#xA0;%</th>
            </tr>
            </THead>
            <TFoot class="pdq-footer">
            <tr>
            <td colspan="4">IC = intervalo de confianza; RR = riesgo relativo; TEV = tromboembolia venosa</td>
            </tr>
            </TFoot>
            <tbody>
            <tr>
            <td>C&#xE1;ncer de mama invasivo</td>
            <td>4,3</td>
            <td>4,41</td>
            <td>1,02, 0,82&#x2013;1,28</td>
            </tr>
            <tr>
            <td>C&#xE1;ncer de mama no invasivo</td>
            <td>1,51</td>
            <td>2,11</td>
            <td>1,4, 0,98-2,00</td>
            </tr>
            <tr>
            <td>C&#xE1;ncer uterino</td>
            <td>2,0</td>
            <td>1,25</td>
            <td>0,62, 0,35-1,08</td>
            </tr>
            <tr>
            <td>TEV</td>
            <td>3,8</td>
            <td>2,6</td>
            <td>0,7, 0,68-0,99</td>
            </tr>
            <tr>
            <td>Cataratas </td>
            <td>12,3</td>
            <td>9,72</td>
            <td>0,79, 0,68-0,92</td>
            </tr>
            <tr>
            <td colspan="4">
            <strong>Incidencia de  s&#xED;ntomas (escala de 0 a 4)</strong>
            </td>
            </tr>
            <tr>
            <td colspan="4">Favorece al tamoxifeno</td>
            </tr>
            <tr>
            <td>Dispareunia</td>
            <td>0,68</td>
            <td>0,78</td>
            <td><em>P </em>&lt; 0,001</td>
            </tr>
            <tr>
            <td>Problemas osteomusculares</td>
            <td>1,10</td>
            <td>1,15</td>
            <td><em>P</em> = 0,002</td>
            </tr>
            <tr>
            <td>Aumento de peso</td>
            <td>0,76</td>
            <td>0,82</td>
            <td><em>P</em> &lt; 0,001</td>
            </tr>
            <tr>
            <td colspan="4">Favorece al raloxifeno</td>
            </tr>
            <tr>
            <td>S&#xED;ntomas vasomotores</td>
            <td>0,96</td>
            <td>0,85</td>
            <td><em>P </em>&lt; 0,001</td>
            </tr>
            <tr>
            <td>S&#xED;ntomas de control de vejiga</td>
            <td>0,88</td>
            <td>0,73</td>
            <td><em>P </em>&lt; 0,001</td>
            </tr>
            <tr>
            <td>Calambres en las piernas</td>
            <td>1,10</td>
            <td>0,91</td>
            <td><em>P </em>&lt; 0,001</td>
            </tr>
            <tr>
            <td>Problemas ginecol&#xF3;gicos</td>
            <td>0,29</td>
            <td>0,19</td>
            <td><em>P </em>&lt; 0,001</td>
            </tr>
            </tbody>
            </table></section><section id="_199"><h4 id="_199_toc">Inhibidores o inactivadores de la aromatasa</h4><p id="_200" tabindex="-1">Otro tipo de f&#xE1;rmacos, disponibles comercialmente para el tratamiento de las mujeres con c&#xE1;ncer de mama sensible a las  hormonas, tambi&#xE9;n pueden prevenir este tipo de c&#xE1;ncer. Estos f&#xE1;rmacos interfieren con la aromatasa, la enzima suprarrenal que permite la producci&#xF3;n de estr&#xF3;geno en las mujeres posmenop&#xE1;usicas. El anastrozol y el letrozol inhiben la actividad de la aromatasa, mientras que el exemestano inactiva la enzima. Los tres f&#xE1;rmacos tienen efectos secundarios similares, como fatiga, artralgia, mialgia, reducci&#xF3;n de la densidad mineral &#xF3;sea y tasa m&#xE1;s alta de fracturas.</p><p id="_748" tabindex="-1">Como se observ&#xF3; en los siguientes estudios, las mujeres con un diagn&#xF3;stico previo de c&#xE1;ncer de mama tienen un riesgo m&#xE1;s bajo de recidivas y de c&#xE1;nceres de mama nuevos cuando se trataron con inhibidores de la aromatasa (IA):</p><div class="pdq-content-list"><ol id="_749"><li>En el ensayo Arimidex, Tamoxifen, Alone or in  Combination, en el que se compar&#xF3; anastrozol con tamoxifeno como terapia adyuvante para el c&#xE1;ncer de mama primario, la tasa de recidivas locorregional y a distancia fue m&#xE1;s baja con anastrozol (7,1 vs. 8,5&#xA0;%), pero m&#xE1;s alta con la combinaci&#xF3;n (9,1&#xA0;%).[<a href="#cit/section_3.113">113</a>] El anastrozol tambi&#xE9;n fue m&#xE1;s eficaz para reducir la incidencia de un nuevo c&#xE1;ncer de mama contralateral (0,4 vs. 1,1 vs. 0,9&#xA0;%).</li><li>En otro ensayo, 5187 mujeres que recibieron tamoxifeno adyuvante durante 5 a&#xF1;os se asignaron al azar para recibir letrozol o un placebo.[<a href="#cit/section_3.114">114</a>] Despu&#xE9;s de una mediana de seguimiento de 2,5 a&#xF1;os, el estudio se cerr&#xF3; debido a que se hab&#xED;an alcanzado los criterios de valoraci&#xF3;n de la eficacia definidos previamente. No solo las pacientes tratadas con letrozol tuvieron una incidencia m&#xE1;s baja de recidivas locorregional y a distancia, sino que tambi&#xE9;n presentaron una incidencia m&#xE1;s baja de un nuevo c&#xE1;ncer de mama contralateral; (14 vs. 26).</li><li>En otro ensayo controlado con placebo en el que participaron 1918 mujeres con c&#xE1;ncer de mama, se examin&#xF3; el efecto de la extensi&#xF3;n del tratamiento con letrozol durante 5 a&#xF1;os adicionales en mujeres que hab&#xED;an recibido tamoxifeno adyuvante seguido de 5 a&#xF1;os de letrozol.[<a href="#cit/section_3.115">115</a>]  En el momento de una mediana de seguimiento de 6,3 a&#xF1;os desde la entrada en el estudio, el grupo que recibi&#xF3; letrozol adicional tuvo una mejor supervivencia sin enfermedad a los 5 a&#xF1;os de 95&#xA0;% (IC 95&#xA0;%, 93&#x2013;96&#xA0;%) en comparaci&#xF3;n con 91&#xA0;% (IC 95&#xA0;%, 89&#x2013;93&#xA0;%) en el grupo de control (CRI, 0,66), pero sin diferencia en la supervivencia general. La diferencia en los diagn&#xF3;sticos de c&#xE1;ncer de mama contralateral nuevo fue estad&#xED;sticamente significativa: 21&#xA0;% (IC 95&#xA0;%, 10&#x2013;32%) para el grupo letrozol adicional comparado con 49&#xA0;% (32&#x2013;67&#xA0;%) para el grupo control (CRI, 0,42). Las mujeres tratadas con letrozol tuvieron m&#xE1;s riesgo de dolor &#xF3;seo (18 vs. 14&#xA0;%), fractura &#xF3;sea (14 vs. 9&#xA0;%) y presentaci&#xF3;n nueva de osteoporosis (11 vs. 6&#xA0;%).</li><li>En un ensayo, se asign&#xF3; al azar a 4742 mujeres que hab&#xED;an recibido tamoxifeno adyuvante durante 2 a&#xF1;os a continuar con el tamoxifeno o cambiar a exemestano.[<a href="#cit/section_3.116">116</a>] Luego de una mediana de seguimiento de 2,4 a&#xF1;os, en el grupo de exemestano se redujo el riesgo de recidivas local o metast&#xE1;sica, y hubo una disminuci&#xF3;n de la incidencia de un nuevo c&#xE1;ncer de mama contralateral (9 vs. 20).</li></ol></div><p id="_750" tabindex="-1">Tambi&#xE9;n se observ&#xF3; que los inhibidores o inactivadores de la aromatasa previenen el c&#xE1;ncer de mama en mujeres con aumento de riesgo, como se advirti&#xF3; en los siguientes estudios:</p><div class="pdq-content-list"><ol id="_751"><li>En un ECA de prevenci&#xF3;n primaria de c&#xE1;ncer de mama, se compar&#xF3; el exemestano con un placebo en 4560 mujeres que presentaban por lo menos un factor de riesgo (&gt;60 a&#xF1;os, riesgo de Gail a 5 a&#xF1;os &gt;1,66&#xA0;% o antecedentes de CDIS con mastectom&#xED;a). Despu&#xE9;s de una mediana de seguimiento de 35 meses, se diagnostic&#xF3; c&#xE1;ncer de mama invasivo con menos frecuencia en el grupo de exemestano (11 vs. 32; CRI, 0,35; IC 95&#xA0;%, 0,18&#x2013;0,70; n&#xFA;mero que es necesario tratar, cerca de 100 durante 35 meses). En comparaci&#xF3;n con el grupo de placebo, las mujeres tratadas con exemestano tuvieron m&#xE1;s sofocos (aumento de 8%) y fatiga (aumento de 2%), pero no hubo diferencia en fracturas o episodios cardiovasculares.[<a href="#cit/section_3.117">117</a>]</li><li>En el International Breast Cancer Intervention Study II (IBIS-II), se asign&#xF3; al azar a 3864 mujeres posmenop&#xE1;usicas que ten&#xED;an un aumento de riesgo de presentar c&#xE1;ncer de mama a recibir anastrozol diario (1 mg) o un placebo durante 5 a&#xF1;os.[<a href="#cit/section_3.118">118</a>] La definici&#xF3;n de riesgo alto vari&#xF3; seg&#xFA;n la edad y se defini&#xF3; por el RR comparado con la poblaci&#xF3;n general: las mujeres de 40 a 44 a&#xF1;os ten&#xED;an que tener un RR m&#xED;nimo de 4; las mujeres de 45 a 60 a&#xF1;os deb&#xED;an tener un RR m&#xED;nimo de 2, y las mujeres de 60 a 70 a&#xF1;os, un RR m&#xED;nimo de 1,5.   Alternativamente, las mujeres con un riesgo estimado de 10 a&#xF1;os de presentar c&#xE1;ncer de mama de por lo menos 5&#xA0;% (seg&#xFA;n el modelo de Tyer-Cuzick) fueron aptas para participar. Las mujeres con CDIS diagnosticado dentro de los 6 meses y tratadas con mastectom&#xED;a unilateral fueron aptas para participar en el ensayo y se asign&#xF3; al azar a 326 de ellas. Despu&#xE9;s de una mediana de seguimiento de 5 a&#xF1;os, se presentaron menos c&#xE1;nceres de mama (invasivos y CDIS) en el grupo tratado con anastrozol que en el grupo de placebo (CRI, 0,47; IC 95&#xA0;%: 0,32&#x2013;0,68). Se redujo el riesgo de c&#xE1;ncer de mama con receptores hormonales positivos, pero no el de c&#xE1;ncer de mama con receptores hormonales negativos. A partir de la incidencia acumulada prevista a lo largo de 7 a&#xF1;os, se calcul&#xF3; que el n&#xFA;mero de mujeres con riesgo alto (seg&#xFA;n los criterios de elegibilidad del ensayo IBIS-II) que necesitaban tratamiento durante 5 a&#xF1;os para prevenir un c&#xE1;ncer de mama durante 7 a&#xF1;os de seguimiento era 36 (IC 95&#xA0;%, 33&#x2013;44). Fue m&#xE1;s probable que las mujeres tratadas con anastrozol que las que recibieron placebo, presentaran s&#xED;ntomas osteomusculares, incluso artralgias (51 vs. 46&#xA0;%), rigidez articular (7 vs. 5&#xA0;%), dolor en mano o pie (9 vs. 8&#xA0;%) y s&#xED;ndrome del t&#xFA;nel carpiano (3 vs. 2&#xA0;%); hipertensi&#xF3;n (5 vs. 3&#xA0;%); s&#xED;ntomas vasomotores (57 vs. 49&#xA0;%), y ojos secos (4 vs. 2&#xA0;%). La relaci&#xF3;n entre el dolor de manos o los pies con el tratamiento con anastrozol tuvo una significaci&#xF3;n estad&#xED;stica lim&#xED;trofe. Todos los otros efectos secundarios mencionados tuvieron una relaci&#xF3;n estad&#xED;stica significativa con el tratamiento con anastrozol.</li></ol></div></section><section id="_166"><h4 id="_166_toc">Mastectom&#xED;a profil&#xE1;ctica</h4><p id="_167" tabindex="-1">Se realiz&#xF3; un estudio de cohortes retrospectivo para evaluar el efecto de la mastectom&#xED;a profil&#xE1;ctica bilateral en la incidencia del c&#xE1;ncer de mama en las mujeres con riesgo alto y moderado, de acuerdo con los antecedentes familiares.[<a href="#cit/section_3.119">119</a>] No se conoc&#xED;a el estado de la mutaci&#xF3;n en <em>BRCA</em>. Se realiz&#xF3; una mastectom&#xED;a subcut&#xE1;nea en lugar de total en 90&#xA0;% de estas mujeres. Tras una mediana de seguimiento posquir&#xFA;rgico de 14 a&#xF1;os, se redujo el riesgo en 89&#xA0;% de 425 mujeres de riesgo moderado; en las 214 mujeres de riesgo alto, fue de 90 a 94&#xA0;%, seg&#xFA;n el m&#xE9;todo utilizado para calcular las tasas previstas de c&#xE1;ncer de mama. La reducci&#xF3;n del riesgo de mortalidad por c&#xE1;ncer de mama fue de 100&#xA0;% en las mujeres con riesgo moderado y de 81&#xA0;% en las mujeres de riesgo alto. Debido a que en este estudio se usaron los antecedentes familiares como un indicador de riesgo, en lugar de pruebas gen&#xE9;ticas, es posible que se sobrestimara el riesgo de c&#xE1;ncer de mama.</p><p id="_713" tabindex="-1">Se notific&#xF3; que la tasa de mastectom&#xED;a bilateral en las mujeres con enfermedad unilateral (DCIS y c&#xE1;ncer de mama invasivo en estadio temprano) aument&#xF3; de 1,9&#xA0;% en 1998 a 11,2&#xA0;% en 2011, seg&#xFA;n informaci&#xF3;n de la U.S. National Cancer Data Base.[<a href="#cit/section_3.120">120</a>]</p><p id="_692" tabindex="-1">No se han realizado estudios sobre los beneficios de la mastectom&#xED;a profil&#xE1;ctica en una poblaci&#xF3;n con riesgo promedio para prevenir el c&#xE1;ncer de mama contralateral en mujeres con c&#xE1;ncer de mama ipsilateral.</p></section><section id="_193"><h4 id="_193_toc">Ooforectom&#xED;a profil&#xE1;ctica</h4><p id="_194" tabindex="-1">La ablaci&#xF3;n ov&#xE1;rica y la ooforectom&#xED;a se relacionan con un riesgo menor de c&#xE1;ncer de mama en mujeres normales y en mujeres con riesgo m&#xE1;s alto por irradiaci&#xF3;n tor&#xE1;cica.  (Para obtener m&#xE1;s informaci&#xF3;n, consultar la subsecci&#xF3;n  <a href="/espanol/tipos/seno/pro/prevencion-seno-pdq#link/_794">Estr&#xF3;geno end&#xF3;geno</a> en la secci&#xF3;n  de este sumario sobre <a href="/espanol/tipos/seno/pro/prevencion-seno-pdq#link/_29">Descripci&#xF3;n de las pruebas</a>). En los estudios de observaci&#xF3;n de mujeres con riesgo alto de c&#xE1;ncer de mama debido a mutaciones en los genes <em>BRCA1</em> o <em>BRCA2</em>, se observ&#xF3; que la ooforectom&#xED;a profil&#xE1;ctica para prevenir el c&#xE1;ncer de ovario tambi&#xE9;n se relacion&#xF3; con una disminuci&#xF3;n de 50&#xA0;% de la incidencia del c&#xE1;ncer de mama.[<a href="#cit/section_3.121">121</a>-<a href="#cit/section_3.123">123</a>] Estos estudios de observaci&#xF3;n se desvirt&#xFA;an por el sesgo de selecci&#xF3;n, las relaciones familiares entre las pacientes y los controles, las indicaciones de ooforectom&#xED;a y la informaci&#xF3;n inadecuada sobre la administraci&#xF3;n de hormonas. En un estudio prospectivo de cohortes, hubo hallazgos similares; hubo una mayor reducci&#xF3;n del riesgo de c&#xE1;ncer de mama en las portadoras de mutaciones  en <em>BRCA2</em> que en aquellas con mutaciones en <em>BRCA1</em>.[<a href="#cit/section_3.124">124</a>]</p></section></section><section id="_433"><h3 id="_433_toc">Factores e intervenciones sin pruebas suficientes de relaci&#xF3;n</h3><section id="_434"><h4 id="_434_toc">Anticonceptivos hormonales</h4><p id="_435" tabindex="-1">Los anticonceptivos orales se relacionaron con un aumento peque&#xF1;o del riesgo de c&#xE1;ncer de mama en las consumidoras actuales que disminuye con el tiempo.[<a href="#cit/section_3.125">125</a>] En un estudio de casos y controles bien realizado, no se observ&#xF3; una relaci&#xF3;n entre el riesgo de c&#xE1;ncer de mama y el consumo de anticonceptivos orales con respecto a cada uso, la duraci&#xF3;n del uso o la proximidad temporal del uso.[<a href="#cit/section_3.126">126</a>]</p><p id="_436" tabindex="-1">En otro estudio de casos y controles no se encontr&#xF3; un aumento del riesgo de c&#xE1;ncer de mama relacionado con el uso de inyecciones o implantes anticonceptivos de progestina sola en mujeres de 35 a 64 a&#xF1;os.[<a href="#cit/section_3.127">127</a>]</p><p id="_810" tabindex="-1">En un estudio de cohortes nacional prospectivo en Dinamarca se observ&#xF3; que las mujeres que usan anticonceptivos hormonales contempor&#xE1;neos en la actualidad o los usaron de forma reciente tienen un riesgo m&#xE1;s alto de c&#xE1;ncer de mama que las mujeres que  nunca usaron anticonceptivos hormonales.  Adem&#xE1;s, el riesgo de c&#xE1;ncer de mama aumentaba mientras m&#xE1;s se prolongaba el uso de anticonceptivos hormonales. No obstante, en t&#xE9;rminos absolutos, el efecto de los anticonceptivos orales en el riesgo de c&#xE1;ncer de mama fue muy bajo. Por ende, se prev&#xE9; que habr&#xE1; un caso adicional de c&#xE1;ncer de mama por cada 7690 mujeres que usan anticonceptivos hormonales durante 1 a&#xF1;o.[<a href="#cit/section_3.128">128</a>]</p></section><section id="_283"><h4 id="_283_toc">Factores ambientales</h4><p id="_284" tabindex="-1">Se ha propuesto que las exposiciones ocupacionales, ambientales o qu&#xED;micas tienen un efecto en el riesgo del c&#xE1;ncer de mama. Si bien algunos resultados indican que las exposiciones a los organoclorados, como aquellas relacionadas con insecticidas, se podr&#xED;an vincular con un aumento del riesgo de c&#xE1;ncer de mama,[<a href="#cit/section_3.129">129</a>,<a href="#cit/section_3.130">130</a>] otros estudios de casos y controles y de casos y controles insertados no lo hacen.[<a href="#cit/section_3.131">131</a>-<a href="#cit/section_3.136">136</a>] Los estudios en los que se notifican relaciones positivas fueron incongruentes en la identificaci&#xF3;n de los organoclorados responsables. Algunas de estas sustancias tienen efectos estrog&#xE9;nicos d&#xE9;biles, pero su efecto en el c&#xE1;ncer de mama contin&#xFA;a sin probarse. En 1972, se prohibi&#xF3; en los Estados Unidos el uso de dicloro difenil tricloroetano y, en 1977, se interrumpi&#xF3; la producci&#xF3;n de bifenilos policlorinados.</p></section></section><section id="_667"><h3 id="_667_toc">Factores e intervenciones con pruebas suficientes de ausencia de relaci&#xF3;n o poca relaci&#xF3;n</h3><section id="_668"><h4 id="_668_toc">Aborto provocado</h4><p id="_669" tabindex="-1"> Se propuso que el aborto provocado es un factor de riesgo de c&#xE1;ncer de mama. Los hallazgos de estudios de observaci&#xF3;n han variado; en algunos estudios, se observ&#xF3; una relaci&#xF3;n, pero no en otros. Los estudios de observaci&#xF3;n en los que se sustenta la relaci&#xF3;n fueron menos rigurosos y posiblemente sesgados debido a los diferentes recuerdos que tienen las mujeres de un tema socialmente sensible.[<a href="#cit/section_3.137">137</a>-<a href="#cit/section_3.140">140</a>] Por ejemplo, el efecto del sesgo de recuerdo o notificaci&#xF3;n se demostr&#xF3; en un estudio en el que se compararon regiones geogr&#xE1;ficas con actitudes sociales diferentes con respecto al aborto provocado.[<a href="#cit/section_3.141">141</a>] El Committee on Gynecologic Practice of the American College of Obstetricians and Gynecologists concluy&#xF3; que &#x201C;en los estudios recientes m&#xE1;s estrictos se demostr&#xF3; que no hay una relaci&#xF3;n de causalidad entre el aborto inducido y el aumento  posterior de riesgo de c&#xE1;ncer de mama&#x201D;.[<a href="#cit/section_3.142">142</a>] En los estudios en los que se usaron datos registrados prospectivamente sobre el aborto provocado, evitando as&#xED; el sesgo de recuerdo, no se observ&#xF3; en gran medida que hubiera un v&#xED;nculo importante con la presentaci&#xF3;n posterior de un c&#xE1;ncer de mama.[<a href="#cit/section_3.143">143</a>-<a href="#cit/section_3.148">148</a>] </p></section><section id="_670"><h4 id="_670_toc">Alimentaci&#xF3;n</h4><p id="_671" tabindex="-1">Cualquier efecto de cambios en la alimentaci&#xF3;n en el c&#xE1;ncer de mama depende, probablemente, del tipo de cambio. Sin embargo, hay pocos datos que indiquen que las modificaciones de cualquier tipo en la alimentaci&#xF3;n afecten la incidencia de c&#xE1;ncer de mama.</p><p id="_736" tabindex="-1">Hay muy pocos ensayos aleatorizados con seres humanos en los que se comparen la incidencia de c&#xE1;ncer con diferentes tipos de alimentaci&#xF3;n. La mayor&#xED;a de los estudios son de observaci&#xF3;n &#x2014;incluso el an&#xE1;lisis <em>a posteriori</em> de los ensayos aleatorizados&#x2014; y est&#xE1;n sujetos a sesgos que pueden ser tan amplios  que dificulten la interpretaci&#xF3;n de la observaci&#xF3;n. En particular, los valores de <em>p</em> y los II no tienen la misma interpretaci&#xF3;n que cuando se calcula el criterio primario de valoraci&#xF3;n en un ensayo aleatorizado.</p><p id="_672" tabindex="-1">En un resumen de estudios ecol&#xF3;gicos publicado antes de  1975, se mostr&#xF3; una correlaci&#xF3;n positiva entre las tasas internacionales de mortalidad por c&#xE1;ncer de mama ajustadas por edad y el c&#xE1;lculo per c&#xE1;pita de consumo de grasas alimenticias.[<a href="#cit/section_3.149">149</a>] Los resultados de los estudios de casos y controles han sido mixtos. Veinte a&#xF1;os despu&#xE9;s, en un an&#xE1;lisis conjunto de los resultados de siete estudios de cohortes,  no se encontr&#xF3; ninguna relaci&#xF3;n entre el consumo total de grasas alimenticias y el riesgo de c&#xE1;ncer de mama.[<a href="#cit/section_3.150">150</a>]</p><p id="_673" tabindex="-1">Se llev&#xF3; a cabo un estudio controlado aleatorizado sobre una modificaci&#xF3;n alimentaria con 48&#xA0;835  mujeres posmenop&#xE1;usicas de 50 a 79 a&#xF1;os que tambi&#xE9;n participaron en el WHI. En la intervenci&#xF3;n, se promovi&#xF3; una meta de reducci&#xF3;n del consumo total de grasas de 20&#xA0;% al aumentar el consumo de vegetales, frutas y cereales. El grupo de intervenci&#xF3;n redujo el consumo de grasas en aproximadamente 10&#xA0;% durante m&#xE1;s de 8,1 a&#xF1;os de seguimiento, lo que redujo las concentraciones de estradiol y gamma-tocoferol, pero no se mostr&#xF3; una p&#xE9;rdida de peso constante. La incidencia del c&#xE1;ncer de mama invasivo fue num&#xE9;rica, pero no estad&#xED;sticamente inferior en el grupo de intervenci&#xF3;n, con un CRI de 0,91 (IC 95&#xA0;%, 0,83&#x2013;1,01).[<a href="#cit/section_3.151">151</a>] No hubo ninguna diferencia en la mortalidad por todas las causas, la mortalidad general ni la incidencia de episodios cardiovasculares.[<a href="#cit/section_3.152">152</a>]</p><p id="_737" tabindex="-1">Con respecto a la ingesta de frutas y vegetales, en un an&#xE1;lisis conjunto de ocho estudios de cohorte en los que se incluy&#xF3; a m&#xE1;s de 350 000 mujeres con 7377 casos nuevos de c&#xE1;ncer de mama, se observ&#xF3; poca o ninguna relaci&#xF3;n  seg&#xFA;n distintos modelos estad&#xED;sticos.[<a href="#cit/section_3.153">153</a>]</p><p id="_694" tabindex="-1">En el Women's Healthy Eating and Living Randomized Trial,[<a href="#cit/section_3.154">154</a>] se examin&#xF3; el efecto de la alimentaci&#xF3;n en la incidencia de c&#xE1;nceres de mama primarios nuevos en mujeres a las que previamente se les diagnostic&#xF3; c&#xE1;ncer de mama. Se inscribieron m&#xE1;s de 3000 mujeres y se asignaron al azar a un r&#xE9;gimen intensivo con mayor ingesta de frutas, vegetales y fibra, y menor ingesta de grasas, o a un grupo de comparaci&#xF3;n que recibi&#xF3; material impreso sobre las pautas alimentarias de &#x201C;cinco al d&#xED;a&#x201D;. Luego de una mediana de seguimiento de 7,3 a&#xF1;os, no hubo reducci&#xF3;n del n&#xFA;mero de c&#xE1;nceres primarios nuevos, no hubo ninguna diferencia en la supervivencia sin enfermedad ni en la supervivencia general.</p><p id="_738" tabindex="-1">En un ensayo aleatorizado realizado en Espa&#xF1;a,[<a href="#cit/section_3.155">155</a>]  las participantes con riesgo cardiovascular alto se asignaron a 1 de 3 dietas: una dieta mediterr&#xE1;nea suplementada con aceite de oliva extra virgen, una dieta mediterr&#xE1;nea suplementada con una mezcla de frutos secos o a una dieta mediterr&#xE1;nea de control (con orientaci&#xF3;n para reducir la ingesta de alimentos grasos). Los investigadores notificaron una reducci&#xF3;n estad&#xED;sticamente significativa de episodios cardiovasculares importantes, que fue el criterio primario de valoraci&#xF3;n del ensayo.[<a href="#cit/section_3.156">156</a>] Los investigadores tambi&#xE9;n abordaron otros criterios primarios de valoraci&#xF3;n, incluso la incidencia de c&#xE1;ncer de mama, aunque no se especific&#xF3; cu&#xE1;ntos se examinaron. A partir de solo 35 casos de c&#xE1;ncer de mama infiltrantes (en comparaci&#xF3;n con 288 episodios cardiovasculares importantes), las tasas respectivas de c&#xE1;ncer de mama fueron 8 de 1476 (0,54&#xA0;%); 10 de 1285 (0,78&#xA0;%) y 17 de 1391 (1,22&#xA0;%) con seguimiento promedio de 4,8, 4,3 y 4,2 a&#xF1;os. Las circunstancias en las que se realiz&#xF3; el estudio hacen dif&#xED;cil determinar la significaci&#xF3;n estad&#xED;stica de estas diferencias.</p></section><section id="_739"><h4 id="_739_toc">Vitaminas</h4><p id="_740" tabindex="-1">En ensayos cl&#xED;nicos se analiz&#xF3; la posible funci&#xF3;n de micronutrientes espec&#xED;ficos en la reducci&#xF3;n del riesgo de c&#xE1;ncer de mama, con la enfermedad cardiovascular y el c&#xE1;ncer como desenlaces. En el Women&#x2019;s Health Study, un ensayo aleatorizado con 39&#xA0;876 mujeres, no se encontr&#xF3; ninguna diferencia en la incidencia del c&#xE1;ncer de mama a los 2 a&#xF1;os en las mujeres asignadas a betacaroteno o placebo.[<a href="#cit/section_3.157">157</a>] En este mismo estudio, no se observ&#xF3; ning&#xFA;n efecto general en el c&#xE1;ncer en las mujeres que tomaban 600 UI de vitamina E en d&#xED;as alternos.[<a href="#cit/section_3.158">158</a>] En el Women&#x2019;s Antioxidant Cardiovascular Study, se examin&#xF3; a 8171 mujeres para determinar la incidencia del c&#xE1;ncer total y el c&#xE1;ncer de mama invasivo, y no se encontr&#xF3; ning&#xFA;n efecto con vitamina C, vitamina E o betacaroteno.[<a href="#cit/section_3.159">159</a>] Dos a&#xF1;os  despu&#xE9;s, un subconjunto de 5442 mujeres se asignaron al azar para tomar 1,5 mg de &#xE1;cido f&#xF3;lico, 50 mg de vitamina B6 y 1 mg de B12 o un placebo. Tras 7,3 a&#xF1;os, no hubo diferencia en la incidencia del c&#xE1;ncer invasivo total o del c&#xE1;ncer de mama invasivo.[<a href="#cit/section_3.160">160</a>]</p><p id="_741" tabindex="-1">La fenretinida [<a href="#cit/section_3.161">161</a>] es un an&#xE1;logo de la vitamina A que mostr&#xF3; reducir la carcinogenia mamaria en estudios precl&#xED;nicos. En un ensayo italiano de fase III, se compar&#xF3; la eficacia de una intervenci&#xF3;n de 5 a&#xF1;os con fenretinida  versus la ausencia de tratamiento en 2972 mujeres de 30  a 70 a&#xF1;os, con c&#xE1;ncer de mama en estadio I o CDIS extra&#xED;do quir&#xFA;rgicamente. En el momento de una mediana de observaci&#xF3;n de 97 meses, no hubo diferencias estad&#xED;sticamente significativas en la presentaci&#xF3;n de c&#xE1;ncer de mama contralateral  (<em>P</em> = 0,642), c&#xE1;ncer de mama ipsilateral (<em>P </em>= 0,177), incidencia de met&#xE1;stasis a distancia, neoplasias malignas que no eran mamarias y mortalidad por todas las causas.[<a href="#cit/section_3.162">162</a>]</p></section><section id="_324"><h4 id="_324_toc">Tabaquismo activo y pasivo</h4><p id="_326" tabindex="-1">Por m&#xE1;s de 30 a&#xF1;os, se ha estudiado la posible funci&#xF3;n del tabaquismo activo en la etiolog&#xED;a del c&#xE1;ncer de mama sin pruebas definidas que establezcan una relaci&#xF3;n.[<a href="#cit/section_3.163">163</a>] A partir de mediados de la d&#xE9;cada de 1990, los estudios del consumo de cigarrillo y el c&#xE1;ncer de mama han considerado m&#xE1;s cuidadosamente la exposici&#xF3;n pasiva al humo de tabaco.[<a href="#cit/section_3.163">163</a>,<a href="#cit/section_3.164">164</a>]   En un metan&#xE1;lisis reciente, se indica que no hay una relaci&#xF3;n general entre la exposici&#xF3;n pasiva al humo del tabaco y el c&#xE1;ncer de mama, y que la metodolog&#xED;a del estudio (determinaci&#xF3;n de la exposici&#xF3;n tras el diagn&#xF3;stico de c&#xE1;ncer de mama) puede ser responsable de las aparentes relaciones de riesgo que se observan en algunos estudios.[<a href="#cit/section_3.165">165</a>]</p></section><section id="_695"><h4 id="_695_toc">Desodorantes o antitraspirantes para las axilas</h4><p id="_696" tabindex="-1">A pesar de que las  publicaciones escritas por personas sin entrenamiento profesional   advierten a las mujeres que usar desodorantes  o antitraspirantes para las axilas causa c&#xE1;ncer de mama, no hay pruebas que respalden esta inquietud. En un estudio en el que se entrevistaron a 813 mujeres con c&#xE1;ncer de mama y 793 controles, no se encontr&#xF3; ninguna relaci&#xF3;n entre el riesgo de c&#xE1;ncer de mama y el uso de antitraspirantes, desodorantes o cuchillas de afeitar antes de aplicar estos productos.[<a href="#cit/section_3.166">166</a>]   Por el contrario, en un estudio de 437 sobrevivientes de c&#xE1;ncer de mama, se encontr&#xF3; que a las mujeres que usaban antitraspirantes o desodorantes y que se afeitaban las axilas con mayor frecuencia se les diagnostic&#xF3; c&#xE1;ncer a una edad significativamente m&#xE1;s temprana. Una posible explicaci&#xF3;n de este hallazgo es que estas mujeres presentaron una menarquia m&#xE1;s temprana o concentraciones m&#xE1;s elevadas de hormonas end&#xF3;genas, ambas conocidas como factores de riesgo de c&#xE1;ncer de mama y estimulantes del crecimiento del vello corporal.[<a href="#cit/section_3.167">167</a>]</p></section><section id="_301"><h4 id="_301_toc">Estatinas</h4><p id="_302" tabindex="-1">En dos metan&#xE1;lisis bien realizados de ECA  [<a href="#cit/section_3.168">168</a>] y de ECA con estudios de observaci&#xF3;n,[<a href="#cit/section_3.169">169</a>] no se encontraron pruebas de que el uso de estatinas aumente o reduzca el riesgo de c&#xE1;ncer de mama.</p></section><section id="_663"><h4 id="_663_toc">Bisfosfonatos</h4><p id="_664" tabindex="-1">  Los bisfosfonatos orales e intravenosos se han estudiado para el tratamiento de la hipercalcemia y la osteoporosis por un posible efecto beneficioso en la prevenci&#xF3;n del c&#xE1;ncer de mama. Los estudios de observaci&#xF3;n iniciales indicaron que las mujeres que usaron estos f&#xE1;rmacos por per&#xED;odos de aproximadamente 1 a 4 a&#xF1;os tuvieron una incidencia m&#xE1;s baja de c&#xE1;ncer de mama.[<a href="#cit/section_3.170">170</a>-<a href="#cit/section_3.173">173</a>] Estas observaciones son confusas por el hecho de que las mujeres con osteoporosis tienen un riesgo m&#xE1;s bajo de c&#xE1;ncer de mama que aquellas con densidad &#xF3;sea normal. Hay pruebas adicionales que provienen de estudios de mujeres diagnosticadas con c&#xE1;ncer de mama; el uso de estos f&#xE1;rmacos se relacion&#xF3; con menos c&#xE1;nceres contralaterales nuevos.[<a href="#cit/section_3.174">174</a>]   Con este antecedente, se realizaron dos ensayos grandes aleatorizados controlados con placebo. En el Fracture Intervention Trial (FIT), se trat&#xF3; a 6194 mujeres osteop&#xE9;nicas posmenop&#xE1;usicas con alendronato o un placebo y no se encontr&#xF3; diferencia en la incidencia de c&#xE1;ncer de mama a los 3,8 a&#xF1;os, con una incidencia de 1,8 a 1,5, respectivamente (CRI, 1,24; IC, 0,84&#x2013;1,83).  En el Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly-Pivotal Fracture Trial (HORIZON-PRT), se examin&#xF3; a 7580 mujeres osteopor&#xF3;ticas posmenop&#xE1;usicas con zolendronato intravenoso o un placebo, y no se encontr&#xF3; diferencia en la incidencia de c&#xE1;ncer de mama a los 2,8 a&#xF1;os, con incidencia de 0,8 y 0,9&#xA0;%, respectivamente (CRI, 1,15; IC, 0,7&#x2013;1,89).[<a href="#cit/section_3.175">175</a>]</p></section><section id="_780"><h4 id="_780_toc">Trabajo en turnos nocturnos</h4><p id="_781" tabindex="-1">En 2007, el Centro Internacional de Investigaciones sobre el C&#xE1;ncer (CIIC) de la Organizaci&#xF3;n Mundial de la Salud clasific&#xF3; el trabajo en turnos que implica alteraci&#xF3;n del ritmo circadiano como posible carcin&#xF3;geno de la mama. Los datos probatorios principales se obtuvieron de estudios con animales. En ese momento los datos probatorios de seres humanos eran pocos.[<a href="#cit/section_3.176">176</a>] En 2013, en un metan&#xE1;lisis de 15 estudios epidemiol&#xF3;gicos se concluy&#xF3; que hab&#xED;an datos probatorios deficientes   sobre aumento de la incidencia de c&#xE1;ncer de mama en las mujeres  que en alg&#xFA;n momento trabajaron en turnos nocturnos.[<a href="#cit/section_3.177">177</a>] En 2016, se combinaron los resultados de 3 estudios prospectivos recientes del Reino Unido, con participaci&#xF3;n de casi  800&#xA0;000 mujeres, con los resultados de 7 estudios prospectivos adicionales y se observ&#xF3; que no hay datos probatorios de relaci&#xF3;n entre la incidencia de c&#xE1;ncer de mama y el trabajo en turnos nocturnos. En especial, los intervalos de confianza  del cociente de tasas de incidencia fueron estrechos, incluso para 20 a&#xF1;os o m&#xE1;s de trabajo en turnos nocturnos (cociente de tasas, 1,01; IC 95&#xA0;%, 0,93&#x2013;1,10). A partir de estos resultados se excluye una relaci&#xF3;n moderada entre la incidencia de c&#xE1;ncer de mama y una duraci&#xF3;n prolongada del trabajo en turnos nocturnos.[<a href="#cit/section_3.178">178</a>]</p></section></section><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_3.1">American Cancer Society: Cancer Facts and Figures 2018. Atlanta, Ga: American Cancer Society, 2018. <a href="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf" title="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf">Available online</a>. Last accessed August 3, 2018.</li><li id="section_3.2">Howlader N, Noone AM, Krapcho M, et al., eds.: SEER Cancer Statistics Review, 1975-2012. Bethesda, Md: National Cancer Institute, 2015. <a href="http://seer.cancer.gov/csr/1975_2012/" title="http://seer.cancer.gov/csr/1975_2012/">Also available online</a>. Last accessed August 13, 2018.</li><li id="section_3.3">American Cancer Society: Cancer Facts and Figures 2017. Atlanta, Ga: American Cancer Society, 2017. <a href="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf" title="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf">Available online</a>. Last accessed August 13, 2018.</li><li id="section_3.4">Altekruse SF, Kosary CL, Krapcho M, et al.: SEER Cancer Statistics Review, 1975-2007. Bethesda, Md: National Cancer Institute, 2010. <a href="http://seer.cancer.gov/archive/csr/1975_2007/" title="http://seer.cancer.gov/archive/csr/1975_2007/">Also available online</a>.    Last accessed August 13, 2018.</li><li id="section_3.5">Pfeiffer RM, Mitani A, Matsuno RK, et al.: Racial differences in breast cancer trends in the United States (2000-2004). J Natl Cancer Inst 100 (10): 751-2, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18477805&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18477805&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.6">Boone CW, Kelloff GJ, Freedman LS: Intraepithelial and postinvasive neoplasia as a stochastic continuum of clonal evolution, and its relationship to mechanisms of chemopreventive drug action. J Cell Biochem Suppl 17G: 14-25, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8007692&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8007692&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.7">Kelloff GJ, Boone CW, Steele VE, et al.: Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials. Cancer Res 54 (7 Suppl): 2015s-2024s, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8137331&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8137331&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.8">Knabbe C, Lippman ME, Wakefield LM, et al.: Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48 (3): 417-28, 1987.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2879636&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2879636&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.9">Parkin DM: Cancers of the breast, endometrium and ovary: geographic correlations. Eur J Cancer Clin Oncol 25 (12): 1917-25, 1989.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2698807&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2698807&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.10">Dunn JE Jr: Breast cancer among American Japanese in the San Francisco Bay area. Natl Cancer Inst Monogr 47: 157-60, 1977.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=613235&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=613235&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.11">Kliewer EV, Smith KR: Breast cancer mortality among immigrants in Australia and Canada. J Natl Cancer Inst 87 (15): 1154-61, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7674320&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7674320&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.12">Brinton LA, Schairer C, Hoover RN, et al.: Menstrual factors and risk of breast cancer. Cancer Invest 6 (3): 245-54, 1988.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3167610&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3167610&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.13">Collaborative Group on Hormonal Factors in Breast Cancer: Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol 13 (11): 1141-51, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23084519&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23084519&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.14">Ritte R, Lukanova A, Tj&#xF8;nneland A, et al.: Height, age at menarche and risk of hormone receptor-positive and -negative breast cancer: a cohort study. Int J Cancer 132 (11): 2619-29, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23090881&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23090881&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.15">Endogenous Hormones and Breast Cancer Collaborative Group: Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94 (8): 606-16, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11959894&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11959894&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.16">Key TJ, Appleby PN, Reeves GK, et al.: Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer 105 (5): 709-22, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21772329&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21772329&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.17">Kaaks R, Rinaldi S, Key TJ, et al.: Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer 12 (4): 1071-82, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16322344&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16322344&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.18">Kaaks R, Berrino F, Key T, et al.: Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 97 (10): 755-65, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15900045&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15900045&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.19">Smith PG, Doll R: Late effects of x irradiation in patients treated for metropathia haemorrhagica. Br J Radiol 49 (579): 224-32, 1976.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1276589&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1276589&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.20">Trichopoulos D, MacMahon B, Cole P: Menopause and breast cancer risk. J Natl Cancer Inst 48 (3): 605-13, 1972.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5058966&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5058966&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.21">Feinleib M: Breast cancer and artificial menopause: a cohort study. J Natl Cancer Inst 41 (2): 315-29, 1968.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5671283&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5671283&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.22">Kampert JB, Whittemore AS, Paffenbarger RS Jr: Combined effect of childbearing, menstrual events, and body size on age-specific breast cancer risk. Am J Epidemiol 128 (5): 962-79, 1988.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3189296&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3189296&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.23">Hirayama T, Wynder EL: A study of the epidemiology of cancer of the breast. II. The influence of hysterectomy. Cancer 15: 28-38, 1962 Jan-Feb.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=13907646&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=13907646&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.24">Colditz GA, Kaphingst KA, Hankinson SE, et al.: Family history and risk of breast cancer: nurses' health study. Breast Cancer Res Treat 133 (3): 1097-104, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22350789&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22350789&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.25">Miki Y, Swensen J, Shattuck-Eidens D, et al.: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266 (5182): 66-71, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7545954&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7545954&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.26">Futreal PA, Liu Q, Shattuck-Eidens D, et al.: BRCA1 mutations in primary breast and ovarian carcinomas. Science 266 (5182): 120-2, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7939630&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7939630&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.27">Wooster R, Neuhausen SL, Mangion J, et al.: Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265 (5181): 2088-90, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8091231&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8091231&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.28">Kuchenbaecker KB, Hopper JL, Barnes DR, et al.: Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA 317 (23): 2402-2416, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28632866&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28632866&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.29">Antoniou A, Pharoah PD, Narod S, et al.: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72 (5): 1117-30, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12677558&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12677558&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.30">Chen S, Parmigiani G: Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25 (11): 1329-33, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17416853&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17416853&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.31">National Cancer Institute: SEER Stat Fact Sheets: Female Breast Cancer. Bethesda, MD: National Cancer Institute. <a href="https://seer.cancer.gov/statfacts/html/breast.html" title="https://seer.cancer.gov/statfacts/html/breast.html">Available online</a>. Last accessed August 13, 2018.</li><li id="section_3.32">Swift M, Morrell D, Massey RB, et al.: Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 325 (26): 1831-6, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1961222&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1961222&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.33">Cybulski C, Woko&#x142;orczyk D, Jakubowska A, et al.: Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol 29 (28): 3747-52, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21876083&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21876083&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.34">Boyd NF, Guo H, Martin LJ, et al.: Mammographic density and the risk and detection of breast cancer. N Engl J Med 356 (3): 227-36, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17229950&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17229950&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.35">Razzaghi H, Troester MA, Gierach GL, et al.: Mammographic density and breast cancer risk in White and African American Women. Breast Cancer Res Treat 135 (2): 571-80, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22864770&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22864770&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.36">McCormack VA, dos Santos Silva I: Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15 (6): 1159-69, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16775176&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16775176&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.37">Gierach GL, Ichikawa L, Kerlikowske K, et al.: Relationship between mammographic density and breast cancer death in the Breast Cancer Surveillance Consortium. J Natl Cancer Inst 104 (16): 1218-27, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22911616&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22911616&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.38">Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 350 (9084): 1047-59, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10213546&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10213546&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.39">Hulley S, Furberg C, Barrett-Connor E, et al.: Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288 (1): 58-66, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12090863&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12090863&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.40">Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288 (3): 321-33, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12117397&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12117397&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.41">Chlebowski RT, Anderson GL, Gass M, et al.: Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304 (15): 1684-92, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20959578&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20959578&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.42">Chlebowski RT, Hendrix SL, Langer RD, et al.: Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289 (24): 3243-53, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12824205&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12824205&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.43">Chlebowski RT, Manson JE, Anderson GL, et al.: Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. J Natl Cancer Inst 105 (8): 526-35, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23543779&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23543779&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.44">Anderson GL, Limacher M, Assaf AR, et al.: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291 (14): 1701-12, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15082697&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15082697&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.45">LaCroix AZ, Chlebowski RT, Manson JE, et al.: Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 305 (13): 1305-14, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21467283&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21467283&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.46">Anderson GL, Chlebowski RT, Aragaki AK, et al.: Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol 13 (5): 476-86, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22401913&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22401913&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.47">Schierbeck LL, Rejnmark L, Tofteng CL, et al.: Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 345: e6409, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23048011&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23048011&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.48">Beral V, Reeves G, Bull D, et al.: Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst 103 (4): 296-305, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21278356&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21278356&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.49">Li CI, Malone KE, Porter PL, et al.: Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289 (24): 3254-63, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12824206&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12824206&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.50">Chlebowski RT, Anderson GL: The influence of time from menopause and mammography on hormone therapy-related breast cancer risk assessment. J Natl Cancer Inst 103 (4): 284-5, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21278357&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21278357&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.51">Prentice RL, Chlebowski RT, Stefanick ML, et al.: Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol 167 (12): 1407-15, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18448442&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18448442&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.52">Chlebowski RT, Kuller LH, Prentice RL, et al.: Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 360 (6): 573-87, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19196674&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19196674&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.53">Cronin KA, Ravdin PM, Edwards BK: Sustained lower rates of breast cancer in the United States. Breast Cancer Res Treat 117 (1): 223-4, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18979196&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18979196&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.54">Ravdin PM, Cronin KA, Howlader N, et al.: The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356 (16): 1670-4, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17442911&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17442911&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.55">Parkin DM: Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy? Eur J Cancer 45 (9): 1649-53, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19217279&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19217279&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.56">Lambe M, Wigertz A, Holmqvist M, et al.: Reductions in use of hormone replacement therapy: effects on Swedish breast cancer incidence trends only seen after several years. Breast Cancer Res Treat 121 (3): 679-83, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19894110&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19894110&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.57">Renard F, Vankrunkelsven P, Van Eycken L, et al.: Decline in breast cancer incidence in the Flemish region of Belgium after a decline in hormonal replacement therapy. Ann Oncol 21 (12): 2356-60, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20439342&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20439342&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.58">Farhat GN, Walker R, Buist DS, et al.: Changes in invasive breast cancer and ductal carcinoma in situ rates in relation to the decline in hormone therapy use. J Clin Oncol 28 (35): 5140-6, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21060026&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21060026&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.59">DeSantis C, Howlader N, Cronin KA, et al.: Breast cancer incidence rates in U.S. women are no longer declining. Cancer Epidemiol Biomarkers Prev 20 (5): 733-9, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21357727&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21357727&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.60">John EM, Kelsey JL: Radiation and other environmental exposures and breast cancer. Epidemiol Rev 15 (1): 157-62, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8405198&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8405198&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.61">Evans JS, Wennberg JE, McNeil BJ: The influence of diagnostic radiography on the incidence of breast cancer and leukemia. N Engl J Med 315 (13): 810-5, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3748092&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3748092&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.62">Andrieu N, Easton DF, Chang-Claude J, et al.: Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group. J Clin Oncol 24 (21): 3361-6, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16801631&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16801631&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.63">Bhatia S, Robison LL, Oberlin O, et al.: Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 334 (12): 745-51, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8592547&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8592547&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.64">Hancock SL, Tucker MA, Hoppe RT: Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 85 (1): 25-31, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8416252&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8416252&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.65">Travis LB, Hill DA, Dores GM, et al.: Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 290 (4): 465-75, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12876089&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12876089&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.66">Sankila R, Garwicz S, Olsen JH, et al.: Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. Association of the Nordic Cancer Registries and the Nordic Society of Pediatric Hematology and Oncology. J Clin Oncol 14 (5): 1442-6, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8622057&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8622057&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.67">van Leeuwen FE, Klokman WJ, Stovall M, et al.: Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 95 (13): 971-80, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12837833&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12837833&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.68">Obedian E, Fischer DB, Haffty BG: Second malignancies after treatment of early-stage breast cancer: lumpectomy and radiation therapy versus mastectomy. J Clin Oncol 18 (12): 2406-12, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10856100&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10856100&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.69">Fisher B, Anderson S, Bryant J, et al.: Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347 (16): 1233-41, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12393820&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12393820&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.70">Veronesi U, Cascinelli N, Mariani L, et al.: Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347 (16): 1227-32, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12393819&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12393819&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.71">Fisher B, Jeong JH, Anderson S, et al.: Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 347 (8): 567-75, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12192016&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12192016&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.72">Morimoto LM, White E, Chen Z, et al.: Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control 13 (8): 741-51, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12420953&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12420953&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.73">Wolin KY, Carson K, Colditz GA: Obesity and cancer. Oncologist 15 (6): 556-65, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20507889&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20507889&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.74">Lawlor DA, Smith GD, Ebrahim S: Hyperinsulinaemia and increased risk of breast cancer: findings from the British Women's Heart and Health Study. Cancer Causes Control 15 (3): 267-75, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15090721&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15090721&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.75">Hamajima N, Hirose K, Tajima K, et al.: Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer 87 (11): 1234-45, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12439712&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12439712&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.76">Pike MC, Krailo MD, Henderson BE, et al.: 'Hormonal' risk factors, 'breast tissue age' and the age-incidence of breast cancer. Nature 303 (5920): 767-70, 1983.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6866078&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6866078&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.77">Lambe M, Hsieh C, Trichopoulos D, et al.: Transient increase in the risk of breast cancer after giving birth. N Engl J Med 331 (1): 5-9, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8202106&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8202106&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.78">Henderson BE, Pike MC, Ross RK, et al.: Epidemiology and risk factors. In: Bonadonna G, ed.: Breast Cancer: Diagnosis and Management. Chichester, NY: John Wiley &amp; Sons, 1984, pp 15-33.</li><li id="section_3.79">Gail MH, Brinton LA, Byar DP, et al.: Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81 (24): 1879-86, 1989.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2593165&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2593165&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.80">Col: Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 360 (9328): 187-95, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12133652&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12133652&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.81">Furberg H, Newman B, Moorman P, et al.: Lactation and breast cancer risk. Int J Epidemiol 28 (3): 396-402, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10405840&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10405840&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.82">Bernstein L, Henderson BE, Hanisch R, et al.: Physical exercise and reduced risk of breast cancer in young women. J Natl Cancer Inst 86 (18): 1403-8, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8072034&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8072034&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.83">Friedenreich CM: Physical activity and cancer prevention: from observational to intervention research. Cancer Epidemiol Biomarkers Prev 10 (4): 287-301, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11319168&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11319168&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.84">Thune I, Brenn T, Lund E, et al.: Physical activity and the risk of breast cancer. N Engl J Med 336 (18): 1269-75, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9113929&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9113929&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.85">Adams-Campbell LL, Rosenberg L, Rao RS, et al.: Strenuous physical activity and breast cancer risk in African-American women. J Natl Med Assoc 93 (7-8): 267-75, 2001 Jul-Aug.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11491277&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11491277&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.86">Nayfield SG, Karp JE, Ford LG, et al.: Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 83 (20): 1450-9, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1920492&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1920492&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.87">Love RR, Barden HS, Mazess RB, et al.: Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 154 (22): 2585-8, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7979855&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7979855&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.88">Powles TJ, Hickish T, Kanis JA, et al.: Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14 (1): 78-84, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8558225&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8558225&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.89">Costantino JP, Kuller LH, Ives DG, et al.: Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst 89 (11): 776-82, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9182975&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9182975&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.90">McDonald CC, Stewart HJ: Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ 303 (6800): 435-7, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1912833&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1912833&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.91">Rutqvist LE, Mattsson A: Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 85 (17): 1398-406, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8350363&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8350363&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.92">Fisher B, Costantino JP, Redmond CK, et al.: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86 (7): 527-37, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8133536&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8133536&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.93">Bergman L, Beelen ML, Gallee MP, et al.: Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet 356 (9233): 881-7, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11036892&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11036892&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.94">Cuzick J, Powles T, Veronesi U, et al.: Overview of the main outcomes in breast-cancer prevention trials. Lancet 361 (9354): 296-300, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12559863&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12559863&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.95">Redmond CK, Wickerham DL, Cronin W, et al.: The NSABP breast cancer prevention trial (BCPT): a progress report. [Abstract] Proceedings of the American Society of Clinical Oncology  12: A-78, 69, 1993.</li><li id="section_3.96">Fisher B, Costantino JP, Wickerham DL, et al.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 (18): 1371-88, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9747868&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9747868&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.97">Fisher B, Costantino JP, Wickerham DL, et al.: Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97 (22): 1652-62, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16288118&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16288118&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.98">Powles T, Eeles R, Ashley S, et al.: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352 (9122): 98-101, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9672274&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9672274&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.99">Veronesi U, Maisonneuve P, Costa A, et al.: Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 352 (9122): 93-7, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9672273&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9672273&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.100">Cuzick J, Forbes J, Edwards R, et al.: First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360 (9336): 817-24, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12243915&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12243915&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.101">Powles TJ, Ashley S, Tidy A, et al.: Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99 (4): 283-90, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17312305&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17312305&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.102">Veronesi U, Maisonneuve P, Rotmensz N, et al.: Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 99 (9): 727-37, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17470740&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17470740&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.103">Martino S, Costantino J, McNabb M, et al.: The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials. Oncologist 9 (2): 116-25, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15047916&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15047916&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.104">Cuzick J, Forbes JF, Sestak I, et al.: Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99 (4): 272-82, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17312304&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17312304&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.105">Fisher B, Dignam J, Wolmark N, et al.: Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353 (9169): 1993-2000, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10376613&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10376613&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.106">Khovidhunkit W, Shoback DM: Clinical effects of raloxifene hydrochloride in women. Ann Intern Med 130 (5): 431-9, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10068418&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10068418&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.107">Cauley JA, Norton L, Lippman ME, et al.: Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65 (2): 125-34, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11261828&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11261828&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.108">Cummings SR, Eckert S, Krueger KA, et al.: The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281 (23): 2189-97, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10376571&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10376571&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.109">Martino S, Cauley JA, Barrett-Connor E, et al.: Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96 (23): 1751-61, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15572757&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15572757&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.110">Grady D, Cauley JA, Geiger MJ, et al.: Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk. J Natl Cancer Inst 100 (12): 854-61, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18544744&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18544744&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.111">Vogel VG, Costantino JP, Wickerham DL, et al.: Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295 (23): 2727-41, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16754727&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16754727&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.112">Land SR, Wickerham DL, Costantino JP, et al.: Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295 (23): 2742-51, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16754728&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16754728&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.113">The ATAC Trialists' Group. Arimidex, tamoxifen alone or in combination: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 (9324): 2131-9, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12090977&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12090977&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.114">Goss PE, Ingle JN, Martino S, et al.: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349 (19): 1793-802, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14551341&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14551341&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.115">Goss PE, Ingle JN, Pritchard KI, et al.: Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. N Engl J Med 375 (3): 209-19, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27264120&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27264120&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.116">Coombes RC, Hall E, Gibson LJ, et al.: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 (11): 1081-92, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15014181&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15014181&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.117">Goss PE, Ingle JN, Al&#xE9;s-Mart&#xED;nez JE, et al.: Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364 (25): 2381-91, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21639806&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21639806&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.118">Cuzick J, Sestak I, Forbes JF, et al.: Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 383 (9922): 1041-8, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24333009&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24333009&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.119">Hartmann LC, Schaid DJ, Woods JE, et al.: Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340 (2): 77-84, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9887158&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9887158&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.120">Kummerow KL, Du L, Penson DF, et al.: Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg 150 (1): 9-16, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25408966&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25408966&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.121">Rebbeck TR, Levin AM, Eisen A, et al.: Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91 (17): 1475-9, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10469748&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10469748&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.122">Kauff ND, Satagopan JM, Robson ME, et al.: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346 (21): 1609-15, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12023992&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12023992&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.123">Rebbeck TR, Lynch HT, Neuhausen SL, et al.: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346 (21): 1616-22, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12023993&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12023993&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.124">Kauff ND, Domchek SM, Friebel TM, et al.: Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 26 (8): 1331-7, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18268356&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18268356&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.125">Breast cancer and hormonal contraceptives: further results. Collaborative Group on Hormonal Factors in Breast Cancer. Contraception 54 (3 Suppl): 1S-106S, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8899264&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8899264&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.126">Marchbanks PA, McDonald JA, Wilson HG, et al.: Oral contraceptives and the risk of breast cancer. N Engl J Med 346 (26): 2025-32, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12087137&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12087137&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.127">Strom BL, Berlin JA, Weber AL, et al.: Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer. Contraception 69 (5): 353-60, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15105056&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15105056&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.128">M&#xF8;rch LS, Skovlund CW, Hannaford PC, et al.: Contemporary Hormonal Contraception and the Risk of Breast Cancer. N Engl J Med 377 (23): 2228-2239, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=29211679&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=29211679&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.129">Wolff MS, Toniolo PG, Lee EW, et al.: Blood levels of organochlorine residues and risk of breast cancer. J Natl Cancer Inst 85 (8): 648-52, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8468722&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8468722&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.130">H&#xF8;yer AP, Grandjean P, J&#xF8;rgensen T, et al.: Organochlorine exposure and risk of breast cancer. Lancet 352 (9143): 1816-20, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9851382&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9851382&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.131">Shames LS, Munekata MT, Pike MC: Re: Blood levels of organochlorine residues and risk of breast cancer. J Natl Cancer Inst 86 (21): 1642-3, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7802816&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7802816&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.132">Krieger N, Wolff MS, Hiatt RA, et al.: Breast cancer and serum organochlorines: a prospective study among white, black, and Asian women. J Natl Cancer Inst 86 (8): 589-99, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8145274&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8145274&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.133">Hunter DJ, Hankinson SE, Laden F, et al.: Plasma organochlorine levels and the risk of breast cancer. N Engl J Med 337 (18): 1253-8, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9345073&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9345073&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.134">Laden F, Collman G, Iwamoto K, et al.: 1,1-Dichloro-2,2-bis(p-chlorophenyl)ethylene and polychlorinated biphenyls and breast cancer: combined analysis of five U.S. studies. J Natl Cancer Inst 93 (10): 768-76, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11353787&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11353787&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.135">Ward EM, Schulte P, Grajewski B, et al.: Serum organochlorine levels and breast cancer: a nested case-control study of Norwegian women. Cancer Epidemiol Biomarkers Prev 9 (12): 1357-67, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11142422&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11142422&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.136">Laden F, Hankinson SE, Wolff MS, et al.: Plasma organochlorine levels and the risk of breast cancer: an extended follow-up in the Nurses' Health Study. Int J Cancer 91 (4): 568-74, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11251983&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11251983&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.137">Huang Y, Zhang X, Li W, et al.: A meta-analysis of the association between induced abortion and breast cancer risk among Chinese females. Cancer Causes Control 25 (2): 227-36, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24272196&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24272196&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.138">Sanderson M, Shu XO, Jin F, et al.: Abortion history and breast cancer risk: results from the Shanghai Breast Cancer Study. Int J Cancer 92 (6): 899-905, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11351314&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11351314&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.139">Beral V, Bull D, Doll R, et al.: Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83,000 women with breast cancer from 16 countries. Lancet 363 (9414): 1007-16, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15051280&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15051280&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.140">Melbye M, Wohlfahrt J, Olsen JH, et al.: Induced abortion and the risk of breast cancer. N Engl J Med 336 (2): 81-5, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8988884&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8988884&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.141">Rookus MA, van Leeuwen FE: Induced abortion and risk for breast cancer: reporting (recall) bias in a Dutch case-control study. J Natl Cancer Inst 88 (23): 1759-64, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8944006&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8944006&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.142">Committee on Gynecologic Practice: ACOG Committee Opinion No. 434: induced abortion and breast cancer risk. Obstet Gynecol 113 (6): 1417-8, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19461458&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19461458&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.143">Henderson KD, Sullivan-Halley J, Reynolds P, et al.: Incomplete pregnancy is not associated with breast cancer risk: the California Teachers Study. Contraception 77 (6): 391-6, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18477486&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18477486&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.144">Lash TL, Fink AK: Null association between pregnancy termination and breast cancer in a registry-based study of parous women. Int J Cancer 110 (3): 443-8, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15095312&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15095312&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.145">Michels KB, Xue F, Colditz GA, et al.: Induced and spontaneous abortion and incidence of breast cancer among young women: a prospective cohort study. Arch Intern Med 167 (8): 814-20, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17452545&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17452545&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.146">Wu JQ, Li YY, Ren JC, et al.: Induced abortion and breast cancer: results from a population-based case control study in China. Asian Pac J Cancer Prev 15 (8): 3635-40, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24870770&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24870770&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.147">Bra&#xFC;ner CM, Overvad K, Tj&#xF8;nneland A, et al.: Induced abortion and breast cancer among parous women: a Danish cohort study. Acta Obstet Gynecol Scand 92 (6): 700-5, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23402419&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23402419&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.148">Guo J, Huang Y, Yang L, et al.: Association between abortion and breast cancer: an updated systematic review and meta-analysis based on prospective studies. Cancer Causes Control 26 (6): 811-9, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25779378&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25779378&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.149">Carroll KK, Khor HT: Dietary fat in relation to tumorigenesis. Prog Biochem Pharmacol 10: 308-53, 1975.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=165553&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=165553&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.150">Hunter DJ, Spiegelman D, Adami HO, et al.: Cohort studies of fat intake and the risk of breast cancer--a pooled analysis. N Engl J Med 334 (6): 356-61, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8538706&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8538706&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.151">Prentice RL, Caan B, Chlebowski RT, et al.: Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 295 (6): 629-42, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16467232&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16467232&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.152">Howard BV, Van Horn L, Hsia J, et al.: Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 295 (6): 655-66, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16467234&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16467234&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.153">Smith-Warner SA, Spiegelman D, Yaun SS, et al.: Intake of fruits and vegetables and risk of breast cancer: a pooled analysis of cohort studies. JAMA 285 (6): 769-76, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11176915&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11176915&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.154">Pierce JP, Natarajan L, Caan BJ, et al.: Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. JAMA 298 (3): 289-98, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17635889&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17635889&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.155">Toledo E, Salas-Salvad&#xF3; J, Donat-Vargas C, et al.: Mediterranean Diet and Invasive Breast Cancer Risk Among Women at High Cardiovascular Risk in the PREDIMED Trial: A Randomized Clinical Trial. JAMA Intern Med 175 (11): 1752-60, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26365989&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26365989&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.156">Estruch R, Ros E, Salas-Salvad&#xF3; J, et al.: Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 368 (14): 1279-90, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23432189&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23432189&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.157">Lee IM, Cook NR, Manson JE, et al.: Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study. J Natl Cancer Inst 91 (24): 2102-6, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10601381&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10601381&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.158">Lee IM, Cook NR, Gaziano JM, et al.: Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA 294 (1): 56-65, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15998891&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15998891&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.159">Lin J, Cook NR, Albert C, et al.: Vitamins C and E and beta carotene supplementation and cancer risk: a randomized controlled trial. J Natl Cancer Inst 101 (1): 14-23, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19116389&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19116389&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.160">Zhang SM, Cook NR, Albert CM, et al.: Effect of combined folic acid, vitamin B6, and vitamin B12 on cancer risk in women: a randomized trial. JAMA 300 (17): 2012-21, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18984888&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18984888&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.161">Costa A, Formelli F, Chiesa F, et al.: Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res 54 (7 Suppl): 2032s-2037s, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8137334&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8137334&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.162">Veronesi U, De Palo G, Marubini E, et al.: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 91 (21): 1847-56, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10547391&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10547391&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.163">The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, Ga: U.S. Department of Health and Human Services, CDC, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2004. <a href="https://www.cdc.gov/tobacco/data_statistics/sgr/2004/index.htm" title="https://www.cdc.gov/tobacco/data_statistics/sgr/2004/index.htm">Also available online</a>.                Last accessed August 13, 2018.</li><li id="section_3.164">U.S. Department of Health and Human Services: The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. Atlanta, Ga: U.S. Department of Health and Human Services, Centers for Disease Control and
            Prevention, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2006. <a href="https://www.ncbi.nlm.nih.gov/books/NBK44324/" title="https://www.ncbi.nlm.nih.gov/books/NBK44324/">Also available online</a>.                       Last accessed   August 13, 2018.</li><li id="section_3.165">Pirie K, Beral V, Peto R, et al.: Passive smoking and breast cancer in never smokers: prospective study and meta-analysis. Int J Epidemiol 37 (5): 1069-79, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18544575&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18544575&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.166">Mirick DK, Davis S, Thomas DB: Antiperspirant use and the risk of breast cancer. J Natl Cancer Inst 94 (20): 1578-80, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12381712&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12381712&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.167">McGrath KG: An earlier age of breast cancer diagnosis related to more frequent use of antiperspirants/deodorants and underarm shaving. Eur J Cancer Prev 12 (6): 479-85, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14639125&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14639125&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.168">Dale KM, Coleman CI, Henyan NN, et al.: Statins and cancer risk: a meta-analysis. JAMA 295 (1): 74-80, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16391219&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16391219&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.169">Bonovas S, Filioussi K, Tsavaris N, et al.: Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 23 (34): 8606-12, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16260694&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16260694&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.170">Newcomb PA, Trentham-Dietz A, Hampton JM: Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer 102 (5): 799-802, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20160722&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20160722&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.171">Rennert G, Pinchev M, Rennert HS: Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 28 (22): 3577-81, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20567021&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20567021&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.172">Chlebowski RT, Chen Z, Cauley JA, et al.: Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 28 (22): 3582-90, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20567009&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20567009&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.173">Cardwell CR, Abnet CC, Veal P, et al.: Exposure to oral bisphosphonates and risk of cancer. Int J Cancer 131 (5): E717-25, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22161552&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22161552&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.174">Monsees GM, Malone KE, Tang MT, et al.: Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancer. J Natl Cancer Inst 103 (23): 1752-60, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22021667&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22021667&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.175">Hue TF, Cummings SR, Cauley JA, et al.: Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid. JAMA Intern Med 174 (10): 1550-7, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25111880&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25111880&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.176">Straif K, Baan R, Grosse Y, et al.: Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol 8 (12): 1065-1066, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28581429&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28581429&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.177">Kamdar BB, Tergas AI, Mateen FJ, et al.: Night-shift work and risk of breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 138 (1): 291-301, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23400581&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23400581&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.178">Travis RC, Balkwill A, Fensom GK, et al.: Night Shift Work and Breast Cancer Incidence: Three Prospective Studies and Meta-analysis of Published Studies. J Natl Cancer Inst 108 (12): , 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27758828&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27758828&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _513
      field_pdq_section_title:
        - format: plain_text
          value: 'Modificaciones a este sumario (08/24/2018)'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_513" class="pdq-sections"><p id="_514" tabindex="-1">Los sumarios del PDQ con informaci&#xF3;n sobre el c&#xE1;ncer se revisan con regularidad y se actualizan a medida que se obtiene nueva informaci&#xF3;n. Esta secci&#xF3;n describe los cambios m&#xE1;s recientes introducidos en este sumario a partir de la fecha arriba indicada.</p><p id="_845" tabindex="-1">Se incorporaron cambios editoriales en este sumario.</p><p id="_disclaimerHP_3" tabindex="-1">Este sumario est&#xE1; redactado y mantenido por el <a href="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/deteccion-prevencion" title="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/deteccion-prevencion">Consejo editorial del PDQ sobre los ex&#xE1;menes de detecci&#xF3;n y la prevenci&#xF3;n</a>, que es editorialmente independiente del NCI. El sumario refleja una revisi&#xF3;n independiente de la bibliograf&#xED;a y no representa una declaraci&#xF3;n de pol&#xED;ticas del NCI o de los NIH. Para mayor informaci&#xF3;n sobre las pol&#xED;ticas de los sumarios y la funci&#xF3;n de los  consejos editoriales  del PDQ que mantienen los sumarios del PDQ, consultar en <a href="/espanol/tipos/seno/pro/prevencion-seno-pdq#link/_AboutThis_1">Informaci&#xF3;n sobre este sumario del PDQ</a> y  la p&#xE1;gina sobre <a href="https://www.cancer.gov/espanol/publicaciones/pdq" title="https://www.cancer.gov/espanol/publicaciones/pdq">Banco de datos de informaci&#xF3;n de c&#xE1;ncer - PDQ&#xAE;</a>.
            </p></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _AboutThis_1
      field_pdq_section_title:
        - format: plain_text
          value: 'Información sobre este sumario del PDQ'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_AboutThis_1" class="pdq-sections"><section id="_AboutThis_2"><h3 id="_AboutThis_2_toc">Prop&#xF3;sito de este sumario</h3><p id="_AboutThis_3" tabindex="-1">Este sumario del PDQ con informaci&#xF3;n sobre el c&#xE1;ncer para profesionales de la salud proporciona informaci&#xF3;n integral revisada por expertos y con fundamento en datos probatorios sobre prevenci&#xF3;n del c&#xE1;ncer de mama. El prop&#xF3;sito es servir como fuente de informaci&#xF3;n y ayuda para los m&#xE9;dicos que atienden a pacientes de c&#xE1;ncer. No  ofrece pautas ni recomendaciones formales para tomar decisiones relacionadas con la atenci&#xF3;n sanitaria.</p></section><section id="_AboutThis_21"><h3 id="_AboutThis_21_toc">Revisores y actualizaciones</h3><p id="_AboutThis_22" tabindex="-1">El  <a href="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/deteccion-prevencion" title="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/deteccion-prevencion">Consejo editorial del PDQ sobre los ex&#xE1;menes de detecci&#xF3;n y la prevenci&#xF3;n</a>, cuya funci&#xF3;n editorial es independiente del Instituto Nacional del C&#xE1;ncer (NCI), revisa con regularidad este sumario y, en caso necesario,   lo actualiza. Este sumario refleja una revisi&#xF3;n bibliogr&#xE1;fica independiente y no constituye una declaraci&#xF3;n de la pol&#xED;tica del Instituto Nacional del C&#xE1;ncer ni de los Institutos Nacionales de la Salud (NIH).</p><p id="_AboutThis_26" tabindex="-1">Cada mes, los miembros de este Consejo  examinan art&#xED;culos  publicados recientemente para determinar si se deben:</p><div class="pdq-content-list"><ul id="_AboutThis_23"><li>tratar en una reuni&#xF3;n,</li><li>citar textualmente, o</li><li>sustituir o actualizar, si ya se citaron con anterioridad.</li></ul></div><p id="_AboutThis_24" tabindex="-1">Los cambios en los sumarios se deciden mediante consenso, una vez que  los integrantes del Consejo eval&#xFA;an la solidez de los datos probatorios en los art&#xED;culos publicados y determinan la forma en que se incorporar&#xE1;n al sumario.</p><p id="_AboutThis_25" tabindex="-1">Cualquier comentario o pregunta sobre el contenido de este sumario se debe enviar mediante el   <a href="https://www.cancer.gov/espanol/contactenos/correo-electronico" title="https://www.cancer.gov/espanol/contactenos/correo-electronico">formulario de comunicaci&#xF3;n</a> en Cancer.gov/espanol del NCI.  No comunicarse con los miembros del Consejo para enviar preguntas o comentarios sobre los sumarios.  Los miembros del Consejo no responder&#xE1;n a preguntas del p&#xFA;blico. </p></section><section id="_AboutThis_9"><h3 id="_AboutThis_9_toc">Grados de comprobaci&#xF3;n cient&#xED;fica</h3><p id="_AboutThis_10" tabindex="-1">En algunas referencias bibliogr&#xE1;ficas de este sumario se indica el grado de comprobaci&#xF3;n cient&#xED;fica. El prop&#xF3;sito de estas designaciones es ayudar al lector a evaluar la solidez de los datos probatorios que sustentan el uso de  ciertas intervenciones  o enfoques. El Consejo editorial del PDQ sobre los ex&#xE1;menes de detecci&#xF3;n y la prevenci&#xF3;n emplea un <a href="/espanol/publicaciones/pdq/grados-comprobacion/deteccion-prevencion">sistema de jerarquizaci&#xF3;n formal</a> para establecer  las designaciones del grado de comprobaci&#xF3;n cient&#xED;fica.</p></section><section id="_AboutThis_11"><h3 id="_AboutThis_11_toc">Permisos para el uso de este sumario</h3><p id="_AboutThis_12" tabindex="-1">PDQ (Physician Data Query) es una marca registrada. Se autoriza el libre uso del texto  de los documentos del PDQ. Sin embargo, no se podr&#xE1; identificar como un sumario de informaci&#xF3;n sobre c&#xE1;ncer del PDQ del  NCI,  salvo que se reproduzca en su totalidad y se actualice con regularidad. Por otra parte, se permitir&#xE1; que un autor  escriba una oraci&#xF3;n como &#x201C;En el sumario del PDQ  del NCI de informaci&#xF3;n sobre la prevenci&#xF3;n del c&#xE1;ncer de mama se describen, en breve, los siguientes riesgos: [incluir fragmento del sumario]&#x201D;.</p><p id="_AboutThis_13" tabindex="-1">Se sugiere citar la referencia bibliogr&#xE1;fica de este sumario del PDQ de la siguiente forma:</p><p id="_AboutThis_14" tabindex="-1">PDQ&#xAE; sobre los ex&#xE1;menes de detecci&#xF3;n y la prevenci&#xF3;n. PDQ Prevenci&#xF3;n del c&#xE1;ncer de seno (mama). Bethesda, MD: National Cancer Institute. Actualizaci&#xF3;n:  &lt;MM/DD/YYYY&gt;. Disponible en: <a href="https://www.cancer.gov/espanol/tipos/seno/pro/prevencion-seno-pdq" title="https://www.cancer.gov/espanol/tipos/seno/pro/prevencion-seno-pdq">https://www.cancer.gov/espanol/tipos/seno/pro/prevencion-seno-pdq</a>.  Fecha de acceso: &lt;MM/DD/YYYY&gt;. </p><p id="_AboutThis_15" tabindex="-1">Las im&#xE1;genes  en este sumario se reproducen  con el permiso del autor, el artista o la  editorial para uso exclusivo en los sumarios del PDQ. La utilizaci&#xF3;n de las im&#xE1;genes fuera del  PDQ requiere la autorizaci&#xF3;n del propietario, que el Instituto Nacional del C&#xE1;ncer no  puede otorgar. Para obtener m&#xE1;s informaci&#xF3;n sobre el uso de las ilustraciones de este sumario o de  otras im&#xE1;genes relacionadas con el c&#xE1;ncer, consultar <a href="https://visualsonline.cancer.gov/" title="https://visualsonline.cancer.gov/">Visuals Online</a>, una colecci&#xF3;n de m&#xE1;s de 2000 im&#xE1;genes cient&#xED;ficas.</p></section><section id="_AboutThis_16"><h3 id="_AboutThis_16_toc">Cl&#xE1;usula sobre el descargo de responsabilidad</h3><p id="_AboutThis_18" tabindex="-1">La informaci&#xF3;n en estos sumarios  no se debe utilizar como base para determinar reembolsos por parte de las aseguradoras. Para obtener m&#xE1;s informaci&#xF3;n  sobre la cobertura de seguros, consultar la p&#xE1;gina <a href="https://www.cancer.gov/espanol/cancer/manejo-del-cancer" title="https://www.cancer.gov/espanol/cancer/manejo-del-cancer">Manejo de la atenci&#xF3;n del c&#xE1;ncer</a> disponible en Cancer.gov/espanol.</p></section><section id="_AboutThis_19"><h3 id="_AboutThis_19_toc">Para obtener m&#xE1;s informaci&#xF3;n</h3><p id="_AboutThis_20" tabindex="-1">En Cancer.gov/espanol,  se ofrece m&#xE1;s informaci&#xF3;n sobre c&#xF3;mo comunicarse o recibir ayuda en  <a href="https://www.cancer.gov/espanol/contactenos" title="https://www.cancer.gov/espanol/contactenos">&#xBF;En qu&#xE9; podemos ayudarle?</a>.
            Tambi&#xE9;n se puede enviar un mensaje de  correo electr&#xF3;nico  mediante este  <a href="https://www.cancer.gov/espanol/contactenos/correo-electronico" title="https://www.cancer.gov/espanol/contactenos/correo-electronico">formulario</a>.</p></section></div>

- entity: node
  type: pdq_cancer_information_summary
  title: 'Lung Cancer Prevention (PDQ®)–Health Professional Version'
  status: 1
  langcode: en
  field_hhs_syndication:
    - syndicate: 1
      keywords: lung cancer, cancer prevention
  moderation_state:
    value: published
  field_pdq_url:
    value: /types/lung/hp/lung-prevention-pdq
  field_pdq_cdr_id:
    value: 62824
  field_pdq_audience:
    value: Health Professionals
  field_pdq_summary_type:
    value: Prevention
  field_date_posted:
    value: '2019-03-11'
  field_date_updated:
    value: '2018-03-02'
  field_browser_title:
    value: 'Lung Cancer Prevention'
  field_page_description:
    value: 'Lung cancer prevention strategies include quitting or avoiding exposure to smoking, occupational carcinogens, and radon. Get detailed information about risk factors and lung cancer prevention in this summary for clinicians. '
  field_public_use:
    value: 1
  field_summary_sections:
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _171
      field_pdq_section_title:
        - format: plain_text
          value: 'Overview'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_171" class="pdq-sections"><div class="pdq-hp-patient-toggle"><a href="/types/lung/patient/lung-prevention-pdq">Go to Patient Version</a></div><p id="_200" tabindex="-1">Note: Separate PDQ summaries on <a href="/types/lung/hp/lung-screening-pdq">Lung Cancer Screening</a>; <a href="/types/lung/hp/small-cell-lung-treatment-pdq">Small Cell Lung
            Cancer Treatment</a>; <a href="/types/lung/hp/non-small-cell-lung-treatment-pdq">Non-Small Cell Lung Cancer Treatment</a>; and <a href="/about-cancer/causes-prevention/risk/tobacco/quit-smoking-hp-pdq">Cigarette Smoking: Health Risks and How to Quit</a> are also available. </p><section id="_166"><h3 id="_166_toc">Who is at Risk?</h3><p id="_167" tabindex="-1">Lung cancer risk is largely a function of older age combined with extensive cigarette smoking history.  Lung cancer is more common in men than women and in those of lower socioeconomic status.  Patterns of lung cancer according to demographic characteristics tend to be strongly correlated with historical patterns of cigarette smoking prevalence.  An exception to this is the very high rate of lung cancer in African American men, a group whose very high lung cancer death rate is not explainable simply by historical smoking patterns.[<a href="#cit/section_1.1">1</a>]</p><p id="_168" tabindex="-1">In nonsmokers, important lung cancer risk factors are exposure to secondhand smoke, exposure to ionizing radiation, and occupational exposure to lung carcinogens, such as asbestos. Radiation exposures relevant to the general population include environmental exposure to radon and radiation exposures administered in the medical care setting, particularly when administered at high doses, such as radiation therapy to the chest or breast.[<a href="#cit/section_1.2">2</a>] Cigarette smoking often interacts with these other factors.  There are several examples, including radon exposure and asbestos exposure, in which the combined exposure to cigarette smoke plus another risk factor results in an increase in risk that is much greater than the sum of the risks associated with each factor alone.</p><section id="_172"><h4 id="_172_toc">Factors associated with increased risk of lung cancer</h4><section id="_173"><h5 id="_173_toc">Cigarette smoking</h5><p id="_174" tabindex="-1">Starting with the 1964 Surgeon General&#x2019;s Report and followed by each subsequent Surgeon General&#x2019;s Report that has included a review of the evidence on smoking and lung cancer, an enormous body of scientific evidence clearly documents that cigarette smoking causes lung cancer, and that cigarette smoking is the major cause of lung cancer.</p><p id="_175" tabindex="-1">Based on solid evidence, cigarette smoking causes lung cancer. The risks of lung cancer associated with cigarette smoking are dose-dependent and increase markedly according to the number of cigarettes smoked per day and the number of years smoked.  On average, current smokers have approximately 20 times the risk of lung cancer compared with nonsmokers. </p><p id="_176" tabindex="-1"><strong>Magnitude of Effect: Increased risk, very large.</strong></p><div class="pdq-content-list"><ul id="_177" class="pdq-address-block"><li>Study Design: Numerous prospective cohort and case-control studies, combined with quasi-experimental evidence showing population-level smoking prevalence predicts the population-level burden of lung cancer.</li><li>Internal Validity: Good.</li><li>Consistency: Good.</li><li>External Validity: Good.</li></ul></div></section><section id="_178"><h5 id="_178_toc">Exposure to secondhand smoke</h5><p id="_179" tabindex="-1">Based on solid evidence, exposure to secondhand smoke is an established cause of lung cancer.</p><p id="_180" tabindex="-1"><strong>Magnitude of Effect: Increased risk, small magnitude.  Compared with nonsmokers not exposed to secondhand smoke, nonsmokers exposed to secondhand smoke have approximately a 20% increased risk of lung cancer.</strong></p><div class="pdq-content-list"><ul id="_181" class="pdq-address-block"><li>Study Design: Prospective cohort and case-control studies.</li><li>Internal Validity: Good.</li><li>Consistency: Good.</li><li>External Validity: Good.</li></ul></div></section><section id="_182"><h5 id="_182_toc">Radiation exposure</h5><p id="_183" tabindex="-1">Based on solid evidence, exposure to radiation increases lung cancer incidence and mortality. Cigarette smoking greatly potentiates this effect.</p><p id="_184" tabindex="-1"><strong>Magnitude of Effect: Increased risk that follows a dose-response gradient, with smaller increases in risk for low levels of exposure and greater increases in risk for high levels of exposure.</strong></p><div class="pdq-content-list"><ul id="_284" class="pdq-address-block"><li>Study Design: Cohort and case-control studies.</li><li>Internal Validity: Fair.</li><li>Consistency: Good.</li><li>External Validity: Good.</li></ul></div></section><section id="_305"><h5 id="_305_toc">Occupational exposure to lung carcinogens</h5><p id="_306" tabindex="-1">Based on solid evidence, workplace exposure to asbestos, arsenic, beryllium, cadmium, chromium, and nickel increases lung cancer incidence and mortality.</p><p id="_307" tabindex="-1"><strong>Magnitude of Effect: Increased risk, large magnitude (more than fivefold).  Risks follow a dose-response gradient, with high-level exposures associated with large increases in risk.  Cigarette smoking also potentiates the effect of many of these lung carcinogens so that the risks are even greater in smokers.</strong></p><div class="pdq-content-list"><ul id="_308" class="pdq-address-block"><li>Study Design: Cohort and case-control studies.</li><li>	Internal Validity: Good. </li><li>	Consistency: Good.</li><li>External Validity: Good.</li></ul></div></section><section id="_309"><h5 id="_309_toc">Air pollution</h5><p id="_310" tabindex="-1">Based on solid evidence, exposure to outdoor air pollution, specifically small particles,  increases lung cancer incidence and mortality.</p><p id="_311" tabindex="-1"><strong>Magnitude of Effect: Increased risk; compared with the lowest exposure categories, those in the highest exposure categories have approximately a 40% increased risk of lung cancer.</strong></p><div class="pdq-content-list"><ul id="_312" class="pdq-address-block"><li>	Study Design: Cohort and case-control studies. </li><li>	Internal Validity: Good. </li><li>Consistency: Good. </li><li>External Validity: Good.</li></ul></div></section></section><section id="_186"><h4 id="_186_toc">Factors of uncertain  association with risk</h4><section id="_187"><h5 id="_187_toc">Dietary factors</h5><p id="_188" tabindex="-1">Based on equivocal evidence, the observed inverse associations between lung cancer and dietary factors, such as fruit and vegetable consumption, are difficult to disentangle from cigarette smoking.</p><p id="_189" tabindex="-1"><strong>Magnitude of Effect: Inverse association, moderate magnitude, but difficult to determine if true cause-effect association or due to confounding by cigarette smoking.</strong></p><div class="pdq-content-list"><ul id="_285" class="pdq-address-block"><li>Study Design: Numerous cohort and case-control studies, and meta-analyses.</li><li>Internal Validity: Fair.</li><li>Consistency: Fair.</li><li>External Validity: Good.</li></ul></div></section><section id="_190"><h5 id="_190_toc">Physical activity</h5><p id="_191" tabindex="-1">Based on equivocal evidence, the observed inverse associations between lung cancer and higher levels of physical activity are difficult to disentangle from cigarette smoking. </p><p id="_192" tabindex="-1"><strong>Magnitude of Effect: Inverse association, moderate magnitude, but difficult to determine if true cause-effect association or due to confounding  by cigarette smoking.</strong></p><div class="pdq-content-list"><ul id="_286" class="pdq-address-block"><li>Study Design: Numerous cohort and case-control studies, and meta-analyses.</li><li>Internal Validity: Fair.</li><li>Consistency: Fair.</li><li>External Validity: Good.</li></ul></div></section></section></section><section id="_158"><h3 id="_158_toc">Interventions Associated With Decreased Risk of Lung Cancer</h3><section id="_159"><h4 id="_159_toc">Smoking avoidance</h4><p id="_160" tabindex="-1">Based on solid evidence, cigarette smoking causes lung cancer and therefore, smoking avoidance results in decreased mortality from primary lung cancers. </p><p id="_193" tabindex="-1"><strong>Magnitude of Effect: Decreased risk, substantial magnitude.</strong></p><div class="pdq-content-list"><ul id="_287" class="pdq-address-block"><li>Study Design: Cohort and case-control studies.</li><li>Internal Validity: Good.</li><li>Consistency: Good.</li><li>External Validity: Good.</li></ul></div></section><section id="_161"><h4 id="_161_toc">Smoking cessation</h4><p id="_162" tabindex="-1">Based on solid evidence, long-term sustained smoking cessation results in decreased incidence of lung cancer and of second primary lung tumors. </p><p id="_194" tabindex="-1"><strong>Magnitude of Effect: Decreased risk, moderate magnitude.</strong></p><div class="pdq-content-list"><ul id="_288" class="pdq-address-block"><li>Study Design: Cohort and case-control studies.</li><li>Internal Validity: Good.</li><li>Consistency: Good.</li><li>External Validity: Good.</li></ul></div></section><section id="_195"><h4 id="_195_toc">Eliminating secondhand smoke</h4><p id="_196" tabindex="-1">Based on solid evidence, exposure to secondhand smoke causes lung cancer and therefore, preventing exposure to secondhand smoke results in decreased incidence and mortality from primary lung cancers. </p><p id="_197" tabindex="-1"><strong>Magnitude of Effect: Decreased risk, small magnitude.</strong></p><div class="pdq-content-list"><ul id="_289" class="pdq-address-block"><li>Study Design: Cohort and case-control studies.</li><li>Internal Validity: Good.</li><li>Consistency: Good.</li><li>External Validity: Good.</li></ul></div></section><section id="_198"><h4 id="_198_toc">Reducing or eliminating occupational exposure to lung carcinogens</h4><p id="_199" tabindex="-1">Based on solid evidence, occupational exposures such as asbestos, arsenic, nickel, and chromium are causally associated with lung cancer.  Reducing or eliminating workplace exposures to known lung carcinogens would be expected to result in a corresponding decrease in the risk of lung cancer.</p><p id="_201" tabindex="-1"><strong>Magnitude of Effect: Decreased risk, with a larger effect, the greater the reduction in exposure.</strong></p><div class="pdq-content-list"><ul id="_290" class="pdq-address-block"><li>Study Design: Cohort and case-control studies.</li><li>Internal Validity: Good.</li><li>Consistency: Good.</li><li>External Validity: Good.</li></ul></div></section><section id="_202"><h4 id="_202_toc">Reducing or eliminating exposure to radon</h4><p id="_203" tabindex="-1">Based on solid evidence, indoor exposure to radon increases lung cancer incidence and mortality, particularly among cigarette smokers.  In homes with high radon concentrations, taking steps to prevent radon from entering homes by sealing the basement would be expected to result in a corresponding decrease in the risk of lung cancer.</p><p id="_204" tabindex="-1"><strong>Magnitude of Effect: Increased risk that follows a dose-response gradient, with small increases in risk for levels experienced in most at-risk homes to greater increases in risk for high-level exposures.</strong></p><div class="pdq-content-list"><ul id="_291" class="pdq-address-block"><li>Study Design: Cohort and case-control studies.</li><li>Internal Validity: Fair.</li><li>Consistency: Good.</li><li>External Validity: Fair.</li></ul></div></section></section><section id="_205"><h3 id="_205_toc">Interventions Associated With an Increased Risk of Lung Cancer</h3><section id="_206"><h4 id="_206_toc">Beta-carotene supplementation in current smokers</h4><p id="_207" tabindex="-1">Based on solid evidence, high-intensity smokers who take pharmacologic doses of  beta-carotene have an increased lung cancer incidence and mortality that is associated with taking the supplement.</p><p id="_208" tabindex="-1"><strong>Magnitude of Effect: Increased risk, small magnitude.</strong></p><div class="pdq-content-list"><ul id="_292" class="pdq-address-block"><li>Study Design: Two randomized controlled trials (RCTs) with consistent results.</li><li>Internal Validity: Good.</li><li>Consistency: Good.</li><li>External Validity: Good.</li></ul></div></section></section><section id="_209"><h3 id="_209_toc">Interventions That Do Not Decrease Risk of Lung Cancer</h3><section id="_210"><h4 id="_210_toc">Beta-carotene in nonsmokers</h4><p id="_211" tabindex="-1">Based on solid evidence, nonsmokers who take pharmacological doses of beta-carotene do not experience significantly different lung cancer incidence or mortality compared with taking a placebo.</p><p id="_212" tabindex="-1"><strong>Magnitude of Effect: No substantive effect.</strong></p><div class="pdq-content-list"><ul id="_293" class="pdq-address-block"><li>Study Design: RCT.</li><li>Internal Validity: Good.</li><li>Consistency: Good.</li><li>External Validity: Fair.</li></ul></div></section><section id="_213"><h4 id="_213_toc">Vitamin E (Tocopherol)</h4><p id="_214" tabindex="-1">Based on solid evidence, taking vitamin E supplements does not affect the risk of lung cancer.</p><p id="_215" tabindex="-1"><strong>Magnitude of Effect: Strong evidence of no association.</strong></p><div class="pdq-content-list"><ul id="_185" class="pdq-address-block"><li>Study Design: RCTs.</li><li>Internal Validity: Good.</li><li>Consistency: Fair.</li><li>External Validity: Good.</li></ul></div></section></section><h6 do-not-show="toc">References</h6><ol><li id="section_1.1">Pinsky PF: Racial and ethnic differences in lung cancer incidence: how much is explained by differences in smoking patterns? (United States). Cancer Causes Control 17 (8): 1017-24, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16933052&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16933052&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.2">Friedman DL, Whitton J, Leisenring W, et al.: Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 102 (14): 1083-95, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20634481&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20634481&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _16
      field_pdq_section_title:
        - format: plain_text
          value: 'Description of the Evidence'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_16" class="pdq-sections"><section id="_217"><h3 id="_217_toc">Incidence and Mortality</h3><p id="_218" tabindex="-1">Lung cancer has a tremendous impact on the health of the American public, with an estimated 234,030 new cases and
            154,050 deaths predicted in 2018 in men and women combined.[<a href="#cit/section_2.1">1</a>] Lung cancer causes more deaths per year in the United States than the next four leading causes of cancer death combined.  Lung cancer incidence and
            mortality rates increased markedly throughout most of the last century, first in
            men and then in women.  The trends in lung cancer incidence and mortality rates  have closely mirrored historical patterns of smoking prevalence, after accounting for an appropriate latency period. Because of historical differences in smoking prevalence between men and women, lung cancer rates in men have been consistently declining  since the mid-1980s, but rates in women have only been declining since the mid-2000s. The incidence rate in men declined from a high of 102.1 cases per 100,000 men in 1984 to 78.6 cases per 100,000 men in 2011.[<a href="#cit/section_2.1">1</a>,<a href="#cit/section_2.2">2</a>]   In the United States, it  is estimated that lung cancer will account for about 25% of new cancer cases and about 25% of all cancer deaths in 2018. Lung
            cancer is  the leading cause of cancer deaths in both men and women.  In 2018, it
            is estimated that  70,500 deaths will occur among U.S. women due to lung
            cancer, compared with  40,920 deaths due to breast cancer.[<a href="#cit/section_2.1">1</a>]</p><p id="_219" tabindex="-1">Lung cancer incidence and mortality is highest in African Americans compared with any other racial/ethnic group in the United States, primarily due to the very high rates in African American men. Between 2010 and 2014, the incidence rate in black men was higher than in white men (83.7 vs.  65.9 cases per 100,000 men, respectively), whereas among women no racial difference in incidence rates was present (49 vs. 50.8 cases  per 100,000 women, respectively). Similarly, the mortality rates among black men were higher than among white men during the same time frame (68 vs. 55.9 deaths per 100,000 men, respectively), whereas the mortality rates among black women were  lower than among white women (34.6 vs. 37.5 deaths per 100,000 women, respectively).[<a href="#cit/section_2.3">3</a>]</p><p id="_220" tabindex="-1">Surgical treatment or radiation therapy is the treatment of choice for early
            stages of cancer.[<a href="#cit/section_2.4">4</a>]  The overall 5-year relative survival rate from lung cancer was  18.1% in 2012. Lung cancer survival is worse for men compared with women and for blacks compared with whites.  For example, 5-year lung cancer survival was  lower in black men compared with white men (12.5% vs. 15.4%, respectively) and  lower in black women compared with white women (18.8% vs. 21.4%, respectively).[<a href="#cit/section_2.5">5</a>]</p><p id="_221" tabindex="-1">The hypothesis has been proposed that women may be more susceptible than men to smoking-caused lung cancer.  However, the results of studies that have compared the association between smoking and lung cancer in men and women using appropriate comparisons do not support  this hypothesis.[<a href="#cit/section_2.6">6</a>]</p><p id="_222" tabindex="-1">The results of the Multi-Ethnic Cohort Study indicated that for a given degree of cigarette smoking, African Americans had a higher risk of lung cancer compared with other racial/ethnic groups.[<a href="#cit/section_2.7">7</a>] Menthol cigarettes have been hypothesized as one potential factor contributing to the observed greater susceptibility to smoking-caused lung cancer in African Americans, but menthol cigarettes have not been observed to be associated with a higher risk of lung cancer than nonmenthol cigarettes.[<a href="#cit/section_2.8">8</a>,<a href="#cit/section_2.9">9</a>]</p></section><section id="_223"><h3 id="_223_toc">Cigarette Smoking is the Primary Risk Factor</h3><p id="_224" tabindex="-1">The epidemic of lung cancer in the 20th century was  primarily due to increases
            in cigarette smoking,  the predominant cause of lung cancer.  The  threefold
            variation in lung cancer mortality rates across the United States more or less parallels
            long-standing state-specific differences in the prevalence of cigarette smoking.  For example,  average annual age-adjusted lung cancer death rates for 1996 to 2000 were
            highest in Kentucky (78 deaths per 100,000 individuals) where 31%  were current
            smokers in 2001; whereas the lung cancer death rates were  lowest in Utah (26 deaths per 100,000 individuals), which had the lowest prevalence of cigarette smoking (13%).[<a href="#cit/section_2.10">10</a>]</p></section><section id="_225"><h3 id="_225_toc">The Biology of Carcinogenesis</h3><p id="_226" tabindex="-1">Understanding the biology of carcinogenesis is crucial to the development of
            effective  prevention and treatment strategies.  Two  important concepts in this regard  are the multistep nature of carcinogenesis and the diffuse field-wide
            carcinogenic process.  Epithelial cancers in the lung appear to develop in a
            series of steps extending over years.  Epithelial carcinogenesis is
            conceptually divided into three phases: initiation, promotion, and progression.
            This process has been inferred from human studies identifying
            clinical-histological premalignant lesions (e.g., metaplasia and dysplasia).
            The concept of field carcinogenesis is that multiple independent neoplastic
            lesions occurring within the lung can result from repeated exposure to
            carcinogens, primarily tobacco.  Patients developing cancers of the
            aerodigestive tract secondary to cigarette smoke also are likely to have
            multiple premalignant lesions of independent origin within the
            carcinogen-exposed field.  The concepts of multistep and field carcinogenesis
            provide a model for prevention studies.[<a href="#cit/section_2.11">11</a>]</p></section><section id="_227"><h3 id="_227_toc">Risk Factors</h3><section id="_228"><h4 id="_228_toc">Factors associated with increased risk of lung cancer</h4><section id="_229"><h5 id="_229_toc">Cigarette smoking</h5><p id="_230" tabindex="-1">The most important risk factor for lung cancer (and for many other cancers) is cigarette smoking.[<a href="#cit/section_2.12">12</a>-<a href="#cit/section_2.14">14</a>] Epidemiologic data have established that cigarette smoking is the predominant cause of lung cancer. This causative link has been widely recognized since the 1960s, when national reports in Great Britain and the United States brought the cancer risk of smoking prominently to the public&#x2019;s attention.[<a href="#cit/section_2.13">13</a>] The percentages of lung cancers estimated to be caused by tobacco smoking in males and females are 90% and 78%, respectively. The manufactured cigarette has changed over time, but there is no evidence to suggest that changes such as <em>low tar</em> or <em>low nicotine</em> cigarettes have resulted in reduced lung cancer risks.[<a href="#cit/section_2.9">9</a>,<a href="#cit/section_2.15">15</a>]  Cigarette smoking is the most important contributor to the lung cancer burden because of its high prevalence of use and because cigarette smokers tend to smoke frequently, but cigar and pipe smoking have also been associated independently in case-control and cohort studies with increased lung cancer risk.[<a href="#cit/section_2.16">16</a>,<a href="#cit/section_2.17">17</a>] The cigar risks are of particular concern because of the increased prevalence of cigar use in the United States.[<a href="#cit/section_2.18">18</a>]</p><p id="_231" tabindex="-1">The development of lung cancer is the culmination of multistep carcinogenesis. Genetic damage caused by chronic exposure to carcinogens, such as  those in cigarette smoke, is the driving force behind the multistep process. Evidence of genetic damage is the association of cigarette smoking with the formation of the DNA adducts in human lung tissue. A strong link between tobacco smoke and lung carcinogenesis has been established by molecular data.[<a href="#cit/section_2.19">19</a>,<a href="#cit/section_2.20">20</a>] </p></section><section id="_232"><h5 id="_232_toc">Secondhand tobacco smoke</h5><p id="_233" tabindex="-1">Secondhand tobacco smoke is also an established cause of lung cancer.[<a href="#cit/section_2.21">21</a>] Secondhand smoke has the same components as inhaled mainstream smoke, though in lower absolute concentrations, between 1% and 10% depending on the constituent. Elevated biomarkers of tobacco exposure, including urinary cotinine, urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolites, and carcinogen-protein adducts, are seen in those who are exposed to secondhand cigarette smoke.[<a href="#cit/section_2.22">22</a>-<a href="#cit/section_2.24">24</a>]</p></section><section id="_234"><h5 id="_234_toc">Family history</h5><p id="_235" tabindex="-1">A positive family history of lung cancer is a risk factor for lung cancer. The results of a meta-analysis of epidemiologic studies indicated that those with a positive family history of lung cancer were at approximately twice the risk of lung cancer compared with those with no affected relatives.[<a href="#cit/section_2.25">25</a>,<a href="#cit/section_2.26">26</a>] Cigarette smoking behavior tends to run in families and family members are exposed to secondhand smoke, so the extent to which measured family history represents a genetic predisposition to lung cancer independent of the shared risk factor of cigarette smoking is uncertain.</p></section><section id="_236"><h5 id="_236_toc">Human immunodeficiency virus (HIV) infection</h5><p id="_237" tabindex="-1">HIV infection has been observed to be statistically associated with an increased lung cancer risk; for example, the results of a meta-analysis of 13 studies indicated HIV-infected individuals had a 2.6-fold higher risk of lung cancer than non-HIV-infected individuals (standard incidence ratio, 2.6; 95% confidence interval [CI], 2.1&#x2013;3.1).[<a href="#cit/section_2.27">27</a>] The clinical significance of this association remains to be elucidated, as it raises the possibility that HIV infection increases susceptibility to lung cancer, but may merely reflect the high smoking prevalence (study estimates ranged from 59% to 96%) among those infected with HIV compared with the general population (smoking prevalence approximately 20%).</p></section><section id="_238"><h5 id="_238_toc">Other environmental causes of lung cancer</h5><section id="_239"><h6 id="_239_toc">Occupational exposures to lung carcinogens</h6><p id="_240" tabindex="-1">Several environmental exposures other than tobacco smoke are causally associated with lung cancer, but the proportion of the lung cancer burden due to these exposures is small compared with cigarette smoking. Many lung carcinogens have been identified in studies of high occupational exposures. Considered in total, occupational exposures have been estimated to account for approximately 10% of lung cancers.[<a href="#cit/section_2.28">28</a>] These carcinogens include asbestos, radon, tar and soot (sources of polycyclic aromatic hydrocarbons), arsenic, chromium, nickel, beryllium, and cadmium.[<a href="#cit/section_2.29">29</a>] For many of these workplace carcinogens, cigarette smoking interacts synergistically to increase the risk.[<a href="#cit/section_2.30">30</a>] In developed countries, workplace exposures to these agents have largely been controlled.</p></section><section id="_241"><h6 id="_241_toc">Radiation exposure</h6><p id="_329" tabindex="-1">Based on studies of populations exposed to high doses of radiation, lung cancer has been determined to be one of the cancers that is causally associated with exposure to ionizing radiation.[<a href="#cit/section_2.31">31</a>]   Two types of radiation that are relevant to lung cancer include high-energy ionizing electromagnetic radiation (such as x-rays and gamma rays) and particles (such as alpha particles and neutrons).  </p><p id="_330" tabindex="-1">An important early source of data about radiation exposure came from studies of atomic bomb survivors in Japan; these studies demonstrated that a single high-dose exposure to gamma rays  is sufficient to increase the risk of lung cancer in a dose-dependent fashion.[<a href="#cit/section_2.32">32</a>]  Lung cancer risk in patients treated with radiation for a number of medical conditions has also been evaluated.  Studies of patients with tuberculosis who were treated with pneumothorax and monitored with frequent fluoroscopy, with resulting cumulative radiation doses of about 85 rads (0.85 Gy) staggered over time, indicated that any lung cancer risks associated with this exposure pattern, if they exist, are difficult to detect.[<a href="#cit/section_2.33">33</a>,<a href="#cit/section_2.34">34</a>]  In contrast, the results of many studies provide clear-cut evidence that radiation therapy to the chest to treat cancer results in an increased risk of lung cancer in a dose-dependent manner.  The evidence is most abundant for breast cancer [<a href="#cit/section_2.35">35</a>-<a href="#cit/section_2.38">38</a>] and Hodgkin lymphoma.[<a href="#cit/section_2.39">39</a>]   The risk of lung cancer after radiation therapy is amplified among patients who smoke cigarettes, as compared with nonsmokers.[<a href="#cit/section_2.35">35</a>,<a href="#cit/section_2.36">36</a>,<a href="#cit/section_2.38">38</a>,<a href="#cit/section_2.39">39</a>]</p><p id="_331" tabindex="-1">The association between radiation exposure and lung cancer has implications for the general population in countries such as the United States, where computed tomography (CT) scans are relatively common and may contribute to an excess of cancer at the population level.[<a href="#cit/section_2.40">40</a>]  In light of the established association between exposure to ionizing radiation and lung cancer risk, researchers have urged caution to minimize risks when cancer screening involves ionizing radiation exposure, such as using of low-dose spiral CT screening for lung cancer instead of higher-dose techniques.[<a href="#cit/section_2.41">41</a>,<a href="#cit/section_2.42">42</a>]</p><p id="_332" tabindex="-1">Because they deposit  concentrated energy in tissue, particles (e.g., alpha particles) produce more biological damage at an equivalent dose than radiation (e.g., x-rays).[<a href="#cit/section_2.43">43</a>]  A public health concern is radon, the primary source of alpha particles. Radon is an inert gas produced naturally in the decay series of uranium.  Along with other supportive scientific evidence, studies of underground uranium miners exposed to very high levels of radon have demonstrated that radon exposure causes lung cancer.[<a href="#cit/section_2.31">31</a>] This effect is amplified considerably in miners who smoke.[<a href="#cit/section_2.44">44</a>]
            Radon has broader societal interest because it can enter buildings as a soil-derived gas and is a prevalent population-level exposure.</p><p id="_242" tabindex="-1">Estimates of the proportion of lung cancer deaths attributable to indoor exposure to radon vary by method of estimation and by the levels of radon exposure in a country, but the median estimates are 26% for lifelong nonsmokers (range 13%&#x2013;50%) and 10% for ever smokers (range 7%&#x2013;13%).[<a href="#cit/section_2.45">45</a>-<a href="#cit/section_2.47">47</a>] Because of a synergistic interaction between cigarette smoking and radon exposure, the radon-associated risk of lung cancer among smokers is considerably greater than for nonsmokers.[<a href="#cit/section_2.48">48</a>] The prevention strategy for residents of homes with high radon concentrations is to have the basement sealed to prevent radon gas from leaking into the home.[<a href="#cit/section_2.49">49</a>]</p></section><section id="_243"><h6 id="_243_toc">Air pollution</h6><p id="_244" tabindex="-1">Although early evidence from case-control and cohort studies did not support an association between air pollution and lung cancer, the evidence now points to a genuine association.[<a href="#cit/section_2.50">50</a>] In particular, two prospective cohort studies provide evidence to  suggest that air pollution is weakly associated with the risk of lung cancer.  In an extended follow-up of a study of six U.S. cities, the adjusted relative risk (RR) of lung cancer mortality for each 10 &#xB5;g/m<span class="sup">3</span> increase in concentration of fine-particulate was 1.27 (95% CI,  0.96&#x2013;1.69).[<a href="#cit/section_2.51">51</a>]  Using data from the American Cancer Society's Cancer Prevention Study II, it was observed that compared with the least polluted areas, residence in areas with high sulfate concentrations was associated with an increased risk of lung cancer (adjusted RR, 1.4; 95% CI, 1.1&#x2013;1.7) after adjustment for occupational exposures and the factors mentioned above.[<a href="#cit/section_2.52">52</a>]	In a subsequent update to this report, the risk of lung cancer was observed to increase 14% for each 10 &#x3BC;g/m<span class="sup">3</span> increase in concentration of fine particles.[<a href="#cit/section_2.53">53</a>] The evidence indicating an association between constituents of ambient air pollution and increased lung cancer mortality continues to strengthen, with reports from Asia,[<a href="#cit/section_2.54">54</a>,<a href="#cit/section_2.55">55</a>] New Zealand,[<a href="#cit/section_2.56">56</a>] and Europe,[<a href="#cit/section_2.57">57</a>] documenting increased risks with exposure to certain components of particulate matter.</p></section></section></section><section id="_245"><h4 id="_245_toc">Factors of uncertain  association with risk</h4><section id="_246"><h5 id="_246_toc">Dietary factors</h5><p id="_247" tabindex="-1">The results of many case-control and prospective cohort studies show that individuals with high dietary intake of fruits or vegetables have a lower risk of lung cancer than those with low fruit or vegetable intake.[<a href="#cit/section_2.58">58</a>] In a systematic review of the evidence, the World Cancer Research Fund (WCRF) rates the evidence as <em>limited suggestive</em> that nonstarchy vegetable consumption decreases lung cancer risk and <em>probable</em> that fruit consumption and foods containing carotenoids decrease lung cancer risk.   However, a subsequent systematic review and meta-analysis limited to prospective studies that adjusted for cigarette smoking found the evidence for carotenoids to be equivocal.[<a href="#cit/section_2.59">59</a>] </p><p id="_248" tabindex="-1">While the focus has been on fruit and vegetable consumption and micronutrients, a wide range of dietary and anthropometric factors have been investigated. Anthropometric measures have  been studied, indicating a tendency for leaner persons to have increased lung cancer risk relative to those with greater body mass index.[<a href="#cit/section_2.60">60</a>,<a href="#cit/section_2.61">61</a>]   The results of a meta-analysis showed that alcohol drinking in the highest consumption categories only (in excess of about a drink a day) was associated with an increased risk of lung cancer.</p><p id="_249" tabindex="-1">Studies of dietary factors have yielded intriguing findings, but because the diets of  smokers tend to be less healthy than those of nonsmokers, it is challenging to separate the influence of dietary factors from the effects of smoking. When considering the relationships between lung cancer and dietary factors, confounding factors related to  cigarette smoking cannot be dismissed as a possible explanation.</p></section><section id="_250"><h5 id="_250_toc">Physical activity</h5><p id="_251" tabindex="-1">A meta-analysis of leisure-time physical activity and lung cancer risk revealed that higher levels of physical activity protect against lung cancer.[<a href="#cit/section_2.62">62</a>] The overall evidence for physical activity has been mixed, but several studies have reported that individuals who are more physically active have a lower risk of lung cancer than those who are more sedentary,[<a href="#cit/section_2.63">63</a>-<a href="#cit/section_2.65">65</a>] even after adjustment for cigarette smoking.   The WCRF evidence review rated the inverse association between physical activity and lung cancer as <em>limited suggestive</em> evidence.[<a href="#cit/section_2.66">66</a>]</p><p id="_282" tabindex="-1">Studies of physical activity yield findings consistent with an inverse association, but because physical activity behaviors differ between smokers and nonsmokers, it is difficult to infer that there is a direct relationship between physical activity and lung cancer risk.</p></section><section id="_320"><h5 id="_320_toc">Lung cancer in never smokers</h5><p id="_322" tabindex="-1">In countries where cigarette smoking is common, about 10% to 20% of lung cancer cases occur in never smokers.[<a href="#cit/section_2.67">67</a>] Radon and second-hand smoke exposure are established causes of lung cancer in never smokers. An increase in lung cancer risk among never smokers also has been observed with exposure to asbestos, ionizing radiation from sources other than radon, and indoor air pollution caused by combustion of coal or other solid fuel.[<a href="#cit/section_2.68">68</a>] Limited data are available about the association of lung cancer in never smokers with physical activity, diet, alcohol, and anthropometry, yet they typically suggest that the relationships do not differ markedly from those in ever smokers.[<a href="#cit/section_2.59">59</a>,<a href="#cit/section_2.60">60</a>,<a href="#cit/section_2.63">63</a>-<a href="#cit/section_2.65">65</a>,<a href="#cit/section_2.69">69</a>,<a href="#cit/section_2.70">70</a>]  Nevertheless, the inability to fully control for confounding by smoking in epidemiologic analyses of ever smokers and the possibility of different lung cancer causal pathways from never and ever smokers warrants care when extrapolating results for ever smokers to never smokers.</p></section></section></section><section id="_252"><h3 id="_252_toc">Interventions Associated With Decreased Risk of Lung Cancer</h3><section id="_253"><h4 id="_253_toc">Smoking avoidance and cessation</h4><p id="_294" tabindex="-1">Substantial harm to public health accrues from addiction to cigarette smoking. Compared with nonsmokers, smokers experience a dose-dependent increase in the risk of developing lung cancer (and many other malignancies).[<a href="#cit/section_2.71">71</a>,<a href="#cit/section_2.72">72</a>]</p><p id="_254" tabindex="-1">Approximately 85% of all lung cancer deaths are estimated to be attributed to cigarette smoking. Substantial benefits accrue to the  smoker by quitting smoking. (Refer to the PDQ summary on <a href="/about-cancer/causes-prevention/risk/tobacco/quit-smoking-hp-pdq">Cigarette Smoking: Health Risks and How to Quit</a> for more information.) Avoidance of tobacco use is the most effective measure to prevent lung cancer. The preventive effect of smoking cessation depends on the duration and intensity of prior smoking and upon time since cessation. Compared with persistent smokers, a 30% to 50% reduction in lung cancer mortality risk has been noted after 10 years of cessation.[<a href="#cit/section_2.12">12</a>,<a href="#cit/section_2.72">72</a>-<a href="#cit/section_2.74">74</a>]</p><p id="_255" tabindex="-1">The benefits of tobacco control at the population level provide strong quasi-experimental evidence that reducing population-level exposure to cigarettes has resulted in population-level declines in the occurrence of lung cancer.  Reduced tobacco consumption, resulting from decreases in smoking initiation and increases in smoking cessation, led to a decline in overall age-adjusted lung cancer mortality among men since the mid-1980s, consistent with reductions in smoking prevalence among men since the 1960s.[<a href="#cit/section_2.75">75</a>] Gender differences in time trends for lung cancer are a reflection of (1) the later adoption of cigarette smoking in women compared with men and (2) the later reduction in smoking prevalence among women compared with men.</p><section id="_256"><h5 id="_256_toc">Smoking cessation guidelines</h5><p id="_257" tabindex="-1">Nicotine dependence exposes smokers in a dose-dependent fashion to carcinogenic
            and genotoxic elements that cause lung cancer.[<a href="#cit/section_2.73">73</a>]  Overcoming nicotine
            dependence is often extremely difficult.  The Agency for Healthcare Research and Quality (formerly the Agency for Health Care Policy and
            Research    [AHCPR])   developed a set of clinical smoking-cessation guidelines for
            helping nicotine-dependent patients and health care providers.[<a href="#cit/section_2.74">74</a>]  The six major
            elements of the guidelines include the following:</p><div class="pdq-content-list"><ol id="_258"><li>Clinicians must document the tobacco-use status of every patient.
            </li><li>Every patient using tobacco should be offered one or more of the
            effective smoking cessation treatments that are available.
            </li><li>Every patient using tobacco should be provided with at least one of the
            effective brief cessation interventions that are available.</li><li>More intense interventions are more effective than less
            intense interventions in producing long-term tobacco abstinence,
            reflecting the dose-response relationship between the intervention and
            its outcome.
            </li><li>One or more of the  three treatment elements identified as being
            particularly effective should be included in smoking-cessation
            treatment:<div class="pdq-content-list"><ol id="_259" class="lower-alpha"><li>Nicotine-replacement (e.g., nicotine patches and gum) or other evidence-based smoking cessation pharmacotherapy (e.g., varenicline or bupropion). </li><li>Social support from clinician in the form of encouragement and
            assistance.
            </li><li>Skills training and problem solving (cessation and abstinence techniques).</li></ol></div></li><li>	To be effective, health care systems must make institutional changes resulting in systematic identification of tobacco users and intervention with these patients at every visit.</li></ol></div></section><section id="_260"><h5 id="_260_toc">Pharmacotherapy for smoking cessation</h5><p id="_261" tabindex="-1">Many pharmacotherapies for smoking cessation, including nicotine replacement therapies (e.g., gum, patch, spray, lozenge, and inhaler) and other smoking cessation pharmacotherapies (e.g., varenicline and bupropion), result in statistically significant increases in smoking cessation rates compared with placebo. Based on a synthesis of the results of 110 randomized trials, nicotine replacement therapy treatments, alone or in combination, improve cessation rates over placebos after 6 months (RR, 1.58; 95% CI, 1.50&#x2013;1.66).[<a href="#cit/section_2.76">76</a>] Since the AHCPR guidelines were published, additional evidence of the effectiveness of such pharmacotherapies for smoking cessation has been published.[<a href="#cit/section_2.77">77</a>-<a href="#cit/section_2.79">79</a>] The choice of therapy should be individualized based on a number of factors, including past experience, preference, and potential agent side effects. (Refer to the PDQ summary on <a href="/about-cancer/causes-prevention/risk/tobacco/quit-smoking-hp-pdq">Cigarette Smoking:  Health Risks and How to Quit</a> for more information on pharmacotherapy for smoking cessation.)</p></section><section id="_262"><h5 id="_262_toc">Population-level interventions</h5><p id="_263" tabindex="-1">In addition to individually focused cessation efforts, a number of tobacco control strategies at the community, state, and national level have been credited with reducing the prevalence of smoking. Strategies include the following:[<a href="#cit/section_2.80">80</a>,<a href="#cit/section_2.81">81</a>]</p><div class="pdq-content-list"><ul id="_295"><li>Reducing minors&#x2019; access to tobacco products.</li><li>Disseminating effective school-based prevention curricula together with media strategies.</li><li>Raising the cost of tobacco products by raising taxes.</li><li>Using tobacco excise taxes to fund community-level interventions including mass media.</li><li>Providing proven quitting strategies through health care organizations.</li><li>Adopting smoke-free laws and policies.</li></ul></div></section><section id="_264"><h5 id="_264_toc">Smoke-free workplace legislation</h5><p id="_265" tabindex="-1">A review of more than 50 studies found that smoke-free workplace legislation was consistently associated with reduced secondhand smoke exposure, whether measured in reduced time of exposure (71%&#x2013;100% reduction) or prevalence of persons exposed to secondhand smoke (22%&#x2013;85% reduction), with particularly marked reductions among hospitality workers.[<a href="#cit/section_2.82">82</a>] Smoke-free workplace legislation was associated with consistent and statistically significant reductions in levels of nicotine, dust, benzene, and particulate matter.  Health indicators including respiratory systems, sensory symptoms, and hospital admissions were reported as outcomes in 25 studies.  With respect to health outcomes, a consistent finding was reduced hospital admissions for cardiac events. Evidence suggested that smoke-free workplace legislation may also result in reduced prevalence of active cigarette smoking; for example, one study observed a 32% decreased smoking prevalence in a county that enacted smoke-free workplace legislation compared with a 2.8% decrease in nearby counties with no smoke-free workplace legislation.</p></section></section><section id="_266"><h4 id="_266_toc">Preventing occupational exposure to lung carcinogens</h4><p id="_267" tabindex="-1">After cigarette smoking and exposure to secondhand smoke, occupational exposure to lung carcinogens, such as asbestos, arsenic, nickel, and chromium, is the most important contributor to the lung cancer burden. When occupational exposure to lung carcinogens are all considered together, 9% to 15% of all lung cancer deaths can be attributed to occupational exposure to lung carcinogens.[<a href="#cit/section_2.9">9</a>]  Reducing or eliminating workplace exposures to known lung carcinogens would be expected to result in a corresponding decrease in the risk of lung cancer.  Consequently, the proportion of the lung cancer burden attributable to occupational exposures is declining over time in countries like the United States that have taken steps to protect the workforce from exposure to known lung carcinogens.</p></section></section><section id="_268"><h3 id="_268_toc">Interventions Associated With Increased Risk of Lung Cancer</h3><section id="_269"><h4 id="_269_toc">Beta-carotene supplementation in smokers</h4><p id="_270" tabindex="-1">Results of the National Cancer Institute (NCI) Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) trial were first
            published in  1994.[<a href="#cit/section_2.83">83</a>]  This trial included 29,133 Finnish male chronic
            smokers aged 50 to 69 years in a 2 &#xD7; 2 factorial design of alpha-tocopherol (50
            mg/day) and beta-carotene (20 mg/day).  Subjects were randomly assigned to one of the following four
            groups for 5 to 8 years: beta-carotene alone, alpha-tocopherol alone, beta-carotene plus
            alpha-tocopherol, or placebo.  Subjects receiving beta-carotene (alone or with alpha-tocopherol) had a higher incidence of lung cancer
            (RR, 1.18; 95% CI, 1.03&#x2013;1.36) and higher
            total mortality (RR, 1.08; 95% CI, 1.01&#x2013;1.16).  This effect appeared to be
            associated with heavier smoking (one or more packs/day) and alcohol intake
            (at least one drink/day).[<a href="#cit/section_2.84">84</a>] Supplementation with
            alpha-tocopherol produced no overall effect on lung cancer (RR, 0.99; 95% CI,
            0.87&#x2013;1.13). </p><p id="_271" tabindex="-1">In  1996, the results of the U.S. Beta-Carotene and Retinol Efficacy Trial
            (CARET) were published.[<a href="#cit/section_2.85">85</a>]  This multicenter trial involved 18,314
            smokers, former smokers, and asbestos-exposed workers who were randomly assigned to
            beta-carotene (at a higher dose than the ATBC trial, 30 mg/day) plus retinyl
            palmitate (25,000 IU/day) or placebo.  The primary endpoint was lung cancer
            incidence.  The trial was terminated early by the Data Monitoring Committee and NCI because its results confirmed the ATBC finding of a harmful
            effect of beta-carotene over that of placebo, which increased lung cancer incidence
            (RR, 1.28; 95% CI, 1.04&#x2013;1.57) and total mortality (RR, 1.17; 95% CI,
            1.03&#x2013;1.33).
            In a follow-up study of CARET participants after  the intervention discontinued, these effects attenuated for a period of time.  After 6 years of postintervention follow-up, the postintervention RR for lung cancer incidence was 1.12 (95% CI, 0.97&#x2013;1.31) and for total mortality was 1.08 (95% CI, 0.99&#x2013;1.71). During the postintervention phase a larger RR among women, rather than men, emerged for both outcomes in subgroup analyses; the reason for this observation, if reliable, is not known.[<a href="#cit/section_2.86">86</a>]</p><p id="_272" tabindex="-1">The overall findings from the ATBC [<a href="#cit/section_2.83">83</a>,<a href="#cit/section_2.84">84</a>] and CARET [<a href="#cit/section_2.85">85</a>,<a href="#cit/section_2.87">87</a>] studies, which
            include over 47,000 subjects, demonstrated that pharmacological doses of beta-carotene increase lung cancer risk in relatively high-intensity smokers.  The
            mechanism of this adverse effect is not known.  Lung cancer risks were not
            increased in subsets of moderate-intensity smokers (less than a pack per day)
            in the ATBC study, or in former smokers in the CARET study.  Evidence from other studies, such as  the Physicians&#x2019; Health Study (PHS),[<a href="#cit/section_2.88">88</a>] does not indicate that beta-carotene supplementation increases lung cancer risk in
            nonsmokers.  Subsequent analyses of participants in these trials and cohorts   suggest that the beneficial outcomes
            associated with high beta-carotene plasma levels may be due to increased
            dietary intake of fruits and vegetables.  These findings show the importance of
            randomized controlled trials (RCTs) to confirm epidemiologic studies.</p></section></section><section id="_273"><h3 id="_273_toc">Interventions With Adequate Evidence That They Do Not Reduce Risk</h3><section id="_274"><h4 id="_274_toc">Chemoprevention</h4><p id="_275" tabindex="-1">Studies have examined whether it is possible to prevent cancer development in
            the lung  using chemopreventive agents.
            Chemoprevention is defined as the use of specific natural or synthetic chemical
            agents to reverse, suppress, or prevent carcinogenesis before the development
            of invasive malignancy.   So far, agents tested for efficacy in lung cancer chemoprevention have been micronutrients, such as beta-carotene and vitamin E.</p><section id="_276"><h5 id="_276_toc">Beta-carotene supplementation in nonsmokers</h5><p id="_277" tabindex="-1">Two other RCTs of beta-carotene were carried out in populations that were not at excess risk of lung cancer. The PHS was designed to study the effects
            of beta-carotene and aspirin in cancer and cardiovascular disease.  The study
            is a randomized, double-blind, placebo-controlled trial begun in 1982 involving
            22,071 male physicians aged 40 to 84 years. After 12 years of follow-up,
            beta-carotene was not associated  with  overall risk of cancer (RR, 0.98) or
            lung cancer among current (11% of study population) or former (39% of study
            population) smokers.[<a href="#cit/section_2.88">88</a>]</p><p id="_278" tabindex="-1">In the Women&#x2019;s Health Study (WHS) approximately 40,000 female health professionals were randomly assigned to 50 mg beta carotene on alternate days or placebo.  After a median of 2.1 years of beta-carotene treatment and 2 additional years of follow-up, there was no evidence that beta-carotene protected against lung cancer, as there were more lung cancer cases observed in the beta-carotene (n = 30) than placebo (n = 21) group.[<a href="#cit/section_2.89">89</a>] The strong evidence from rigorous randomized, placebo-controlled trials clearly indicate that beta-carotene supplementation does not lower the risk of lung cancer in populations that are not high-risk for lung cancer.</p></section><section id="_279"><h5 id="_279_toc">Vitamin E supplementation</h5><p id="_280" tabindex="-1">The Heart Outcomes Prevention Evaluation (HOPE) trial began in 1993 and continued follow-up as the HOPE-The Ongoing Outcomes (HOPE-TOO) through 2003.  In this randomized, placebo-controlled trial, patients aged 55 years or older with vascular disease or diabetes were assigned to 400 IU vitamin E or placebo.  With a median follow-up of 7 years, the group randomly assigned to vitamin E had a significantly lower lung cancer incidence rate (1.4%) than the placebo group (2.0%) (RR, 0.72; 95% CI, 0.53&#x2013;0.98).[<a href="#cit/section_2.90">90</a>]  However, the protective association between vitamin E supplements and lung cancer in the HOPE-TOO study needs to be interpreted in the context of evidence from other randomized trials.  In the ATBC study, supplementation with alpha-tocopherol produced no overall effect on lung cancer (RR, 0.99; 95% CI, 0.87&#x2013;1.13). In the WHS of 40,000 female health professionals, using 600 IU of vitamin E every other day showed no evidence of protection against lung cancer in women (RR, 1.09; 95% CI, 0.83&#x2013;1.44).[<a href="#cit/section_2.91">91</a>] The  Medical Research Council/British Heart Foundation   Heart Protection Study (HPS) is a randomized, placebo-controlled trial to test antioxidant vitamin supplementation with vitamin E, vitamin C, and beta-carotene among 20,536 United Kingdom adults with coronary disease, other occlusive arterial disease, or diabetes.  The trial began recruitment in 1994, and as of the 2001 follow-up the results showed a slightly higher rate of lung cancer in the vitamin group compared with the placebo group (1.6% vs. 1.4%, respectively).[<a href="#cit/section_2.92">92</a>]</p><p id="_281" tabindex="-1">Looking at the vitamin E results for the ATBC, HPS, and HOPE-TOO studies combined, the summary odds ratio was 0.97 (95% CI, 0.87&#x2013;1.08),[<a href="#cit/section_2.90">90</a>] and adding the results from the WHS to this would bring the association even closer to the null.   The combined evidence for vitamin E supplementation thus continues to be consistent with no effect on lung cancer risk.</p></section></section></section><h6 do-not-show="toc">References</h6><ol><li id="section_2.1">American Cancer Society: Cancer Facts and Figures 2018. Atlanta, Ga: American Cancer Society, 2018. <a href="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf" title="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf">Available online</a>. Last accessed August 3, 2018.</li><li id="section_2.2">Edwards BK, Brown ML, Wingo PA, et al.: Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97 (19): 1407-27, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16204691&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16204691&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.3">National Cancer Institute: SEER Stat Fact Sheets: Lung and Bronchus. Bethesda, MD: National Institutes of Health. <a href="https://seer.cancer.gov/statfacts/html/lungb.html" title="https://seer.cancer.gov/statfacts/html/lungb.html">Available online</a>. Last accessed November 29, 2017.</li><li id="section_2.4">Spira A, Ettinger DS: Multidisciplinary management of lung cancer. N Engl J Med 350 (4): 379-92, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14736930&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14736930&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.5">Howlader N, Noone AM, Krapcho M, et al., eds.: SEER Cancer Statistics Review (CSR) 1975-2014. Bethesda, Md: National Cancer Institute. <a href="https://seer.cancer.gov/csr/1975_2014/" title="https://seer.cancer.gov/csr/1975_2014/">Also available online</a>. Last accessed August 2, 2018.</li><li id="section_2.6">Bain C, Feskanich D, Speizer FE, et al.: Lung cancer rates in men and women with comparable histories of smoking. J Natl Cancer Inst 96 (11): 826-34, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15173266&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15173266&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.7">Haiman CA, Stram DO, Wilkens LR, et al.: Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med 354 (4): 333-42, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16436765&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16436765&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.8">Blot WJ, Cohen SS, Aldrich M, et al.: Lung cancer risk among smokers of menthol cigarettes. J Natl Cancer Inst 103 (10): 810-6, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21436064&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21436064&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.9">Alberg AJ, Ford JG, Samet JM, et al.: Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132 (3 Suppl): 29S-55S, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17873159&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17873159&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.10">Weir HK, Thun MJ, Hankey BF, et al.: Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95 (17): 1276-99, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12953083&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12953083&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.11">Lippman SM, Benner SE, Hong WK: Cancer chemoprevention. J Clin Oncol 12 (4): 851-73, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8151328&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8151328&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.12">Schottenfeld D, Fraumeni JF Jr, eds.: Cancer Epidemiology and Prevention. 2nd ed. New York, NY: Oxford University Press, 1996.</li><li id="section_2.13">Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service. Washington, DC: US Department of Health, Education, and Welfare, 1965. PHS Publ No 1103.</li><li id="section_2.14">Gazdar AF, Minna JD: Cigarettes, sex, and lung adenocarcinoma. J Natl Cancer Inst 89 (21): 1563-5, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9362148&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9362148&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.15">Song MA, Benowitz NL, Berman M, et al.: Cigarette Filter Ventilation and its Relationship to Increasing Rates of Lung Adenocarcinoma. J Natl Cancer Inst 109 (12): , 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28525914&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28525914&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.16">Iribarren C, Tekawa IS, Sidney S, et al.: Effect of cigar smoking on the risk of cardiovascular disease, chronic obstructive pulmonary disease, and cancer in men. N Engl J Med 340 (23): 1773-80, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10362820&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10362820&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.17">Boffetta P, Pershagen G, J&#xF6;ckel KH, et al.: Cigar and pipe smoking and lung cancer risk: a multicenter study from Europe. J Natl Cancer Inst 91 (8): 697-701, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10218507&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10218507&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.18">Satcher D: Cigars and public health. N Engl J Med 340 (23): 1829-31, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10362829&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10362829&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.19">Mao L, Lee JS, Kurie JM, et al.: Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 89 (12): 857-62, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9196251&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9196251&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.20">Wistuba II, Lam S, Behrens C, et al.: Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst 89 (18): 1366-73, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9308707&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9308707&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.21">Hackshaw AK, Law MR, Wald NJ: The accumulated evidence on lung cancer and environmental tobacco smoke. BMJ 315 (7114): 980-8, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9365295&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9365295&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.22">Anderson KE, Carmella SG, Ye M, et al.: Metabolites of a tobacco-specific lung carcinogen in nonsmoking women exposed to environmental tobacco smoke. J Natl Cancer Inst 93 (5): 378-81, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11238699&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11238699&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.23">Anderson KE, Kliris J, Murphy L, et al.: Metabolites of a tobacco-specific lung carcinogen in nonsmoking casino patrons. Cancer Epidemiol Biomarkers Prev 12 (12): 1544-6, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14693752&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14693752&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.24">Tulunay OE, Hecht SS, Carmella SG, et al.: Urinary metabolites of a tobacco-specific lung carcinogen in nonsmoking hospitality workers. Cancer Epidemiol Biomarkers Prev 14 (5): 1283-6, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15894687&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15894687&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.25">Lissowska J, Foretova L, Dabek J, et al.: Family history and lung cancer risk: international multicentre case-control study in Eastern and Central Europe and meta-analyses. Cancer Causes Control 21 (7): 1091-104, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20306329&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20306329&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.26">Matakidou A, Eisen T, Houlston RS: Systematic review of the relationship between family history and lung cancer risk. Br J Cancer 93 (7): 825-33, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16160696&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16160696&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.27">Shiels MS, Cole SR, Kirk GD, et al.: A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 52 (5): 611-22, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19770804&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19770804&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.28">Alberg AJ, Samet JM: Epidemiology of lung cancer. Chest 123 (1 Suppl): 21S-49S, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12527563&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12527563&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.29">Straif K, Benbrahim-Tallaa L, Baan R, et al.: A review of human carcinogens--part C: metals, arsenic, dusts, and fibres. Lancet Oncol 10 (5): 453-4, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19418618&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19418618&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.30">Saracci R: The interactions of tobacco smoking and other agents in cancer etiology. Epidemiol Rev 9: 175-93, 1987.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3315716&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3315716&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.31">Committee on Health Risks of Exposure to Radon (BEIR VI): Health Effects of Exposure to Radon: BEIR VI. Washington, DC: National Academies Press, 1999. <a href="https://www.ncbi.nlm.nih.gov/pubmed/25121310" title="https://www.ncbi.nlm.nih.gov/pubmed/25121310">Also available online</a>. Last accessed November 29, 2017.</li><li id="section_2.32">Shimizu Y, Kato H, Schull WJ: Studies of the mortality of A-bomb survivors. 9. Mortality, 1950-1985: Part 2. Cancer mortality based on the recently revised doses (DS86). Radiat Res 121 (2): 120-41, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2305030&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2305030&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.33">Davis FG, Boice JD Jr, Hrubec Z, et al.: Cancer mortality in a radiation-exposed cohort of Massachusetts tuberculosis patients. Cancer Res 49 (21): 6130-6, 1989.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2790825&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2790825&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.34">Howe GR: Lung cancer mortality between 1950 and 1987 after exposure to fractionated moderate-dose-rate ionizing radiation in the Canadian fluoroscopy cohort study and a comparison with lung cancer mortality in the Atomic Bomb survivors study. Radiat Res 142 (3): 295-304, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7761580&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7761580&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.35">Lorigan P, Califano R, Faivre-Finn C, et al.: Lung cancer after treatment for breast cancer. Lancet Oncol 11 (12): 1184-92, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20541465&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20541465&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.36">Grantzau T, Thomsen MS, V&#xE6;th M, et al.: Risk of second primary lung cancer in women after radiotherapy for breast cancer. Radiother Oncol 111 (3): 366-73, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24909095&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24909095&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.37">Grantzau T, Overgaard J: Risk of second non-breast cancer after radiotherapy for breast cancer: a systematic review and meta-analysis of 762,468 patients. Radiother Oncol 114 (1): 56-65, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25454172&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25454172&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.38">Kaufman EL, Jacobson JS, Hershman DL, et al.: Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J Clin Oncol 26 (3): 392-8, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18202415&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18202415&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.39">Lorigan P, Radford J, Howell A, et al.: Lung cancer after treatment for Hodgkin's lymphoma: a systematic review. Lancet Oncol 6 (10): 773-9, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16198983&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16198983&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.40">Alberg AJ, Brock MV, Ford JG, et al.: Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143 (5 Suppl): e1S-29S, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23649439&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23649439&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.41">Berrington de Gonz&#xE1;lez A, Kim KP, Berg CD: Low-dose lung computed tomography screening before age 55: estimates of the mortality reduction required to outweigh the radiation-induced cancer risk. J Med Screen 15 (3): 153-8, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18927099&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18927099&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.42">Mascalchi M, Belli G, Zappa M, et al.: Risk-benefit analysis of X-ray exposure associated with lung cancer screening in the Italung-CT trial. AJR Am J Roentgenol 187 (2): 421-9, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16861547&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16861547&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.43">Hendee WR: Estimation of radiation risks. BEIR V and its significance for medicine. JAMA 268 (5): 620-4, 1992.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1629990&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1629990&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.44">Saccomanno G, Huth GC, Auerbach O, et al.: Relationship of radioactive radon daughters and cigarette smoking in the genesis of lung cancer in uranium miners. Cancer 62 (7): 1402-8, 1988.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3416280&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3416280&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.45">Kim SH, Hwang WJ, Cho JS, et al.: Attributable risk of lung cancer deaths due to indoor radon exposure. Ann Occup Environ Med 28: 8, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26925236&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26925236&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.46">Lubin JH, Boice JD Jr: Lung cancer risk from residential radon: meta-analysis of eight epidemiologic studies. J Natl Cancer Inst 89 (1): 49-57, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8978406&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8978406&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.47">Krewski D, Lubin JH, Zielinski JM, et al.: Residential radon and risk of lung cancer: a combined analysis of 7 North American case-control studies. Epidemiology 16 (2): 137-45, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15703527&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15703527&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.48">Environmental Protection Agency: Exposure to Radon Causes Lung Cancer In Non-smokers and Smokers Alike. Washington, DC: Environmental Protection Agency, 2011. <a href="https://www.epa.gov/radon/health-risk-radon#head" title="https://www.epa.gov/radon/health-risk-radon#head">Available online</a>. Last accessed November 30, 2017.</li><li id="section_2.49">Gray A, Read S, McGale P, et al.: Lung cancer deaths from indoor radon and the cost effectiveness and potential of policies to reduce them. BMJ 338: a3110, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19129153&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19129153&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.50">Vineis P, Forastiere F, Hoek G, et al.: Outdoor air pollution and lung cancer: recent epidemiologic evidence. Int J Cancer 111 (5): 647-52, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15252832&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15252832&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.51">Laden F, Schwartz J, Speizer FE, et al.: Reduction in fine particulate air pollution and mortality: Extended follow-up of the Harvard Six Cities study. Am J Respir Crit Care Med 173 (6): 667-72, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16424447&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16424447&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.52">Pope CA 3rd, Thun MJ, Namboodiri MM, et al.: Particulate air pollution as a predictor of mortality in a prospective study of U.S. adults. Am J Respir Crit Care Med 151 (3 Pt 1): 669-74, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7881654&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7881654&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.53">Pope CA 3rd, Burnett RT, Thun MJ, et al.: Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution. JAMA 287 (9): 1132-41, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11879110&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11879110&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.54">Katanoda K, Sobue T, Satoh H, et al.: An association between long-term exposure to ambient air pollution and mortality from lung cancer and respiratory diseases in Japan. J Epidemiol 21 (2): 132-43, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21325732&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21325732&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.55">Cao J, Yang C, Li J, et al.: Association between long-term exposure to outdoor air pollution and mortality in China: a cohort study. J Hazard Mater 186 (2-3): 1594-600, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21194838&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21194838&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.56">Hales S, Blakely T, Woodward A: Air pollution and mortality in New Zealand: cohort study. J Epidemiol Community Health 66 (5): 468-73, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20966448&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20966448&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.57">Raaschou-Nielsen O, Andersen ZJ, Beelen R, et al.: Air pollution and lung cancer incidence in 17 European cohorts: prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE). Lancet Oncol 14 (9): 813-22, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23849838&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23849838&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.58">Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. Washington, DC: World Cancer Research Fund/American Institute for Cancer Research, 2007. <a href="http://www.aicr.org/assets/docs/pdf/reports/Second_Expert_Report.pdf" title="http://www.aicr.org/assets/docs/pdf/reports/Second_Expert_Report.pdf">Also available online</a>. Last accessed August 7, 2018.</li><li id="section_2.59">Gallicchio L, Boyd K, Matanoski G, et al.: Carotenoids and the risk of developing lung cancer: a systematic review. Am J Clin Nutr 88 (2): 372-83, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18689373&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18689373&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.60">Calle EE, Rodriguez C, Walker-Thurmond K, et al.: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348 (17): 1625-38, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12711737&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12711737&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.61">Olson JE, Yang P, Schmitz K, et al.: Differential association of body mass index and fat distribution with three major histologic types of lung cancer: evidence from a cohort of older women. Am J Epidemiol 156 (7): 606-15, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12244029&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12244029&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.62">Tardon A, Lee WJ, Delgado-Rodriguez M, et al.: Leisure-time physical activity and lung cancer: a meta-analysis. Cancer Causes Control 16 (4): 389-97, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15953981&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15953981&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.63">Lee IM, Sesso HD, Paffenbarger RS Jr: Physical activity and risk of lung cancer. Int J Epidemiol 28 (4): 620-5, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10480687&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10480687&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.64">Thune I, Lund E: The influence of physical activity on lung-cancer risk: A prospective study of 81,516 men and women. Int J Cancer 70 (1): 57-62, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8985091&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8985091&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.65">Mao Y, Pan S, Wen SW, et al.: Physical activity and the risk of lung cancer in Canada. Am J Epidemiol 158 (6): 564-75, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12965882&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12965882&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.66">Wiseman M: The second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Proc Nutr Soc 67 (3): 253-6, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18452640&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18452640&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.67">Peto R, Lopez AD, Boreham J, et al.: Mortality from Smoking in Developed Countries, 1950-2000: Indirect Estimates from National Vital Statistics. New York, NY: Oxford University Press, 1994.</li><li id="section_2.68">Samet JM, Avila-Tang E, Boffetta P, et al.: Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clin Cancer Res 15 (18): 5626-45, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19755391&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19755391&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.69">Lam TK, Moore SC, Brinton LA, et al.: Anthropometric measures and physical activity and the risk of lung cancer in never-smokers: a prospective cohort study. PLoS One 8 (8): e70672, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23940620&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23940620&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.70">Korte JE, Brennan P, Henley SJ, et al.: Dose-specific meta-analysis and sensitivity analysis of the relation between alcohol consumption and lung cancer risk. Am J Epidemiol 155 (6): 496-506, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11882523&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11882523&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.71">The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, Ga: U.S. Department of Health and Human Services, CDC, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2004. <a href="https://www.cdc.gov/tobacco/data_statistics/sgr/2004/index.htm" title="https://www.cdc.gov/tobacco/data_statistics/sgr/2004/index.htm">Also available online</a>.                Last accessed August 13, 2018.</li><li id="section_2.72">The Health Benefits of Smoking Cessation: a report of the Surgeon General. Rockville: US Department of Health and Human Services, Public Health Service, Centers for Disease Control, Centers for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, DHHS Publ No (CDC) 90-8416, 1990.</li><li id="section_2.73">Cinciripini PM, Hecht SS, Henningfield JE, et al.: Tobacco addiction: implications for treatment and cancer prevention. J Natl Cancer Inst 89 (24): 1852-67, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9414173&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9414173&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.74">Fiore MC, Bailey WC, Cohen SJ, et al.: Smoking Cessation: Clinical Practice Guideline No 18. Rockville, Md: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1996. AHCPR Publ No 96-0692.</li><li id="section_2.75">Greenlee RT, Murray T, Bolden S, et al.: Cancer statistics, 2000. CA Cancer J Clin 50 (1): 7-33, 2000 Jan-Feb.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10735013&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10735013&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.76">Silagy C, Lancaster T, Stead L, et al.: Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev  (3): CD000146, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15266423&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15266423&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.77">Hurt RD, Sachs DP, Glover ED, et al.: A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337 (17): 1195-202, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9337378&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9337378&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.78">Jorenby DE, Leischow SJ, Nides MA, et al.: A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340 (9): 685-91, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10053177&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10053177&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.79">Hughes JR, Goldstein MG, Hurt RD, et al.: Recent advances in the pharmacotherapy of smoking. JAMA 281 (1): 72-6, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9892454&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9892454&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.80">Wingo PA, Ries LA, Giovino GA, et al.: Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst 91 (8): 675-90, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10218505&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10218505&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.81">Koh HK: The end of the "tobacco and cancer" century. J Natl Cancer Inst 91 (8): 660-1, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10218498&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10218498&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.82">Callinan JE, Clarke A, Doherty K, et al.: Legislative smoking bans for reducing secondhand smoke exposure, smoking prevalence and tobacco consumption. Cochrane Database Syst Rev  (4): CD005992, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20393945&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20393945&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.83">The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 330 (15): 1029-35, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8127329&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8127329&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.84">Albanes D, Heinonen OP, Taylor PR, et al.: Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J Natl Cancer Inst 88 (21): 1560-70, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8901854&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8901854&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.85">Omenn GS, Goodman GE, Thornquist MD, et al.: Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334 (18): 1150-5, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8602180&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8602180&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.86">Goodman GE, Thornquist MD, Balmes J, et al.: The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements. J Natl Cancer Inst 96 (23): 1743-50, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15572756&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15572756&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.87">Omenn GS, Goodman GE, Thornquist MD, et al.: Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 88 (21): 1550-9, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8901853&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8901853&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.88">Hennekens CH, Buring JE, Manson JE, et al.: Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 334 (18): 1145-9, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8602179&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8602179&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.89">Lee IM, Cook NR, Manson JE, et al.: Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study. J Natl Cancer Inst 91 (24): 2102-6, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10601381&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10601381&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.90">Lonn E, Bosch J, Yusuf S, et al.: Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 293 (11): 1338-47, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15769967&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15769967&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.91">Lee IM, Cook NR, Gaziano JM, et al.: Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA 294 (1): 56-65, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15998891&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15998891&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.92">Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (9326): 23-33, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12114037&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12114037&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _80
      field_pdq_section_title:
        - format: plain_text
          value: 'Changes to This Summary (03/02/2018)'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_80" class="pdq-sections"><p id="_82" tabindex="-1">The PDQ cancer information summaries are reviewed regularly and updated as
            new information becomes available.  This section describes the latest
            changes made to this summary as of the date above.</p><p id="_337" tabindex="-1"><strong><a href="/types/lung/hp/lung-prevention-pdq#link/_16">Description of the Evidence</a></strong></p><p id="_346" tabindex="-1">Updated <a href="/types/lung/hp/lung-prevention-pdq#link/_218">statistics</a> with estimated new cases and deaths for 2018 (cited American Cancer Society as reference 1).</p><p id="_disclaimerHP_3" tabindex="-1">This summary is written and maintained by the <a href="https://www.cancer.gov/publications/pdq/editorial-boards/screening-prevention" title="https://www.cancer.gov/publications/pdq/editorial-boards/screening-prevention">PDQ Screening and Prevention Editorial Board</a>, which is
            editorially independent of NCI.  The summary reflects an independent review of
            the literature and does not represent a policy statement of NCI or NIH.  More
            information about summary policies and the role of the PDQ Editorial Boards  in
            maintaining the PDQ summaries can be found on the <a href="/types/lung/hp/lung-prevention-pdq#link/_AboutThis_1">About This PDQ Summary</a> and <a href="https://www.cancer.gov/publications/pdq" title="https://www.cancer.gov/publications/pdq">PDQ&#xAE; - NCI's Comprehensive Cancer Database</a> pages.
            </p></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _AboutThis_1
      field_pdq_section_title:
        - format: plain_text
          value: 'About This PDQ Summary'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_AboutThis_1" class="pdq-sections"><section id="_AboutThis_2"><h3 id="_AboutThis_2_toc">Purpose of This Summary</h3><p id="_AboutThis_3" tabindex="-1">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about lung cancer prevention. It is intended as a resource to inform and assist clinicians who care for cancer patients.  It does not provide formal guidelines or recommendations for making health care decisions.</p></section><section id="_AboutThis_4"><h3 id="_AboutThis_4_toc">Reviewers and Updates</h3><p id="_AboutThis_5" tabindex="-1">This summary is reviewed regularly and updated as necessary by the <a href="https://www.cancer.gov/publications/pdq/editorial-boards/screening-prevention" title="https://www.cancer.gov/publications/pdq/editorial-boards/screening-prevention">PDQ Screening and Prevention Editorial Board</a>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</p><p id="_AboutThis_22" tabindex="-1"> Board members review recently published articles each month to determine whether an article should:</p><div class="pdq-content-list"><ul id="_AboutThis_6"><li>be discussed at a meeting,</li><li>be cited with text, or</li><li>replace or update an existing article that is already cited.</li></ul></div><p id="_AboutThis_7" tabindex="-1">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</p><p id="_AboutThis_9" tabindex="-1">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <a href="https://www.cancer.gov/contact/email-us" title="https://www.cancer.gov/contact/email-us">Email Us</a>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</p></section><section id="_AboutThis_10"><h3 id="_AboutThis_10_toc">Levels of Evidence</h3><p id="_AboutThis_11" tabindex="-1">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Screening and Prevention Editorial Board uses a <a href="/publications/pdq/levels-evidence/screening-prevention">formal evidence ranking system</a> in developing its level-of-evidence designations.</p></section><section id="_AboutThis_12"><h3 id="_AboutThis_12_toc">Permission to Use This Summary</h3><p id="_AboutThis_13" tabindex="-1">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as &#x201C;NCI&#x2019;s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].&#x201D;</p><p id="_AboutThis_14" tabindex="-1">The preferred citation for this PDQ summary is:</p><p id="_AboutThis_15" tabindex="-1">PDQ&#xAE; Screening and Prevention Editorial Board. PDQ Lung Cancer Prevention. Bethesda, MD: National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <a href="https://www.cancer.gov/types/lung/hp/lung-prevention-pdq" title="https://www.cancer.gov/types/lung/hp/lung-prevention-pdq">https://www.cancer.gov/types/lung/hp/lung-prevention-pdq</a>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 26389452]</p><p id="_AboutThis_16" tabindex="-1">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <a href="https://visualsonline.cancer.gov/" title="https://visualsonline.cancer.gov/">Visuals Online</a>, a collection of over 2,000 scientific images.
            </p></section><section id="_AboutThis_17"><h3 id="_AboutThis_17_toc">Disclaimer</h3><p id="_AboutThis_19" tabindex="-1">The information in these summaries should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <a href="https://www.cancer.gov/about-cancer/managing-care" title="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</a> page.</p></section><section id="_AboutThis_20"><h3 id="_AboutThis_20_toc">Contact Us</h3><p id="_AboutThis_21" tabindex="-1">More information about contacting us or receiving help with the Cancer.gov website can be found on our <a href="https://www.cancer.gov/contact" title="https://www.cancer.gov/contact">Contact Us for Help</a> page. Questions can also be submitted to Cancer.gov through the website&#x2019;s <a href="https://www.cancer.gov/contact/email-us" title="https://www.cancer.gov/contact/email-us">Email Us</a>.</p></section></div>
  title__ES:
    value: 'Prevención del cáncer de pulmón (PDQ®)–Versión para profesionales de salud'
  status__ES:
    value: 1
  langcode__ES:
    value: es
  moderation_state__ES:
    value: published
  field_pdq_url__ES:
    value: /tipos/pulmon/pro/prevencion-pulmon-pdq
  field_pdq_cdr_id__ES:
    value: 733624
  field_pdq_audience__ES:
    value: Health Professionals
  field_pdq_summary_type__ES:
    value: Prevention
  field_date_posted__ES:
    value: '2012-08-22'
  field_date_updated__ES:
    value: '2018-03-19'
  field_browser_title__ES:
    value: 'Prevención del cáncer de pulmón'
  field_page_description__ES:
    value: 'Sumario de información revisada por expertos sobre factores que influyen en el riesgo de presentar cáncer de pulmón y sobre las investigaciones dirigidas a la prevención de esta enfermedad.'
  field_public_use__ES:
    value: 1
  field_summary_sections__ES:
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _1
      field_pdq_section_title:
        - format: plain_text
          value: 'Aspectos generales'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_1" class="pdq-sections"><div class="pdq-hp-patient-toggle"><a href="/espanol/tipos/pulmon/paciente/prevencion-pulmon-pdq">Vaya a la versi&#xF3;n para pacientes</a></div><p id="_3" tabindex="-1">Nota: tambi&#xE9;n est&#xE1;n disponibles sumarios  del PDQ separados sobre <a href="/espanol/tipos/pulmon/pro/deteccion-pulmon-pdq">Ex&#xE1;menes de detecci&#xF3;n del c&#xE1;ncer de pulm&#xF3;n</a>; <a href="/espanol/tipos/pulmon/pro/tratamiento-pulmon-celulas-pequenas-pdq">Tratamiento del c&#xE1;ncer de pulm&#xF3;n de c&#xE9;lulas peque&#xF1;as</a>; <a href="/espanol/tipos/pulmon/pro/tratamiento-pulmon-celulas-no-pequenas-pdq">Tratamiento del c&#xE1;ncer de pulm&#xF3;n de c&#xE9;lulas no peque&#xF1;as</a> y el sumario  sobre <a href="/espanol/cancer/causas-prevencion/riesgo/tabaco/dejar-fumar-pro-pdq">Consumo de cigarrillo: riesgos para la salud y c&#xF3;mo dejar de fumar</a>. </p><section id="_4"><h3 id="_4_toc">&#xBF;Qui&#xE9;n est&#xE1; en riesgo?</h3><p id="_6" tabindex="-1">El riesgo de c&#xE1;ncer de pulm&#xF3;n es en gran medida una funci&#xF3;n de la edad avanzada en combinaci&#xF3;n con antecedentes de consumo excesivo de cigarrillos. El c&#xE1;ncer de pulm&#xF3;n es m&#xE1;s com&#xFA;n en los hombres que en las mujeres y en las personas de nivel socioecon&#xF3;mico m&#xE1;s bajo. Los patrones de este tipo de c&#xE1;ncer seg&#xFA;n las caracter&#xED;sticas demogr&#xE1;ficas tienden a correlacionarse s&#xF3;lidamente con patrones hist&#xF3;ricos de prevalencia del consumo de cigarrillos. Una excepci&#xF3;n a esto es la tasa tan alta en hombres afroamericanos, grupo cuya tasa tan alta de mortalidad por c&#xE1;ncer de pulm&#xF3;n  no se explica simplemente mediante patrones hist&#xF3;ricos de tabaquismo.[<a href="#cit/section_1.1">1</a>]</p><p id="_7" tabindex="-1">En los no fumadores, los factores de riesgo importantes para el c&#xE1;ncer de pulm&#xF3;n son la exposici&#xF3;n al humo de otros fumadores, exposici&#xF3;n a la radiaci&#xF3;n ionizante y la exposici&#xF3;n ocupacional a carcin&#xF3;genos pulmonares, como el asbesto o amianto. Los tipos de exposici&#xF3;n a la radiaci&#xF3;n importantes para la poblaci&#xF3;n general son la exposici&#xF3;n medioambiental al rad&#xF3;n y las exposiciones a la radiaci&#xF3;n en el entorno m&#xE9;dico, sobre todo cuando se administra en dosis altas como en el caso de la radioterapia dirigida al t&#xF3;rax o la mama.[<a href="#cit/section_1.2">2</a>] El tabaquismo suele interactuar con estos otros factores. Hay varios ejemplos como la exposici&#xF3;n al rad&#xF3;n y la exposici&#xF3;n al asbesto, en los que la exposici&#xF3;n combinada al humo del cigarrillo m&#xE1;s otro factor de riesgo aumentan el riesgo de una manera mucho mayor a la suma de los riesgos relacionados con cada factor por s&#xED; solo.</p><section id="_8"><h4 id="_8_toc">Factores relacionados con un aumento de riesgo de c&#xE1;ncer de pulm&#xF3;n</h4><section id="_9"><h5 id="_9_toc">Tabaquismo</h5><p id="_10" tabindex="-1">A partir del informe de 1964 Surgeon General&#x2019;s Report y en cada uno de los informes subsiguientes que incluyeron una revisi&#xF3;n de los datos probatorios sobre el tabaquismo y el c&#xE1;ncer de pulm&#xF3;n, gran cantidad de datos cient&#xED;ficos documentan claramente que el consumo de cigarrillos produce c&#xE1;ncer y que se trata de la principal causa del c&#xE1;ncer de pulm&#xF3;n.</p><p id="_11" tabindex="-1">Con base en pruebas s&#xF3;lidas, el consumo de cigarrillos produce c&#xE1;ncer de pulm&#xF3;n. Los riesgos de padecer este tipo de c&#xE1;ncer por el tabaquismo dependen de la dosis y aumenta marcadamente seg&#xFA;n el n&#xFA;mero de cigarrillos fumados a diario y el n&#xFA;mero de a&#xF1;os durante los que se fuma. En promedio, los fumadores actuales se enfrentan a un riesgo de padecer c&#xE1;ncer de pulm&#xF3;n alrededor de 20 veces m&#xE1;s alto que los no fumadores. </p><p id="_12" tabindex="-1"><strong>Magnitud del efecto: aumento del riesgo, muy grande.</strong></p><div class="pdq-content-list"><ul id="_13" class="pdq-address-block"><li>Dise&#xF1;o de los estudios: numerosos estudios de cohortes y casos y controles prospectivos, combinados con datos cuasi experimentales que revelan que la prevalencia poblacional del tabaquismo predice la cantidad de casos de c&#xE1;ncer a nivel de la poblaci&#xF3;n.</li><li>Validez interna: buena.</li><li>Congruencia: buena.</li><li>Validez externa: buena.</li></ul></div></section><section id="_14"><h5 id="_14_toc">Exposici&#xF3;n pasiva al humo de tabaco</h5><p id="_15" tabindex="-1">Con base en pruebas s&#xF3;lidas, la exposici&#xF3;n pasiva al humo de tabaco es una causa establecida de c&#xE1;ncer de pulm&#xF3;n.</p><p id="_16" tabindex="-1"><strong>Magnitud del efecto: aumento del riesgo, magnitud peque&#xF1;a. En comparaci&#xF3;n con los no fumadores sin exposici&#xF3;n pasiva al humo de tabaco, los no fumadores con exposici&#xF3;n  pasiva al humo de tabaco tienen un aumento de riesgo de cerca de 20&#xA0;% de contraer c&#xE1;ncer de pulm&#xF3;n.</strong></p><div class="pdq-content-list"><ul id="_17" class="pdq-address-block"><li>Dise&#xF1;o de los estudios: estudios prospectivos de cohortes y casos y controles.</li><li>Validez interna: buena.</li><li>Congruencia: buena.</li><li>Validez externa: buena.</li></ul></div></section><section id="_18"><h5 id="_18_toc">Exposici&#xF3;n al rad&#xF3;n</h5><p id="_19" tabindex="-1">Con base en pruebas s&#xF3;lidas, la exposici&#xF3;n al rad&#xF3;n aumenta la incidencia del c&#xE1;ncer de pulm&#xF3;n y la mortalidad por c&#xE1;ncer de pulm&#xF3;n.</p><p id="_20" tabindex="-1"><strong>Magnitud del efecto: aumento de riesgo que sigue un gradiente dosis-respuesta, con aumentos peque&#xF1;os de riesgo para niveles bajos de exposici&#xF3;n y mayor riesgo con niveles altos de exposici&#xF3;n.</strong></p><div class="pdq-content-list"><ul id="_21" class="pdq-address-block"><li>Dise&#xF1;o de los estudios: estudios de cohortes y de casos y controles.</li><li>Validez interna: razonable.</li><li>Congruencia: buena.</li><li>Validez externa: razonable.</li></ul></div></section><section id="_147"><h5 id="_147_toc">Exposici&#xF3;n ocupacional a carcin&#xF3;genos pulmonares</h5><p id="_148" tabindex="-1">Con base en pruebas s&#xF3;lidas, la exposici&#xF3;n en el lugar de trabajo a asbesto, ars&#xE9;nico, berilio, cadmio, cromo y n&#xED;quel aumenta la incidencia y la mortalidad por c&#xE1;ncer de pulm&#xF3;n.</p><p id="_149" tabindex="-1"><strong>Magnitud del efecto: aumento de riesgo, gran magnitud (m&#xE1;s de cinco veces). Los riesgos siguen una gradiente de respuesta a la dosis, los niveles altos de exposici&#xF3;n se relacionan con mayores incrementos de riesgo. El tabaquismo tambi&#xE9;n potencia el efecto de muchos de estos carcin&#xF3;genos pulmonares, por lo tanto, los riesgos son mucho m&#xE1;s altos en los fumadores.</strong></p><div class="pdq-content-list"><ul id="_150" class="pdq-address-block"><li>Dise&#xF1;o del estudio: estudios de cohortes y de casos y controles.</li><li>Validez interna: buena.</li><li>Congruencia: buena.</li><li>Validez externa: buena.</li></ul></div></section><section id="_151"><h5 id="_151_toc">Contaminaci&#xF3;n del aire</h5><p id="_152" tabindex="-1">Con base en pruebas s&#xF3;lidas, la exposici&#xF3;n a la contaminaci&#xF3;n del aire, en especial, de part&#xED;culas peque&#xF1;as aumenta la incidencia de c&#xE1;ncer de pulm&#xF3;n y la mortalidad por esta enfermedad.</p><p id="_153" tabindex="-1"><strong>Magnitud del efecto: aumento de riesgo; en comparaci&#xF3;n con las categor&#xED;as de exposici&#xF3;n m&#xE1;s bajas, aquellos con las categor&#xED;as de exposici&#xF3;n m&#xE1;s altas tienen un aumento de riesgo de c&#xE1;ncer de pulm&#xF3;n de aproximadamente 40&#xA0;%.</strong></p><div class="pdq-content-list"><ul id="_154" class="pdq-address-block"><li>Dise&#xF1;o del estudio: estudios de cohortes y de casos y controles.</li><li>Validez interna: buena.</li><li>Congruencia: buena.</li><li>Validez externa: buena.</li></ul></div></section></section><section id="_22"><h4 id="_22_toc">Factores de relaci&#xF3;n incierta con el riesgo</h4><section id="_23"><h5 id="_23_toc">Factores alimentarios</h5><p id="_24" tabindex="-1">Con base en pruebas equ&#xED;vocas, las relaciones inversas observadas entre el c&#xE1;ncer de pulm&#xF3;n y los factores alimentarios, como el consumo de frutas y verduras, son dif&#xED;ciles de separar del consumo de cigarrillos.</p><p id="_25" tabindex="-1"><strong>Magnitud del efecto: relaci&#xF3;n inversa, magnitud moderada pero dif&#xED;cil de determinar si se trata de una verdadera relaci&#xF3;n de causa-efecto o debida a confusi&#xF3;n por el tabaquismo.</strong></p><div class="pdq-content-list"><ul id="_26" class="pdq-address-block"><li>Dise&#xF1;o de los estudios: numerosos estudios de cohortes y de casos y controles, y metan&#xE1;lisis.</li><li>Validez interna: razonable.</li><li>Congruencia: razonable.</li><li>Validez externa: buena.</li></ul></div></section><section id="_27"><h5 id="_27_toc">Actividad f&#xED;sica</h5><p id="_28" tabindex="-1">Con base en pruebas equ&#xED;vocas, las relaciones inversas observadas entre el c&#xE1;ncer de pulm&#xF3;n y los niveles m&#xE1;s altos de actividad f&#xED;sica son dif&#xED;ciles de aislar del tabaquismo.</p><p id="_29" tabindex="-1"><strong>Magnitud del efecto: relaci&#xF3;n inversa, magnitud moderada pero dif&#xED;cil de determinar si se trata de una verdadera relaci&#xF3;n causa-efecto o debida a confusi&#xF3;n por el tabaquismo.</strong></p><div class="pdq-content-list"><ul id="_30" class="pdq-address-block"><li>Dise&#xF1;o de los estudios: numerosos estudios de cohorte y de casos y controles, y metan&#xE1;lisis.</li><li>Validez interna: razonable.</li><li>Congruencia: razonable.</li><li>Validez externa: buena.</li></ul></div></section></section></section><section id="_31"><h3 id="_31_toc">Intervenciones relacionadas con la disminuci&#xF3;n del riesgo de c&#xE1;ncer de pulm&#xF3;n</h3><section id="_32"><h4 id="_32_toc">Abstinencia del tabaquismo</h4><p id="_33" tabindex="-1">Con base en pruebas s&#xF3;lidas, el tabaquismo provoca c&#xE1;ncer de pulm&#xF3;n y, en consecuencia, la abstinencia de fumar produce una reducci&#xF3;n de la mortalidad por c&#xE1;nceres de pulm&#xF3;n primarios. </p><p id="_34" tabindex="-1"><strong>Magnitud del efecto: disminuci&#xF3;n del riesgo, magnitud considerable.</strong></p><div class="pdq-content-list"><ul id="_35" class="pdq-address-block"><li>Dise&#xF1;o de los estudios: estudios de cohorte y de casos y controles.</li><li>Validez interna: buena.</li><li>Congruencia: buena.</li><li>Validez externa: buena.</li></ul></div></section><section id="_36"><h4 id="_36_toc">Cese del tabaquismo</h4><p id="_37" tabindex="-1">Con base en pruebas s&#xF3;lidas, el cese continuado del h&#xE1;bito de fumar a largo plazo produce una disminuci&#xF3;n de la incidencia del c&#xE1;ncer de pulm&#xF3;n y de segundos tumores de pulm&#xF3;n primarios.</p><p id="_38" tabindex="-1"><strong>Magnitud del efecto: disminuci&#xF3;n del riesgo, magnitud moderada.</strong></p><div class="pdq-content-list"><ul id="_39" class="pdq-address-block"><li>Dise&#xF1;o de los estudios: estudios de cohorte y de casos y controles.</li><li>Validez interna: buena.</li><li>Congruencia: buena.</li><li>Validez externa: buena.</li></ul></div></section><section id="_40"><h4 id="_40_toc">Eliminaci&#xF3;n de la exposici&#xF3;n pasiva al humo de tabaco</h4><p id="_41" tabindex="-1">Con base en pruebas s&#xF3;lidas, la exposici&#xF3;n pasiva al humo de tabaco causa c&#xE1;ncer de pulm&#xF3;n y, en consecuencia, prevenir la exposici&#xF3;n pasiva al humo de tabaco produce una reducci&#xF3;n de la incidencia y la mortalidad por c&#xE1;nceres de pulm&#xF3;n primarios. </p><p id="_42" tabindex="-1"><strong>Magnitud del efecto: disminuci&#xF3;n del riesgo, magnitud peque&#xF1;a.</strong></p><div class="pdq-content-list"><ul id="_43" class="pdq-address-block"><li>Dise&#xF1;o de los estudios: estudios de cohorte y de casos y controles.</li><li>Validez interna: buena.</li><li>Congruencia: buena.</li><li>Validez externa: buena.</li></ul></div></section><section id="_44"><h4 id="_44_toc">Reducci&#xF3;n o eliminaci&#xF3;n de la exposici&#xF3;n ocupacional a carcin&#xF3;genos pulmonares</h4><p id="_45" tabindex="-1">Con base en pruebas s&#xF3;lidas, las exposiciones en el lugar de trabajo a asbesto, ars&#xE9;nico, n&#xED;quel y cromo se relacionan de manera causal con el c&#xE1;ncer de pulm&#xF3;n.  Se prev&#xE9; que la reducci&#xF3;n o la eliminaci&#xF3;n de las exposiciones en el lugar de trabajo a carcin&#xF3;genos pulmonares conocidos llevar&#xE1; a una disminuci&#xF3;n correspondiente del riesgo de c&#xE1;ncer de pulm&#xF3;n.</p><p id="_46" tabindex="-1"><strong>Magnitud del efecto: disminuci&#xF3;n del riesgo, con un efecto m&#xE1;s grande por una reducci&#xF3;n mayor de la exposici&#xF3;n.</strong></p><div class="pdq-content-list"><ul id="_47" class="pdq-address-block"><li>Dise&#xF1;o de los estudios: estudios de cohortes y de casos y controles.</li><li>Validez interna: buena.</li><li>Congruencia: buena.</li><li>Validez externa: buena.</li></ul></div></section><section id="_48"><h4 id="_48_toc">Reducci&#xF3;n o eliminaci&#xF3;n de la exposici&#xF3;n al rad&#xF3;n</h4><p id="_49" tabindex="-1">Con base en pruebas s&#xF3;lidas, la exposici&#xF3;n al rad&#xF3;n en ambientes cerrados aumenta la incidencia y la mortalidad por c&#xE1;ncer de pulm&#xF3;n, en especial entre los fumadores. En los hogares con altas concentraciones de rad&#xF3;n, se espera que la toma de medidas para evitar el ingreso del rad&#xF3;n mediante el sellado del s&#xF3;tano produzca una disminuci&#xF3;n correspondiente del riesgo de c&#xE1;ncer de pulm&#xF3;n.</p><p id="_50" tabindex="-1"><strong>Magnitud del efecto: aumento del riesgo que sigue un gradiente de dosis-respuesta, con aumentos peque&#xF1;os de riesgo para los niveles de exposici&#xF3;n de la mayor&#xED;a de los hogares vulnerables hasta aumentos mayores del riesgo debido a niveles m&#xE1;s altos de exposici&#xF3;n.</strong></p><div class="pdq-content-list"><ul id="_51" class="pdq-address-block"><li>Dise&#xF1;o de los estudios: estudios de cohorte y de casos y controles.</li><li>Validez interna: razonable.</li><li>Congruencia: buena.</li><li>Validez externa: razonable.</li></ul></div></section></section><section id="_52"><h3 id="_52_toc">Intervenciones relacionadas con un aumento de riesgo de c&#xE1;ncer de pulm&#xF3;n</h3><section id="_53"><h4 id="_53_toc">Complementaci&#xF3;n con betacaroteno para los fumadores actuales</h4><p id="_54" tabindex="-1">Con base en pruebas s&#xF3;lidas, los fumadores empedernidos que toman dosis farmacol&#xF3;gicas de betacaroteno tienen un aumento de incidencia y mortalidad por c&#xE1;ncer de pulm&#xF3;n a ra&#xED;z del consumo del complemento.</p><p id="_55" tabindex="-1"><strong>Magnitud del efecto: aumento del riesgo, magnitud peque&#xF1;a.</strong></p><div class="pdq-content-list"><ul id="_56" class="pdq-address-block"><li>Dise&#xF1;o de los estudios: dos estudios o ensayos cl&#xED;nicos controlados aleatorizados (ECA) con resultados congruentes.</li><li>Validez interna: buena.</li><li>Congruencia: buena.</li><li>Validez externa: buena.</li></ul></div></section></section><section id="_57"><h3 id="_57_toc">Intervenciones que no disminuyen el riesgo de c&#xE1;ncer de pulm&#xF3;n</h3><section id="_58"><h4 id="_58_toc">Betacaroteno en no fumadores</h4><p id="_59" tabindex="-1">Con base en pruebas s&#xF3;lidas, los no fumadores que toman dosis farmacol&#xF3;gicas de betacaroteno no presentan una diferencia de incidencia o mortalidad por c&#xE1;ncer de pulm&#xF3;n en comparaci&#xF3;n con los que toman un placebo.</p><p id="_60" tabindex="-1"><strong>Magnitud del efecto: ausencia de un efecto sustancial.</strong></p><div class="pdq-content-list"><ul id="_61" class="pdq-address-block"><li>Dise&#xF1;o de los estudios: ECA.</li><li>Validez interna: buena.</li><li>Congruencia: buena.</li><li>Validez externa: razonable.</li></ul></div></section><section id="_62"><h4 id="_62_toc">Vitamina E (tocoferol)</h4><p id="_63" tabindex="-1">Con base en pruebas s&#xF3;lidas, el consumo de complementos de vitamina E no afecta al riesgo de c&#xE1;ncer de pulm&#xF3;n.</p><p id="_64" tabindex="-1"><strong>Magnitud del efecto: pruebas fehacientes de ausencia de  relaci&#xF3;n.</strong></p><div class="pdq-content-list"><ul id="_65" class="pdq-address-block"><li>Dise&#xF1;o de los estudios: ECA.</li><li>Validez interna: buena.</li><li>Congruencia: razonable.</li><li>Validez externa: buena.</li></ul></div></section></section><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_1.1">Pinsky PF: Racial and ethnic differences in lung cancer incidence: how much is explained by differences in smoking patterns? (United States). Cancer Causes Control 17 (8): 1017-24, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16933052&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16933052&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.2">Friedman DL, Whitton J, Leisenring W, et al.: Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 102 (14): 1083-95, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20634481&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20634481&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _177
      field_pdq_section_title:
        - format: plain_text
          value: 'Descripción de las pruebas'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_177" class="pdq-sections"><section id="_68"><h3 id="_68_toc">Incidencia y mortalidad</h3><p id="_69" tabindex="-1">El c&#xE1;ncer de pulm&#xF3;n tiene un impacto tremendo en la salud de la poblaci&#xF3;n de los Estados Unidos, con un total de alrededor de 234&#xA0;030 casos nuevos y 154&#xA0;050 defunciones previstas para 2018 en hombres y mujeres.[<a href="#cit/section_2.1">1</a>] El c&#xE1;ncer de pulm&#xF3;n provoca m&#xE1;s defunciones por a&#xF1;o en los Estados Unidos que las pr&#xF3;ximas cuatro causas principales de mortalidad por c&#xE1;ncer combinadas. Las tasas de incidencia y mortalidad por c&#xE1;ncer de pulm&#xF3;n aumentaron de forma notable  a lo largo de gran parte del &#xFA;ltimo siglo, primero en hombres y luego en mujeres. Las tendencias en las tasas de incidencia y mortalidad por c&#xE1;ncer de pulm&#xF3;n han reflejado estrechamente los patrones hist&#xF3;ricos de prevalencia del tabaquismo, despu&#xE9;s de tener en cuenta un per&#xED;odo de latencia apropiado. A la luz de diferencias hist&#xF3;ricas en la prevalencia del tabaquismo entre los hombres y las mujeres, las tasas de c&#xE1;ncer de pulm&#xF3;n se redujeron de manera constante desde  mediados de los a&#xF1;os ochenta, pero las tasas en las mujeres solo disminuyeron desde mediados de la d&#xE9;cada de 2000. La tasa de incidencia en los hombres disminuy&#xF3; de un m&#xE1;ximo de 102,1 casos por 100 000 hombres en 1984 a 78,6 casos por 100 000 hombres en 2011.[<a href="#cit/section_2.1">1</a>,<a href="#cit/section_2.2">2</a>] En los Estados Unidos, se calcula que el c&#xE1;ncer de pulm&#xF3;n representar&#xE1; alrededor de 25&#xA0;% de los casos nuevos de c&#xE1;ncer y casi 25&#xA0;% de todas las defunciones por c&#xE1;ncer en 2018. El c&#xE1;ncer de pulm&#xF3;n es la causa principal de muerte por c&#xE1;ncer, tanto  en hombres como en mujeres. En 2018, se calcula que en los Estados Unidos se producir&#xE1;n 70&#xA0;500 defunciones de mujeres  por c&#xE1;ncer de pulm&#xF3;n, en comparaci&#xF3;n con 40&#xA0;920 defunciones por c&#xE1;ncer de mama.[<a href="#cit/section_2.1">1</a>]</p><p id="_70" tabindex="-1">La incidencia y la mortalidad por c&#xE1;ncer de pulm&#xF3;n son m&#xE1;s altas entre los afroamericanos que en cualquier otro grupo racial o &#xE9;tnico de los Estados Unidos, sobre todo debido a las tasas muy altas en los hombres afroamericanos. Entre 2010 y 2014, la tasa de incidencia en los hombres negros fue m&#xE1;s alta que en los hombres blancos (83,7 vs. 65,9 casos por 100 000 hombres, respectivamente), mientras que entre las mujeres no hubo diferencia racial en las tasas de incidencia (49 vs. 50,8 casos cada 100 000 mujeres, respectivamente). Del mismo modo, las tasas de mortalidad en hombres negros fueron m&#xE1;s altas que en los hombres blancos en el mismo per&#xED;odo (68 vs. 55,9 muertes por 100 000 hombres, respectivamente), mientras que las tasas de mortalidad en mujeres negras fueron m&#xE1;s bajas que en las mujeres blancas (34,6 vs. 37,5 defunciones por 100 000 mujeres, respectivamente).[<a href="#cit/section_2.3">3</a>]</p><p id="_71" tabindex="-1">El tratamiento quir&#xFA;rgico o la radioterapia es el tratamiento elegido para los estadios tempranos del c&#xE1;ncer.[<a href="#cit/section_2.4">4</a>] La tasa de supervivencia relativa general a 5 a&#xF1;os de los pacientes con c&#xE1;ncer de pulm&#xF3;n fue de 18,1&#xA0;% en 2012. La supervivencia de los pacientes con c&#xE1;ncer de pulm&#xF3;n es peor en los hombres que en las mujeres y en las personas negras que en  las personas blancas. Por ejemplo, la supervivencia a 5 a&#xF1;os de los pacientes de c&#xE1;ncer de pulm&#xF3;n fue  m&#xE1;s baja en hombres negros que en hombres blancos (12,5 vs. 15,4&#xA0;%, respectivamente) y  m&#xE1;s baja en mujeres negras que en mujeres blancas (18,8 vs. 21,4&#xA0;%, respectivamente).[<a href="#cit/section_2.5">5</a>]</p><p id="_72" tabindex="-1">Se propuso la hip&#xF3;tesis de que es posible que las mujeres sean m&#xE1;s susceptibles que los hombres al c&#xE1;ncer de pulm&#xF3;n provocado por el tabaquismo. No obstante, los resultados de estudios en los que se compar&#xF3; la relaci&#xF3;n entre el tabaquismo y el c&#xE1;ncer de pulm&#xF3;n en hombres y mujeres mediante comparaciones pertinentes no respaldan esta hip&#xF3;tesis.[<a href="#cit/section_2.6">6</a>]</p><p id="_73" tabindex="-1">Los resultados del Multi-Ethnic Cohort Study indicaron que, para un grado determinado de tabaquismo, los afroamericanos tuvieron un riesgo m&#xE1;s alto de c&#xE1;ncer de pulm&#xF3;n en comparaci&#xF3;n con otros grupos raciales o &#xE9;tnicos.[<a href="#cit/section_2.7">7</a>] Se plante&#xF3; como hip&#xF3;tesis que los cigarrillos de mentol son un posible factor que contribuye a la mayor susceptibilidad al c&#xE1;ncer de pulm&#xF3;n provocado por el tabaquismo observada en los afroamericanos, pero no se observ&#xF3; que los cigarrillos de mentol estuvieran relacionados con un riesgo m&#xE1;s alto de c&#xE1;ncer de pulm&#xF3;n que los cigarrillos sin mentol.[<a href="#cit/section_2.8">8</a>,<a href="#cit/section_2.9">9</a>]</p></section><section id="_74"><h3 id="_74_toc">El tabaquismo es el principal factor de riesgo</h3><p id="_75" tabindex="-1">La epidemia de c&#xE1;ncer de pulm&#xF3;n del siglo XX se debi&#xF3; principalmente al aumento del tabaquismo, la causa predominante del c&#xE1;ncer de pulm&#xF3;n. La variaci&#xF3;n, que es tres veces m&#xE1;s alta en las tasas de mortalidad por c&#xE1;ncer de pulm&#xF3;n en los Estados Unidos, es m&#xE1;s o menos paralela a las diferencias espec&#xED;ficas  por estado que existen desde hace tiempo en la prevalencia del tabaquismo. Por ejemplo, las tasas anuales promedio de mortalidad por c&#xE1;ncer de pulm&#xF3;n ajustadas por edad de 1996 a 2000 fueron las m&#xE1;s altas en Kentucky (78 muertes por 100 000 personas) donde 31&#xA0;% eran fumadores actuales en 2001; mientras que las tasas de mortalidad por c&#xE1;ncer de pulm&#xF3;n m&#xE1;s bajas fueron en Utah (26 muertes por 100 000 personas), donde se ubica la prevalencia m&#xE1;s baja de tabaquismo (13&#xA0;%).[<a href="#cit/section_2.10">10</a>]</p></section><section id="_76"><h3 id="_76_toc">Caracter&#xED;sticas biol&#xF3;gicas de la carcinogenia</h3><p id="_77" tabindex="-1">Entender las caracter&#xED;sticas biol&#xF3;gicas de la carcinogenia es esencial para la formulaci&#xF3;n de estrategias de prevenci&#xF3;n y tratamiento eficaces. Dos conceptos importantes relacionados son la naturaleza de etapas m&#xFA;ltiples de la carcinogenia y el proceso carcinog&#xE9;nico difuso con difusi&#xF3;n a todo el campo. Los c&#xE1;nceres epiteliales de pulm&#xF3;n parecen presentarse en una serie de etapas que se extienden a lo largo de los a&#xF1;os. La carcinogenia epitelial se divide conceptualmente en tres fases: inicio, promoci&#xF3;n y progresi&#xF3;n. Este proceso se infiri&#xF3; de estudios en seres humanos en los que se identifican lesiones cl&#xED;nico-histol&#xF3;gicas premalignas (por ejemplo, metaplasia y displasia). El concepto de carcinogenia de campo es que m&#xFA;ltiples lesiones neopl&#xE1;sicas independientes en el pulm&#xF3;n pueden ser el resultado de la exposici&#xF3;n repetida a carcin&#xF3;genos, principalmente el tabaco. Es m&#xE1;s probable que los pacientes de c&#xE1;nceres del tracto aerodigestivo secundarios al tabaquismo tengan m&#xFA;ltiples lesiones premalignas de origen independiente dentro del campo expuesto al carcin&#xF3;geno. Los conceptos de carcinogenia en etapas m&#xFA;ltiples y de campo proporcionan un modelo para los estudios de prevenci&#xF3;n.[<a href="#cit/section_2.11">11</a>]</p></section><section id="_78"><h3 id="_78_toc">Factores de riesgo</h3><section id="_79"><h4 id="_79_toc">Factores relacionados con un aumento de riesgo de c&#xE1;ncer de pulm&#xF3;n</h4><section id="_80"><h5 id="_80_toc">Tabaquismo</h5><p id="_81" tabindex="-1">El factor de riesgo m&#xE1;s importante de c&#xE1;ncer de pulm&#xF3;n (y para muchos otros c&#xE1;nceres) es el tabaquismo.[<a href="#cit/section_2.12">12</a>-<a href="#cit/section_2.14">14</a>] En los datos epidemiol&#xF3;gicos se estableci&#xF3; que el tabaquismo es la causa predominante de c&#xE1;ncer de pulm&#xF3;n. Este v&#xED;nculo causal fue reconocido ampliamente desde la d&#xE9;cada de 1960, cuando en los informes nacionales de Gran Breta&#xF1;a y los Estados Unidos trajeron prominentemente a la atenci&#xF3;n del p&#xFA;blico el riesgo de c&#xE1;ncer por ese h&#xE1;bito.[<a href="#cit/section_2.13">13</a>] Los porcentajes calculados de c&#xE1;nceres de pulm&#xF3;n producidos por el tabaquismo en los hombres y las mujeres son de 90 y 78&#xA0;%, respectivamente. Si bien la fabricaci&#xF3;n de cigarrillo se modific&#xF3; con el tiempo, no hay pruebas que indiquen que cambios como el <em>bajo contenido de alquitr&#xE1;n</em> o <em>bajo contenido de nicotina</em> hayan reducido los riesgos de c&#xE1;ncer de pulm&#xF3;n.[<a href="#cit/section_2.9">9</a>,<a href="#cit/section_2.15">15</a>] El tabaquismo es el factor contribuyente m&#xE1;s importante a la carga de casos de c&#xE1;ncer de pulm&#xF3;n por su alta prevalencia de uso y porque los fumadores de cigarrillos tienden a fumar con frecuencia, pero el consumo de cigarros y pipa tambi&#xE9;n se relacion&#xF3; de forma independiente con un aumento de riesgo de c&#xE1;ncer de pulm&#xF3;n en estudios de casos y controles y de cohortes.[<a href="#cit/section_2.16">16</a>,<a href="#cit/section_2.17">17</a>]  Los riesgos del cigarro son de especial preocupaci&#xF3;n por el aumento de prevalencia de su uso en los Estados Unidos.[<a href="#cit/section_2.18">18</a>]</p><p id="_82" tabindex="-1">La presentaci&#xF3;n de c&#xE1;ncer de pulm&#xF3;n es la culminaci&#xF3;n de una carcinogenia en etapas m&#xFA;ltiples. El da&#xF1;o gen&#xE9;tico que causa la exposici&#xF3;n cr&#xF3;nica a carcin&#xF3;genos, como los del humo del cigarrillo, es la fuerza motora del proceso en etapas m&#xFA;ltiples. La prueba del da&#xF1;o gen&#xE9;tico es la relaci&#xF3;n del tabaquismo con la formaci&#xF3;n de aductos del ADN en el tejido pulmonar humano. Datos moleculares establecieron un v&#xED;nculo s&#xF3;lido entre el humo del tabaco y la carcinogenia pulmonar.[<a href="#cit/section_2.19">19</a>,<a href="#cit/section_2.20">20</a>] </p></section><section id="_83"><h5 id="_83_toc">Exposici&#xF3;n pasiva al humo del tabaco</h5><p id="_84" tabindex="-1">La exposici&#xF3;n pasiva al humo del tabaco es tambi&#xE9;n una causa establecida de c&#xE1;ncer de pulm&#xF3;n.[<a href="#cit/section_2.21">21</a>] Este humo tiene los mismos componentes del humo directo inhalado por el fumador, si bien en concentraciones absolutas m&#xE1;s bajas, entre 1 y 10&#xA0;% seg&#xFA;n el elemento que lo constituye. Los biomarcadores elevados de la exposici&#xF3;n al tabaco, como la cotinina en la orina, los metabolitos de 4-(metilnitrosamino)-1-(3-piridil)-1-butanona (NNK) en la orina y los aductos de la prote&#xED;na carcinog&#xE9;nica, se observan en las personas con exposici&#xF3;n pasiva al humo del tabaco.[<a href="#cit/section_2.22">22</a>-<a href="#cit/section_2.24">24</a>]</p></section><section id="_85"><h5 id="_85_toc">Antecedentes familiares</h5><p id="_86" tabindex="-1">Un antecedente familiar de c&#xE1;ncer de pulm&#xF3;n es un factor de riesgo de este c&#xE1;ncer. Los resultados de un metan&#xE1;lisis de estudios epidemiol&#xF3;gicos indicaron que aquellos con antecedentes familiares de c&#xE1;ncer de pulm&#xF3;n ten&#xED;an aproximadamente un riesgo doble de c&#xE1;ncer de pulm&#xF3;n que aquellos sin parientes afectados.[<a href="#cit/section_2.25">25</a>,<a href="#cit/section_2.26">26</a>] Como el tabaquismo tiende a ser caracter&#xED;stico de familias y los familiares se someten a una exposici&#xF3;n pasiva al humo del tabaco,  resulta incierto el grado en que los antecedentes familiares medidos representan una predisposici&#xF3;n gen&#xE9;tica al c&#xE1;ncer de pulm&#xF3;n independiente del factor de riesgo compartido del tabaquismo.</p></section><section id="_87"><h5 id="_87_toc">Infecci&#xF3;n por el virus de la inmunodeficiencia humana</h5><p id="_88" tabindex="-1">Se ha observado que la infecci&#xF3;n por el virus de la inmunodeficiencia humana (VIH) se relaciona estad&#xED;sticamente con un riesgo m&#xE1;s alto de padecer c&#xE1;ncer de pulm&#xF3;n; por ejemplo, los resultados de un metan&#xE1;lisis de 13 estudios indicaron que las personas infectadas por el VIH ten&#xED;an un riesgo 2,6 veces m&#xE1;s alto de c&#xE1;ncer de pulm&#xF3;n que las personas no infectadas por el VIH (coeficiente de incidencia est&#xE1;ndar, 2,6; intervalo de confianza [IC], 95&#xA0;% 2,1 a 3,1).[<a href="#cit/section_2.27">27</a>] Todav&#xED;a no se dilucid&#xF3; el significado cl&#xED;nico de esta relaci&#xF3;n, dado que crea la posibilidad de que la infecci&#xF3;n por el VIH aumente la susceptibilidad al c&#xE1;ncer de pulm&#xF3;n, pero puede meramente reflejar la prevalencia alta del tabaquismo (los c&#xE1;lculos del estudio oscilaron entre 59 y 96&#xA0;%) entre los infectados por el VIH en comparaci&#xF3;n con la poblaci&#xF3;n general (prevalencia aproximada del tabaquismo de 20&#xA0;%).</p></section><section id="_89"><h5 id="_89_toc">Otras causas ambientales del c&#xE1;ncer de pulm&#xF3;n</h5><section id="_90"><h6 id="_90_toc">Exposiciones ocupacionales a carcin&#xF3;genos pulmonares</h6><p id="_91" tabindex="-1">Varias exposiciones ambientales, m&#xE1;s all&#xE1; del humo del tabaco, se relacionan de manera causal con el c&#xE1;ncer de pulm&#xF3;n; sin embargo, la proporci&#xF3;n de la carga de casos de c&#xE1;ncer de pulm&#xF3;n debida a estas exposiciones es peque&#xF1;a en comparaci&#xF3;n con el tabaquismo. En estudios de exposiciones ocupacionales altas se identificaron muchos agentes carcin&#xF3;genos pulmonares. Consideradas en su totalidad, se calcul&#xF3; que las exposiciones ocupacionales representan aproximadamente 10&#xA0;% de los casos de c&#xE1;ncer de pulm&#xF3;n.[<a href="#cit/section_2.28">28</a>] Estos carcin&#xF3;genos incluyen amianto, rad&#xF3;n, alquitr&#xE1;n y holl&#xED;n (fuentes de hidrocarburos polic&#xED;clicos arom&#xE1;ticos), ars&#xE9;nico, cromo, n&#xED;quel berilio y cadmio.[<a href="#cit/section_2.29">29</a>] Para muchos de estos agentes carcin&#xF3;genos en el lugar de trabajo, el tabaquismo interact&#xFA;a de manera sin&#xE9;rgica para aumentar el riesgo.[<a href="#cit/section_2.30">30</a>] En los pa&#xED;ses desarrollados, se han controlado en gran medida las exposiciones ocupacionales a estas sustancias.</p></section><section id="_92"><h6 id="_92_toc">Exposici&#xF3;n a la radiaci&#xF3;n</h6><p id="_170" tabindex="-1">Sobre la base de estudios de poblaciones expuestas a dosis altas de radiaci&#xF3;n, se determin&#xF3; que el c&#xE1;ncer de pulm&#xF3;n es uno de los c&#xE1;nceres que habitualmente se relacionan con la exposici&#xF3;n a la radiaci&#xF3;n ionizante.[<a href="#cit/section_2.31">31</a>]   Los dos tipos de radiaci&#xF3;n importantes para el c&#xE1;ncer de pulm&#xF3;n son la radiaci&#xF3;n electromagn&#xE9;tica ionizante de alta energ&#xED;a (como los rayos X y los rayos &#x3B3;) y part&#xED;culas (como las part&#xED;culas &#x3B1; y los neutrones).</p><p id="_171" tabindex="-1">Una fuente temprana importante de datos sobre la exposici&#xF3;n a la radiaci&#xF3;n proviene de estudios de sobrevivientes de la bombas at&#xF3;micas en Jap&#xF3;n; en estos estudios se demostr&#xF3; que una sola exposici&#xF3;n a dosis altas de rayos &#x3B3; es suficiente para aumentar el riesgo de c&#xE1;ncer de pulm&#xF3;n seg&#xFA;n la dosis.[<a href="#cit/section_2.32">32</a>]  Tambi&#xE9;n se ha evaluado el riesgo de c&#xE1;ncer de pulm&#xF3;n en pacientes tratados con radiaci&#xF3;n por distintas afecciones. En los estudios de pacientes de tuberculosis tratados con neumot&#xF3;rax y controlados con fluoroscopias frecuentes, con el resultado de dosis acumuladas de radiaci&#xF3;n de aproximadamente 85 rads (0,85 Gy) escalonados en el tiempo, se indic&#xF3; que es dif&#xED;cil detectar cualquier riesgo de c&#xE1;ncer de pulm&#xF3;n relacionado con estas caracter&#xED;sticas de exposici&#xF3;n, si lo hubiera.[<a href="#cit/section_2.33">33</a>,<a href="#cit/section_2.34">34</a>]  En contraste, los resultados de muchos estudios proporcionan pruebas claras de que la radioterapia dirigida al t&#xF3;rax para tratar un c&#xE1;ncer produce un aumento del riesgo de c&#xE1;ncer de pulm&#xF3;n que depender&#xE1; de la dosis. Las pruebas son m&#xE1;s abundantes con respecto al c&#xE1;ncer de mama [<a href="#cit/section_2.35">35</a>-<a href="#cit/section_2.38">38</a>] y el linfoma de Hodgkin.[<a href="#cit/section_2.39">39</a>]   El riesgo de c&#xE1;ncer de pulm&#xF3;n despu&#xE9;s de la radioterapia se amplifica en los pacientes fumadores en comparaci&#xF3;n con los no fumadores.[<a href="#cit/section_2.35">35</a>,<a href="#cit/section_2.36">36</a>,<a href="#cit/section_2.38">38</a>,<a href="#cit/section_2.39">39</a>]</p><p id="_172" tabindex="-1">La relaci&#xF3;n entre la exposici&#xF3;n a la radiaci&#xF3;n y el c&#xE1;ncer de pulm&#xF3;n tiene consecuencias para la poblaci&#xF3;n general en pa&#xED;ses como los Estados Unidos donde las tomograf&#xED;as computarizadas (TC) son relativamente comunes y es posible que contribuyan a un exceso de c&#xE1;ncer a nivel demogr&#xE1;fico.[<a href="#cit/section_2.40">40</a>]  A la luz de la relaci&#xF3;n establecida entre la exposici&#xF3;n a la radiaci&#xF3;n ionizante y el riesgo de c&#xE1;ncer de pulm&#xF3;n, los investigadores han instado a usar precauci&#xF3;n para reducir al m&#xED;nimo los riesgos cuando los ex&#xE1;menes de detecci&#xF3;n del c&#xE1;ncer implican exposici&#xF3;n a la radiaci&#xF3;n ionizante, como el uso de la exploraci&#xF3;n por TC en espiral de dosis bajas para detectar el c&#xE1;ncer de pulm&#xF3;n en lugar de t&#xE9;cnicas para las que se utilizan dosis m&#xE1;s altas.[<a href="#cit/section_2.41">41</a>,<a href="#cit/section_2.42">42</a>]</p><p id="_173" tabindex="-1">Dado que estas t&#xE9;cnicas depositan energ&#xED;a concentrada en el tejido, las part&#xED;culas (por ejemplo, part&#xED;culas &#x3B1;) producen m&#xE1;s da&#xF1;o biol&#xF3;gico en una dosis equivalente de radiaci&#xF3;n (por ejemplo, los rayos X).[<a href="#cit/section_2.43">43</a>]  El rad&#xF3;n, la fuente principal de part&#xED;culas &#x3B1;, constituye un problema de salud p&#xFA;blica. El rad&#xF3;n es un gas inerte producido naturalmente en la serie de desintegraci&#xF3;n del uranio. Junto con otras pruebas cient&#xED;ficas de apoyo, en los estudios de mineros de uranio subterr&#xE1;neo expuestos a concentraciones muy altas de rad&#xF3;n se demostr&#xF3; que la exposici&#xF3;n al rad&#xF3;n causa c&#xE1;ncer de pulm&#xF3;n.[<a href="#cit/section_2.31">31</a>] Este efecto se amplifica considerablemente en los mineros que fuman.[<a href="#cit/section_2.44">44</a>]
            El rad&#xF3;n tiene un inter&#xE9;s social m&#xE1;s amplio porque puede entrar en edificios como gas derivado del suelo y es una fuente importante de exposici&#xF3;n de la poblaci&#xF3;n a la radiaci&#xF3;n.</p><p id="_93" tabindex="-1">Las estimaciones de la proporci&#xF3;n de muertes que se atribuyen a la exposici&#xF3;n al rad&#xF3;n en ambientes cerrados var&#xED;an seg&#xFA;n el m&#xE9;todo de c&#xE1;lculo y la concentraci&#xF3;n de la exposici&#xF3;n en cada pa&#xED;s; sin embargo, la media para las personas que fumaron toda la vida se calcula en 26&#xA0;% (intervalo de 13 a 50&#xA0;%) y en 10&#xA0;% para las personas que fumaron alguna vez (intervalo de 7 a 13&#xA0;%).[<a href="#cit/section_2.45">45</a>-<a href="#cit/section_2.47">47</a>] Debido a una interacci&#xF3;n sin&#xE9;rgica entre el tabaquismo y la exposici&#xF3;n al rad&#xF3;n, el riesgo de c&#xE1;ncer de pulm&#xF3;n a ra&#xED;z del rad&#xF3;n entre los fumadores es considerablemente mayor que entre los no fumadores.[<a href="#cit/section_2.48">48</a>] La estrategia de prevenci&#xF3;n para los residentes de hogares con altas concentraciones de rad&#xF3;n es sellar el s&#xF3;tano para evitar el escape del gas rad&#xF3;n hacia el hogar.[<a href="#cit/section_2.49">49</a>]</p></section><section id="_94"><h6 id="_94_toc">Contaminaci&#xF3;n atmosf&#xE9;rica</h6><p id="_95" tabindex="-1">Aunque los primeros datos de los estudios de casos y controles y de cohortes no respaldaron una relaci&#xF3;n entre la contaminaci&#xF3;n atmosf&#xE9;rica y el c&#xE1;ncer de pulm&#xF3;n; sin embargo, las pruebas apuntan a una relaci&#xF3;n genuina.[<a href="#cit/section_2.50">50</a>] En especial, dos estudios de cohortes prospectivos suministran pruebas de que la contaminaci&#xF3;n atmosf&#xE9;rica tiene una relaci&#xF3;n d&#xE9;bil con el riesgo de c&#xE1;ncer de pulm&#xF3;n. En un seguimiento extenso de un estudio de 6 ciudades estadounidenses, el riesgo relativo (RR) ajustado de la mortalidad por c&#xE1;ncer de pulm&#xF3;n para cada aumento de 10 &#xB5;g/m<span class="sup">3</span> en la concentraci&#xF3;n de part&#xED;culas finas fue de 1,27 (IC 95&#xA0;%, 0,96&#x2013;1,69).[<a href="#cit/section_2.51">51</a>] Con datos del Cancer Prevention Study II de la Sociedad Americana contra el C&#xE1;ncer, se observ&#xF3; que en comparaci&#xF3;n con las zonas menos contaminadas, la residencia en zonas con concentraciones altas de sulfato se relacion&#xF3; con un mayor riesgo de c&#xE1;ncer de pulm&#xF3;n (RR ajustado = 1,4; IC 95&#xA0;%, 1,1&#x2013;1,7) despu&#xE9;s de la correcci&#xF3;n por exposiciones ocupacionales y los factores mencionados anteriormente.[<a href="#cit/section_2.52">52</a>] En una actualizaci&#xF3;n posterior de este informe, se observ&#xF3; un aumento del riesgo de c&#xE1;ncer de pulm&#xF3;n de 14&#xA0;% para cada aumento de 10 &#x3BC;g/m<span class="sup">3</span> en la concentraci&#xF3;n de part&#xED;culas finas.[<a href="#cit/section_2.53">53</a>] Las pruebas que indican una relaci&#xF3;n entre los componentes de la contaminaci&#xF3;n atmosf&#xE9;rica y el aumento de la mortalidad por c&#xE1;ncer de pulm&#xF3;n contin&#xFA;an fortaleci&#xE9;ndose, con informes provenientes de Asia,[<a href="#cit/section_2.54">54</a>,<a href="#cit/section_2.55">55</a>] Nueva Zelandia,[<a href="#cit/section_2.56">56</a>] y Europa,[<a href="#cit/section_2.57">57</a>] que documentan un aumento de los riesgos de la  exposici&#xF3;n a ciertos componentes de part&#xED;culas.</p></section></section></section><section id="_96"><h4 id="_96_toc">Factores de relaci&#xF3;n incierta con el riesgo</h4><section id="_97"><h5 id="_97_toc">Factores alimentarios</h5><p id="_98" tabindex="-1">Los resultados de muchos estudios prospectivos de casos y controles y de cohortes muestran que las personas con una ingesta alimentaria alta de frutas o verduras tienen un riesgo m&#xE1;s bajo de c&#xE1;ncer de pulm&#xF3;n que aquellas con una ingesta baja de frutas o verduras.[<a href="#cit/section_2.58">58</a>] En una revisi&#xF3;n sistem&#xE1;tica de las pruebas, el World Cancer Research Fund (WCRF) califica los datos como <em>indicativos limitados</em> de que el consumo de verduras no amil&#xE1;ceas disminuye el riesgo de c&#xE1;ncer de pulm&#xF3;n y que es <em>probable</em>  que el consumo de frutas y alimentos con carotenoides disminuya el riesgo de c&#xE1;ncer de pulm&#xF3;n. Sin embargo, en una revisi&#xF3;n sistem&#xE1;tica y metan&#xE1;lisis posteriores limitados a estudios prospectivos que se ajustaron por el tabaquismo, se determin&#xF3; que las pruebas sobre carotenoides eran ambiguas.[<a href="#cit/section_2.59">59</a>]</p><p id="_99" tabindex="-1">Si bien el foco ha girado en torno al consumo de frutas y verduras, as&#xED; como de micronutrientes, se investig&#xF3; una amplia gama de factores alimentarios y antropom&#xE9;tricos. Se estudiaron mediciones antropom&#xE9;tricas, indicando una tendencia para las personas m&#xE1;s delgadas de un aumento de riesgo de c&#xE1;ncer de pulm&#xF3;n en relaci&#xF3;n con las personas con un &#xED;ndice de masa corporal mayor.[<a href="#cit/section_2.60">60</a>,<a href="#cit/section_2.61">61</a>]  En los resultados de un metan&#xE1;lisis, se observ&#xF3; que solo el consumo de alcohol en las categor&#xED;as de consumo m&#xE1;s altas  (en exceso de alrededor  de una bebida al d&#xED;a) se vincul&#xF3; con un aumento de riesgo de c&#xE1;ncer de pulm&#xF3;n.</p><p id="_100" tabindex="-1">Los estudios de los factores alimentarios produjeron hallazgos interesantes, pero dado que los reg&#xED;menes alimentarios de los fumadores tienden a ser menos saludables que los de los no fumadores es dif&#xED;cil  separar la influencia de los factores alimentarios de los efectos del tabaquismo. Cuando se consideran las relaciones entre el c&#xE1;ncer de pulm&#xF3;n y los factores alimentarios, no se pueden rechazar los factores de confusi&#xF3;n relacionados con el h&#xE1;bito de fumar cigarrillos como una explicaci&#xF3;n posible. </p></section><section id="_101"><h5 id="_101_toc">Actividad f&#xED;sica</h5><p id="_102" tabindex="-1">En un metan&#xE1;lisis de actividad f&#xED;sica en el tiempo libre y el riesgo de c&#xE1;ncer de pulm&#xF3;n, se revel&#xF3; que los niveles m&#xE1;s altos de actividad f&#xED;sica protegen contra el c&#xE1;ncer de pulm&#xF3;n.[<a href="#cit/section_2.62">62</a>] Las pruebas generales para la actividad f&#xED;sica fueron variados, pero en varios estudios se notific&#xF3; que las personas m&#xE1;s activas f&#xED;sicamente  tienen un riesgo m&#xE1;s bajo de c&#xE1;ncer de pulm&#xF3;n que quienes son m&#xE1;s sedentarias,[<a href="#cit/section_2.63">63</a>-<a href="#cit/section_2.65">65</a>] incluso despu&#xE9;s de ajustes por el h&#xE1;bito de fumar cigarrillos.  En la revisi&#xF3;n de los datos del WCRF, se clasific&#xF3; la relaci&#xF3;n inversa entre la actividad f&#xED;sica y el c&#xE1;ncer de pulm&#xF3;n como <em>indicativos limitados</em>.[<a href="#cit/section_2.66">66</a>]</p><p id="_103" tabindex="-1">Los estudios de la actividad f&#xED;sica producen hallazgos congruentes con una relaci&#xF3;n inversa, pero dado que los comportamientos de actividad f&#xED;sica difieren entre los fumadores y los no fumadores, es dif&#xED;cil  inferir una relaci&#xF3;n directa entre la actividad f&#xED;sica y el riesgo de c&#xE1;ncer de pulm&#xF3;n.</p></section><section id="_162"><h5 id="_162_toc">C&#xE1;ncer de pulm&#xF3;n en quienes nunca fumaron</h5><p id="_163" tabindex="-1">En los pa&#xED;ses donde es com&#xFA;n fumar cigarrillos, cerca de 10 a 20&#xA0;% de los casos de c&#xE1;ncer de pulm&#xF3;n se presentan en personas que nunca fumaron.[<a href="#cit/section_2.67">67</a>] El rad&#xF3;n y la exposici&#xF3;n pasiva al humo de tabaco son causas establecidas de c&#xE1;ncer de pulm&#xF3;n en los que nunca han fumado. Tambi&#xE9;n se ha observado un aumento de riesgo entre quienes nunca fumaron con la exposici&#xF3;n al amianto, la radiaci&#xF3;n ionizante de fuentes distintas al rad&#xF3;n y la contaminaci&#xF3;n atmosf&#xE9;rica en ambientes cerrados por causa de la combusti&#xF3;n de carb&#xF3;n u otros combustibles s&#xF3;lidos.[<a href="#cit/section_2.68">68</a>] Los datos disponibles sobre la relaci&#xF3;n del c&#xE1;ncer de pulm&#xF3;n en los que nunca han fumado con la actividad f&#xED;sica, la alimentaci&#xF3;n, el alcohol y la antropometr&#xED;a son limitados; aun as&#xED;, estos indican, por lo general, que las relaciones no difieren de forma marcada de los que alguna vez fumaron.[<a href="#cit/section_2.59">59</a>,<a href="#cit/section_2.60">60</a>,<a href="#cit/section_2.63">63</a>-<a href="#cit/section_2.65">65</a>,<a href="#cit/section_2.69">69</a>,<a href="#cit/section_2.70">70</a>]  Sin embargo, la incapacidad  de controlar en su totalidad la confusi&#xF3;n creada por el tabaquismo en los an&#xE1;lisis epidemiol&#xF3;gicos  de los que alguna vez fumaron y la posibilidad de encontrar causas diferentes de c&#xE1;ncer de pulm&#xF3;n en los que nunca fumaron y los que alguna vez fumaron, ameritan  cuidado cuando se extrapolan los resultados de los que  alguna vez fumaron y los que nunca lo han hecho.</p></section></section></section><section id="_104"><h3 id="_104_toc">Intervenciones relacionadas con una disminuci&#xF3;n del riesgo de c&#xE1;ncer de pulm&#xF3;n</h3><section id="_105"><h4 id="_105_toc">Evitaci&#xF3;n y cese del tabaquismo</h4><p id="_106" tabindex="-1">La adicci&#xF3;n al h&#xE1;bito de fumar cigarrillos redunda en un da&#xF1;o sustancial para la salud p&#xFA;blica. En comparaci&#xF3;n con los no fumadores, los fumadores experimentan un aumento del riesgo de c&#xE1;ncer de pulm&#xF3;n (y muchos otras neoplasias malignas) que depende de dosis.[<a href="#cit/section_2.71">71</a>,<a href="#cit/section_2.72">72</a>]</p><p id="_107" tabindex="-1">Se calcula que aproximadamente 85&#xA0;% de todas las defunciones por c&#xE1;ncer de pulm&#xF3;n se atribuyen al tabaquismo. El fumador se beneficia marcadamente al cesar de fumar. (Para obtener m&#xE1;s informaci&#xF3;n, consultar el sumario del PDQ  <a href="/espanol/cancer/causas-prevencion/riesgo/tabaco/dejar-fumar-pro-pdq">Consumo de cigarrillo: riesgos para la salud y c&#xF3;mo dejar de fumar</a>). Evitar el consumo de tabaco es la medida m&#xE1;s eficaz para prevenir el c&#xE1;ncer de pulm&#xF3;n. El efecto preventivo del cese del tabaquismo depende de la duraci&#xF3;n y la intensidad del tabaquismo previo, as&#xED; como del tiempo transcurrido desde que se dej&#xF3; de fumar. En comparaci&#xF3;n con los fumadores empedernidos, se observ&#xF3; una reducci&#xF3;n de 30 a 50&#xA0;% del riesgo de mortalidad por c&#xE1;ncer de pulm&#xF3;n al cabo de 10 a&#xF1;os de dejar el h&#xE1;bito.[<a href="#cit/section_2.12">12</a>,<a href="#cit/section_2.72">72</a>-<a href="#cit/section_2.74">74</a>]</p><p id="_108" tabindex="-1">Los beneficios del control del tabaco a nivel de la poblaci&#xF3;n ofrecen pruebas cuasi experimentales de que la reducci&#xF3;n de la exposici&#xF3;n de la poblaci&#xF3;n a los cigarrillos produjo disminuciones de la presentaci&#xF3;n de c&#xE1;ncer de pulm&#xF3;n. La reducci&#xF3;n en el consumo de tabaco, como resultado de las disminuciones en el inicio del h&#xE1;bito y aumentos en el cese del tabaquismo, llevaron a una reducci&#xF3;n de la mortalidad por c&#xE1;ncer de pulm&#xF3;n general ajustada por edad entre los hombres desde mediados de la d&#xE9;cada de 1980, de manera congruente con las reducciones en la prevalencia del tabaquismo entre los hombres desde la d&#xE9;cada de 1960.[<a href="#cit/section_2.75">75</a>] Las diferencias de sexo en las tendencias temporales del c&#xE1;ncer de pulm&#xF3;n son un reflejo de 1) la incorporaci&#xF3;n m&#xE1;s tarde del h&#xE1;bito de fumar cigarrillos en las mujeres que en los hombres y 2) la reducci&#xF3;n posterior de la prevalencia del tabaquismo entre las mujeres en comparaci&#xF3;n con los hombres.</p><section id="_109"><h5 id="_109_toc">Directrices para dejar de fumar</h5><p id="_110" tabindex="-1">La dependencia de la nicotina expone a los fumadores, seg&#xFA;n la dosis, a elementos carcin&#xF3;genos y genot&#xF3;xicos que provocan c&#xE1;ncer de pulm&#xF3;n.[<a href="#cit/section_2.73">73</a>] La superaci&#xF3;n de la dependencia de la nicotina suele ser sumamente dif&#xED;cil. La Agency for Healthcare Research and Quality (anteriormente Agency for Health Care Policy and
            Research    [AHCPR]) formul&#xF3; una serie de directrices cl&#xED;nicas para dejar de fumar a fin de ayudar a los pacientes dependientes de la nicotina y a los prestadores de atenci&#xF3;n de la salud.[<a href="#cit/section_2.74">74</a>] Los seis elementos principales de las directrices son los siguientes:</p><div class="pdq-content-list"><ol id="_111"><li>	Los m&#xE9;dicos deben documentar la situaci&#xF3;n de uso de tabaco de cada paciente. </li><li>Cada paciente fumador debe recibir una oferta de uno o m&#xE1;s de los tratamientos eficaces disponibles para cesar de fumar. </li><li>Cada paciente fumador debe ser provisto de por lo menos una de las intervenciones eficaces y breves disponibles para cesar de fumar.</li><li>Las intervenciones m&#xE1;s intensas son m&#xE1;s eficaces que las intervenciones menos intensas para lograr la abstinencia del tabaco a largo plazo, reflejando la relaci&#xF3;n dosis-respuesta entre la intervenci&#xF3;n y su resultado.</li><li>El tratamiento para cesar de fumar deber&#xE1; incluir uno o m&#xE1;s de los tres elementos de tratamiento identificados como especialmente eficaces:<div class="pdq-content-list"><ol id="_112" class="lower-alpha"><li>Reemplazo de nicotina (por ejemplo, parches y goma de mascar de nicotina) u otras terapias farmacol&#xF3;gicas con base en pruebas para dejar de fumar (por ejemplo, vareniclina o bupropi&#xF3;n). </li><li>Apoyo social del m&#xE9;dico en forma de est&#xED;mulo y asistencia. </li><li>Capacitaci&#xF3;n en aptitudes y resoluci&#xF3;n de problemas (t&#xE9;cnicas de cesaci&#xF3;n y abstinencia).</li></ol></div></li><li>Para ser eficaces, los sistemas de atenci&#xF3;n de la salud deben realizar cambios institucionales que lleven a la identificaci&#xF3;n sistem&#xE1;tica de los fumadores y a la intervenci&#xF3;n con estos pacientes en cada consulta.</li></ol></div></section><section id="_113"><h5 id="_113_toc">Tratamientos farmacol&#xF3;gicos para dejar de fumar</h5><p id="_114" tabindex="-1">Muchos tratamientos farmacol&#xF3;gicos para dejar de fumar, como terapias de reemplazo de nicotina (por ejemplo, goma de mascar, parche, atomizador, tableta e inhalador) y otros  tratamientos farmacol&#xF3;gicos para dejar de fumar (por ejemplo, vareniclina y bupropi&#xF3;n) aumentan con significaci&#xF3;n estad&#xED;stica las tasas de cese del tabaquismo en comparaci&#xF3;n con un placebo. Seg&#xFA;n una s&#xED;ntesis de los resultados de 110 ensayos aleatorizados, tratamientos con terapia de reemplazo de nicotina, solos o en combinaci&#xF3;n, mejoran las tasas de abandono del h&#xE1;bito en comparaci&#xF3;n con los placebos al cabo de 6 meses (RR, 1,58; IC 95&#xA0;%, 1,50&#x2013;1,66).[<a href="#cit/section_2.76">76</a>] Desde la publicaci&#xF3;n de las directrices de la AHCPR, se publicaron m&#xE1;s pruebas de la eficacia de dichos tratamientos farmacol&#xF3;gicos para dejar de fumar.[<a href="#cit/section_2.77">77</a>-<a href="#cit/section_2.79">79</a>] La elecci&#xF3;n del tratamiento debe ser individualizada de acuerdo con algunos factores, como experiencia previa, preferencia y posibles efectos secundarios de las sustancias. (Para obtener m&#xE1;s informaci&#xF3;n sobre  tratamientos farmacol&#xF3;gicos para dejar de fumar, consultar el sumario del PDQ  <a href="/espanol/cancer/causas-prevencion/riesgo/tabaco/dejar-fumar-pro-pdq">Consumo de cigarrillo: riesgos para la salud y c&#xF3;mo dejar de fumar</a>).</p></section><section id="_115"><h5 id="_115_toc">Intervenciones poblacionales</h5><p id="_116" tabindex="-1">Adem&#xE1;s de las iniciativas para dejar de fumar enfocadas en las personas, se atribuy&#xF3; la reducci&#xF3;n de la prevalencia del tabaquismo a algunas estrategias para el control del tabaco a nivel comunitario, estatal y nacional. Las estrategias son las siguientes:[<a href="#cit/section_2.80">80</a>,<a href="#cit/section_2.81">81</a>]</p><div class="pdq-content-list"><ul id="_117"><li>Reducci&#xF3;n del acceso de los menores a los productos de tabaco.</li><li>Diseminaci&#xF3;n de programas de estudio escolares eficaces para la prevenci&#xF3;n junto con estrategias en los medios de comunicaci&#xF3;n.</li><li>Incremento del costo de los productos de tabaco mediante el aumento de los impuestos.</li><li>Utilizaci&#xF3;n de los impuestos indirectos al tabaco para financiar intervenciones comunitarias, por ejemplo en los medios de comunicaci&#xF3;n masiva.</li><li>Proporcionar estrategias comprobadas para abandonar el h&#xE1;bito a trav&#xE9;s de organizaciones de atenci&#xF3;n de la salud.</li><li>Aprobaci&#xF3;n de leyes y pol&#xED;ticas que proh&#xED;ban fumar.</li></ul></div></section><section id="_118"><h5 id="_118_toc">Legislaci&#xF3;n sobre lugares de trabajo sin humo de tabaco</h5><p id="_119" tabindex="-1">En una revisi&#xF3;n de m&#xE1;s de 50 estudios se hall&#xF3; que la legislaci&#xF3;n sobre lugares de trabajo sin humo de tabaco se relacion&#xF3; sistem&#xE1;ticamente con la reducci&#xF3;n a la exposici&#xF3;n pasiva al humo de tabaco, si se med&#xED;a con la reducci&#xF3;n del tiempo de la exposici&#xF3;n (reducci&#xF3;n de 71 a 100&#xA0;%) o la prevalencia de personas expuestas de modo pasivo al humo de tabaco (reducci&#xF3;n de 22 a 85&#xA0;%), con reducciones particularmente acentuadas entre trabajadores del sector hotelero.[<a href="#cit/section_2.82">82</a>] La legislaci&#xF3;n sobre lugares de trabajo libres de humo de tabaco se relacion&#xF3; con reducciones sistem&#xE1;ticas y estad&#xED;sticamente significativas en las concentraciones de nicotina, polvo, benceno y part&#xED;culas. Se notificaron indicadores de salud, como aparatos respiratorios, s&#xED;ntomas sensoriales e ingresos hospitalarios, como resultados en 25 estudios.   Con respecto a los resultados en materia de salud, un hallazgo uniforme incluy&#xF3; menos ingresos hospitalarios por episodios card&#xED;acos.  Las pruebas indicaron que la legislaci&#xF3;n sobre lugares de trabajo libres de humo de tabaco puede producir una reducci&#xF3;n de la prevalencia del h&#xE1;bito activo de fumar cigarrillos; por ejemplo en un estudio se observ&#xF3; una disminuci&#xF3;n de la prevalencia del h&#xE1;bito de fumar de 32&#xA0;% en un condado en el que se sancion&#xF3; legislaci&#xF3;n para lugares de trabajo libres de humo, en comparaci&#xF3;n con una disminuci&#xF3;n de 2,8&#xA0;% en condados cercanos sin legislaci&#xF3;n de este tipo.</p></section></section><section id="_120"><h4 id="_120_toc">Prevenci&#xF3;n de la exposici&#xF3;n ocupacional a carcin&#xF3;genos pulmonares</h4><p id="_121" tabindex="-1">Despu&#xE9;s del tabaquismo y la exposici&#xF3;n pasiva al humo de tabaco, la exposici&#xF3;n laboral a carcin&#xF3;genos pulmonares, como asbesto, ars&#xE9;nico, n&#xED;quel y cromo, es el factor contribuyente m&#xE1;s importante a la carga de  c&#xE1;ncer de pulm&#xF3;n. Cuando la exposici&#xF3;n laboral a carcin&#xF3;genos pulmonares se consideran juntos, 9 a 15&#xA0;% de todas las defunciones por c&#xE1;ncer de pulm&#xF3;n se puede atribuir a la exposici&#xF3;n laboral a carcin&#xF3;genos pulmonares.[<a href="#cit/section_2.9">9</a>] Se prev&#xE9; que la reducci&#xF3;n o la eliminaci&#xF3;n de las exposiciones en el lugar de trabajo a carcin&#xF3;genos pulmonares conocidos redundar&#xE1; en una disminuci&#xF3;n correspondiente del riesgo de c&#xE1;ncer de pulm&#xF3;n. En consecuencia, la proporci&#xF3;n de la carga de casos de c&#xE1;ncer de pulm&#xF3;n atribuibles a las exposiciones ocupacionales est&#xE1; disminuyendo con el tiempo en pa&#xED;ses como los Estados Unidos que han tomado medidas para proteger a la fuerza laboral de la exposici&#xF3;n a carcin&#xF3;genos pulmonares conocidos.</p></section></section><section id="_122"><h3 id="_122_toc">Intervenciones relacionadas con un aumento de riesgo de c&#xE1;ncer de pulm&#xF3;n</h3><section id="_123"><h4 id="_123_toc">Complementaci&#xF3;n con betacaroteno en fumadores</h4><p id="_124" tabindex="-1">Los resultados del ensayo Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) del Instituto Nacional de C&#xE1;ncer (NCI) se publicaron por primera vez en 1994.[<a href="#cit/section_2.83">83</a>] Este ensayo incluy&#xF3; a 29 133 hombres finlandeses fumadores cr&#xF3;nicos de 50 a 69 a&#xF1;os de edad, en un dise&#xF1;o factorial de 2 &#xD7; 2 de alfa-tocoferol (50 mg/d&#xED;a) y betacaroteno (20 mg/d&#xED;a). Los sujetos se asignaron al azar a uno de los siguientes 4 grupos durante 5 a 8 a&#xF1;os: betacaroteno solo, alfa-tocoferol solo, betacaroteno y alfa-tocoferol, o placebo. Los sujetos que recibieron betacaroteno  (solo o con alfa-tocoferol) tuvieron una mayor incidencia de c&#xE1;ncer de pulm&#xF3;n (RR, 1,18; IC 95&#xA0;%, 1,03&#x2013;1,36) y mortalidad total m&#xE1;s alta (RR, 1,08; IC 95&#xA0;%, 1,01&#x2013;1,16). Este efecto pareci&#xF3; relacionarse con tabaquismo m&#xE1;s intenso (una o m&#xE1;s cajetillas/d&#xED;a) e ingesta de alcohol (al menos una bebida/d&#xED;a).[<a href="#cit/section_2.84">84</a>] La complementaci&#xF3;n con alfa-tocoferol no produjo ning&#xFA;n efecto general en el c&#xE1;ncer de pulm&#xF3;n (RR, 0,99; IC 95&#xA0;%, 0,87&#x2013;1,13). </p><p id="_125" tabindex="-1">En 1996, se publicaron los resultados del U.S. Beta-Carotene and Retinol Efficacy Trial
            (CARET).[<a href="#cit/section_2.85">85</a>] Este ensayo multic&#xE9;ntrico incluy&#xF3; a 18 314 fumadores, exfumadores y trabajadores expuestos al asbesto a quienes se asignaron al azar a betacaroteno (una dosis m&#xE1;s alta que en el ensayo de ATBC, 30 mg/d&#xED;a) m&#xE1;s palmitato de retinilo (25&#xA0;000 UI/d&#xED;a) o placebo. El criterio primario de valoraci&#xF3;n fue la incidencia de c&#xE1;ncer de pulm&#xF3;n. El  Data Monitoring Committee del NCI cerr&#xF3; temprano el ensayo porque los resultados confirmaron el hallazgo del ATBC de un efecto nocivo del betacaroteno en comparaci&#xF3;n con el placebo, que aument&#xF3; la incidencia del c&#xE1;ncer de pulm&#xF3;n (RR, 1,28; IC 95&#xA0;%, 1,04&#x2013;1,57) y la mortalidad total (RR, 1,17; IC 95&#xA0;%, 1,03&#x2013;1,33). En un estudio de seguimiento de los participantes de CARET despu&#xE9;s de que se interrumpi&#xF3; la intervenci&#xF3;n, estos efectos se atenuaron durante un tiempo. Al cabo de 6 a&#xF1;os de seguimiento despu&#xE9;s de la intervenci&#xF3;n, el RR de incidencia de c&#xE1;ncer de pulm&#xF3;n fue de 1,12 (IC 95&#xA0;%, 0,97&#x2013;1,31) y de la mortalidad total fue de 1,08 (IC 95&#xA0;%, 0,99&#x2013;1,71). Durante la fase posterior a la intervenci&#xF3;n surgi&#xF3; un RR m&#xE1;s alto entre las mujeres, en lugar de los hombres, para ambos desenlaces en los an&#xE1;lisis de los subgrupos; la raz&#xF3;n para esta observaci&#xF3;n, si fuera confiable, no se conoce.[<a href="#cit/section_2.86">86</a>]</p><p id="_126" tabindex="-1">Los hallazgos generales de los estudios de ATBC,[<a href="#cit/section_2.83">83</a>,<a href="#cit/section_2.84">84</a>] y CARET [<a href="#cit/section_2.85">85</a>,<a href="#cit/section_2.87">87</a>] que incluyeron a m&#xE1;s de 47 000 sujetos, demostraron que las dosis farmacol&#xF3;gicas de betacaroteno aumentan el riesgo de c&#xE1;ncer de pulm&#xF3;n en fumadores de intensidad relativamente alta. No se conoce el mecanismo de este efecto adverso. Los riesgos de c&#xE1;ncer de pulm&#xF3;n no aumentaron en subconjuntos de fumadores de intensidad moderada (menos de un atado por d&#xED;a), en el estudio ATBC o en ex fumadores, en el estudio CARET. Los datos de otros estudios, como el Physicians&#x2019; Health Study (PHS),[<a href="#cit/section_2.88">88</a>] no indican que la complementaci&#xF3;n con betacaroteno aumenta el riesgo de c&#xE1;ncer de pulm&#xF3;n en los no fumadores. Los an&#xE1;lisis subsiguientes de los participantes en estos ensayos y cohortes indican que los resultados beneficiosos asociados con concentraciones altas de betacaroteno en el plasma se pueden deber a la ingesta mayor de frutas y verduras en el r&#xE9;gimen alimentario. Estos hallazgos demuestran la importancia de los ensayos comparativos aleatorizados (ECA) para confirmar los estudios epidemiol&#xF3;gicos.</p></section></section><section id="_127"><h3 id="_127_toc">Intervenciones con pruebas adecuadas de que no reducen el riesgo</h3><section id="_128"><h4 id="_128_toc">Quimioprevenci&#xF3;n</h4><p id="_129" tabindex="-1">En los estudios se evalu&#xF3; la posibilidad de prevenir el c&#xE1;ncer en el pulm&#xF3;n con el uso de agentes quimiopreventivos. La quimioprevenci&#xF3;n se define como el uso de sustancias qu&#xED;micas naturales o sint&#xE9;ticas espec&#xED;ficas para revertir, eliminar o prevenir la carcinogenia antes de la formaci&#xF3;n de una neoplasia maligna invasora. Hasta ahora, las sustancias de quimioprevenci&#xF3;n del c&#xE1;ncer de pulm&#xF3;n que se evaluaron fueron los micronutrientes, como el betacaroteno y la vitamina E.</p><section id="_130"><h5 id="_130_toc">Complementaci&#xF3;n con betacaroteno para no fumadores</h5><p id="_131" tabindex="-1">Otros dos ECA del betacaroteno fueron realizados en poblaciones sin exceso de riesgo de c&#xE1;ncer de pulm&#xF3;n. El PHS  se dise&#xF1;&#xF3; para estudiar los efectos del betacaroteno y la aspirina en el c&#xE1;ncer y la enfermedad cardiovascular. El estudio, que  es aleatorizado, con enmascaramiento doble y controlado con placebo, comenz&#xF3; en 1982 con 22 071 m&#xE9;dicos varones de 40 a 84 a&#xF1;os. Despu&#xE9;s de 12 a&#xF1;os de seguimiento, el betacaroteno no se relacion&#xF3; con un riesgo general de c&#xE1;ncer (RR, 0,98) o c&#xE1;ncer de pulm&#xF3;n entre fumadores actuales (11&#xA0;% de la poblaci&#xF3;n del estudio) o ex fumadores (39&#xA0;% de la poblaci&#xF3;n del estudio).[<a href="#cit/section_2.88">88</a>]</p><p id="_132" tabindex="-1">En el Women&#x2019;s Health Study (WHS), se asign&#xF3; al azar a 40 000 mujeres profesionales de la salud a recibir 50 mg de betacaroteno d&#xED;a de por medio o placebo. Al cabo de una mediana de 2,1 a&#xF1;os de tratamiento con betacaroteno y otros 2 a&#xF1;os adicionales de seguimiento, no se obtuvieron pruebas de que el betacaroteno protegiese del c&#xE1;ncer de pulm&#xF3;n dado que se observaron m&#xE1;s casos de c&#xE1;ncer de pulm&#xF3;n en el grupo tratado con betacaroteno (n = 30) que en el de placebo (n = 21).[<a href="#cit/section_2.89">89</a>] Las pruebas s&#xF3;lidas de ensayos rigurosos controlados aleatorizados con placebo indican claramente que la complementaci&#xF3;n con betacaroteno no reduce el riesgo de c&#xE1;ncer de pulm&#xF3;n en las poblaciones que no tienen riesgo alto de c&#xE1;ncer de pulm&#xF3;n.</p></section><section id="_133"><h5 id="_133_toc">Complementaci&#xF3;n con vitamina E</h5><p id="_134" tabindex="-1">El ensayo Heart Outcomes Prevention Evaluation (HOPE) comenz&#xF3; en 1993 y continu&#xF3; el seguimiento como HOPE-The Ongoing Outcomes (HOPE-TOO) hasta 2003. En este ensayo aleatorizado controlado con placebo, pacientes de 55 o m&#xE1;s a&#xF1;os con enfermedad vascular o diabetes se asignaron al azar a recibir 400 UI de vitamina E o placebo. Con una mediana de  seguimiento a 7 a&#xF1;os, el grupo asignado al azar a la vitamina E tuvo una tasa de incidencia de c&#xE1;ncer de pulm&#xF3;n significativamente m&#xE1;s baja (1,4&#xA0;%) que el grupo tratado con el placebo (2,0&#xA0;%) (RR, 0,72; IC 95&#xA0;%, 0,53&#x2013;0,98).[<a href="#cit/section_2.90">90</a>] Sin embargo, se debe interpretar la relaci&#xF3;n protectora entre los complementos de la vitamina E y el c&#xE1;ncer de pulm&#xF3;n en el estudio de HOPE-TOO en el contexto de las pruebas obtenidas en otros ensayos aleatorizados. En el estudio ATBC, la complementaci&#xF3;n con alfa-tocoferol no produjo un efecto general en el c&#xE1;ncer de pulm&#xF3;n (RR, 0,99; IC 95&#xA0;%, 0,87&#x2013;1,13). En el WHS de 40 000 mujeres profesionales de la salud, la administraci&#xF3;n de 600 UI de vitamina E d&#xED;a de por medio no proporcion&#xF3; pruebas de protecci&#xF3;n del c&#xE1;ncer de pulm&#xF3;n en mujeres (RR, 1,09; IC 95&#xA0;%, 0,83&#x2013;1,44).[<a href="#cit/section_2.91">91</a>] El Medical Research Council/British Heart Foundation   Heart Protection Study (HPS)  es un ensayo aleatorizado controlado con placebo para evaluar la complementaci&#xF3;n con vitaminas antioxidantes E, C y betacaroteno en 20 536 adultos del Reino Unido con enfermedad coronaria, otras enfermedades arteriales oclusivas o diabetes. El ensayo comenz&#xF3; con la inscripci&#xF3;n de participantes en 1994 y, en el momento del seguimiento en 2001, los resultados mostraron una tasa levemente superior de c&#xE1;ncer de pulm&#xF3;n en el grupo tratado con vitamina en comparaci&#xF3;n con el grupo tratado con placebo (1,6 vs. 1,4&#xA0;%, respectivamente).[<a href="#cit/section_2.92">92</a>]</p><p id="_135" tabindex="-1">Considerando los resultados de la vitamina E en los estudios de ATBC, HPS y HOPE-TOO combinados, la oportunidad relativa resumida fue de 0,97 (IC 95&#xA0;%, 0,87&#x2013;1,08),[<a href="#cit/section_2.90">90</a>] y, al agregar los resultados del WHS, esto aproximar&#xED;a incluso m&#xE1;s la relaci&#xF3;n a ser nula. Las pruebas combinadas para la complementaci&#xF3;n con vitamina E contin&#xFA;an siendo congruentes con la ausencia de efecto en el riesgo de c&#xE1;ncer de pulm&#xF3;n.</p></section></section></section><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_2.1">American Cancer Society: Cancer Facts and Figures 2018. Atlanta, Ga: American Cancer Society, 2018. <a href="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf" title="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf">Available online</a>. Last accessed August 3, 2018.</li><li id="section_2.2">Edwards BK, Brown ML, Wingo PA, et al.: Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97 (19): 1407-27, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16204691&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16204691&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.3">National Cancer Institute: SEER Stat Fact Sheets: Lung and Bronchus. Bethesda, MD: National Institutes of Health. <a href="https://seer.cancer.gov/statfacts/html/lungb.html" title="https://seer.cancer.gov/statfacts/html/lungb.html">Available online</a>. Last accessed November 29, 2017.</li><li id="section_2.4">Spira A, Ettinger DS: Multidisciplinary management of lung cancer. N Engl J Med 350 (4): 379-92, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14736930&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14736930&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.5">Howlader N, Noone AM, Krapcho M, et al., eds.: SEER Cancer Statistics Review (CSR) 1975-2014. Bethesda, Md: National Cancer Institute. <a href="https://seer.cancer.gov/csr/1975_2014/" title="https://seer.cancer.gov/csr/1975_2014/">Also available online</a>. Last accessed August 2, 2018.</li><li id="section_2.6">Bain C, Feskanich D, Speizer FE, et al.: Lung cancer rates in men and women with comparable histories of smoking. J Natl Cancer Inst 96 (11): 826-34, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15173266&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15173266&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.7">Haiman CA, Stram DO, Wilkens LR, et al.: Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med 354 (4): 333-42, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16436765&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16436765&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.8">Blot WJ, Cohen SS, Aldrich M, et al.: Lung cancer risk among smokers of menthol cigarettes. J Natl Cancer Inst 103 (10): 810-6, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21436064&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21436064&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.9">Alberg AJ, Ford JG, Samet JM, et al.: Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132 (3 Suppl): 29S-55S, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17873159&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17873159&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.10">Weir HK, Thun MJ, Hankey BF, et al.: Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95 (17): 1276-99, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12953083&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12953083&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.11">Lippman SM, Benner SE, Hong WK: Cancer chemoprevention. J Clin Oncol 12 (4): 851-73, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8151328&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8151328&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.12">Schottenfeld D, Fraumeni JF Jr, eds.: Cancer Epidemiology and Prevention. 2nd ed. New York, NY: Oxford University Press, 1996.</li><li id="section_2.13">Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service. Washington, DC: US Department of Health, Education, and Welfare, 1965. PHS Publ No 1103.</li><li id="section_2.14">Gazdar AF, Minna JD: Cigarettes, sex, and lung adenocarcinoma. J Natl Cancer Inst 89 (21): 1563-5, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9362148&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9362148&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.15">Song MA, Benowitz NL, Berman M, et al.: Cigarette Filter Ventilation and its Relationship to Increasing Rates of Lung Adenocarcinoma. J Natl Cancer Inst 109 (12): , 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28525914&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28525914&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.16">Iribarren C, Tekawa IS, Sidney S, et al.: Effect of cigar smoking on the risk of cardiovascular disease, chronic obstructive pulmonary disease, and cancer in men. N Engl J Med 340 (23): 1773-80, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10362820&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10362820&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.17">Boffetta P, Pershagen G, J&#xF6;ckel KH, et al.: Cigar and pipe smoking and lung cancer risk: a multicenter study from Europe. J Natl Cancer Inst 91 (8): 697-701, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10218507&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10218507&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.18">Satcher D: Cigars and public health. N Engl J Med 340 (23): 1829-31, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10362829&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10362829&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.19">Mao L, Lee JS, Kurie JM, et al.: Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 89 (12): 857-62, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9196251&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9196251&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.20">Wistuba II, Lam S, Behrens C, et al.: Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst 89 (18): 1366-73, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9308707&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9308707&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.21">Hackshaw AK, Law MR, Wald NJ: The accumulated evidence on lung cancer and environmental tobacco smoke. BMJ 315 (7114): 980-8, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9365295&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9365295&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.22">Anderson KE, Carmella SG, Ye M, et al.: Metabolites of a tobacco-specific lung carcinogen in nonsmoking women exposed to environmental tobacco smoke. J Natl Cancer Inst 93 (5): 378-81, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11238699&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11238699&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.23">Anderson KE, Kliris J, Murphy L, et al.: Metabolites of a tobacco-specific lung carcinogen in nonsmoking casino patrons. Cancer Epidemiol Biomarkers Prev 12 (12): 1544-6, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14693752&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14693752&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.24">Tulunay OE, Hecht SS, Carmella SG, et al.: Urinary metabolites of a tobacco-specific lung carcinogen in nonsmoking hospitality workers. Cancer Epidemiol Biomarkers Prev 14 (5): 1283-6, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15894687&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15894687&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.25">Lissowska J, Foretova L, Dabek J, et al.: Family history and lung cancer risk: international multicentre case-control study in Eastern and Central Europe and meta-analyses. Cancer Causes Control 21 (7): 1091-104, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20306329&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20306329&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.26">Matakidou A, Eisen T, Houlston RS: Systematic review of the relationship between family history and lung cancer risk. Br J Cancer 93 (7): 825-33, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16160696&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16160696&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.27">Shiels MS, Cole SR, Kirk GD, et al.: A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 52 (5): 611-22, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19770804&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19770804&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.28">Alberg AJ, Samet JM: Epidemiology of lung cancer. Chest 123 (1 Suppl): 21S-49S, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12527563&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12527563&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.29">Straif K, Benbrahim-Tallaa L, Baan R, et al.: A review of human carcinogens--part C: metals, arsenic, dusts, and fibres. Lancet Oncol 10 (5): 453-4, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19418618&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19418618&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.30">Saracci R: The interactions of tobacco smoking and other agents in cancer etiology. Epidemiol Rev 9: 175-93, 1987.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3315716&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3315716&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.31">Committee on Health Risks of Exposure to Radon (BEIR VI): Health Effects of Exposure to Radon: BEIR VI. Washington, DC: National Academies Press, 1999. <a href="https://www.ncbi.nlm.nih.gov/pubmed/25121310" title="https://www.ncbi.nlm.nih.gov/pubmed/25121310">Also available online</a>. Last accessed November 29, 2017.</li><li id="section_2.32">Shimizu Y, Kato H, Schull WJ: Studies of the mortality of A-bomb survivors. 9. Mortality, 1950-1985: Part 2. Cancer mortality based on the recently revised doses (DS86). Radiat Res 121 (2): 120-41, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2305030&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2305030&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.33">Davis FG, Boice JD Jr, Hrubec Z, et al.: Cancer mortality in a radiation-exposed cohort of Massachusetts tuberculosis patients. Cancer Res 49 (21): 6130-6, 1989.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2790825&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2790825&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.34">Howe GR: Lung cancer mortality between 1950 and 1987 after exposure to fractionated moderate-dose-rate ionizing radiation in the Canadian fluoroscopy cohort study and a comparison with lung cancer mortality in the Atomic Bomb survivors study. Radiat Res 142 (3): 295-304, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7761580&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7761580&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.35">Lorigan P, Califano R, Faivre-Finn C, et al.: Lung cancer after treatment for breast cancer. Lancet Oncol 11 (12): 1184-92, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20541465&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20541465&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.36">Grantzau T, Thomsen MS, V&#xE6;th M, et al.: Risk of second primary lung cancer in women after radiotherapy for breast cancer. Radiother Oncol 111 (3): 366-73, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24909095&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24909095&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.37">Grantzau T, Overgaard J: Risk of second non-breast cancer after radiotherapy for breast cancer: a systematic review and meta-analysis of 762,468 patients. Radiother Oncol 114 (1): 56-65, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25454172&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25454172&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.38">Kaufman EL, Jacobson JS, Hershman DL, et al.: Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J Clin Oncol 26 (3): 392-8, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18202415&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18202415&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.39">Lorigan P, Radford J, Howell A, et al.: Lung cancer after treatment for Hodgkin's lymphoma: a systematic review. Lancet Oncol 6 (10): 773-9, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16198983&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16198983&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.40">Alberg AJ, Brock MV, Ford JG, et al.: Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143 (5 Suppl): e1S-29S, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23649439&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23649439&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.41">Berrington de Gonz&#xE1;lez A, Kim KP, Berg CD: Low-dose lung computed tomography screening before age 55: estimates of the mortality reduction required to outweigh the radiation-induced cancer risk. J Med Screen 15 (3): 153-8, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18927099&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18927099&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.42">Mascalchi M, Belli G, Zappa M, et al.: Risk-benefit analysis of X-ray exposure associated with lung cancer screening in the Italung-CT trial. AJR Am J Roentgenol 187 (2): 421-9, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16861547&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16861547&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.43">Hendee WR: Estimation of radiation risks. BEIR V and its significance for medicine. JAMA 268 (5): 620-4, 1992.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1629990&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1629990&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.44">Saccomanno G, Huth GC, Auerbach O, et al.: Relationship of radioactive radon daughters and cigarette smoking in the genesis of lung cancer in uranium miners. Cancer 62 (7): 1402-8, 1988.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3416280&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3416280&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.45">Kim SH, Hwang WJ, Cho JS, et al.: Attributable risk of lung cancer deaths due to indoor radon exposure. Ann Occup Environ Med 28: 8, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26925236&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26925236&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.46">Lubin JH, Boice JD Jr: Lung cancer risk from residential radon: meta-analysis of eight epidemiologic studies. J Natl Cancer Inst 89 (1): 49-57, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8978406&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8978406&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.47">Krewski D, Lubin JH, Zielinski JM, et al.: Residential radon and risk of lung cancer: a combined analysis of 7 North American case-control studies. Epidemiology 16 (2): 137-45, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15703527&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15703527&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.48">Environmental Protection Agency: Exposure to Radon Causes Lung Cancer In Non-smokers and Smokers Alike. Washington, DC: Environmental Protection Agency, 2011. <a href="https://www.epa.gov/radon/health-risk-radon#head" title="https://www.epa.gov/radon/health-risk-radon#head">Available online</a>. Last accessed November 30, 2017.</li><li id="section_2.49">Gray A, Read S, McGale P, et al.: Lung cancer deaths from indoor radon and the cost effectiveness and potential of policies to reduce them. BMJ 338: a3110, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19129153&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19129153&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.50">Vineis P, Forastiere F, Hoek G, et al.: Outdoor air pollution and lung cancer: recent epidemiologic evidence. Int J Cancer 111 (5): 647-52, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15252832&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15252832&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.51">Laden F, Schwartz J, Speizer FE, et al.: Reduction in fine particulate air pollution and mortality: Extended follow-up of the Harvard Six Cities study. Am J Respir Crit Care Med 173 (6): 667-72, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16424447&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16424447&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.52">Pope CA 3rd, Thun MJ, Namboodiri MM, et al.: Particulate air pollution as a predictor of mortality in a prospective study of U.S. adults. Am J Respir Crit Care Med 151 (3 Pt 1): 669-74, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7881654&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7881654&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.53">Pope CA 3rd, Burnett RT, Thun MJ, et al.: Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution. JAMA 287 (9): 1132-41, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11879110&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11879110&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.54">Katanoda K, Sobue T, Satoh H, et al.: An association between long-term exposure to ambient air pollution and mortality from lung cancer and respiratory diseases in Japan. J Epidemiol 21 (2): 132-43, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21325732&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21325732&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.55">Cao J, Yang C, Li J, et al.: Association between long-term exposure to outdoor air pollution and mortality in China: a cohort study. J Hazard Mater 186 (2-3): 1594-600, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21194838&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21194838&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.56">Hales S, Blakely T, Woodward A: Air pollution and mortality in New Zealand: cohort study. J Epidemiol Community Health 66 (5): 468-73, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20966448&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20966448&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.57">Raaschou-Nielsen O, Andersen ZJ, Beelen R, et al.: Air pollution and lung cancer incidence in 17 European cohorts: prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE). Lancet Oncol 14 (9): 813-22, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23849838&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23849838&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.58">Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. Washington, DC: World Cancer Research Fund/American Institute for Cancer Research, 2007. <a href="http://www.aicr.org/assets/docs/pdf/reports/Second_Expert_Report.pdf" title="http://www.aicr.org/assets/docs/pdf/reports/Second_Expert_Report.pdf">Also available online</a>. Last accessed August 7, 2018.</li><li id="section_2.59">Gallicchio L, Boyd K, Matanoski G, et al.: Carotenoids and the risk of developing lung cancer: a systematic review. Am J Clin Nutr 88 (2): 372-83, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18689373&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18689373&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.60">Calle EE, Rodriguez C, Walker-Thurmond K, et al.: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348 (17): 1625-38, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12711737&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12711737&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.61">Olson JE, Yang P, Schmitz K, et al.: Differential association of body mass index and fat distribution with three major histologic types of lung cancer: evidence from a cohort of older women. Am J Epidemiol 156 (7): 606-15, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12244029&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12244029&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.62">Tardon A, Lee WJ, Delgado-Rodriguez M, et al.: Leisure-time physical activity and lung cancer: a meta-analysis. Cancer Causes Control 16 (4): 389-97, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15953981&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15953981&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.63">Lee IM, Sesso HD, Paffenbarger RS Jr: Physical activity and risk of lung cancer. Int J Epidemiol 28 (4): 620-5, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10480687&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10480687&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.64">Thune I, Lund E: The influence of physical activity on lung-cancer risk: A prospective study of 81,516 men and women. Int J Cancer 70 (1): 57-62, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8985091&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8985091&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.65">Mao Y, Pan S, Wen SW, et al.: Physical activity and the risk of lung cancer in Canada. Am J Epidemiol 158 (6): 564-75, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12965882&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12965882&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.66">Wiseman M: The second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Proc Nutr Soc 67 (3): 253-6, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18452640&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18452640&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.67">Peto R, Lopez AD, Boreham J, et al.: Mortality from Smoking in Developed Countries, 1950-2000: Indirect Estimates from National Vital Statistics. New York, NY: Oxford University Press, 1994.</li><li id="section_2.68">Samet JM, Avila-Tang E, Boffetta P, et al.: Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clin Cancer Res 15 (18): 5626-45, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19755391&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19755391&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.69">Lam TK, Moore SC, Brinton LA, et al.: Anthropometric measures and physical activity and the risk of lung cancer in never-smokers: a prospective cohort study. PLoS One 8 (8): e70672, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23940620&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23940620&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.70">Korte JE, Brennan P, Henley SJ, et al.: Dose-specific meta-analysis and sensitivity analysis of the relation between alcohol consumption and lung cancer risk. Am J Epidemiol 155 (6): 496-506, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11882523&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11882523&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.71">The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, Ga: U.S. Department of Health and Human Services, CDC, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2004. <a href="https://www.cdc.gov/tobacco/data_statistics/sgr/2004/index.htm" title="https://www.cdc.gov/tobacco/data_statistics/sgr/2004/index.htm">Also available online</a>.                Last accessed August 13, 2018.</li><li id="section_2.72">The Health Benefits of Smoking Cessation: a report of the Surgeon General. Rockville: US Department of Health and Human Services, Public Health Service, Centers for Disease Control, Centers for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, DHHS Publ No (CDC) 90-8416, 1990.</li><li id="section_2.73">Cinciripini PM, Hecht SS, Henningfield JE, et al.: Tobacco addiction: implications for treatment and cancer prevention. J Natl Cancer Inst 89 (24): 1852-67, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9414173&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9414173&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.74">Fiore MC, Bailey WC, Cohen SJ, et al.: Smoking Cessation: Clinical Practice Guideline No 18. Rockville, Md: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1996. AHCPR Publ No 96-0692.</li><li id="section_2.75">Greenlee RT, Murray T, Bolden S, et al.: Cancer statistics, 2000. CA Cancer J Clin 50 (1): 7-33, 2000 Jan-Feb.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10735013&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10735013&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.76">Silagy C, Lancaster T, Stead L, et al.: Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev  (3): CD000146, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15266423&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15266423&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.77">Hurt RD, Sachs DP, Glover ED, et al.: A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337 (17): 1195-202, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9337378&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9337378&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.78">Jorenby DE, Leischow SJ, Nides MA, et al.: A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340 (9): 685-91, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10053177&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10053177&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.79">Hughes JR, Goldstein MG, Hurt RD, et al.: Recent advances in the pharmacotherapy of smoking. JAMA 281 (1): 72-6, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9892454&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9892454&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.80">Wingo PA, Ries LA, Giovino GA, et al.: Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst 91 (8): 675-90, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10218505&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10218505&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.81">Koh HK: The end of the "tobacco and cancer" century. J Natl Cancer Inst 91 (8): 660-1, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10218498&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10218498&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.82">Callinan JE, Clarke A, Doherty K, et al.: Legislative smoking bans for reducing secondhand smoke exposure, smoking prevalence and tobacco consumption. Cochrane Database Syst Rev  (4): CD005992, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20393945&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20393945&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.83">The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 330 (15): 1029-35, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8127329&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8127329&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.84">Albanes D, Heinonen OP, Taylor PR, et al.: Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J Natl Cancer Inst 88 (21): 1560-70, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8901854&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8901854&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.85">Omenn GS, Goodman GE, Thornquist MD, et al.: Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334 (18): 1150-5, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8602180&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8602180&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.86">Goodman GE, Thornquist MD, Balmes J, et al.: The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements. J Natl Cancer Inst 96 (23): 1743-50, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15572756&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15572756&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.87">Omenn GS, Goodman GE, Thornquist MD, et al.: Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 88 (21): 1550-9, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8901853&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8901853&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.88">Hennekens CH, Buring JE, Manson JE, et al.: Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 334 (18): 1145-9, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8602179&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8602179&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.89">Lee IM, Cook NR, Manson JE, et al.: Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study. J Natl Cancer Inst 91 (24): 2102-6, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10601381&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10601381&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.90">Lonn E, Bosch J, Yusuf S, et al.: Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 293 (11): 1338-47, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15769967&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15769967&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.91">Lee IM, Cook NR, Gaziano JM, et al.: Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA 294 (1): 56-65, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15998891&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15998891&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.92">Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (9326): 23-33, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12114037&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12114037&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _136
      field_pdq_section_title:
        - format: plain_text
          value: 'Modificaciones a este sumario (03/19/2018)'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_136" class="pdq-sections"><p id="_139" tabindex="-1">Los sumarios del PDQ con informaci&#xF3;n sobre el c&#xE1;ncer se revisan con regularidad y se actualizan a medida  que se obtiene nueva informaci&#xF3;n.  Esta secci&#xF3;n describe los cambios m&#xE1;s recientes introducidos en este sumario a partir de la fecha arriba indicada.</p><p id="_174" tabindex="-1"><strong><a href="/espanol/tipos/pulmon/pro/prevencion-pulmon-pdq#link/_177">Descripci&#xF3;n de las pruebas</a></strong></p><p id="_178" tabindex="-1">Se actualizaron las <a href="/espanol/tipos/pulmon/pro/prevencion-pulmon-pdq#link/_69">estad&#xED;sticas</a> con el c&#xE1;lculo de casos nuevos y defunciones en 2018 (se cit&#xF3; a la American Cancer Society como referencia 1).</p><p id="_disclaimerHP_3" tabindex="-1">Este sumario est&#xE1; redactado y mantenido por el <a href="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/deteccion-prevencion" title="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/deteccion-prevencion">Consejo editorial del PDQ sobre los ex&#xE1;menes de detecci&#xF3;n y la prevenci&#xF3;n</a>, que es editorialmente independiente del NCI. El sumario refleja una revisi&#xF3;n independiente de la bibliograf&#xED;a y no representa una declaraci&#xF3;n de pol&#xED;ticas del NCI o de los NIH. Para mayor informaci&#xF3;n sobre las pol&#xED;ticas de los sumarios y la funci&#xF3;n de los  consejos editoriales  del PDQ que mantienen los sumarios del PDQ, consultar en <a href="/espanol/tipos/pulmon/pro/prevencion-pulmon-pdq#link/_AboutThis_1">Informaci&#xF3;n sobre este sumario del PDQ</a> y  la p&#xE1;gina sobre <a href="https://www.cancer.gov/espanol/publicaciones/pdq" title="https://www.cancer.gov/espanol/publicaciones/pdq">Banco de datos de informaci&#xF3;n de c&#xE1;ncer - PDQ&#xAE;</a>.
            </p></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _AboutThis_1
      field_pdq_section_title:
        - format: plain_text
          value: 'Información sobre este sumario del PDQ'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_AboutThis_1" class="pdq-sections"><section id="_AboutThis_2"><h3 id="_AboutThis_2_toc">Prop&#xF3;sito de este sumario</h3><p id="_AboutThis_3" tabindex="-1">Este sumario del PDQ con informaci&#xF3;n sobre el c&#xE1;ncer para profesionales de la salud proporciona informaci&#xF3;n integral revisada por expertos y con fundamento en datos probatorios sobre prevenci&#xF3;n del c&#xE1;ncer de pulm&#xF3;n. El prop&#xF3;sito es servir como fuente de informaci&#xF3;n y ayuda para los m&#xE9;dicos que atienden a pacientes de c&#xE1;ncer. No  ofrece pautas ni recomendaciones formales para tomar decisiones relacionadas con la atenci&#xF3;n sanitaria.</p></section><section id="_AboutThis_21"><h3 id="_AboutThis_21_toc">Revisores y actualizaciones</h3><p id="_AboutThis_22" tabindex="-1">El  <a href="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/deteccion-prevencion" title="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/deteccion-prevencion">Consejo editorial del PDQ sobre los ex&#xE1;menes de detecci&#xF3;n y la prevenci&#xF3;n</a>, cuya funci&#xF3;n editorial es independiente del Instituto Nacional del C&#xE1;ncer (NCI), revisa con regularidad este sumario y, en caso necesario,   lo actualiza. Este sumario refleja una revisi&#xF3;n bibliogr&#xE1;fica independiente y no constituye una declaraci&#xF3;n de la pol&#xED;tica del Instituto Nacional del C&#xE1;ncer ni de los Institutos Nacionales de la Salud (NIH).</p><p id="_AboutThis_26" tabindex="-1">Cada mes, los miembros de este Consejo  examinan art&#xED;culos  publicados recientemente para determinar si se deben:</p><div class="pdq-content-list"><ul id="_AboutThis_23"><li>tratar en una reuni&#xF3;n,</li><li>citar textualmente, o</li><li>sustituir o actualizar, si ya se citaron con anterioridad.</li></ul></div><p id="_AboutThis_24" tabindex="-1">Los cambios en los sumarios se deciden mediante consenso, una vez que  los integrantes del Consejo eval&#xFA;an la solidez de los datos probatorios en los art&#xED;culos publicados y determinan la forma en que se incorporar&#xE1;n al sumario.</p><p id="_AboutThis_25" tabindex="-1">Cualquier comentario o pregunta sobre el contenido de este sumario se debe enviar mediante el   <a href="https://www.cancer.gov/espanol/contactenos/correo-electronico" title="https://www.cancer.gov/espanol/contactenos/correo-electronico">formulario de comunicaci&#xF3;n</a> en Cancer.gov/espanol del NCI.  No comunicarse con los miembros del Consejo para enviar preguntas o comentarios sobre los sumarios.  Los miembros del Consejo no responder&#xE1;n a preguntas del p&#xFA;blico. </p></section><section id="_AboutThis_9"><h3 id="_AboutThis_9_toc">Grados de comprobaci&#xF3;n cient&#xED;fica</h3><p id="_AboutThis_10" tabindex="-1">En algunas referencias bibliogr&#xE1;ficas de este sumario se indica el grado de comprobaci&#xF3;n cient&#xED;fica. El prop&#xF3;sito de estas designaciones es ayudar al lector a evaluar la solidez de los datos probatorios que sustentan el uso de  ciertas intervenciones  o enfoques. El Consejo editorial del PDQ sobre los ex&#xE1;menes de detecci&#xF3;n y la prevenci&#xF3;n emplea un <a href="/espanol/publicaciones/pdq/grados-comprobacion/deteccion-prevencion">sistema de jerarquizaci&#xF3;n formal</a> para establecer  las designaciones del grado de comprobaci&#xF3;n cient&#xED;fica.</p></section><section id="_AboutThis_11"><h3 id="_AboutThis_11_toc">Permisos para el uso de este sumario</h3><p id="_AboutThis_12" tabindex="-1">PDQ (Physician Data Query) es una marca registrada. Se autoriza el libre uso del texto  de los documentos del PDQ. Sin embargo, no se podr&#xE1; identificar como un sumario de informaci&#xF3;n sobre c&#xE1;ncer del PDQ del  NCI,  salvo que se reproduzca en su totalidad y se actualice con regularidad. Por otra parte, se permitir&#xE1; que un autor  escriba una oraci&#xF3;n como &#x201C;En el sumario del PDQ  del NCI de informaci&#xF3;n sobre la prevenci&#xF3;n del c&#xE1;ncer de mama se describen, en breve, los siguientes riesgos: [incluir fragmento del sumario]&#x201D;.</p><p id="_AboutThis_13" tabindex="-1">Se sugiere citar la referencia bibliogr&#xE1;fica de este sumario del PDQ de la siguiente forma:</p><p id="_AboutThis_14" tabindex="-1">PDQ&#xAE; sobre los ex&#xE1;menes de detecci&#xF3;n y la prevenci&#xF3;n. PDQ Prevenci&#xF3;n del c&#xE1;ncer de pulm&#xF3;n. Bethesda, MD: National Cancer Institute. Actualizaci&#xF3;n:  &lt;MM/DD/YYYY&gt;. Disponible en: <a href="https://www.cancer.gov/espanol/tipos/pulmon/pro/prevencion-pulmon-pdq" title="https://www.cancer.gov/espanol/tipos/pulmon/pro/prevencion-pulmon-pdq">https://www.cancer.gov/espanol/tipos/pulmon/pro/prevencion-pulmon-pdq</a>.  Fecha de acceso: &lt;MM/DD/YYYY&gt;. </p><p id="_AboutThis_15" tabindex="-1">Las im&#xE1;genes  en este sumario se reproducen  con el permiso del autor, el artista o la  editorial para uso exclusivo en los sumarios del PDQ. La utilizaci&#xF3;n de las im&#xE1;genes fuera del  PDQ requiere la autorizaci&#xF3;n del propietario, que el Instituto Nacional del C&#xE1;ncer no  puede otorgar. Para obtener m&#xE1;s informaci&#xF3;n sobre el uso de las ilustraciones de este sumario o de  otras im&#xE1;genes relacionadas con el c&#xE1;ncer, consultar <a href="https://visualsonline.cancer.gov/" title="https://visualsonline.cancer.gov/">Visuals Online</a>, una colecci&#xF3;n de m&#xE1;s de 2000 im&#xE1;genes cient&#xED;ficas.</p></section><section id="_AboutThis_16"><h3 id="_AboutThis_16_toc">Cl&#xE1;usula sobre el descargo de responsabilidad</h3><p id="_AboutThis_18" tabindex="-1">La informaci&#xF3;n en estos sumarios  no se debe utilizar como base para determinar reembolsos por parte de las aseguradoras. Para obtener m&#xE1;s informaci&#xF3;n  sobre la cobertura de seguros, consultar la p&#xE1;gina <a href="https://www.cancer.gov/espanol/cancer/manejo-del-cancer" title="https://www.cancer.gov/espanol/cancer/manejo-del-cancer">Manejo de la atenci&#xF3;n del c&#xE1;ncer</a> disponible en Cancer.gov/espanol.</p></section><section id="_AboutThis_19"><h3 id="_AboutThis_19_toc">Para obtener m&#xE1;s informaci&#xF3;n</h3><p id="_AboutThis_20" tabindex="-1">En Cancer.gov/espanol,  se ofrece m&#xE1;s informaci&#xF3;n sobre c&#xF3;mo comunicarse o recibir ayuda en  <a href="https://www.cancer.gov/espanol/contactenos" title="https://www.cancer.gov/espanol/contactenos">&#xBF;En qu&#xE9; podemos ayudarle?</a>.
            Tambi&#xE9;n se puede enviar un mensaje de  correo electr&#xF3;nico  mediante este  <a href="https://www.cancer.gov/espanol/contactenos/correo-electronico" title="https://www.cancer.gov/espanol/contactenos/correo-electronico">formulario</a>.</p></section></div>
